{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import os\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import spacy\n",
    "# import json\n",
    "# from sklearn.model_selection import train_test_split\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "train_data_raw = 'phase1_lymphoma.json'\n",
    "test_data_raw = 'phase1_lungcancer.json'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# columns of interest\n",
    "[\n",
    "    'study_duration_days',\n",
    "    'study_eq_bins',\n",
    "    'study_eq_labels',\n",
    "    'num_oms',\n",
    "    'masking',\n",
    "    'number_of_intervention_types',\n",
    "    \"num_locations\",\n",
    "    'number_of_conditions',\n",
    "    'allocation',\n",
    "    'masking',\n",
    "    'enroll_count',\n",
    "    'biological_intervention',\n",
    "    'procedure_intervention',\n",
    "    'drug_intervention',\n",
    "    'radiation_intervention',\n",
    "    'treatment_purpose',\n",
    "    'prevention_purpose',\n",
    "    'us_led',\n",
    "    'us_included',\n",
    "    'nci_sponsor'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def validate_columns(file, yaml_file):\n",
    "    \n",
    "    if '.csv' in file:\n",
    "        df = pd.read_csv(file)\n",
    "    elif '.json' in file:\n",
    "       raw_df = pd.read_json(file)\n",
    "       df = pd.json_normalize(raw_df['protocolSection'], sep='_')\n",
    "       df.columns = ['protocolSection_' + col for col in df.columns]\n",
    "\n",
    "    # Load YAML schema\n",
    "    config = load_yaml(yaml_file)\n",
    "\n",
    "    # Validate columns\n",
    "    expected_columns = config['columns']\n",
    "    actual_columns = df.columns.tolist()\n",
    "\n",
    "    missing_columns = [col for col in expected_columns if col not in actual_columns]\n",
    "    # extra_columns = [col for col in actual_columns if col not in expected_columns]\n",
    "\n",
    "    if missing_columns:\n",
    "        missing_msg = f\"Missing columns in CSV: {', '.join(missing_columns)}\"\n",
    "        logger.warning(missing_msg)\n",
    "        print(missing_msg)\n",
    "\n",
    "    # if not missing_columns and not extra_columns:\n",
    "    if not missing_columns:\n",
    "        success_msg = \"CSV file columns match the YAML schema.\"\n",
    "        logger.info(success_msg)\n",
    "        print(success_msg)\n",
    "    return df\n",
    "\n",
    "# Function to convert dates to datetime, handling YYYY-MM format\n",
    "def convert_to_datetime(date_str):\n",
    "    try:\n",
    "        return pd.to_datetime(date_str, format='%Y-%m-%d')\n",
    "    except ValueError:\n",
    "        try:\n",
    "            return pd.to_datetime(date_str, format='%Y-%m') + pd.offsets.MonthBegin(0)  # Assume first day of the month\n",
    "        except ValueError:\n",
    "            return np.nan  # If conversion fails, return NaN\n",
    "\n",
    "def safe_eval(item):\n",
    "    if isinstance(item, str):  # Check if the item is a string\n",
    "        return eval(item)\n",
    "    return item  # Return the item unchanged if it's not a string\n",
    "\n",
    "# Function to extract 'type' from list of dictionaries\n",
    "def extract_type(interventions):\n",
    "    return [d['type'] for d in interventions]\n",
    "\n",
    "# function to count number of sites\n",
    "def count_loc(value):\n",
    "  if pd.isna(value):\n",
    "    return np.nan\n",
    "  else:\n",
    "    new_string = value.split(\", \")\n",
    "    counter = 0\n",
    "    for i in new_string:\n",
    "      if \"facility\" in i:\n",
    "        counter += 1\n",
    "    return counter\n",
    "\n",
    "# function to count number of sites\n",
    "def trial_loc(value):\n",
    "  if pd.isna(value):\n",
    "    return np.nan\n",
    "  else:\n",
    "    new_string = value.split(\", \")\n",
    "    temp_list = []\n",
    "    for i in new_string:\n",
    "      if \"country\" in i:\n",
    "        temp_list.append(i)\n",
    "    has_us = [i for i in temp_list if \"United States\" in i]\n",
    "\n",
    "    if all(i == temp_list[0] for i in temp_list) and has_us:\n",
    "        loc = 'USA'\n",
    "    elif not has_us:\n",
    "        loc = \"non-USA\"\n",
    "    else:\n",
    "        loc = \"USA & non-USA\"\n",
    "    return loc\n",
    "\n",
    "def extract_measures(outcomes):\n",
    "    # Check if 'outcomes' is iterable (i.e., a list in this context)\n",
    "    if isinstance(outcomes, list):\n",
    "        return [item.get('measure', 'No description available') for item in outcomes]\n",
    "    else:\n",
    "        return ['No description available']  # Return a list with a default message if not iterable\n",
    "\n",
    "# Extracting timeframe in number of days    \n",
    "def extract_timeframes(outcomes):\n",
    "    # Check if 'outcomes' is iterable (i.e., a list in this context)\n",
    "    if isinstance(outcomes, list):\n",
    "        return [item.get('timeFrame', 'No description available') for item in outcomes]\n",
    "    else:\n",
    "        return ['No description available']  # Return a list with a default message if not iterable\n",
    "\n",
    "\n",
    "def extract_time_length_from_list(timeFrames):\n",
    "    # Dictionary to convert written numbers to numeric values\n",
    "    written_numbers = {\n",
    "        \"one\": 1, \"two\": 2, \"three\": 3, \"four\": 4, \"five\": 5, \n",
    "        \"six\": 6, \"seven\": 7, \"eight\": 8, \"nine\": 9, \"ten\": 10,\n",
    "        \"eleven\": 11, \"twelve\": 12, \"thirteen\": 13, \"fourteen\": 14,\n",
    "        \"fifteen\": 15, \"sixteen\": 16, \"seventeen\": 17, \"eighteen\": 18,\n",
    "        \"nineteen\": 19, \"twenty\": 20\n",
    "    }\n",
    "\n",
    "    # Regular expression components\n",
    "    number_pattern = r\"(\\d+(\\.\\d+)?)\"\n",
    "    written_number_pattern = r\"(one|two|three|four|five|six|seven|eight|nine|ten|eleven|twelve|thirteen|fourteen|fifteen|sixteen|seventeen|eighteen|nineteen|twenty)\"\n",
    "    unit_pattern = r\"(hour|day|week|month|year|minute)s?\"\n",
    "    reversed_pattern = rf\"(?P<unit3>{unit_pattern})\\s+(?P<number2>\\d+(\\.\\d+)?)\"\n",
    "\n",
    "    # Combine the components into a single regular expression with VERBOSE flag for readability\n",
    "    time_pattern = re.compile(\n",
    "        rf\"\"\"\n",
    "        (?:\n",
    "            (?P<number>{number_pattern})\\s*(?P<unit1>{unit_pattern})           # Numeric values followed by unit\n",
    "            |                         # OR\n",
    "            (?P<written>{written_number_pattern})\\s*(?P<unit2>{unit_pattern})   # Written out numbers followed by unit\n",
    "            |                         # OR\n",
    "            {reversed_pattern}         # Reversed order: Day 15\n",
    "        )\n",
    "        \"\"\",\n",
    "        re.IGNORECASE | re.VERBOSE\n",
    "    )\n",
    "\n",
    "    # Function to extract time length from a single timeframe string\n",
    "    def extract_time_length(timeFrame):\n",
    "        results = time_pattern.findall(timeFrame)\n",
    "        time_durations = []\n",
    "        \n",
    "        for result in results:\n",
    "            if result[0]:  # Numeric values followed by unit\n",
    "                number = result[0]\n",
    "                unit = result[3]\n",
    "            elif result[5]:  # Written out numbers followed by unit\n",
    "                number = written_numbers[result[5].lower()]\n",
    "                unit = result[7]\n",
    "            elif result[10]:  # Reversed order: Day 15\n",
    "                number = result[11]\n",
    "                unit = result[9]\n",
    "\n",
    "            if isinstance(number, str):\n",
    "                number = float(number)\n",
    "            time_durations.append((number, unit.lower()))\n",
    "        return time_durations\n",
    "    \n",
    "    combined_durations = []\n",
    "    for timeFrame in timeFrames:\n",
    "        if timeFrame:  # This checks if the timeFrame is not empty or None\n",
    "            combined_durations.extend(extract_time_length(timeFrame))\n",
    "    return combined_durations\n",
    "\n",
    "def convert_to_days(amount, unit):\n",
    "    if unit == 'minutes' or unit == 'minute':\n",
    "        return np.ceil(amount / 1440)\n",
    "    elif unit == 'hours' or unit =='hour' :\n",
    "        return np.ceil(amount / 24)\n",
    "    elif unit == 'weeks' or unit == 'week':\n",
    "        return amount * 7\n",
    "    elif unit == 'months' or unit == 'month':\n",
    "        return amount * 30  # Simplified conversion, assuming each month has 30 days\n",
    "    elif unit == 'years' or unit == 'year':\n",
    "        return amount * 365  # Simplified conversion, assuming each year has 365 days\n",
    "    elif unit == 'days' or unit =='day':\n",
    "        return amount\n",
    "    else:\n",
    "        return 0\n",
    "\n",
    "def find_max_duration(durations):\n",
    "    if not durations:  # Check if the list is empty\n",
    "        return np.nan  # Use numpy Nan to indicate no data\n",
    "    max_days = max(convert_to_days(amount, unit) for amount, unit in durations)\n",
    "    return max_days\n",
    "\n",
    "# Function to remove specified characters\n",
    "def remove_special_chars(col):\n",
    "    return col.replace(\"[\", \"\").replace(\"]\", \"\").replace(\"'\", \"\").replace(\", \", \"_\")\n",
    "\n",
    "def count_criteria(criteria):\n",
    "    if pd.isna(criteria):\n",
    "        return np.nan, np.nan\n",
    "    # pattern\n",
    "    # line break, \\n, followed by any amount of whitespace\n",
    "    # followed by an alphanumeric character 1-2 characters in length followed by a period\n",
    "    # OR an asterisk\n",
    "    # OR a hyphen\n",
    "    pattern =  r'\\n\\s*\\w{1,2}\\.|[*]|\\-'\n",
    "    if \"exclusion criteria\" in criteria.lower():\n",
    "        parts = criteria.lower().split(\"exclusion criteria\")\n",
    "        inclusion_criteria = parts[0]\n",
    "        exclusion_criteria = parts[1]\n",
    "\n",
    "        inclusion_matches = re.findall(pattern, inclusion_criteria)\n",
    "        exclusion_matches = re.findall(pattern, exclusion_criteria)\n",
    "        num_inclusion = len(inclusion_matches)\n",
    "        num_exclusion = len(exclusion_matches)\n",
    "    else:\n",
    "        inclusion_matches = re.findall(pattern, criteria)\n",
    "        num_inclusion = len(inclusion_matches)\n",
    "        num_exclusion = np.nan\n",
    "    \n",
    "    return num_inclusion, num_exclusion\n",
    "\n",
    "def conditions_map(condition):\n",
    "  if 'cell lung' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'head and neck' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'squamous cell' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'small cell' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'lung' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'keratosis' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'myeloma' in condition:\n",
    "    return 'myeloma'\n",
    "  if 'sarcoma' in condition:\n",
    "    return 'sarcoma'\n",
    "  if 'lymphoma' in condition:\n",
    "    return 'lymphoma'\n",
    "  if 'brain cancer' in condition:\n",
    "    return 'brain'\n",
    "  if 'melanoma' in condition:\n",
    "    return 'melanoma'\n",
    "  if 'adenocarcinoma' in condition:\n",
    "    return 'adeno'\n",
    "  if 'prostate cancer' in condition:\n",
    "    return 'adeno'\n",
    "  if 'breast' in condition:\n",
    "    return 'ductal'\n",
    "  if 'leukemia' in condition:\n",
    "    return 'leukemia'\n",
    "  if 'colorectal' in condition:\n",
    "    return 'adeno'\n",
    "  if 'glioblastoma' in condition:\n",
    "    return 'brain'\n",
    "  if 'kidney' in condition:\n",
    "    return 'adeno'\n",
    "  if 'renal' in condition:\n",
    "    return 'adeno'\n",
    "  if 'hematopoietic' in condition:\n",
    "    return 'leukemia'\n",
    "  if 'lymphoid' in condition:\n",
    "    return 'lymphoma'\n",
    "  if 'cervix' in condition:\n",
    "    return 'adeno'\n",
    "  if 'cervical' in condition:\n",
    "    return 'adeno'\n",
    "  if 'liver' in condition:\n",
    "    return 'adeno'\n",
    "  if 'hepatic' in condition:\n",
    "    return 'adeno'\n",
    "  if 'hepatocellular' in condition:\n",
    "    return 'adeno'\n",
    "  if 'nsclc' in condition:\n",
    "    return 'squamous cell'\n",
    "  if 'thyroid' in condition:\n",
    "    return 'adeno'\n",
    "  if 'pain' in condition:\n",
    "    return 'pain'\n",
    "  elif 'carcinoma' in condition:\n",
    "    return 'carcinoma'\n",
    "  return 'other'\n",
    "\n",
    "def list_to_lower_string(lst):\n",
    "    # Ensure the input is a list\n",
    "    if isinstance(lst, list):\n",
    "        # Convert each element to a lowercase string and join with spaces\n",
    "        return \", \".join(map(str, lst)).lower()\n",
    "\n",
    "def drop_outliers(df, threshold=5):\n",
    "    # Calculate the mean and standard deviation for each column\n",
    "    means = df.mean()\n",
    "    stds = df.std()\n",
    "    # Identify outliers\n",
    "    outliers = (np.abs((df - means) / stds) > threshold)\n",
    "    # Create a DataFrame to store the outliers\n",
    "    dropped_values = df[outliers]\n",
    "    # Drop the rows with outliers\n",
    "    df_cleaned = df.drop(index=dropped_values.dropna(how='all').index)\n",
    "    return df_cleaned\n",
    "\n",
    "def interval_to_string(o):\n",
    "    if isinstance(o, pd.Interval):\n",
    "        return str(o)\n",
    "    raise TypeError(f\"Object of type {o.__class__.__name__} is not JSON serializable\")\n",
    "\n",
    "def save_dict_to_json(filename, data):\n",
    "    with open(filename, 'w') as json_file:\n",
    "        json.dump(data, json_file, indent=4, default=interval_to_string)\n",
    "\n",
    "def convert_dtypes(df):\n",
    "    # Convert all int64 columns to int\n",
    "    int_cols = df.select_dtypes(include=['int8', 'int16', 'int32', 'int64']).columns\n",
    "    df[int_cols] = df[int_cols].astype(int)\n",
    "    \n",
    "    # Convert all float64 columns to float\n",
    "    float_cols = df.select_dtypes(include=['float16', 'float32', 'float64']).columns\n",
    "    df[float_cols] = df[float_cols].astype(float)\n",
    "    \n",
    "    return df\n",
    "\n",
    "def trial_loc_counter(value):\n",
    "    # Initialize the counter\n",
    "    counter = {\"USA\": 0, \"non-USA\": 0}\n",
    "    \n",
    "    # Check if the value is a list of dictionaries\n",
    "    if isinstance(value, list):\n",
    "        for i in value:\n",
    "            if isinstance(i, dict) and 'country' in i:\n",
    "                if i['country'] == 'United States':\n",
    "                    counter[\"USA\"] += 1\n",
    "                else:\n",
    "                    counter[\"non-USA\"] += 1\n",
    "        # Return True if USA has more counts than non-USA\n",
    "        return counter['USA'] > counter['non-USA']\n",
    "    else:\n",
    "        # Return a default or handle the error case as appropriate\n",
    "        return False\n",
    "    \n",
    "def check_crossover(item):\n",
    "    if isinstance(item, str):  # Ensure item is a string\n",
    "        # Check if \"CROSSOVER\" is in the string\n",
    "        return \"CROSSOVER\" in item.upper()  # Convert to uppercase for case-insensitive check\n",
    "    return False  # Return False if item is not a string\n",
    "\n",
    "def create_all_terms(value):\n",
    "    if isinstance(value, (list, dict)):\n",
    "        all_terms = []\n",
    "        for i in value:\n",
    "            text = i[\"measure\"].lower()\n",
    "            all_terms.append(text)\n",
    "        return all_terms\n",
    "    else:\n",
    "        return np.nan\n",
    "\n",
    "def concatenate_strings(series:list):\n",
    "    # Filter out np.nan and flatten the lists\n",
    "    all_strings = []\n",
    "    for i in series:\n",
    "        all_strings.extend(i.dropna().sum())  # Concatenate lists while dropping NaN\n",
    "    return ' '.join(all_strings)\n",
    "\n",
    "def spacy_list(keyword:str, ref_text):\n",
    "    # Process the keyword and the large text\n",
    "    keyword_doc = nlp(keyword)\n",
    "    text_doc = nlp(ref_text)\n",
    "\n",
    "    # Set a threshold for similarity\n",
    "    similarity_threshold = 0.8\n",
    "\n",
    "    high_similarity_phrases = []\n",
    "    seen_phrases = set()  # Set to track unique words or phrases\n",
    "\n",
    "    # Check individual tokens\n",
    "    for token in text_doc:\n",
    "        # Skip stop words and punctuation\n",
    "        if not token.is_stop and not token.is_punct:\n",
    "            # Compute similarity\n",
    "            similarity_score = token.similarity(keyword_doc)\n",
    "            if similarity_score >= similarity_threshold and token.text not in seen_phrases:\n",
    "                high_similarity_phrases.append((token.text, similarity_score))\n",
    "                seen_phrases.add(token.text)  # Add to the set of seen phrases\n",
    "\n",
    "    # Check multi-word phrases\n",
    "    for chunk in text_doc.noun_chunks:\n",
    "        # Compute similarity with the keyword\n",
    "        similarity_score = chunk.similarity(keyword_doc)\n",
    "        if similarity_score >= similarity_threshold and chunk.text not in seen_phrases:\n",
    "            high_similarity_phrases.append((chunk.text, similarity_score))\n",
    "            seen_phrases.add(chunk.text)  # Add to the set of seen phrases\n",
    "    return high_similarity_phrases\n",
    "\n",
    "def check_terms_in_outcomes(outcomes, terms):\n",
    "    if isinstance(outcomes, list):  # Only proceed if 'outcomes' is a list\n",
    "        for outcome in outcomes:\n",
    "            if isinstance(outcome, dict):  # Ensure each item is a dictionary\n",
    "                for value in outcome.values():  # Check each value in the dictionary\n",
    "                    if isinstance(value, str) and any(term in value for term, _ in terms):\n",
    "                        return True\n",
    "    return False\n",
    "\n",
    "def check_tmax_in_outcomes(outcomes, terms):\n",
    "    if isinstance(outcomes, list):  # Only proceed if 'outcomes' is a list\n",
    "        for outcome in outcomes:\n",
    "            if isinstance(outcome, dict):  # Ensure each item is a dictionary\n",
    "                for value in outcome.keys():  # Check each value in the dictionary\n",
    "                    if value == terms:\n",
    "                        return True\n",
    "    return False"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>protocolSection_statusModule_dispFirstPostDateStruct_date</th>\n",
       "      <th>protocolSection_statusModule_dispFirstPostDateStruct_type</th>\n",
       "      <th>protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>protocolSection_designModule_designInfo_maskingInfo_whoMasked</th>\n",
       "      <th>protocolSection_oversightModule_isUsExport</th>\n",
       "      <th>protocolSection_designModule_designInfo_maskingInfo_maskingDescription</th>\n",
       "      <th>protocolSection_referencesModule_availIpds</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_nctId</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_statusForNctId</th>\n",
       "      <th>protocolSection_oversightModule_isUnapprovedDevice</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2011-02-25</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 86 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     protocolSection_statusModule_dispFirstPostDateStruct_date  \\\n",
       "0                                                   NaN          \n",
       "1                                                   NaN          \n",
       "2                                                   NaN          \n",
       "3                                                   NaN          \n",
       "4                                                   NaN          \n",
       "...                                                 ...          \n",
       "1095                                         2011-02-25          \n",
       "1096                                                NaN          \n",
       "1097                                                NaN          \n",
       "1098                                                NaN          \n",
       "1099                                                NaN          \n",
       "\n",
       "     protocolSection_statusModule_dispFirstPostDateStruct_type  \\\n",
       "0                                                   NaN          \n",
       "1                                                   NaN          \n",
       "2                                                   NaN          \n",
       "3                                                   NaN          \n",
       "4                                                   NaN          \n",
       "...                                                 ...          \n",
       "1095                                          ESTIMATED          \n",
       "1096                                                NaN          \n",
       "1097                                                NaN          \n",
       "1098                                                NaN          \n",
       "1099                                                NaN          \n",
       "\n",
       "     protocolSection_outcomesModule_otherOutcomes  \\\n",
       "0                                             NaN   \n",
       "1                                             NaN   \n",
       "2                                             NaN   \n",
       "3                                             NaN   \n",
       "4                                             NaN   \n",
       "...                                           ...   \n",
       "1095                                          NaN   \n",
       "1096                                          NaN   \n",
       "1097                                          NaN   \n",
       "1098                                          NaN   \n",
       "1099                                          NaN   \n",
       "\n",
       "     protocolSection_designModule_designInfo_maskingInfo_whoMasked  \\\n",
       "0                                                   NaN              \n",
       "1                                                   NaN              \n",
       "2                                                   NaN              \n",
       "3                                                   NaN              \n",
       "4                                                   NaN              \n",
       "...                                                 ...              \n",
       "1095                                                NaN              \n",
       "1096                                                NaN              \n",
       "1097                                                NaN              \n",
       "1098                                                NaN              \n",
       "1099                                                NaN              \n",
       "\n",
       "     protocolSection_oversightModule_isUsExport  \\\n",
       "0                                           NaN   \n",
       "1                                           NaN   \n",
       "2                                           NaN   \n",
       "3                                           NaN   \n",
       "4                                           NaN   \n",
       "...                                         ...   \n",
       "1095                                        NaN   \n",
       "1096                                        NaN   \n",
       "1097                                        NaN   \n",
       "1098                                        NaN   \n",
       "1099                                        NaN   \n",
       "\n",
       "     protocolSection_designModule_designInfo_maskingInfo_maskingDescription  \\\n",
       "0                                                   NaN                       \n",
       "1                                                   NaN                       \n",
       "2                                                   NaN                       \n",
       "3                                                   NaN                       \n",
       "4                                                   NaN                       \n",
       "...                                                 ...                       \n",
       "1095                                                NaN                       \n",
       "1096                                                NaN                       \n",
       "1097                                                NaN                       \n",
       "1098                                                NaN                       \n",
       "1099                                                NaN                       \n",
       "\n",
       "     protocolSection_referencesModule_availIpds  \\\n",
       "0                                           NaN   \n",
       "1                                           NaN   \n",
       "2                                           NaN   \n",
       "3                                           NaN   \n",
       "4                                           NaN   \n",
       "...                                         ...   \n",
       "1095                                        NaN   \n",
       "1096                                        NaN   \n",
       "1097                                        NaN   \n",
       "1098                                        NaN   \n",
       "1099                                        NaN   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_nctId  \\\n",
       "0                                                   NaN      \n",
       "1                                                   NaN      \n",
       "2                                                   NaN      \n",
       "3                                                   NaN      \n",
       "4                                                   NaN      \n",
       "...                                                 ...      \n",
       "1095                                                NaN      \n",
       "1096                                                NaN      \n",
       "1097                                                NaN      \n",
       "1098                                                NaN      \n",
       "1099                                                NaN      \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_statusForNctId  \\\n",
       "0                                                   NaN               \n",
       "1                                                   NaN               \n",
       "2                                                   NaN               \n",
       "3                                                   NaN               \n",
       "4                                                   NaN               \n",
       "...                                                 ...               \n",
       "1095                                                NaN               \n",
       "1096                                                NaN               \n",
       "1097                                                NaN               \n",
       "1098                                                NaN               \n",
       "1099                                                NaN               \n",
       "\n",
       "     protocolSection_oversightModule_isUnapprovedDevice  \n",
       "0                                                   NaN  \n",
       "1                                                   NaN  \n",
       "2                                                   NaN  \n",
       "3                                                   NaN  \n",
       "4                                                   NaN  \n",
       "...                                                 ...  \n",
       "1095                                                NaN  \n",
       "1096                                                NaN  \n",
       "1097                                                NaN  \n",
       "1098                                                NaN  \n",
       "1099                                                NaN  \n",
       "\n",
       "[1100 rows x 86 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "raw_df = pd.read_json(train_data_raw)\n",
    "df = pd.json_normalize(raw_df['protocolSection'], sep='_')\n",
    "df.columns = ['protocolSection_' + col for col in df.columns]\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "49 rows were dropped due to missing values in one of: ['protocolSection_statusModule_startDateStruct_date', 'protocolSection_statusModule_primaryCompletionDateStruct_date', 'protocolSection_statusModule_completionDateStruct_date']\n",
      "Bin labels and their corresponding intervals are: {-1: nan, 0: 'Low', 1: 'High'}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/t7/9qpt6ghx7x132zp3932q2fb80000gn/T/ipykernel_72909/937492853.py:365: UserWarning: [W008] Evaluating Token.similarity based on empty vectors.\n",
      "  similarity_score = token.similarity(keyword_doc)\n",
      "/var/folders/t7/9qpt6ghx7x132zp3932q2fb80000gn/T/ipykernel_72909/937492853.py:373: UserWarning: [W008] Evaluating Span.similarity based on empty vectors.\n",
      "  similarity_score = chunk.similarity(keyword_doc)\n"
     ]
    }
   ],
   "source": [
    "# len of rows\n",
    "rows0 = len(df)\n",
    "\n",
    "#study duration, float\n",
    "df['start_date'] = df['protocolSection_statusModule_startDateStruct_date'].apply(convert_to_datetime)\n",
    "df['primary_completion_date'] = df['protocolSection_statusModule_primaryCompletionDateStruct_date'].apply(convert_to_datetime)\n",
    "df['completion_date'] = df['protocolSection_statusModule_completionDateStruct_date'].apply(convert_to_datetime)\n",
    "df['primary_study_duration_days'] = (df['primary_completion_date'] - df['start_date']).dt.days\n",
    "df['study_duration_days'] = (df['completion_date'] - df['start_date']).dt.days\n",
    "\n",
    "# cols that are vital for accurate prediction\n",
    "need_cols = [\n",
    "    # 'primary_study_duration_days',\n",
    "    'protocolSection_statusModule_startDateStruct_date',\n",
    "    'protocolSection_statusModule_primaryCompletionDateStruct_date',\n",
    "    'protocolSection_statusModule_completionDateStruct_date',]\n",
    "    # 'study_duration_days',\n",
    "    # 'protocolSection_designModule_enrollmentInfo_count']\n",
    "\n",
    "# remove rows with NaNs for primary_study_duration_days, study_duration_days,\n",
    "df = df.dropna(subset=need_cols).copy()\n",
    "# len of rows after dropping NaNs\n",
    "rows1 = len(df)\n",
    "msg = f\"{rows0 - rows1} rows were dropped due to missing values in one of: {need_cols}\"\n",
    "# logger.info(msg)\n",
    "print(msg)\n",
    "\n",
    "# make bins with average duration\n",
    "avg_dur = np.mean(df['study_duration_days'])\n",
    "df['study_eq_bins'] = pd.cut(df['study_duration_days'], bins=[df['study_duration_days'].min(), avg_dur, df['study_duration_days'].max()], labels=['Low', 'High'], right=False)\n",
    "\n",
    "df['study_eq_labels'] = df['study_eq_bins'].cat.codes\n",
    "\n",
    "bins_dict = df.groupby('study_eq_labels')['study_eq_bins'].apply(lambda x: x.unique()[0]).to_dict()\n",
    "msg2 = f\"Bin labels and their corresponding intervals are: {bins_dict}\"\n",
    "print(msg2)\n",
    "# logger.info(msg2)\n",
    "\n",
    "# sponsor type, categorical\n",
    "spon_map = {\n",
    "    'OTHER_GOV': 'OTHER',\n",
    "    'NETWORK': 'OTHER',\n",
    "    'NIH': 'OTHER',\n",
    "    'FED': 'OTHER',\n",
    "    'INDIV': 'OTHER'\n",
    "}\n",
    "\n",
    "spon_map2 = {\n",
    "    \"INDUSTRY\": True,\n",
    "    \"OTHER\": False\n",
    "}\n",
    "\n",
    "df['sponsor_type0'] = df['protocolSection_sponsorCollaboratorsModule_leadSponsor_class'].replace(spon_map)\n",
    "df['sponsor_type'] = df['sponsor_type0'].map(spon_map2)\n",
    "\n",
    "# responsible party, categorical (mapped to int)\n",
    "party_map = {\n",
    "    \"PRINCIPAL_INVESTIGATOR\": 0,\n",
    "    \"SPONSOR\": 1,\n",
    "    \"SPONSOR_INVESTIGATOR\": 2\n",
    "}\n",
    "\n",
    "df['resp_party'] = df['protocolSection_sponsorCollaboratorsModule_responsibleParty_type'].map(party_map)\n",
    "\n",
    "# allocation, categorical (mapped to int)\n",
    "allo_map = {\n",
    "    'NON_RANDOMIZED': False,\n",
    "    'RANDOMIZED': True\n",
    "}\n",
    "\n",
    "df['allocation'] = df['protocolSection_designModule_designInfo_allocation'].map(allo_map)\n",
    "\n",
    "df['masking'] = df['protocolSection_designModule_designInfo_maskingInfo_masking'].apply(lambda x: False if x == \"NONE\" else True)\n",
    "\n",
    "# number of conditions, int\n",
    "df['protocolSection_conditionsModule_conditions'] = df['protocolSection_conditionsModule_conditions'].apply(safe_eval)\n",
    "df['number_of_conditions'] = df['protocolSection_conditionsModule_conditions'].apply(lambda x: len(x))\n",
    "\n",
    "# number of outcome measures, int\n",
    "oms = [col for col in df.columns if \"outcome\" in col]\n",
    "for i in oms:\n",
    "    df[i].apply(list_to_lower_string)\n",
    "    df[f\"num_{i}\"] = df[i].apply(lambda x: len(x) if isinstance(x, list) else 0)\n",
    "num_om_cols = [col for col in df.columns if \"num\" in col and \"outcome\" in col]\n",
    "df['num_oms'] = df[num_om_cols].sum(axis=1)\n",
    "\n",
    "# primary purpose, bool/int\n",
    "# Extract purposes into new columns\n",
    "df['protocolSection_designModule_designInfo_primaryPurpose'] = df['protocolSection_designModule_designInfo_primaryPurpose'].fillna('')\n",
    "df['treatment_purpose'] = df['protocolSection_designModule_designInfo_primaryPurpose'].apply(lambda x: 1 if 'TREATMENT' in x else 0)\n",
    "df['prevention_purpose'] = df['protocolSection_designModule_designInfo_primaryPurpose'].apply(lambda x: 1 if 'PREVENTION' in x else 0)\n",
    "\n",
    "# intervention type, bool/int\n",
    "# Extract interventions into new columns\n",
    "df['procedure_intervention'] = df['protocolSection_armsInterventionsModule_interventions'].apply(lambda x: True if 'PROCEDURE' in x else False)\n",
    "df['drug_intervention'] = df['protocolSection_armsInterventionsModule_interventions'].apply(lambda x: True if 'DRUG' in x else False)\n",
    "df['radiation_intervention'] = df['protocolSection_armsInterventionsModule_interventions'].apply(lambda x: True if 'RADIATION' in x else False)\n",
    "df['biological_intervention'] = df['protocolSection_armsInterventionsModule_interventions'].apply(lambda x: True if 'BIOLOGICAL' in x else False)\n",
    "\n",
    "# number of intervention types, int\n",
    "df['protocolSection_armsInterventionsModule_interventions'] = df['protocolSection_armsInterventionsModule_interventions'].apply(safe_eval)\n",
    "df['intervention_types'] = df['protocolSection_armsInterventionsModule_interventions'].apply(extract_type)\n",
    "df['number_of_intervention_types'] = df['intervention_types'].apply(len)\n",
    "\n",
    "# number of locations, int\n",
    "df[\"num_locations\"] = df[\"protocolSection_contactsLocationsModule_locations\"].astype(str).apply(count_loc)\n",
    "\n",
    "loc_map = {\n",
    "    \"USA\": 0,\n",
    "    \"non-USA\": 1,\n",
    "    \"USA & non-USA\": 2\n",
    "}\n",
    "# location of trials, US-led, bool\n",
    "# \"Trial primarily led in the US\"\n",
    "# I'm interpreting this to mean there are more trial sites in the USA than outside the USA\n",
    "df['us_led'] = df[\"protocolSection_contactsLocationsModule_locations\"].apply(lambda x: trial_loc_counter(x))\n",
    "# location of trials, US-included, bool\n",
    "df['us_included'] = df[\"protocolSection_contactsLocationsModule_locations\"].astype(str).apply(trial_loc).apply(lambda x: True if x == \"USA\" or x == \"USA & non-USA\" else False)\n",
    "\n",
    "# nic sponsorship, bool\n",
    "df['nci_sponsor'] = df['protocolSection_sponsorCollaboratorsModule_leadSponsor_name'].apply(lambda x: True if \"National Cancer Institute (NCI)\" in x else False)\n",
    "\n",
    "# crossover assignment, bool\n",
    "df['crossover'] = df['protocolSection_designModule_designInfo_interventionModel'].apply(check_crossover)\n",
    "\n",
    "# outcome measures, bool/int\n",
    "# Combine outcome measures\n",
    "df['all_primary_terms'] = df['protocolSection_outcomesModule_primaryOutcomes'].apply(lambda x: create_all_terms(x))\n",
    "df[\"all_secondary_terms\"] = df['protocolSection_outcomesModule_secondaryOutcomes'].apply(lambda x: create_all_terms(x))\n",
    "# create a string all text from outcome measures in it for spacy perusal\n",
    "all_terms = concatenate_strings([df['all_primary_terms'],df[\"all_secondary_terms\"]]) # text from both primary and secondary measures\n",
    "primary_terms = concatenate_strings([df['all_primary_terms']]) # test from primary measures only\n",
    "# load the spacy model\n",
    "nlp = spacy.load(\"en_core_web_md\")  # Load the medium-sized model\n",
    "\n",
    "# initiate dictionaries to hold the list of terms with the highest similarity values as calculated by spacy\n",
    "spacy_dict = {}\n",
    "lead_spacy_dict = {}\n",
    "\n",
    "# create a list of the terms of intererst (for overall outcome measures)\n",
    "terms = {\n",
    "    \"aes\": \"adverse events\",\n",
    "    \"osr\": \"overall survival rate\",\n",
    "    \"mtd\": \"maximally tolerated dose\",\n",
    "    \"dor\": \"duration of response\",\n",
    "    \"dlt\": \"dose limiting toxicity\",\n",
    "    \"cmax\": \"maximum measured concentration\"\n",
    "}\n",
    "# for primary outcome measures only\n",
    "lead_terms = {\n",
    "    \"aes\": \"adverse events\",\n",
    "    \"mtd\": \"maximally tolerated dose\",\n",
    "    \"dlt\": \"dose limiting toxicity\",\n",
    "}\n",
    "\n",
    "# fill the dictionaries\n",
    "for i in terms:\n",
    "    spacy_dict[i] = spacy_list(keyword=terms[i], ref_text=all_terms)\n",
    "for i in lead_terms:\n",
    "    lead_spacy_dict[i] = spacy_list(keyword=terms[i], ref_text=primary_terms)\n",
    "\n",
    "#create the boolean outcome measure features\n",
    "df['outcome_measures'] = df['protocolSection_outcomesModule_primaryOutcomes'].apply(lambda x: x if isinstance(x, list) else [x]).fillna('') + \\\n",
    "                        df['protocolSection_outcomesModule_secondaryOutcomes'].apply(lambda x: x if isinstance(x, list) else [x]).fillna('')\n",
    "\n",
    "for i in terms:\n",
    "    df[f\"spacy_{i}_outcome\"] = df['outcome_measures'].apply(\n",
    "    lambda x: check_terms_in_outcomes(x, spacy_dict[i])\n",
    ")\n",
    "\n",
    "for i in lead_terms:\n",
    "    df[f\"spacy_{i}_lead_outcome\"] = df['protocolSection_outcomesModule_primaryOutcomes'].apply(\n",
    "    lambda x: check_terms_in_outcomes(x, lead_spacy_dict[i])\n",
    ")\n",
    "\n",
    "# tmax measure, bool\n",
    "    # if the cmax is included in outcome measure and the timeframe of the cmax is included\n",
    "df['spacy_tmax_outcome'] = df.loc[df[\"spacy_cmax_outcome\"] == True, 'outcome_measures'].apply(\n",
    "    lambda x: check_tmax_in_outcomes(x, \"timeFrame\"))\n",
    "\n",
    "# rename some columns\n",
    "df = df.rename(columns={'protocolSection_designModule_enrollmentInfo_count': 'enroll_count'})\n",
    "\n",
    "# df['phase'] = df['phase'].astype(str)\n",
    "\n",
    "#make a dataframe with just the columns of interest\n",
    "cols = [\n",
    "    'study_duration_days',\n",
    "    'study_eq_bins',\n",
    "    'study_eq_labels',\n",
    "    'num_oms',\n",
    "    'masking',\n",
    "    'number_of_intervention_types',\n",
    "    \"num_locations\",\n",
    "    'number_of_conditions',\n",
    "    'allocation',\n",
    "    'enroll_count',\n",
    "    'biological_intervention',\n",
    "    'procedure_intervention',\n",
    "    'drug_intervention',\n",
    "    'radiation_intervention',\n",
    "    'treatment_purpose',\n",
    "    'prevention_purpose',\n",
    "    'us_led',\n",
    "    'us_included',\n",
    "    'nci_sponsor',\n",
    "    'spacy_aes_outcome',\n",
    "    'spacy_osr_outcome',\n",
    "    'spacy_mtd_outcome',\n",
    "    'spacy_dor_outcome',\n",
    "    'spacy_dlt_outcome',\n",
    "    'spacy_cmax_outcome',\n",
    "    'spacy_aes_lead_outcome',\n",
    "    'spacy_dlt_lead_outcome',\n",
    "    'spacy_mtd_lead_outcome',\n",
    "    'spacy_tmax_outcome'\n",
    "]\n",
    "\n",
    "clean_df = df[cols].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "study_duration_days               0\n",
       "study_eq_bins                     1\n",
       "study_eq_labels                   0\n",
       "num_oms                           0\n",
       "masking                           0\n",
       "number_of_intervention_types      0\n",
       "num_locations                     0\n",
       "number_of_conditions              0\n",
       "allocation                      613\n",
       "enroll_count                     30\n",
       "biological_intervention           0\n",
       "procedure_intervention            0\n",
       "drug_intervention                 0\n",
       "radiation_intervention            0\n",
       "treatment_purpose                 0\n",
       "prevention_purpose                0\n",
       "us_led                            0\n",
       "us_included                       0\n",
       "nci_sponsor                       0\n",
       "spacy_aes_outcome                 0\n",
       "spacy_osr_outcome                 0\n",
       "spacy_mtd_outcome                 0\n",
       "spacy_dor_outcome                 0\n",
       "spacy_dlt_outcome                 0\n",
       "spacy_cmax_outcome                0\n",
       "spacy_aes_lead_outcome            0\n",
       "spacy_dlt_lead_outcome            0\n",
       "spacy_mtd_lead_outcome            0\n",
       "spacy_tmax_outcome              550\n",
       "dtype: int64"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_df.isna().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>masking</th>\n",
       "      <th>number_of_intervention_types</th>\n",
       "      <th>num_locations</th>\n",
       "      <th>number_of_conditions</th>\n",
       "      <th>allocation</th>\n",
       "      <th>enroll_count</th>\n",
       "      <th>...</th>\n",
       "      <th>spacy_aes_outcome</th>\n",
       "      <th>spacy_osr_outcome</th>\n",
       "      <th>spacy_mtd_outcome</th>\n",
       "      <th>spacy_dor_outcome</th>\n",
       "      <th>spacy_dlt_outcome</th>\n",
       "      <th>spacy_cmax_outcome</th>\n",
       "      <th>spacy_aes_lead_outcome</th>\n",
       "      <th>spacy_dlt_lead_outcome</th>\n",
       "      <th>spacy_mtd_lead_outcome</th>\n",
       "      <th>spacy_tmax_outcome</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>13.0</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>18.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>missing</td>\n",
       "      <td>37.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>missing</td>\n",
       "      <td>60.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>43.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>9</td>\n",
       "      <td>missing</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>5</td>\n",
       "      <td>1</td>\n",
       "      <td>12</td>\n",
       "      <td>True</td>\n",
       "      <td>7.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>missing</td>\n",
       "      <td>30.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>3</td>\n",
       "      <td>1</td>\n",
       "      <td>67</td>\n",
       "      <td>missing</td>\n",
       "      <td>43.0</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>False</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>32.0</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1051 rows Ã— 29 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      study_duration_days study_eq_bins  study_eq_labels  num_oms  masking  \\\n",
       "0                   901.0           Low                0        3    False   \n",
       "1                   912.0           Low                0        4    False   \n",
       "2                  1065.0           Low                0        5    False   \n",
       "3                  1916.0          High                1        4    False   \n",
       "4                   730.0           Low                0        1    False   \n",
       "...                   ...           ...              ...      ...      ...   \n",
       "1095               1127.0           Low                0        0     True   \n",
       "1096               1646.0           Low                0        2     True   \n",
       "1097               1461.0           Low                0        0     True   \n",
       "1098               2343.0          High                1        5    False   \n",
       "1099                342.0           Low                0        9    False   \n",
       "\n",
       "      number_of_intervention_types  num_locations  number_of_conditions  \\\n",
       "0                                1              1                     1   \n",
       "1                                1              1                     2   \n",
       "2                                1              3                     2   \n",
       "3                                1              2                     2   \n",
       "4                                1              3                     2   \n",
       "...                            ...            ...                   ...   \n",
       "1095                             2              1                     9   \n",
       "1096                             5              1                    12   \n",
       "1097                             2              1                     1   \n",
       "1098                             3              1                    67   \n",
       "1099                             2              1                     2   \n",
       "\n",
       "     allocation  enroll_count  ...  spacy_aes_outcome  spacy_osr_outcome  \\\n",
       "0         False          13.0  ...               True              False   \n",
       "1         False          18.0  ...              False               True   \n",
       "2       missing          37.0  ...              False              False   \n",
       "3       missing          60.0  ...              False               True   \n",
       "4         False          43.0  ...              False              False   \n",
       "...         ...           ...  ...                ...                ...   \n",
       "1095    missing           NaN  ...              False              False   \n",
       "1096       True           7.0  ...              False               True   \n",
       "1097    missing          30.0  ...              False              False   \n",
       "1098    missing          43.0  ...              False              False   \n",
       "1099      False          32.0  ...               True               True   \n",
       "\n",
       "      spacy_mtd_outcome  spacy_dor_outcome  spacy_dlt_outcome  \\\n",
       "0                 False              False              False   \n",
       "1                 False              False               True   \n",
       "2                 False              False              False   \n",
       "3                  True              False               True   \n",
       "4                 False              False              False   \n",
       "...                 ...                ...                ...   \n",
       "1095              False              False              False   \n",
       "1096               True              False               True   \n",
       "1097              False              False              False   \n",
       "1098               True              False               True   \n",
       "1099              False              False              False   \n",
       "\n",
       "      spacy_cmax_outcome  spacy_aes_lead_outcome  spacy_dlt_lead_outcome  \\\n",
       "0                  False                    True                   False   \n",
       "1                  False                   False                    True   \n",
       "2                   True                   False                   False   \n",
       "3                   True                   False                    True   \n",
       "4                  False                   False                   False   \n",
       "...                  ...                     ...                     ...   \n",
       "1095               False                   False                   False   \n",
       "1096               False                   False                    True   \n",
       "1097               False                   False                   False   \n",
       "1098               False                   False                    True   \n",
       "1099                True                    True                   False   \n",
       "\n",
       "      spacy_mtd_lead_outcome  spacy_tmax_outcome  \n",
       "0                      False             missing  \n",
       "1                      False             missing  \n",
       "2                      False                True  \n",
       "3                       True                True  \n",
       "4                      False             missing  \n",
       "...                      ...                 ...  \n",
       "1095                   False             missing  \n",
       "1096                    True             missing  \n",
       "1097                   False             missing  \n",
       "1098                    True             missing  \n",
       "1099                   False                True  \n",
       "\n",
       "[1051 rows x 29 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Select only the categorical columns (object type)\n",
    "categorical_columns = clean_df.select_dtypes(include=['object']).columns\n",
    "\n",
    "# Replace NaN with \"missing\" in categorical columns\n",
    "clean_df[categorical_columns] = clean_df[categorical_columns].fillna('missing')\n",
    "\n",
    "clean_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>masking</th>\n",
       "      <th>number_of_intervention_types</th>\n",
       "      <th>num_locations</th>\n",
       "      <th>number_of_conditions</th>\n",
       "      <th>allocation</th>\n",
       "      <th>enroll_count</th>\n",
       "      <th>...</th>\n",
       "      <th>spacy_aes_outcome</th>\n",
       "      <th>spacy_osr_outcome</th>\n",
       "      <th>spacy_mtd_outcome</th>\n",
       "      <th>spacy_dor_outcome</th>\n",
       "      <th>spacy_dlt_outcome</th>\n",
       "      <th>spacy_cmax_outcome</th>\n",
       "      <th>spacy_aes_lead_outcome</th>\n",
       "      <th>spacy_dlt_lead_outcome</th>\n",
       "      <th>spacy_mtd_lead_outcome</th>\n",
       "      <th>spacy_tmax_outcome</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>13.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>18.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>missing</td>\n",
       "      <td>37.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>missing</td>\n",
       "      <td>60.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>43.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>9</td>\n",
       "      <td>missing</td>\n",
       "      <td>48.03526</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>5</td>\n",
       "      <td>1</td>\n",
       "      <td>12</td>\n",
       "      <td>True</td>\n",
       "      <td>7.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>missing</td>\n",
       "      <td>30.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>3</td>\n",
       "      <td>1</td>\n",
       "      <td>67</td>\n",
       "      <td>missing</td>\n",
       "      <td>43.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>missing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>False</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>32.00000</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1051 rows Ã— 29 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      study_duration_days study_eq_bins  study_eq_labels  num_oms  masking  \\\n",
       "0                   901.0           Low                0        3    False   \n",
       "1                   912.0           Low                0        4    False   \n",
       "2                  1065.0           Low                0        5    False   \n",
       "3                  1916.0          High                1        4    False   \n",
       "4                   730.0           Low                0        1    False   \n",
       "...                   ...           ...              ...      ...      ...   \n",
       "1095               1127.0           Low                0        0     True   \n",
       "1096               1646.0           Low                0        2     True   \n",
       "1097               1461.0           Low                0        0     True   \n",
       "1098               2343.0          High                1        5    False   \n",
       "1099                342.0           Low                0        9    False   \n",
       "\n",
       "      number_of_intervention_types  num_locations  number_of_conditions  \\\n",
       "0                                1              1                     1   \n",
       "1                                1              1                     2   \n",
       "2                                1              3                     2   \n",
       "3                                1              2                     2   \n",
       "4                                1              3                     2   \n",
       "...                            ...            ...                   ...   \n",
       "1095                             2              1                     9   \n",
       "1096                             5              1                    12   \n",
       "1097                             2              1                     1   \n",
       "1098                             3              1                    67   \n",
       "1099                             2              1                     2   \n",
       "\n",
       "     allocation  enroll_count  ...  spacy_aes_outcome  spacy_osr_outcome  \\\n",
       "0         False      13.00000  ...               True              False   \n",
       "1         False      18.00000  ...              False               True   \n",
       "2       missing      37.00000  ...              False              False   \n",
       "3       missing      60.00000  ...              False               True   \n",
       "4         False      43.00000  ...              False              False   \n",
       "...         ...           ...  ...                ...                ...   \n",
       "1095    missing      48.03526  ...              False              False   \n",
       "1096       True       7.00000  ...              False               True   \n",
       "1097    missing      30.00000  ...              False              False   \n",
       "1098    missing      43.00000  ...              False              False   \n",
       "1099      False      32.00000  ...               True               True   \n",
       "\n",
       "      spacy_mtd_outcome  spacy_dor_outcome  spacy_dlt_outcome  \\\n",
       "0                 False              False              False   \n",
       "1                 False              False               True   \n",
       "2                 False              False              False   \n",
       "3                  True              False               True   \n",
       "4                 False              False              False   \n",
       "...                 ...                ...                ...   \n",
       "1095              False              False              False   \n",
       "1096               True              False               True   \n",
       "1097              False              False              False   \n",
       "1098               True              False               True   \n",
       "1099              False              False              False   \n",
       "\n",
       "      spacy_cmax_outcome  spacy_aes_lead_outcome  spacy_dlt_lead_outcome  \\\n",
       "0                  False                    True                   False   \n",
       "1                  False                   False                    True   \n",
       "2                   True                   False                   False   \n",
       "3                   True                   False                    True   \n",
       "4                  False                   False                   False   \n",
       "...                  ...                     ...                     ...   \n",
       "1095               False                   False                   False   \n",
       "1096               False                   False                    True   \n",
       "1097               False                   False                   False   \n",
       "1098               False                   False                    True   \n",
       "1099                True                    True                   False   \n",
       "\n",
       "      spacy_mtd_lead_outcome  spacy_tmax_outcome  \n",
       "0                      False             missing  \n",
       "1                      False             missing  \n",
       "2                      False                True  \n",
       "3                       True                True  \n",
       "4                      False             missing  \n",
       "...                      ...                 ...  \n",
       "1095                   False             missing  \n",
       "1096                    True             missing  \n",
       "1097                   False             missing  \n",
       "1098                    True             missing  \n",
       "1099                   False                True  \n",
       "\n",
       "[1051 rows x 29 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# impute the mean for missing enrollment count\n",
    "clean_df['enroll_count'] = clean_df['enroll_count'].fillna(clean_df[\"enroll_count\"].mean())\n",
    "clean_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "466    NaN\n",
       "Name: study_eq_bins, dtype: category\n",
       "Categories (2, object): ['Low' < 'High']"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_df.loc[clean_df['study_eq_bins'].isna(), 'study_eq_bins']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_all_terms(value):\n",
    "    if isinstance(value, (list, dict)):\n",
    "        all_terms = []\n",
    "        for i in value:\n",
    "            text = i[\"measure\"].lower()\n",
    "            all_terms.append(text)\n",
    "        return all_terms\n",
    "    else:\n",
    "        return np.nan\n",
    "\n",
    "def concatenate_strings(series:list):\n",
    "    # Filter out np.nan and flatten the lists\n",
    "    all_strings = []\n",
    "    for i in series:\n",
    "        all_strings.extend(i.dropna().sum())  # Concatenate lists while dropping NaN\n",
    "    return ' '.join(all_strings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'number of participants with treatment-related adverse events as assessed by ctcae v4.0 to determine the mtd of allogenetic nk cells to determine mtd and dlt of gemcitabine oral formulation safety and tolerability of repeated ascending oral doses of 4sc-205. determination of the maximum tolerated dose (mtd) and dose-limiting toxicities (dlt). best objective response based on recist criteria (evaluable for response analysis set for recist criteria) dose-limiting toxicity dose limiting toxicity (dlts) maximum tolerated dose (mtd) of belinostat according to degree of liver dysfunction number of participants experiencing adverse events considered to be at least possibly related to the study drug pharmacokinetics (pk) of a single-dose belinostat (400 mg/m^2)) according to degree of liver dysfunction: maximum plasma concentrations (cmax) pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: area under the plasma concentration time curve extrapolated to infinity(auc0-inf) pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: area under the plasma concentration time curve extrapolated to infinity(auc0-inf) of belinostat pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: half-life (t1/2) pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: clearance (cl) pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: volume of distribution at steady state (vss) pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: metabolic ratios of maximum plasma concentrations (cmax) for the belinostat metabolic pathway pharmacokinetics (pk) of single-dose belinostat (400 mg/m^2) according to degree of liver dysfunction: metabolic ratios of area under the plasma concentration time curve extrapolated to infinity (auc0-inf) for the belinostat metabolic pathway phase i part: determination of the recommended dose of rad001 in combination with rituximab. phase ii part: complete response rate (cr+cru) safety maximum tolerated dose (mtd) pharmacokinetics assess the safety and tolerability of arq 092 in subjects with advanced solid tumors and recurrent malignant lymphoma by monitoring frequency and severity of adverse events safety and tolerability profile area under the plasma concentration time-curve from time 0 to the time of the last quantifiable concentration (auc0-t)of romidepsin area under the plasma concentration time-curve from time 0 to 24-hour (auc 0-24) area under the plasma concentration time-curve from time 0 extrapolated to infinity (auc0-âˆž) maximum observed plasma concentration (cmax) time to maximum observed plasma concentration (tmax) estimate of the terminal elimination half-life in plasma (t1/2) apparent total plasma clearance (cl) apparent total volume of distribution (vz) area under the plasma concentration time-curve from time 0 to the time of the last quantifiable concentration (auc0-t)of romidepsin area under the plasma concentration time-curve from time 0 to 24-hour (auc0-24) for romidepsin area under the plasma concentration time-curve from time zero extrapolated to infinity (auc0-âˆž). maximum observed plasma concentration (cmax)of romidepsin time to maximum observed plasma concentration (tmax) estimate of the terminal elimination half-life in plasma (t1/2) clearance (cl): apparent total plasma clearance. apparent total volume of distribution (vz). determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan. evaluate feasibility of repetitive cycles of this combination . aes saes incidence of dose limiting toxicities (dlts) - single agent incidence of dose limiting toxicities (dlts) - combination agents incidence of treatment emergent adverse events (safety and tolerability) incidence of adverse events (aes) safety and tolerability of the combination of abt-888 with topotecan hydrochloride in patients with refractory solid tumors and lymphomas; establish the maximum tolerated dose of abt-888 with topotecan hydrochloride. number of patients with adverse events maximum plasma concentration (cmax) of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib time of maximum plasma concentration (tmax) of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib terminal phase rate constant (Î»z) of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib in plasma terminal exponential half-life (t1/2) of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib in plasma area under the plasma concentration-time curve from time zero to time t (auc(0-t)) area under the plasma concentration-time curve from time zero to infinity (auc(0-inf)) percentage of area under the plasma concentration curve extrapolated to infinity (%auc(extra)) apparent clearance (cl/f) of lenvatinib from plasma apparent terminal volume of distribution in the terminal phase of lenvatinib (vz/f) renal clearance of lenvatinib (clr) percentage recovery of 14^c- lenvatinib related material in the urine percentage recovery of 14^c- lenvatinib related material in the feces to determine the maximum tolerated dose (mtd) and the recommended dose (rd) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas. maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) number of participants with adverse events and serious adverse events number of participants with abnormal clinical laboratory values reported as adverse events number of participants with clinically significant changes in vital signs reported as adverse events cmax: maximum observed concentration for alisertib tmax: time to first occurrence of cmax for alisertib aucÏ„: area under the concentration-time curve from time 0 to end of dosing interval (Ï„) for alisertib dose normalized aucÏ„: area under the concentration-time curve from time 0 to time t for alisertib t1/2: terminal half-life for alisertib rac: accumulation ratio for alisertib ptr: peak trough ratio during a dosing interval, at steady state for alisertib clss/f: apparent clearance after extravascular administration, at steady state, calculated using aucÏ„ for alisertib to describe the dose limiting toxicities, adverse event profile, and phase ii recommended dose of camptothecin-20-o-propionate hydrate (cz48). the number of patients with a dose-limiting toxicity (dlt) in the first treatment cycle maximum tolerated dose (mtd) of ca-170 recommended phase 2 dose (rp2d) of ca-170 primary outcome measures: maximum tolerated dose of lee011 when administered orally once daily, as assessed by frequency of dlts as a function of lee011 dose toxicity number of participants experiencing dose limiting toxicities (dlts) maximum tolerated dose (mtd) and dose-limiting toxicity (dlt) number, frequency and type of adverse events number of participants experiencing dose-limiting toxicities (dlts) maximum tolerated dose of idarubicin maximum tolerated dose (mtd) of medi-551 number of participants with treatment-emergent adverse events (teaes) or treatment-emergent serious adverse events (tesaes) number of participants with treatment-emergent adverse events (teaes) related to clinical laboratory abnormalities number of participants with treatment-emergent adverse events (teaes) related to vital signs, physical findings abnormalities number of participants with best overall response maximum tolerated dose (mtd) of lenalidomide in combination with rituximab maximum tolerated dose (mtd) of carfilzomib (cfz) after autologous stem cell transplantation (asct) safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory fl, assessed by number of subjects with adverse events (aes) tolerance score of cd5789 0.01% cream number of participants with adverse events (e.g. toxicity) response rate (complete response (cr) and partial response (pr)) maximum tolerable dose (mtd) of bortezomib when given in combination with ice chemotherapy in participants with relapsed and refractory classical hodgkin lymphoma (hl) number of participants with adverse events safety of lo-chop phase 1: number of participants with any treatment-emergent adverse event (teae) phase 1: number of participants with any grade 3 or higher teae phase 1: number of participants with any dose-limiting toxicity (dlt) phase 2: objective response rate (orr), defined as the percentage of participants achieving either a complete response (cr) or a partial response (pr), per the modified lugano classification for diffuse large b-cell lymphoma (dlbcl) percentage of participants with dose limiting toxicities (dlts) recommended phase 2 dose (rp2d) of atezolizumab mtd of everolimus in combination with r-chop adverse events profile toxicity profile proportion of patients who have a significant toxicity percentage of participants with cr at eoi, as determined by the investigator on the basis of positron emission tomography and computed tomography (pet-ct) scan safety and immunogenicity number of dose limiting toxicity incidents as per national cancer institute (nci) common terminology criteria for adverse events (ctcae) version (v) 3.0 (phase i) proportion of complete tumor responses defined as complete remission (cr) as the objective status (phase ii) overall response rate (orr; cheson 2007 criteria) number of participants reporting treatment-emergent adverse events maximum observed plasma concentration (cmax) of duvelisib time to maximum observed concentration (tmax) of duvelisib area under the plasma concentration-time curve (auc) of duvelisib dose limiting toxicity (dlt) maximum tolerated dose (mtd) response rate number of subjects with dose-limiting toxicities evaluation of the response to locally injected drugs maximum tolerated dose (mtd) of everolimus with panobinostat phase i maximum tolerated dose (mtd) of vorinostat number of participants with dose limiting toxicity for determination phase i (schedule a) mtd of vorinostat phase ii mtd of vorinostat response rate maximum tolerated dose overall survival median 3-year overall survival phase ib: percentage of participants with adverse events (aes) arm g+h (phase ii nf cohort): percentage of participants with aes cohort 1a (phase ib): percentage of participants with treatment emergent anti-drug antibodies (adas) to polatuzumab vedotin cohort 1b (phase ib): percentage of participants with treatment emergent adas to polatuzumab vedotin and obinutuzumab arms g+h: (phase ii nf cohorts): percentage of participants with treatment emergent adas to polatuzumab vedotin (lyophilized) phase ii randomized and nf cohorts: percentage of participants with complete response (cr) at primary response assessment (pra) based on positron emission tomography (pet)-computed tomography (ct) scan as determined by independent review committee (irc) arm h (phase ii nf cohort): percentage of participants with cr at pra based on pet-ct as determined by the irc arm g (phase ii nf cohort): area under concentration-time curve (auc) of polatuzumab vedotin (lyophilized) arm g (phase ii nf cohort): maximum concentration (cmax) of polatuzumab vedotin (lyophilized) arm g (phase ii nf cohort): systemic clearance (cl) of polatuzumab vedotin (lyophilized) arm g (phase ii nf cohort): steady-state volume of distribution (vss) of polatuzumab vedotin (lyophilized) feasibility (generation of autologous clinical grade ade1-lmp-specific ctl from the blood of ebv-positive lymphoma patients) safety as assessed by adverse event monitoring. patients will be questioned and toxicities recorded according to the international common toxicity criteria. reconstitution of ebv-specific ctl immunity with anti-viral efficacy measured by immunological & virological assessment of blood samples including immunophenotyping, intracellular cytokine assays, cd107 cytotoxicity assays and ebv dna load analysis. dose-limiting toxicity (phase i) maximum-tolerated dose (phase i) objective response (complete and partial response) (phase ii) safety as assessed by dose limiting toxicities (dlts) safety as assessed by determination of the maximum tolerated dose (mtd) safety as assessed by determination of the recommended phase 2 dose (rp2d) safety as assessed by and adverse events, laboratory assessments and physical examinations safety as assessed by mini-mental state examination (mmse) parts i & ii: number of participants experiencing clinical or laboratory adverse experiences (ae) part i: number of participants experiencing dose limiting toxicity (dlt) number of participants who experience adverse events as a measure of safety and tolerability overall response rate as assessed according to the\"revised response criteria for malignant lymphoma\" (cheson 2007). clinical benefit rate as assessed according to the \"revised response criteria for malignant lymphoma\" (cheson 2007). toxicity after every 3 courses of treatment and every month for up to a year after completion of study treatment dose limiting toxicity (dlt) for phase i patients maximum tolerated dose (mtd)for phase i patients overall objective response rate safety of 131i-anti-b1 radioimmunotherapy when combined with high-dose beam or beac chemotherapy & hsct frequency of dose-limiting toxicities (dlts) associated with cpi-0610 administration during the first cycle (first 21 days) of treatment dose limiting toxicity and recommended phase 2 dose to define the dose-limiting toxicity and maximum tolerable dose to evaluate the overall response rate determine the toxicity and maximum tolerated dose of doxorubicin hcl liposome when administered with combination chemotherapy in patients with aids-associated non-hodgkin\\'s lymphoma. to perform a dose escalation trial of atc armed with cd20bi immunotherapy after pbsct to determine the maximum tolerated dose (mtd) of atc armed with cd20bi. number of patients achieving complete response (cr) number of patients with grade 3 or greater toxicity 5-year overall survival (phase ii) 5-year disease-free survival (phase ii) safety of treatment using the national cancer institute (nci) hematologic common terminology criteria for adverse events (ctcae) version 3.0 survival of shi-tar-ccr5rz-marked cells in the peripheral blood, demonstrated by presence of transgene by q-pcr using primers specific for rhiv7-shi-tar-ccr5rz in serial samples of peripheral blood determination of rna transgene expression in samples of peripheral blood mononuclear cells (pbmcs) or marrow before and after infusion, analyzed by northern blotting/hybridization analysis of vector rescue by hiv ability to obtain suitable numbers of lentiviral vector treated hpc-a determination of replication competent lentivirus (rcl) and hiv-1/vector recombination complete response rate at 20 weeks number of participants with grade 3-5 adverse events percentage of participants with an increase in frequency of lmp2-specific cd8+ t cells maximum tolerated dose of bortezomib dose-limiting toxicity number of participants reporting one or more treatment-emergent adverse events (teaes) and serious adverse events (saes) number of participants reporting at least 1 teae related to laboratory assessments number of participants with clinically significant change from baseline in vital signs maximum tolerated dose (mtd) recommended phase 2 dose (rp2d) maximum tolerated dose of bortezomib overall lymphoma response rate safety as assessed using the ctcae platelet (plt) nadir days platelets count of < 100k/Î¼l dose-limiting toxicity of high-dose melphalan in combination with yttrium y 90 ibritumomab tiuxetan determine the maximum tolerated dose of absorbed radiation to critical organs delivered with this combination of study treatments response rate overall response rate (orr) overall response rate maximum tolerated dose safety and efficacy maximally tolerated dose (mtd) number of participants with dose limiting toxicities (dlt) recommended dose of vorinostat for combination with gemcitabine/busulfan/melphalan (gembumel) based on dose limiting toxicity (dlt) part 1: safety: subject incidence of treatment emergent adverse events, dose limiting toxicities, the severity of adverse events and clinically significant changes in safety laboratory tests, physical examinations, or vital signs. part 2: objective response rate of amg 655 therapy as determined by using iwg criteria at the dose selected in part 1, in combination with bortezomib in subjects with mantle cell lymphoma maximal tolerated doses of bortezomib and vincristine when used in combination of bortezomib, rituximab and the chop chemotherapy regimen (phase i) maximum tolerated dose (mtd) phase i-ii study of dose dense of peg-filgrastim and gm-csf combined with chop-r phase i: mtd / phase ii: orr maximum tolerated dose (mtd) to establish the maximum tolerated dose of sb1518 as a single agent when administered orally daily in subjects with advanced lymphoid malignancies. number of participants with adverse events (aes) dose limiting toxicities (dlt) during the first cycle safety and tolerability: frequency and severity of adverse events (ctcae v4.03) maximum tolerated dose (mtd) of t-cells Â± il-2 number of patients able to proceed to transplant number of patients achieving neutrophil engraftment number of patients achieving platelet engraftment toxicity toxicity percentage of participants who experienced a dose-limiting toxicity in phase i of the study percentage of participants with best overall response in phase ii of the study maximum tolerated dose (mtd) occurrence of adverse events grade â‰¥ 3 as assessed by ctcaev5 evaluating the diagnostic quality of thoracic ct exams performed at 50% of standard dose parameters adverse events evaluated by ctcae 4.03 number of participants who experienced dose-limiting toxicities (dlts) recommended dose of camidanlumab tesirine for part 2 number of participants reporting at least one treatment emergent adverse event (teae) number of participants reporting at least one treatment emergent serious adverse event (sae) proportion of patients with toxicities as assessed by the national cancer institute common terminology criteria for adverse events (nci/ctcae) version 3.0 grade >/= 3 to the magnicon generated idiotype (id) vaccine overall safety of idelalisib clinical response: overall response rate incidence rate of dose-limiting toxicities and adverse events maximum tolerated dose part a, phase i part a, phase iia part b, phase iib the maximum tolerated dose (mtd) of ruxolitinib in combination with standard dose bortezomib objective response rate (orr) assessed by independent radiology review committee (irrc) per the lugano 2014 classification number of subjects with adverse events (aes) determine the maximum tolerated dose (mtd) of snx-5422 when administered twice a week for 28 days. to establish the safety and tolerability of weekly (days 1, 8, 15 q28-day cycle) lmp400 in patients with refractory solid tumors and lymphomas incidence of dose limiting toxicities incidence of treatment-emergent adverse events (safety and tolerability) maximum tolerated dose (mtd) of aurixim -measure plasma concentrations of ipdr, idurd, and idurd metabolites after a single oral dose of ipdr.-determine the safety of administering a single oral dose of ipdr. overall response rate (orr) of nivolumab in combination with bendamustine hydrochloride in patients with hodgkin\\'s lymphoma percentage of participants achieving complete response (cr) at end of induction (eoi), as determined by the independent review committee (irc) using modified lugano 2014 criteria maximum tolerated dose (mtd) of brentuximab vedotin and bendamustine (phase 1) dose limiting toxicities (dlt) of brentuximab vedotin and bendamustine (phase 1) overall response rate for the combination of brentuximab vedotin and bendamustine (phase 2) area under the concentration (auc) time curve of bi 695500 and rituximab (mabtheraÂ®) over the first dosing interval (pre-infusion on day 1 to pre-infusion on day 8) plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, predose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 2, predose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, predose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 0.5 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 2, 0.5 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 0.5 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 4 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 4 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 24 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 24 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 48 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 48 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 72 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 72 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 96 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 96 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 144 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 144 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 1, 336 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 336 hour postdose plasma concentration of monomethylauristatin e (mmae) and its metabolites at cycle 3, 480 hour postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, predose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 0-24 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 24-48 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 48-72 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 72-96 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 96-120 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 120-144 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 144-168 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 336-360 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 1, 480-504 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, predose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 0-24 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 24-48 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 48-72 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 72-96 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 96-120 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 120-144 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 144-168 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 336-360 hours postdose amount of monomethylauristatin e (mmae) and its metabolites excreted in urine at cycle 3, 480-504 hours postdose minimum observed plasma trough concentration (c trough) determine the safety and the maximum tolerated dose of jnj-26481585. determine how jnj-26481585 and its metabolite, jnj-26395018, are absorbed, broken down and eliminated after oral administration safety safety and toxicity by nci ctc toxicity scale in patients w/ recurr. or refract. cd20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr determination of the maximum tolerated dose (mtd), dose-limiting toxicities (dlts), and recommended phase 2 dose (rp2d) of the combination of lenalidomide and brentuximab vedotin safety, tolerability, and maximum tolerated dose of oral administration of two formulations of xl147 in two treatment schedules safety and tolerability of oral dosing with xl147 capsules in subjects with lymphoma, and of xl147 capsules and tablets in subjects with solid tumors primary endpoints (phase i) - incidence rate of dlt and ae primary endpoint (phase ii) - response rate maximum tolerated dose overall response rate (orr) determine the maximum tolerated dose (mtd) of ezn-2968. maximum tolerated dose (mtd) number of participants with adverse events (aes) complete remission rate number of participants experiencing dose limiting toxicity (dlt) during combination treatment procedure-related mortality (prm) procedure-related mortality (prm) assessment of toxicity assessment of toxicity maximum tolerated dose dose limiting toxicities (dlt) maximum tolerated dose acceptable for participants maximum tolerated doses of carfilzomib and belinostat in combination maximum tolerated dose (mtd) of bortezomib incidence of adverse events incidence of laboratory abnormalities identification of the maximum tolerated dose and identification of the recommended dose of xmabÂ®2513 for evaluation in future studies. to determine the safety and tolerability of afm13 monotherapy. dose limiting toxicity rate (dlt) complete remission rate (cr) event free survival number of participants with a dose limiting toxicity (dlt) percentage of participants reporting one or more treatment-emergent adverse events (teaes), grade 3 or higher adverse events (aes), serious adverse events (saes) and aes leading to discontinuation number of participants with clinically significant vital signs findings (treatment related and unrelated) [phase 1] number of participants with clinically significant changes in electrocardiograms (ecgs) [phase 1] number of participants with clinically significant changes in multigated acquisition (muga)/ echocardiogram (echo) [phase 1] number of participants with clinically significant changes in physical examination findings [phase 1] number of participants with clinically significant laboratory tests reported as adverse events [phase 1] number of participants with treatment-emergent adverse events [phase 1] overall response rate [phase 2] objective response rate (orr) proportion of responders (complete -cr- or partial pr-) dose-limiting toxicity maximum tolerated dose (mtd) of panobinostat + ice number of participants with complete remission (cr) area under the curve (auc) at 0 to 120, 0 to 168, and 0 to infinity hours maximum concentration (cmax) values terminal phase half-life (tÂ½) clearance (cl) values volume of distribution at steady state (vss) establish the safety and tolerability of the combination of abt-888 with metronomic cyclophosphamide in patients with refractory solid tumors and lymphomas. establish the mtd of the combination of abt-888 with metronomic cyclophosphamide. dose-limiting toxicity number of participants with treatment-related adverse events as assessed by ctcae criteriaand astct 2018 (crs/nt) dose-limiting toxicity maximum tolerated dose whether intra-csf administration of rituximab in combination with mtx in patients with recurrent cns and intraocular lymphoma is associated with neurotoxicity safety of ha20 with this administration schedule and dosing tolerance of ha20 with this administration schedule and dosing immunogenicity of ha20 with this administration schedule and dosing maximum tolerated dose (mtd) maximal administered dose (mad) adverse event (ae) determine the maximal tolerated dose (mtd) of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma number of patients who received 2 doses of natural killer (nk) cell infusions number of patients who received the highest dose level of nk cells (1x10^6 nk cells/kg for patients with related donors and 1 x10^5 nk cells/kg for patients with unrelated donors) with sustained donor lymphoid engraftment maximum tolerated dose (mtd) of donor lymphocyte infusion (dli) incidence of adverse events and laboratory abnormalities all phase i-ii participants: overall response rate (orr) phase i participants only: overall response rate (orr) gamma camera-based whole-body 99mtc-1-thio-d-glucose uptake value (percent) spect-based 99mtc-1-thio-d-glucose value in tumor lesions (counts) spect-based 99mtc-1-thio-d-glucose uptake value (counts) tumor-to-background ratio (spect) evaluate the safety and tolerability of alrn-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (wt) tp53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - phase 1 evaluate the safety and tolerability of alrn-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (wt) tp53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - phase 2 determine the maximum tolerated dose (mtd) - phase 1 determine overall response rate - phase 2 to establish the mtd and dlt of pazopanib in groups of patients with varying degrees of hepatic dysfunction (mild, moderate, and severe) to provide appropriate dosing recommendations for panzopanib in such patients. maximum tolerated dose (mtd) of t-cell infusions occurrence of any grade 4 or greater suspected adverse reaction occurrence of grade iii or iv acute graft-versus-host disease (agvhd) frequency of dose-limiting toxicities (dlts) plasma pk of [14c] tazemetostat, tazemetostat, and its metabolite epz-6930 after iv administration of approximately 12 Âµg of [14c] tazemetostat containing approximately 500 nci of radioactivity and oral bid administration of 800 mg tazemetostat (auc 0-7) total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14c] tazemetostat containing approximately 400 Âµci (14.8 mbq) of radioactivity phase 1b/2 : overall response rate of number of participants number of patients without gvhd at 100 days maximum tolerated dose maximum tolerated dose (mtd) of the combination of pralatrexate and romidepsin overall response rate (orr) (complete + partial response) of the combination of pralatrexate and romidepsin in patients with relapsed/refractory t-cell lymphoma maximum tolerated dose toxicity profile of et190l1 artemisâ„¢ t-cell treatment tmax of serum cytokine levels time to baseline for serum cytokine levels auc of serum cytokine levels duration of in vivo engraftment of et190l1 artemisâ„¢ t cells the number of adverse events, serious adverse events, and dose limiting toxicities as a measure of safety and tolerability overall response maximum tolerated dose (mtd) of mitoxantrone number of participants with graft failure maximum tolerated dose toxicity efficacy dose-limiting toxicity percentage of participants with adverse events. objective remission rate(orr) maximum tolerated dose (mtd) and pharmacokinetics (pk) of rp6530 percentage of participants with complete response (cr) at end of induction (eoi), as determined by the independent review committee (irc) using modified lugano 2014 criteria percentage of participants with adverse events safety: incidence and severity of (serious) adverse events n each patient according to the nci-ctcae4.03 grading incidence of adverse events mtd based on the incidence of dose-limiting toxicity (dlt) assessed by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 to determine the safety of giving 3rd party ebv-ctls to develop a third party bank of lmp-specific ctl determine rate of dose limiting toxicities number of participants with dose limiting toxicities to determine maximum tolerated dose. pharmacokinetics: serum concentration of cpx-351 components (cytarabine and daunorubicin) and metabolites. number of treatment-emergent adverse events (teaes) severe infusional toxicity safety of administering fucosylated umbilical cord blood (cb) regulatory t cells (tregs) in a cbt, mrd, or mud transplant phase i maximum tolerated dose phase ii overall response dose escalation: maximum tolerated dose (mtd) of tislelizumab dose escalation: rp2d of tislelizumab maximum tolerated dose of anti-tumor necrosis factor (tnf) receptor superfamily member 8 (cd30) chimeric antigen receptor (car) in participants with advanced cd30-expressing lymphomas number of participants with and without dose limiting toxicities (dlts) number of deaths due to adverse events (aes) number of treatment discontinuations due to ae proportion of participants with serious adverse events (saes) proportion of participants with cytokine release syndrome (crs) by grade of severity incidence rate of dose-limiting toxicities (dlts) observed during the dlt assessment period (cycle 1) at each dose level examined non-hematological toxicity; > grade three(ctcae v.3.0), during the treatment cycle (twenty one days) mtd of lenalidomide (phase i) progression free survival (phase ii) percentage of participants with cr at eoi determined by an independent review committee (irc) on the basis of positron emission tomography (pet) and computed tomography (ct) scans fl cohorts: percentage of participants with adverse events (aes) and serious adverse events (saes) dlbcl cohorts: percentage of participants with aes and saes number of participants with dose-limiting toxicities (dlts) rp2d of polatuzumab vedotin rp2d of venetoclax dose-limiting toxicity (dlt) and maximum tolerated dose (mtd) number of participants with adverse events overall response rate percentage of enrolled participants who actually get treated to determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose of cddo when administered in adult patients with solid tumors and lymphomas. number of participants who experienced dose-limiting toxicities (dlts) recommended dose of adct-402 for part 2 number of participants reporting at least one treatment emergent adverse event (teae) number of participants reporting at least one treatment emergent serious adverse event (sae) number of participants (par.) during initial treatment exposed to the indicated dose levels of the therapeutic dose (td), re-dose, and total dose (td + re-dose) number of participants during retreatment exposed to the indicated dose levels of the td, re-dose, and total dose (td + re-dose) maximum tolerated dose (mtd) of tst/i 131 tst evaluated in the study tumor/organ dosimetry of tst/i 131 tst for all predoses (initial treatment) pharmacokinetic indexes, cmax maximum concentration (cmax) pharmacokinetic indexes, tmax pharmacokinetic indexes, maximum concentration (cmax,u) number of participants who received preparative chemotherapy followed by cluster of differentiation (cd)19-chimeric antigen receptor (car): cd19 car t-cells with < grade 4 cytokine release syndrome number of participants in which the prescribed dose of cluster of differentiation (cd)19-chimeric antigen receptor (car): cd19 car t-cells were successfully manufactured toxicity and safety of concurrent chop and alemtuzumab maximum tolerated dose (mtd) of recombinant human interleukin-15 (rhil-15) for 10 day dosing maximum tolerated dose (mtd) of recombinant human interleukin-15 (rhil-15) for 5 day dosing number of participants with grades 3, 4 or 5 dose-limiting toxicity (dlt) related to study drug part i: number of participants experiencing treatment-emergent adverse events and treatment-emergent serious adverse events part ii: overall response rate (orr) of zanubrutinib in participants with fl and mzl part ii: complete response rate (crr) of zanubrutinib in participants with fl and mzl part ii: partial response rate (prr) of zanubrutinib in participants with fl and mzl part ii: duration of response (dor) of zanubrutinib in participants with fl and mzl part ii: progression free survival (pfs) of zanubrutinib in participants with fl and mzl area under the curve (auc) for gb241 and rituximab concentrations maximum tolerated dose of lenalidomide combined with bortezomib and rituximab in phase i participants incidence of non-serious adverse events as a measure of safety and tolerability, phase ii frequency of dlt participants with event-free survival (efs) phase i: the maximum tolerated dose (mtd) of temsirolimus in combination with bortezomib, rituximab and dexamethasone phase ii: progression-free survival dose limiting toxicity (dlt) maximum tolerated dose (mtd) non-tolerated dose (ntd) adverse events (aes) occurrence of dose-limiting toxicities (dlt) incidence and severity of adverse events (aes) incidence of dose limiting toxicities objective response rate the occurrence of dose limiting toxicity (dlt); determine mtd change in cardiac assessment findings percentage of subjects with adverse events change in clinical laboratory test results number of subjects with adverse events change in physical exam finding, including vital signs the number of subjects experiencing a dose limiting toxicity at various dose levels when given multiple doses of cx-072 as a monotherapy or in combination with ipilimumab or vemurafenib number of patients who achieved complete response to determine the maximum tolerated dose (mtd) to determine the safety profile pharmacokinetic profile effect on pharmacodynamic biomarkers antitumor activity dose-limiting toxicity (dlt) maximum tolerated dose maximum tolerated dose (mtd) of nc-4016 maximal tolerable dose (mtd) absorbed dose to the liver, safety and time to treatment failure (ttf) recommended dose global response rate prior to asct complete response correlation coefficient between change from baseline in fluoro-l-thymidine positron emission tomography (flt-pet) maximum standard uptake value (suvmax) and in phosphorylated retinoblastoma (phospho-rb) percent positive cells at cycle 1 day 21 correlation coefficient between change from baseline in fluorodeoxyglucose positron emission tomography (fdg-pet) maximum standard uptake value (suvmax) and in phosphorylated retinoblastoma (phospho-rb) percent positive cells at cycle 1 day 21 change from baseline in maximum standard uptake value (suvmax) at cycle 1 day 21 correlation between positron emission tomography (pet) response and progression-free survival (pfs) correlation between positron emission tomography (pet) response and objective response (or) phosphorylated retinoblastoma (phospho-rb) percent positive cells at baseline phosphorylated retinoblastoma (phospho-rb) percent positive cells at cycle 1 day 21 ki-67 composite score at baseline ki-67 composite score at cycle 1 day 21 cyclin d1 composite score at baseline cyclin d1 composite score at cycle 1 day 21 number of participants with laboratory test abnormalities number of participants with treatment-emergent adverse events by severity number of participants with treatment-related adverse events (aes) and serious adverse events (saes) part 1: percentage of participants who experienced a dose-limiting toxicity (dlt) per common terminology criteria for adverse events, version 4.0 (ctcae 4.0) parts 1 and 2: number of participants who experienced one or more adverse events (aes) parts 1 and 2: number of participants who discontinued study drug due to an ae number of dose-limiting toxicities auc0-inf of ibi301 and rituximab the primary objectives of this study are to determine: a) the appropriate doses of bortezomib and 131i-tositumomab when used in combination. b) toxicities of the combination treatment. participants reporting dose limiting toxicity (dlt) adverse events (aes) for participants in the de cohort and the mtd confirmation cohort for arm 1 participants reporting dlt aes for participants in the de cohort and the mtd confirmation cohort for arm 2 percentage of participants with best overall response (or) of complete response (cr) or partial response (pr) according to international response criteria for nhls in the mtd and ee cohorts percentage of participants with a treatment emergent ae percentage of participants with any grade 3/4 chemistry abnormality during therapy percentage of participants with any grade 3/4 hematology abnormality during therapy incidence of dose-limiting toxicity (dlt), phase i patients only complete response (phase ii) overall response rate (phase ii) number of participants with dose-limiting toxicity (dlt) incidence of adverse events incidence of laboratory abnormalities number of participants with adverse events intensity of ae objective tumor response (or) recommended dose determined in the dose escalation/safety evaluation adverse events and lab abnormalities. maximum tolerated dose (mtd) of hbi-8000 in adult japanese patients with non hodgkin\\'s lymphoma (nhl) for whom no other standard therapy is suitable based on the frequency of dose-limiting toxicities (dlts) which occur within 28 days. number of participants with treatment-emergent adverse events (aes) and serious adverse events (saes) number of participants with grade 3 or higher grades treatment-emergent adverse events (teaes) based on severity maximum tolerated dose (mtd): part 1 (dose escalation cohorts) number of participants with dose-limiting toxicity (dlt) incidence of adverse events assessed using nci ctcae version 4 mtd defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity assessed using national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4 optimal bendamustine dosage for further studies maximum tolerated dose of bortezomib (phase i) time to failure (phase ii) pk parameter pk parameter pk parameter pk parameter pk parameter to evaluate the the number of subjects with adverse events who receive sb-485232 when given in combination with ofatumumab to assess the safety and tolerability of rad001 in japanese patients with relapsed or refractory non-hodgkin\\'s lymphoma to assess the pharmacokinetics in japanese patients maximum tolerated dose (mtd) of inotuzumab ozogamicin in combination with rituximab (375 mg/m^2 ) percentage of participants with a treatment emergent adverse event (teae) (safety population) incidence and severity of adverse events, dose-limiting toxicities, and changes in laboratory test results. incidence of dlt(s) at each dose level tolerated dose (mtd) of clofarabine characterize and quantify the toxicity profile associated with clofarabine determine the overall response rate, plus partial response of clofarabine safety and tolerance of different dose levels percentage of participants with a best overall response (or) of complete response (cr) or partial response (pr) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c) duration of objective response (dor) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c) percentage of participants with cr at end of treatment (eot) based on positron emission tomographic/computed tomography (pet/ct) assessment determined by independent review committee (irc) per lugano 2014 response criteria: cohorts e, g, and h maximum tolerated dose (mtd) of vorinostat given orally for 10 days in combination with cyclophosphamide, etoposide, prednisone and rituximab for elderly patients with relapsed diffuse large b-cell lymphoma determination of the maximum tolerated dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin\\'s lymphoma determination of peak concentration (cmax), trough concentration (ctrough) and/or area under the concentration versus time curve (auc) of abt-199, bendamustine and rituximab in the dose escalation cohort number of participants with adverse events as a measure of safety and tolerability determination of the recommended phase 2 dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin\\'s lymphoma determine the response rate to obatoclax in combination with bortezomib and characterize the safety profile incidence and severity of adverse events through 1 month after completing treatment incidence and grade of clinical laboratory abnormalities through 1 month after treatment number of participants with dose-limiting toxicities (dlt) cmax (cycle 1 day 1) of copanlisib auc(0-24) (cycle 1 day 1) of copanlisib auc(0-tlast) (cycle 1 day 1) of copanlisib cmax (cycle 1 day 15) of copanlisib auc(0-24) (cycle 1 day 15) of copanlisib number of participants with dose limiting-toxicities (dlts) after sc administration number of participants with dlts ctcae grade â‰¥ 3 after sc administration number of participants with treatment-emergent adverse events (teaes) after sc administration selected dose of aflibercept based on dose limiting toxicities observed phase i: maximum-tolerated dose of bendamustine in combination with ofatumumab, carboplatin and etoposide (boce) overall frequency of response with combination of bendamustine, ofatumumab, carboplatin, and etoposide at maximum tolerated dose (mtd) maximum tolerated dose assessed by the number of subjects with dose-limiting toxicities (dlts) evaluation of safety and tolerability maximum tolerated dose the maximum tolerated dose of iodine-131 anti b-1 antibody in patients with previously treated nhl having more than 25% bone marrow involvement with lymphoma. pet and ct (w/oral and iv contrast) number of participants with treatment-related adverse events as assessed by ctcae v4.0 plasma levels for gsk461364 will be taken at:schedule 1:day 1, 8, 15, & 22 for cycle 1 and day 1, 8 & 15 for subsequent cycles.schedule 2:day 1, 2, 8, 9, 15, & 16 for all cycles.schedule 3:day 1 to 5 for all cycles. adverse events determination of the maximum tolerated dose (mtd) based on the occurrence of dose-limiting toxicity (dlt) in first cycle in caucasian patients number of subjects with dose limiting toxicities (dlt) in first cycle in caucasian patients number of participants with adverse events percentage of participants with dose-limiting toxicities maximum tolerated dose (mtd) of dcds0780a recommended phase 2 dose (rp2d) of dcds0780a phase i: maximum tolerated dose (mtd) of lenalidomide to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin\\'s lymphoma maximum tolerated dose for cyclophosphamide (mtd) to characterize the safety profile of idec-114 and to define their duration and reversibility safety of rp6530 overall response rate incidence of hematological toxicities > grade 2 by common terminology criteria v4.0 to determine the maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) of oral fimepinostat (cudc-907) in combination with venetoclax and rituximab to assess the safety and tolerability of fimepinostat in combination with anti-cancer regimens by evaluating the number of participants with adverse events assessed using the nci common terminology criteria for adverse events (ctcae, v4.0). to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating orr to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating dor percentage of participants with adverse events (aes) percentage of participants with dose-limiting toxicities (dlts) maximum tolerated dose (mtd) of gdc-0575 recommended phase ii dose of gdc-0575 area under the curve from time zero to extrapolated infinite time (auc0-inf) of gdc-0575 area under the curve from time zero to end of dosing interval (auctau) maximum observed plasma concentration (cmax) gdc-0575 minimum observed plasma trough concentration (cmin) of gdc-0575 time to reach maximum observed plasma concentration (tmax) of gdc-0575 apparent terminal half-life (t1/2) of gdc-0575 apparent oral clearance (cl/f) of gdc-0575 accumulation ratio (rac) of gdc-0575 pk-dose proportionality as assessed with cmax of gdc-0575 pk-dose proportionality as assessed with auc of gdc-0575 phospho-cyclin-dependent kinase 2 (pcdk2) levels in fresh tumor phospho-cyclin-dependent kinase 2 (pcdk2) levels in skin tissue gamma-h2ax (Î³-h2ax) levels in fresh tumor gamma-h2ax (Î³-h2ax) levels in skin tissue treatment related toxicity engraftment cmax: maximum observed plasma concentration for ixazomib auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for ixazomib tmax: time to reach the maximum plasma concentration (cmax) for ixazomib part 1: maximum tolerated dose (mtd) of jnj-42756493 dose-limiting toxicityï¼ˆdltï¼‰ maximum tolerated dosed (mtd) pharmacokinetics (pk) cd19+ b lymphocyte ratio anti drug antibodies (ada) orr number of participants with adverse events in diffuse large b-cell lymphoma (dlbcl) population number of participants with adverse events in non-dlbcl population number of participants with dose limiting toxicities (dlts) in dlbcl population number of participants with dlts in non-dlbcl population number and percentage of participants with adverse event, serious adverse event, clinically defined abnormal vital signs, laboratory values, ecg abnormalities maximum tolerated dose (mtd) for brentuximab vedotin adverse events graded according to national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 the number of patients with relapsed or refractory hl who achieved complete response (cr) safety: number of participants with dose-limiting toxicities (dlts) percentage of previously untreated dlbcl participants with complete response (cr) defined by positron emission tomography-computed tomography (pet/ct) scan using the modified lugano classification assessed by independent review committee (irc) percentage of participants with cr defined by pet/ct scan in previously untreated dlbcl co-expressing both bcl-2 and c-myc proteins (de-dlbcl) participants assessed by irc part a: effect of cyp3a inhibition by fluconazole on the pk of tazemetostat (auc0-t, auc0-8) part a: cmax of tazemetostat during co-administration with fluconazole part b: the potential of tazemetostat to inhibit or induce cyp2c8 using repaglinide as a probe substrate (auc0-t, auc0-âˆž) part b: cmax of repaglinide during co-administration with tazemetostat part b: the potential of tazemetostat to inhibit or induce cyp2c19 using omeprazole as probe a substrate (auc0-t, auc0-âˆž) part b: cmax of omeprazole during co-administration with tazemetostat part b: effect of increased gastric ph by omeprazole on the pk of tazemetostat (auc0-t, auc0-8) part b: cmax of tazemetostat during co-administration with omeprazole maximum tolerated dose recommended phase ii dose determination of the maximum tolerable dose and evaluation of response rate maximum tolerated dose dose limiting toxicities percentage of participants with adverse events (aes) - relapsed/refractory population percentage of participants with aes - first-line population to characterize the safety profile and to define the dose of galiximab to be used for the phase ii portion of the study the primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of ar-12. incidence of dose limiting toxicity(ies) at each tested dose level cmax: maximum observed concentration for alisertib in presence and absence of esomeprazole auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib in presence and absence of esomeprazole aucâˆž: area under the plasma concentration-time curve from time 0 to infinity for alisertib in presence and absence of esomeprazole tmax: time to reach the maximum plasma concentration (cmax) for alisertib in presence and absence of esomeprazole terminal phase elimination half-life (t1/2) for alisertib in presence and absence of esomeprazole cmax: maximum observed concentration for alisertib in presence and absence of rifampin auc(last): area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib in presence and absence of rifampin aucâˆž: area under the plasma concentration-time curve from time 0 to infinity for alisertib in presence or absence of rifampin tmax: time to reach the maximum plasma concentration (cmax) for alisertib in presence and absence of rifampin phase elimination half-life (t1/2) for alisertib in presence and absence of rifampin change from the time-matched baseline in the individually corrected qtc interval (qtci) safety, tolerability and maximum tolerated dose of orally administered pxd101 for each cohort determination of maximum observed plasma concentration (cmax), time to cmax (peak time, tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (auc) of abt-199 incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose determine the maximum tolerated dose (mtd) of clofarabine in association with high-dose etoposide and cyclophosphamide followed by asct in patients with refractory lymphoma malignancies. maximum change from baseline in expression of pathway inhibition (pakt) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy percentage of participants experiencing treatment-emergent adverse events (teaes) and serious adverse events (saes) within 28 days of idelalisib exposure percentage of participants experiencing teaes related to idelalisib within 28 days of idelalisib exposure percentage of participants experiencing treatment-emergent laboratory abnormalities within 28 days of idelalisib exposure by worst grade at postbaseline percentage of participants who permanently discontinued idelalisib due to a teae within 28 days of idelalisib exposure plasma concentration of idelalisib and its major metabolite gs-563117 on day 1 plasma concentration of idelalisib and its major metabolite gs-563117 on day 8 plasma concentration of idelalisib and its major metabolite gs-563117 on day 15 plasma concentration of idelalisib and its major metabolite gs-563117 on day 22 plasma concentration of idelalisib and its major metabolite gs-563117 on day 29 orr assess the safety and tolerability of emd 521873 to determine whether the mtd is reached with emd 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose cpa in patients with metastatic or locally advanced solid tumors or b-cell non-hodgkin lymphoma safety/tolerability number of participants with a grade 3 or higher toxicity graded according to national cancer institute common terminology criteria for adverse events version 4.0 determine the safety and adverse-event profile for combination therapy of sgn-40 with gemcitabine and rituximab. pb cd34+ kinetics using vtp195183 plus g-csf phase i to determine the maximum tolerated dose (mtd) of mgd when administered once weekly to patients with relapsed or refractory cll/sll to determine the dose-limiting toxicities (dlts) of mgd when administered once weekly to patients with relapsed or refractory cll/sll phase ii to assess the complete and partial response rate in patients with relapsed or refractory cll/sll when administered mgd once weekly at the mtd number of participants with serious and non-serious adverse events maximum tolerated dose (mtd) of siplizumab mtd of pomalidomide when given in combination with dexamethasone determined by dose-limiting toxicities graded according to national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.0 the safety of lenalidomide evaluated based on the severity of adverse events and their causality maximum tolerated dose maximum tolerated dose acceptable for participants number of participants who experienced one or more adverse events (aes): number of participants who discontinued study treatment due to an adverse event (ae) objective response rate (orr) in cohort 1: myelodysplastic syndrome (mds) objective response rate (orr) in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) complete remission rate (crr) in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) objective response rate (orr) in participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) objective response rate (orr) in the cohort 4 non-hodgkin lymphoma (nhl) individual sub-cohorts (cohorts 4a, 4b, 4c, and 4d) objective response rate (orr) in participants pooled from cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide) relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) safety/tolerability of combination treatment for 4 weeks safety/tolerability of sb-485232 for additional 8 weeks complete response number of adverse events after car 20/19-t cell infusion dose-limiting toxicity (dlt) maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin. determination of the maximal tolerated dose (mtd) determination of dose limiting toxicity (dlt) occurrence of dose limiting toxicities (dlt) adverse events in terms of dose-limiting toxicity (dlt) and mtd of bendamustine hydrochloride (phase i) maximum tolerated dose (mtd) of gemcitabine with busulfan + melphalan number of participants with adverse events as a measure of safety and tolerability maximum tolerated dose acceptable for participants evaluate the safety of the micro array needle doxorubicin (mna-d) system confirmed by vital signs, hematology, comprehensive metabolic panel, assessment for skin toxicity, and adverse event evaluation. maximum tolerated dose (mtd) and recommended dose (rd) phase 1a: determine dose limiting toxicity (dlt), maximum tolerated dose (mtd) and recommended phase 2 dose (rptd) and schedule - intermittent dosing. phase 1b: determine dose limiting toxicity (dlt), maximum tolerated dose (mtd) and recommended phase 2 dose (rptd) and schedule - continuous dosing. phase 2a: continued assessment of safety profile at the recommended phase 2 dose (rptd) and schedule - continuous dosing. phase 2a: assessment of preliminary efficacy signals including biomarker assessment - continuous dosing. extension study: continued assessment of the safety profile of abt-263 extension study: continued assessment of the preliminary efficacy signals of abt-263. incidence of dose limiting toxicities safety: adverse events, vital signs, clinical and laboratory parameters, physical exams, and ecgs efficacy: evaluate tumor response as measured by the composite assessment of index lesion disease severity (ca). the primary endpoint will be the overall tumor response rate as assessed by the ca. maximum tolerated dose (recommended phase ii dose) adverse events (type, frequency, severity) number of subjects with adverse event number of adverse events number of subjects with abnormality (common terminology criteria for adverse events [ctcae] grade â‰¥3) in laboratory test values number of subjects with grade â‰¥3 physical examination finding number of subjects with dose limiting toxicity in dlbcl arm maximum tolerated dose determine an effective and well-tolerated dose and schedule of pralatrexate with vitamin b12 and folic acid supplementation for patients with relapsed or refractory cutaneous t-cell lymphoma (ctcl) maximum tolerated dose of the combination of romidepsin and carfilzomib best overall response rate (pr + cr) at the mtd change in the absolute number of cmv-induced adaptive nk cells (cd56dimcd57+nkg2c+) between days 28 and 100 post-auto-hct in patients with lymphoid malignancies. number of participants with treatment-emergent adverse events (â‰¥10% overall) in participants receiving milademetan number of participants with dose-limiting toxicities in participants receiving milademetan by preferred term and worst grade by nci ctcae number of participants with melanoma and diffuse large b cell lymphoma who achieved objective response number of participants with treatment related dose limiting toxicity as assessed by nci ctcae v4.0 number of participants with adverse events as a measure of safety and tolerability percentage of patients with complete or partial response as measured by change in lesion severity using cails (composite assessment of index lesion severity) maximum tolerated dose (mtd) and dose limiting toxicity (dlt) recommended phase 2 dose objective response rate (orr) per independent central review committee to identify the mtd of tak-901 administered as either a 3-hour or 1-hour infusion. to adaptively adjust the estimate of the mtd of tak-901 from the escalation phase in an expansion cohort of subjects. maximum tolerated dose the number of participants that tolerated the maximum drug dose to assess the safety and to determine the maximum tolerated dose of pemetrexed given intravenously for the treatment of recurrent lymphoma invading the cns. maximum tolerated dose (mtd), dose limiting toxicity (dlt) and recommended phase ii dose (rp2d) safety of cnct19 therapy: ctcae v5.0 maximum tolerated dose (mtd) of carfilzomib maximum tolerated dose (mtd) incidence of dose-limiting toxicity and adverse events maximum tolerated dose/maximum administered dose (mtd/mad) (phase 1) complete response rate (crr); percentage of participants experiencing positron emission tomography (pet)-negative complete response (cr) (phase 2) number of participants with abemaciclib dose-limiting toxicity (dlt) cmax: maximum observed plasma concentration of alisertib auc(last): area under the plasma concentration curve from time 0 to the time of the last quantifiable concentration of alisertib aucâˆž: area under the plasma concentration curve from time 0 to infinity of alisertib incidence of dose-limiting toxicity and adverse events maximum tolerated dose of cpg 7909 as determined using the number of participants with a dlt at each dose level tumor response safety of the study treatments when given in combination [incidence of adverse events] number of participants with a response assessed by the response criteria for malignant lymphoma incidence and severity of aes and saes, incl. changes in laboratory parameters, vital signs and ecgs. incidence of dlts during the first cycle of treatment with single agent mik665 during the dose escalation phase only tolerability: dose interruptions tolerability: dose reductions tolerability: dose intensity safety and tolerability of vorinostat (saha) after autologous stem cell transplantation number of adverse events maximum tolerated dose maximum tolerated dose (mtd) incidence of related adverse events [safety and tolerability] safety and tolerability of bexarotene in combination with ecp, assessed with nci toxicity assessment, at each treatment visit, every 3 weeks and at final one month foll to determine the maximum tolerated dose and phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors. define toxicities and pharmacokinetics. relief degree evaluated by the recist number of participants with dose-limiting toxicity (dlt) in accordance with national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 3.0 as determined by the efficacy and safety evaluation committee (esec) percentage of ptcl participants with an overall best response in accordance with a modified international workshop response criteria (iwc) 1999 in phase 2 maximum tolerated dose dlt mtd an evaluation of general safety will be undertaken: Â· number of systemic clinical and biological adverse events occurring during the study. Â· number of patients who prematurely discontinued study treatment for reasons linked to the general safety. determine maximum tolerated dose of the drug pharmacokinetics (pk) of leucovorin safety of the anti-cd74 antibody will be evaluated based upon physical examinations, hematology and chemistry laboratory evaluations and toxicity events maximum tolerated dose of di-leu16-il2 optimal biologic dose of di-leu16-il2 toxicities associated with the di-leu16-il2 regimen maximally tolerated dose of bendamustine hydrochloride that can be combined with rituximab, carboplatin, and etoposide chemotherapy in patients with relapsed or refractory lymphoid malignancies safety and toxicity of this regimen percentage of participants with dose-limiting toxiciities (dlt)- part 1 percentage of participants with adverse events (aes) - part 1 percentage of participants with clinically significant changes in vital signs, physical examination, clinical laboratory results and electrocardiogram (ecg) findings- part 1 complete response (cr) rate as determined by independent radiological central review (icr) using modified lugano response criteria- recommended dose (rd) expansion - part 2 overall response (or) rate as determined by independent radiological central review (icr) using modified lugano response criteria- rd expansion - part 2 number of participants with adverse events based on the ctcae v.4 pharmacokinetics (pk): area under the concentration -time curve over a dosing interval at steady state (auct,ss) of enzastaurin, it\\'s metabolites and total analytes in plasma pk: maximum observed drug concentration at steady state (cmax,ss) of enzastaurin, it\\'s metabolites and total analytes in plasma pk: time of maximal plasma concentration at steady state (tmax, ss) of enzastaurin, it\\'s metabolites and total analytes in plasma pk: average concentration during a dosing interval at steady state (cav,ss) of enzastaurin, it\\'s metabolites and total analytes in plasma pk: terminal elimination half-life of enzastaurin, it\\'s metabolites and total analytes in plasma incidence of dose limiting toxicities (dlt) to characterize the pk profile of 3 daily intravenous (iv) doses of rhukgf before total body irradiation (tbi) / high-dose chemotherapy conditioning treatment and after pbpc transplantation safety and tolerability clinically significant or > or = to grade 3 ctcae changes in safety laboratory tests, physical exams, ecgs or vital signs pk parameters clinical/radiological response rate for cll subjects treatment-emergent adverse events maximum-tolerated dose (mtd) of yttrium-90-bc8-dota progression-free survival following autologous stem cell transplant (asct) mtd defined as the dose level at which no more than one of 6 patients experiences a dlt summarized using the national cancer institute (nci) ctcae version 4.0 qtc interval maximum tolerated dose of lenalidomide (phase i) maximum tolerated dose of bendamustine part 1 and 2: area under plasma concentration-time curve from time zero to infinity (aucinf) part 1 and 2: area under the plasma concentration time curve from time zero to time of last quantifiable concentration (auclast) part 1 and part 2: maximum observed plasma concentration (cmax) part 1 and part 2: area under the plasma concentration-time curve from time zero to 24 hours post dose (auc0-24) part 1 and 2: time to reach maximum observed plasma concentration (tmax) part 1 and 2: half-life associated with terminal slope (Î»z) of a semi-logarithmic concentrationtime curve (t1/2) part 1 and 2: mean residence time of the drug in the systemic circulation from zero to infinity (mrt) part 1 and 2: terminal elimination rate constant (Î»z) part 1 and 2: apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only (cl/f) part 1 and 2: apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (vz/f) part 1 and 2: metabolite to parent ratio based on aucinf and/or auclast (m:p[auc]) part 1 and 2: metabolite to parent ratio based on cmax (m:p[cmax]) incidence of adverse events and laboratory abnormalities mtd, safety and toxicity objective response rate (orr) time elapsed (in hours) from end of hdmtx to a serum methotrexate level <0.1 micromol/l to determine the mtd of px-478 administered orally on days one to five of a 21 day cycle number of patients that experienced dlt during cycle 1 of therapy cmax: maximum observed plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution tmax: time of first occurrence of cmax for alisertib and drug-related material in plasma following a single dose of [^14c]-alisertib oral solution auclast: area under the concentration-time curve from time 0 to time of the last quantifiable plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution aucâˆž: area under the concentration-time curve from time 0 to infinity, calculated using the observed value of the last quantifiable plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution t1/2: terminal half life for alisertib and drug-related material in plasma following a single dose of [^14c]-alisertib oral solution cl/f: apparent clearance after extravascular administration, calculated using the observed value of the last quantifiable plasma concentration for alisertib following a single dose of [^14c]-alisertib oral solution ratio of whole blood total radioactivity (tra) cmax to plasma tra cmax ratio of alisertib plasma cmax to drug-related material tra plasma cmax ratio of whole blood tra auclast to plasma tra auclast ratio of alisertib plasma auclast to drug-related material tra plasma auclast ratio of whole blood tra aucâˆž to plasma tra aucâˆž ratio of alisertib plasma aucâˆž to drug-related material tra plasma aucâˆž fe: fraction of administered dose of [^14c]-alisertib excreted in urine fe: fraction of administered dose of [^14c]-alisertib excreted in feces ae: amount of [^14c]-alisertib excreted in urine ae: amount of [^14c]-alisertib excreted in feces percent of total radioactivity (tra) in urine and feces fe: fraction of administered dose of alisertib excreted in urine ae: amount of alisertib excretion in urine renal clearance (clr) of alisertib duration of exposure to idela toxicity of administration of idela number, frequency and type of adverse events incidence of adverse events incidence of laboratory abnormalities identification of dose-limiting toxicity (dlt) and maximum tolerated dose (mtd) maximum tolerated dose (mtd) of entospletinib in combination with obinutuzumab complete response (cr) defined as the percentage of subjects who achieve cr toxicity data (nci-ctc version 2.0 criteria) skin toxicity hepatotoxicity mucosal toxicity hematologic toxicity neurologic toxicity treatment response cd34+ cell count peak level time to cd34+ count peak level time to reach level >5 x 10^6.l area under curve for duration of time spent with cd34+ count >5 x 10^6/l peripheral blood colony forming unit assays peak cfu-gemm level time to peak cfu-gemm level part a: cmax: maximum observed plasma concentration for ixazomib part a: tmax: time to reach the maximum observed plasma concentration (cmax) for ixazomib part a: auc(0-312): area under the plasma concentration-time curve from time 0 to 312 hrs post-dose for ixazomib part a: cmax: maximum observed plasma concentration of tra part a: tmax: time to reach the cmax for tra part a: auc(0-816): area under the plasma concentration-time curve from time 0 to 816 hrs post-dose for tra part a: cmax: maximum observed whole blood concentration of tra part a: tmax: time to reach the maximum observed whole blood concentration (cmax) for tra part a: auc(0-816): area under the whole blood concentration-time curve from time 0 to 816 hrs post-dose for tra part a: cumulative percentage of ixazomib dose recovered in the urine part a: cumulative percentage of the total radioactivity dose excreted in feces part a: cumulative percentage of the total radioactivity dose excreted in urine part a: renal clearance of ixazomib percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study parts a and b: safety and tolerability in terms of ae and sae (including death), as recorded in safety measures. percent of participants recieving pembrolizumab per protocol schedule dose timing part: incidence of dose limiting toxicities (dlts) expansion part: overall response rate (orr) maximum tolerated dose (mtd) number of participants with adverse events determine mtd safety and identification of dose-limiting toxicities pharmacokinetics assessment of treatment emergent adverse events (aes) meeting dose-limiting toxicity (dlt) criteria. maximum tolerated dose (mtd) number of dose-limiting toxicity (dlt) events of ipilimumab plus a fixed dose of sd-101 (1 mg/week) phase 1: determination of maximum tolerated dose (mtd) first without and then with administration of prophylactic g-csf. number of patients reporting dose-limiting toxicity (dlt) (phase i) best response to dose level 0 assessment of treatment related adverse events (aes). safety and tolerability of hsc835 for clinical use were measured by infusional toxicity (within first 48 hours after transplant) and absence of graft failure after 32 days in excess of that currently observed with ucbt. incidence of adverse events as graded by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (utilized for adverse event reporting beginning april 1, 2018) maximum tolerated dose graded according to nci ctcae version 5.0 establishment of maximum tolerable dose of valproate. maximum tolerated dose response rate dlts in the first 2 cycles of single drug administration mtd of azd3965 number of patients who experienced dlts number of patients who experienced serious aes number of patients who experienced non-serious aes number of participants experiencing dose-limiting toxicities number of participants experiencing clinical and laboratory adverse events (aes) maximum tolerated dose incidence of adverse events maximum tolerated dosage (mtd) of selinexor/kpt-330 when combined with rice chemo in a relapsed/refractory aggressive b-cell lymphoma setting. to establish the maximal tolerated dose (mtd) of lenalidomide in patients with recurrent cns nhl and intraocular nhl number of participants with dose-limiting toxicities (dlt) maximum administered dose (mad) maximum tolerated dose (mtd)/recommended phase 2 dose level (rp2d) number of dose-limiting toxicities (dlts) categorized as per the nature number of participants with treatment emergent adverse events categorized by severity number of participants with treatment-related treatment emergent adverse events number of participants who died due to adverse event on the basis of relatedness to study drug maximum observed plasma concentration (cmax) on day 1: single dose maximum observed plasma concentration (cmax) on day 8: multiple dose maximum observed plasma concentration (cmax) on day 14/21 dose-corrected to 125 mg: multiple dose maximum observed plasma concentration (cmax) on day 1: food effect time to reach maximum observed plasma concentration (tmax) on day 1: single dose time to reach maximum observed plasma concentration (tmax) on day 8: multiple dose time to reach maximum observed plasma concentration (tmax) on day 14/21 dose-corrected to 125 mg: multiple dose time to reach maximum observed plasma concentration (tmax) on day 1: food effect terminal half-life (tÂ½ ) on day 1: single dose terminal half-life (tÂ½ ) on day 8: multiple dose terminal half-life (tÂ½) on day 14/21 dose-corrected to 125 mg: multiple dose terminal half-life (tÂ½ ) on day 1: food effect area under the curve from time zero to the last measured concentration (auclast) on day 1: single dose area under the curve from time zero to the last measured concentration (auclast) on day 8: multiple dose area under the curve from time zero to the last measured concentration (auclast) on day 14/21 dose-corrected to 125 mg: multiple dose area under the curve from time zero to the last measured concentration (auclast) on day 1: food effect area under the curve from time zero to end of the dosing interval [auc(0 to tau)] on day 14/21 dose-corrected to 125 mg: multiple dose area under the curve from time zero to extrapolated infinite time [auc (0 - âˆž)] on day 1: single dose area under the curve from time zero to extrapolated infinite time [auc (0 - âˆž)] on day 8: multiple dose area under the curve from time zero to extrapolated infinite time [auc (0 - âˆž)] on day 1: food effect apparent oral clearance (cl/f) on day 1: single dose apparent oral clearance (cl/f) on day 8: multiple dose apparent oral clearance (cl/f) on day 14/21 dose-corrected to 125 mg: multiple dose apparent oral clearance (cl/f) on day 1: food effect apparent volume of distribution (vz/f) on day 1: single dose apparent volume of distribution (vz/f) on day 8: multiple dose apparent volume of distribution (vz/f) on day 14/21 dose-corrected to 125 mg: multiple dose apparent volume of distribution (vz/f) on day 1: food effect accumulation ratio (rac) on day 8: multiple dose accumulation ratio (rac) on day 14/21 dose-corrected to 125 mg: multiple dose terminal phase rate constant [lambda (z)] on day 1: single dose terminal phase rate constant [lambda (z)] on day 8: multiple dose terminal phase rate constant [lambda (z)] on day 14/21 dose-corrected to 125 mg: multiple dose terminal phase rate constant [lambda (z)] on day 1: food effect cumulative amount of drug recovered unchanged in the urine (ae): single dose cumulative amount of drug recovered unchanged in the urine (ae): food effect percent dose recovered unchanged in urine (percent ae): single dose percent dose recovered unchanged (percent ae) in urine: food effect number of participants with best response inhibition of cyclin-dependent kinases 4 and 6 (cdk4/6) based on phosphorylated retinoblastoma (p-rb) in tumor tissue correlation of cyclin-dependent kinases 4 and 6 (cdk4/6) with pd 0322991 dose correlation of cyclin-dependent kinases 4 and 6 (cdk4/6) with exposure correlation of cyclin-dependent kinases 4 and 6 (cdk4/6) with tumor response safety as measured by grade and frequency of adverse events maximum tolerated dose (mtd) as measured by the number of dose-limiting toxicities in each dose level (cohort) objective response rate (orr) number of participants with adverse events (aes) and serious adverse events (saes) (phase 1) number of participants with abnormal clinical laboratory values reported as aes (phase 1) number of participants with clinically significant vital signs values reported as aes (phase 1) antibody-drug conjugate (adc) serum concentrations (phase 1) serum concentration of total antibodies (conjugated and unconjugated) (phase 1) monomethyl auristatin e (mmae) plasma concentrations (phase 1) overall response rate (orr) (phase 1 and 2) pharmacokinetics: maximum plasma concentration (cmax) of s-warfarin and r-warfarin pharmacokinetics: time of maximal plasma concentration (tmax) of s-warfarin and r-warfarin pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity [auc(0-âˆž)] of s-warfarin and r-warfarin number of treatment-emergent adverse events (teaes) to evaluate number of participants with adverse events with r-ice plus bortezomib (vr-ice) auc0-t auc0-inf cmax pk parameter for hmpl-523: auc0-t pk parameter for hmpl-523: auc0-inf pk parameter for hmpl-523: cmax pk parameter for hmpl-523: tmax maximum tolerated dose (mtd) of lenalidomide and choep number of participants with adverse events graded according to common toxicity criteria (ctc) (phase i) complete response rate (phase ii) overall response rate maximum tolerated dose (mtd) of idelalisib and lenalidomide, determined according to incidence of dose-limiting toxicity (dlt) graded using the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 (phase i) progression free survival (pfs) of the combination of lenalidomide, with or without idelalisib (phase ii) part 1: assessment of treatment emergent adverse events (aes) meeting dlt criteria. part 2: assessment of treatment emergent adverse events (aes) meeting dlt criteria. part 3: assessment of treatment emergent adverse events (aes) meeting dlt criteria. area under the serum concentration time curve from zero to day 7 (auc0-7) of obinutuzumab on day 1, cycle 1 maximum observed serum concentration (cmax) of obinutuzumab on day 1, cycle 1 area under the serum concentration versus time curve from 0 to day 21 (auc0-21) of obinutuzumab at cycle 8 cmax of obinutuzumab at cycle 8 complete response determination of the recommended dose of cc-292 and lenalidomide in patients with relapsed/refractory b-cell lymphoma phase 1 maximum tolerated dose (mtd) for jnj-40346527 phase 2 overall response rate objective responses assessed by international workshop criteria (iwc) mtd, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (dlt) graded according to the revised national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 incidence of toxicities, graded according to nci ctcae version 4.0 maximum tolerated dose maximally tolerated dose occurence of dlts for both schedules number of participants with dose-limiting toxicities as a measure of safety and tolerability number of participants with complete responses (cr) and partial responses (pr) as a measure of efficacy-orr number of participants with dlts to determine the mtd safety of ionis-stat3rx in patients with advanced cancers maximum-tolerated dose (mtd) of ionis-stat3rx in patients with advanced cancers. phase i of the study: to evaluate the safety and the maximum-tolerated dose (mtd) of the combination r-eshap with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large b-cell lymphoma (determine maximum tolerated dose) phase ii of the study: phase ii: to evaluate orr of lr-eshap in patients with relapsed or refractory dlbcl candidates to hdt and asct (determine the overall response rate) maximum tolerated dose of veliparib when combined with bendamustine hydrochloride response rate number of participants with adverse events total number of subjects with a complete response (cr) following myeloablative conditioning (mac) and autologous stem cell transplantation (autosct) total number of subjects with a disease relapse or progression following mac autosct total number of subjects with partial response or stable disease following mac autosct the recommended phase 2 dose (rp2d) overall response rate (orr) change in platelet nadir adverse events described using the nci ctcae criteria maximum tolerated dose response rate for participants with non-hodgkin\\'s lymphoma number of participants with adverse events, injection site reactions, and concomitant medications number of participants affected by adverse events by meddra system organ class (soc) and preferred term (pt) number of participants with dose-limiting toxicity (dlt) maximum tolerated dose (mtd) of alisertib cmax: maximum observed concentration for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 1 cmax: maximum observed concentration for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 tmax: time of first occurrence of cmax for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 1 tmax: time of first occurrence of cmax for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 auct: area under the concentration time curve from time 0 to time t for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 terminal half-life (t1/2) for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 accumulation ratio (rac) for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 peak/trough ratio for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 clss/f: apparent oral clearance at steady state for alisertib as pill in capsule (pic) with once daily for 21 days (qd21d) dosing at day 21 cmax: maximum observed concentration for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 1 cmax: maximum observed concentration for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 14 tmax: time of first occurrence of cmax for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 1 tmax: time of first occurrence of cmax for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 14 auct: area under the concentration time curve from time 0 to time t for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 14 accumulation ratio (rac) for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 14 peak/trough ratio for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 14 clss/f: apparent oral clearance at steady state for alisertib as pill in capsule (pic) with once daily for 14 days (qd14d) dosing at day 14 cmax: maximum observed concentration for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 1 cmax: maximum observed concentration for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 14 tmax: time of first occurrence of cmax for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 1 tmax: time of first occurrence of cmax for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 14 auct: area under the concentration time curve from time 0 to time t for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 14 terminal half life for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 14 peak/trough ratio for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 14 clss/f: apparent oral clearance at steady state for alisertib as enteric coated tablet (ect) with once daily for 14 days (qd14d) dosing at day 14 cmax: maximum observed concentration for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 1 cmax: maximum observed concentration for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 tmax: time of first occurrence of cmax for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 1 tmax: time of first occurrence of cmax for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 auct: area under the concentration time curve from time 0 to time t for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 1 auct: area under the concentration time curve from time 0 to time t for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 terminal half-life (t1/2) for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 accumulation ratio (rac) for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 peak/trough ratio for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 clss/f: apparent oral clearance at steady state for alisertib as enteric coated tablet (ect) with twice daily for 7 days (bid7d) dosing at day 7 number of participants dlt in arm 1 in dose escalation phase number of participants dlt in arm 2 in dose escalation phase mtd of 6,8-bis(benzylthio)octanoic acid when used in combination with bendamustine hydrochloride, defined as the dose level immediately below the dose level that induced a dose-limiting toxicity in < 2 patients safety maximum tolerated dose (mtd) of efavirenz number of participants who experienced dose-limiting toxicities (dlts) phase â…°, safety/tolerability: dose-limiting toxicity (dlt) phase â…°, safety/tolerability: maximum tolerated dose (mtd) phase â…°, safety/tolerability: incidence and severity of treatment emergent adverse events (teae) phase â…°, safety/tolerability: incidence and severity of study treatment related ae phase â…°, safety/tolerability: incidence and severity of aes of special interest (cytokine release syndrome [crs], cart-cell-related encephalopathy syndrome [cres]) phase â…°, safety/tolerability: incidence and severity of dose-limiting toxicity (dlt) of dose escalation experiment phase â…°, safety/tolerability: recommended phase ii dose (rp2d) phase â…±, efficacy: overall remission rate (orr) dose limiting toxicities (dlt) and maximum tolerated dose (mtd) of cep 18770 percent of participants with positive anc engraftment maximum tolerated dose (mtd) of iv amd3100 + g-csf in mobilization of peripheral blood stem cell in patients with lymphoma (phase i only) number of participants who experienced dose limiting toxicities in phase i portion of study mtd of alisertib defined as the highest dose tested in which less than 33% of patients experienced dose-limiting toxicity (dlt) graded according to the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version (v.)4.0 maximum tolerated dose (mtd) of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies mtd of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies dose limiting toxicities (dlts) completion remission (cr) rate acute gvhd chronic graft-versus-host disease nonrelapse mortality (nrm) relapse of malignancy area under the curve (auc) for hlx01 and rituximab concentrations incidence and severity of treatment-emergent adverse events (teaes) determination of the recommended dose of r-cmc544 ae number of participants with infusion-related reaction and with drug-related adverse events. part a and f: number of participants with dose limiting toxicities (dlts) part b, c, d, e and f: number of participants with tumor response phase 1b: recommended phase 2 dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in participants with relapsed or refractory diffuse large b cell lymphoma (dlbcl) phase 1b: number of participants with treatment-emergent adverse events (teaes), serious teaes, and discontinuations due to teaes phase 2: overall response rate (orr) occurrence of adverse events occurrence of dose-limiting toxicities occurrence of grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0980 pk parameters after doses of gdc-0980 the primary outcome for the study is the average deviation in set-up. midazolam blood concentrations +/- brentuximab vedotin brentuximab vedotin blood concentrations +/- rifampin brentuximab vedotin in urine, feces, and blood brentuximab vedotin blood concentrations in special populations brentuximab vedotin blood concentrations +/- ketoconazole incidence of dose limiting toxicities (dlts) by nci ctcae v4.0 grade and associated dose of gdc-0349 tolerability of treatment as measured by number of participants with grade 3 or higher adverse events efficacy of treatment as measured by best overall response number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events number of subjects experiencing dose-limiting toxicities engraftment of hla identical pbsc allografts non-relapse mortality effectiveness of rasburicase in treatment of patients with leukemia and/or lymphoma who are at high or potential risk for tls. mtd of everolimus, defined as the dose that produces dose-limiting toxicity (dlt) in =< 1/6 patients, determined by incidence of dlt graded according to the national cancer institute common terminology criteria for adverse events (ctcae) version 4.0 occurrence of adverse events occurrence of dose-limiting toxicities pk parameters after doses of gdc-0980 occurrence of grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0980 safety, tolerability, maximum tolerated dose (mtd), and dose-limiting toxicity of oral administration of xl184 evaluate plasma pharmacokinetics and estimate renal elimination of oral administration of xl184 to determine safety, tolerability, and maximum tolerated dose of ap23573 when administered once daily for 5 days on a every 2 week schedule maximum tolerated dose (mtd) number of participants reporting adverse events (ae) number of participants discontinuing due to aes maximum tolerated dose of carfilzomib with hyper-cvad, defined as the dose that produces dose limiting toxicity in 17% or fewer (1/6) of patients, graded according to national cancer institute common terminology criteria for adverse events (nci ctcae) v4 maximum tolerated dose (mtd) recommended phase 2 dose (rp2d) of tazemetostat as a single-agent and in combination with prednisolone (phase 1 only) objective response rate (orr; complete response + partial response [cr + pr]) (phase 2) regimen related toxicities one-year overall survival rate for aml stage i - safety (type, frequency, severity and relationship of adverse events to study treatment) and tolerability stage ii - overall response rate stage iii - overall response rate obtaining a stable mean dna-tgn level > 500 fmol/microgram dna after addition of 6tg. dna-tgn calculated as a 4 weeks mean (maximum 6tg dose 12.5 mg/m.xq.). maximum tolerable dose (mtd) of bortezomib in combination with azacitidine specific toxicities and the dose limiting toxicity (dlt) of bortezomib in combination with azacitidine as assessed by nci ctcae (common toxicity criteria for adverse effects) v4.0 occurrence of adverse events by nci ctcae grade and associated dose of gdc-0941 occurrence of dose-limiting toxicities (dlts) by nci ctcae grade and associated dose of gdc-0941 occurrence of grade 3 or 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0941 pk parameters after single and multiple doses of gdc-0941 define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator nat2 genotype (nat2 5, nat2 6, nat2 7, or nat2 14) patients with solid tumors and lymphomas. percentage of participants with dose-limiting toxicities (dlts) percentage of participants with adverse events (aes) percentage of participants with complete response (cr) at end of induction (eoi), determined by an independent review committee (irc) on the basis of positron emission tomography (pet) and computed tomography (ct) scans maximum tolerated dose (mtd) of two dosing regimens (once daily and twice daily) dose limiting toxicity (dlt) of two dosing regimens (once daily and twice daily) plasma blood concentrations of chemical markers percentage of participants with complete response (cr) as assessed by response evaluation criteria in solid tumors (phase ii) percentage of participant experiencing adverse events (aes) for each treatment arm as assessed by common terminology criteria for adverse events version 4.0 (ctcae v4.0) (phase ii) recommended phase ii dose of vorinostat determined according to dose-limiting toxicities graded using common terminology criteria for adverse events version 4.0 (ctcae v4.0) (phase i) feasibility of adequate leucapheresis collection and generation of car19 t cells. toxicity evaluation following car19 t-cell administration. efficacy of car19 t-cells. recommended phase ii dose number of subjects with dose-limiting toxicities overall response rate (orr) the maximum tolerated dose (mtd) of niacinamide in the combination of vorinostat and niacinamide number of phase i participants with dose-limiting toxicity events (phase i) overall response rate (phase ii) evaluation of the safety profile of wp1220 applied topically (adverse events) mtd, defined as the highest dose level below the maximally administered dose at which no more than 1 out of 6 patients experience dlt graded according to nci ctcae version 4.0 number of patients with adverse events maximum tolerated dose (mtd) of 90y-hat clinical response dose limiting toxicity assessment for each patient. adverse events pharmacokinetic/ pharmacodynamic assessments safety as assessed by adverse events safety as assessed by clinical laboratory tests safety as assessed by vital signs safety as assessed by electrocardiograms (ecg) determination of the maximum tolerated dose (mtd) of cep-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma. incidence of dose-limiting toxicity (dlt). to measure the amount of tumor motion in breathing synchronized ct scans and determine the fraction of patients whose radiation treatment planning margins would be modified based on this information. frequency and severity of adverse events graded according to ctcae v4.0 to determine the safety of pnt2258 in patients with advanced solid tumors safety of reduced-dose tacrolimus as assessed by percentage of participants with severe graft versus host disease (gvhd) tolerability of tacrolimus as assessed by percentage of participants with treatment-emergent adverse events tolerability incidence of dose-limiting toxicities (dlts) maximum tolerated dose (mtd) pharmacokinetics-plasma kw-0761 concentrations pharmacokinetics-pharmacokinetic parameters of kw-0761 (auc0-7 days) pharmacokinetics-pharmacokinetic parameters of kw-0761 (t1/2) death within 8 weeks of the study cell infusion thought to be definitely or probably related to chimeric antigen receptor (car) t cell therapy dose limiting toxicities objective response rate of complete response and partial response overall survival progression free survival response determine if there are any dose limiting toxicities to this therapy, as well as the maximum tolerated dose. to evaluate safety of gp2013 area under the curve calculated from start of dose to the end of the dosing interval (tau) of gp2013 maximum observed concentration of gp2013 time to reach maximum concentration of gp2013 minimum (trough) observed concentration during each dosing interval of gp2013 terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of gp2013 elimination half-life associated with the terminal slope of gp2013 safety: incidence and severity of adverse events efficacy: remission rate dose-limiting toxicity (dlt) to determine dose-limiting toxicity (dlt), maximum tolerated dose (mtd), and/or recommended phase ii dose (rp2d) of cn1 administered to patients with advanced solid tumor or b-cell lymphoma. immediate toxicity (incidence of reactions to glucarpidase) as determined by the nci ctc incidence and severity of renal dysfunction as determined by the nci ctc incidence and severity of mucositis as determined by the nci ctc and who mucositis grading scale incidence and severity of cns toxicity and neurocognitive changes taken from patients\\' medical records and measured using the mini-mental state questionnaire and mri data maximum tolerated dose (mtd) of interleukin 15 adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ecgassessment of pharmacokinetic endpoints of 506u78, ara-g and intracellular ara-gtp concentration. maximum tolerated dose of the combination of ibrutinib with standard dosing r-ice, graded using the common terminology criteria for adverse events 4.0 toxicity of the combination of ibrutinib with standard dosing r-ice, graded using the ctcae 4.0 unbound cmax: maximum observed plasma concentration for alisertib unbound auclast: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib unbound auc0-âˆž: area under the concentration-time curve from time 0 to infinity for alisertib evaluate the safety and tolerability of vli. to determine the feasibility and toxicity of the combination of etanercept and rituximab in patients with cll/sll. determine if etanercept increases the complete response rate while decreasing the frequency of infusion-related toxicity in patients with cll/sll receiving rituximab therapy. maximum tolerated dose percentage of participants with dose limiting toxicities (dlts) in cycle 1 number of participants with adverse events (aes), grade 3 and 4 aes, serious adverse events (saes), discontinuations for aes part 1: number of participants with dose limiting toxicities (dlts) number of participants with treatment-emergent adverse events to determine the tolerance and toxicity profile pharmacokinetics cmax: maximum observed concentration of alisertib in presence and absence of itraconazole in part a auc(last): area under the plasma concentration curve from time 0 to the time of the last quantifiable concentration of alisertib in presence and absence of itraconazole in part a aucâˆž: area under the plasma concentration curve from time 0 to infinity of alisertib in presence and absence of itraconazole in part a cmax of venetoclax + navitoclax auc of venetoclax + navitoclax tmax of venetoclax + navitoclax cl/f of venetoclax + navitoclax number of participants with dose-limiting toxicities (dlt) dose limiting toxicity (dlt) rate incidence of adverse events and laboratory abnormalities to provide erwinase to patients with acute lymphoblastic leukemia (all) or non-hodgkins lymphoma who are intolerant or have developed hypersensitivity to e. coli asparaginase and/or peg-asparaginase maximum tolerated dose (mtd) number of participants with dose-limiting toxicities determination of dose limiting toxicity (dlt), maximum tolerated dose (mtd), recommended phase two dose (rptd), and lead-in period regimen number of subjects with adverse events determination of plasma peak concentration (cmax) of abt-199 determination of trough concentration (ctrough) of abt-199 determination of area under the concentration versus time curve (auc) of abt-199 maximum-tolerated dose of lenalidomide in combination with bendamustine hydrochloride and rituximab prilinostat mesylate pharmacokinetics (pk)ï¼šcmax prilinostat mesylate pharmacokinetics (pk)ï¼štmax prilinostat mesylate pharmacokinetics (pk)ï¼šauc0-72h prilinostat mesylate pharmacokinetics (pk)ï¼šauc0-âˆž prilinostat mesylate pharmacokinetics (pk)ï¼šmrt prilinostat mesylate pharmacokinetics (pk)ï¼švd prilinostat mesylate pharmacokinetics (pk)ï¼št1/2 prilinostat mesylate pharmacokinetics (pk)ï¼šclz/f prilinostat mesylate pharmacokinetics (pk)ï¼švz/f prilinostat mesylate pharmacokinetics (pk)ï¼ške incidence of toxicities according to the common terminology criteria for adverse events version 4 percentage of participants with dose-limiting toxicities (dlts) maximum tolerated dose proposed phase ii dose of polatuzumab vedotin percentage of participants with adverse events (aes) occurrence of dose limiting toxicities assess the safety profile, to determine the maximum tolerated dose and recommended phase two dose of abt-199 when administered in combination with rituximab (r) in subjects with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. maximum tolerated dose (mtd) incidence and nature of dose-limiting toxicities (dlts) maximum tolerated dose and recommended phase ii dose of vorinostat and decitabine number of participants with dose limiting toxicities (dlts) number of participants with treatment emergent adverse events (teaes) and treatment emergent serious adverse events (tesaes) number of participants with vital signs abnormalities recorded as treatment-emergent adverse events (teaes) number of participants with clinically significant laboratory abnormalities recorded as treatment-emergent adverse events (teaes) treatment-emergent adverse events (teaes) related to chemistry abnormalities occurring in greater than (>) 5 percent of participants number of participants with abnormalities in ophthalmologic examination at end of treatment that were not present at baseline number of participants with change from baseline in normal sinus rhythm findings in ecg change from baseline to end of treatment in clinical findings in electrocardiogram (ecg) qt, qtc interval and ventricular rate best overall tumor response objective response rate (orr) percentage of participants with relapse of disease time to disease response duration of response (dr) time to disease progression (tdp) progression-free survival (pfs) overall survival (os) maximum observed serum concentration (cmax) for moxetumomab pasudotox area under the serum concentration time curve from time zero to infinity (auc [0 to infinity]) for moxetumomab pasudotox systemic clearance (cl) for moxetumomab pasudotox terminal phase elimination half life (t1/2) for moxetumomab pasudotox maximum tolerated dose (mtd) number of participants with dose limiting toxicities (dlts) number of participants with treatment-emergent adverse events (teaes) and treatment-emergent serious adverse events (tesaes) number of participants with clinically significant laboratory abnormalities recorded as treatment-emergent adverse events (teaes) number of participants with vital signs abnormalities recorded as treatment-emergent adverse events (teaes) number of participants with electrocardiogram (ecg) abnormalities recorded as treatment-emergent adverse events (teaes) pharmacokinetics number of participants who experienced a dose-limiting toxicity (dlt) during cycle 0 and cycle 1 based on national cancer institute common terminology criteria for adverse events version 3.0 (ctcae v 3.0) number of participants who experienced an adverse event (ae) number of participants who discontinued study treatment due to an ae dose-limiting toxicities and maximum tolerated dose pharmacology and pharmacokinetics number of participants experiencing a dose limiting toxicity (dlt) safety profile of mdx-1203 and determine the maximum tolerated dose (mtd) maximum-tolerated dose (mtd) of pomalidomide incidence of adverse events percentage of participants with grade 3 or higher adverse events considered at least possibly related to treatment maximum tolerated dose dose limiting toxicity recommended phase ii dose area under the plasma concentration-time curve (auc) 0-72 hours number of subjects with study related adverse events. determine the safety and maximum tolerated dose (mtd) of adenovirus-cd154 (ad-isf35) when injected directly into lymph nodes of patients with cll/sll. maximum tolerated dose of 4-hpr/lxs oral powder safety toxicity number of participants with adverse events safety efficacy maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity pharmacokinetic parameters of dasatinib to determine the maximum tolerated dose of tpi 287 administered every 21 days occurrence of study related adverse events phase 1: number of participants with a dose limiting toxicity (dlt) phase 2a: number of participants achieving overall response rate (partial response [pr] plus complete response [cr]) as assessed by the investigator to determine the maximum tolerated dose of tpi 287 to evaluate the safety of ublituximab in combination with ibrutinib in patients with select b-cell malignancies part 1 maximum tolerated dose of ibrutinib adverse events as a measure of safety of intrathecal administration of rituximab serum concentration of rituximab cerebrospinal fluid (csf) concentration of rituximab percentage of participants experiencing dose-limiting toxicities occurrence of study related adverse events defined as nci ctcae 4.0 > grade 3 possibly, probably, or definitely related to study treatment. number of participants reporting a dose limiting toxicity (dlt) proportion of confirmed tumor responses number of participants with adverse events as a measure of safety and tolerability maximum-tolerated dose and/or recommended phase ii dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma toxicities of imetelstat sodium maximum tolerated dose (mtd) feasibility of nk-dli production safety of nk dli infusion phase i part: determination of the recommended dose of lenalidomide in combination with fixed doses of ga101 phase ii part: overall response rate (cr+cru+pr) after 6 cycles maximum tolerated dose toxicity dose limiting toxicity (dlt) rate by the nci common toxicity criteria (ctcae) v2.0 and the method of przepiorka et al (protocol appendix i) determination of toxicity related to allostim infusion in accordance with nci common toxicity criteria v.3 to determine the optimal regimen of post-graft immunosuppression with high-dose cy following fludarabine, busulfan, and transplantation of fully hla-matched bone marrow that leads to an acceptable incidence of grades iii/iv acute gvhd phase i: incidence of any dlt attributed to dt2219 in the first cycle phase ll: overall disease response number of phase i participants experiencing toxicity phase ii: overall survival rate at 2 years (including phase i patients at same dose) maximum tolerated dose as assessed by nci ctcae v.30 safety, tolerability, toxicity profile, and dose-limiting toxicities as assessed by nci ctcae v.30 pharmacokinetic profile as measured on days 1, 2, and 4 in course 1 correlation of toxicity profile with pharmacokinetics safety of b001 as assessed by adverse reactions and events maximum tolerated dose of lapatinib and everolimus (part i) dose defining safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation maximum tolerated dose (mtd) of subcutaneous recombinant human il-15 (s.c. rhil-15) number of dose-limiting toxicities (dlts) of subcutaneous recombinant human il-15 (s.c. rhil-15) administered with 3 times per week intravenous (iv) alemtuzumab number of participants with serious adverse events possibly, probably, and/or definitely related to subcutaneous (s.c. rhil-15) by grade who have refractory or relapsed chronic and acute adult t-cell leukemia (atl)cancer number of participants with adverse events maximum tolerated dose (mtd) and dose-limiting toxicities (dlt) of combination treatment with bevacizumab and bortezomib car t cell persistence maximum tolerated dose acceptable for participants number of participants with dose-limiting toxicities (dlts) number of participants with adverse events toxicities related to radiolabelled antibody. number of participants with dose limiting toxicity events number of participants with progression free survival at 6 months number of participants who experienced dose-limiting toxicities (dlts) to determine the dose limiting toxicities safety and tolerability of cobomarsen based on vital signs, physical examination, clinical laboratory tests, ecg, and incidence and severity of adverse events to determine the toxicity profile and maximum tolerated dose (mtd) of hll1 when administered to patients with recurrent non-hodgkin\\'s lymphoma and chronic lymphocytic leukemia patients with dose limiting toxicities after t-cell infusions to assess safety of parathyroid hormone in combination with g-csf when used as a mobilization agent at four different dosing levels. to evaluate the 100-day transplant-related (non-relapse) mortality, including relapse-related mortality associated with grade 4 toxicity. number of participants with treatment-related adverse events as assessed by ctcae v5.0. area under the concentration-time curve (auc) of plx2853. maximum observed concentration (cmax) of plx2853. time to peak concentration (tmax) of plx2853. half life (t1/2) of plx2853. number of participants who experience dose limiting toxicity as defined in the protocol. change in disease burden using recist 1.1 (solid tumors) or lugano criteria (nhl). occurrence (individual listings and summary) of dose-limiting toxicities incidence of gvhd maximum tolerated dose local toxicity as measured by physical exam and punch biopsy treatment efficacy as measured by physical exam and punch biopsy systemic photosensitivity as measured by minimum erythema dose (med) testing safety: incidence of dose-limiting toxicities (dlts) of gdc-0853 safety: maximum tolerated dose (mtd) of gdc-0853 the maximum tolerated dose of plerixafor when combined with rituximab as treatment for previously treated patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) safety and tolerability of tru-016 administered iv in patients with cll or nhl safety and tolerability of sch 727965, including maximum administered dose and dose-limiting toxicity in part 1 and part 2, pharmacodynamic effects of sch 727965 with an ex vivo lymphocyte stimulation assay of participant\\'s peripheral blood lymphocytes. documenting adverse events (aes), serious adverse events (saes), dose limiting toxicities (dlts) (graded according to nci-ctcae version 4.02) and laboratory parameters and determining their causality in relation to bi-1206. documenting aes, saes (graded according to nci-ctcae version 4.02) and laboratory parameters and determining their causality in relation to bi-1206 and, where appropriate, anti-cd20 antibody. to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed hodgkin lymphoma after asct, as measured by dropout rate. body temperature blood pressure- diastolic blood pressure- systolic pulse rate respiratory rate adverse events the safety of two iv injections of auto ebv specific ctls will be determined through adverse event measurement. these ctls may be marked with the neomycin resistance gene introduced by a retroviral vector. to determine the feasibility of generating ebv specific cytotoxic t cell lines from patients with active ebv positive lymphoma including hodgkin disease (hd) or non-hodgkin lymphoma (nhl). to determine the survival, immunological efficacy and anti-tumor effects of ebv specific cytotoxic t-lymphocyte lines. maximum-tolerated dose and recommended phase 2 dose of crizotinib number of participants with toxicities of crizotinib steady state c max of crizotinib steady state c average of crizotinib steady state auc of crizotinib steady state clearance of crizotinib to determine a safe dose recommended (sdr) for the routine application of oral vorinostat (involving dose escalation) in children and adolescents (3-18 years) with relapsed/refractory solid tumor, lymphoma or leukemia. number of participants with adverse events maximum tolerated dose (mtd) of eribulin mesylate number of participants with treatment-emergent adverse events (teaes) and serious adverse events (saes) number of participants with clinically significant change from baseline in clinical laboratory values number of participants with clinically significant vital sign values number of participants with clinically significant electrocardiogram (ekg) t1/2: terminal half-life for eribulin mesylate cmax: maximum observed plasma concentration for eribulin mesylate tmax: time to reach the maximum plasma concentration (cmax) for eribulin mesylate auc 0-t: area under the concentration-time curve from zero (pre-dose) to time of last quantifiable concentration for eribulin mesylate auc 0-inf: area under the concentration-time curve from zero (pre-dose) extrapolated to infinite time for eribulin mesylate cl: clearance for eribulin mesylate vd: volume of distribution for eribulin mesylate number of participants with dose-limiting toxicities (dlts) in first 2 cycles of portion a number of participants with dlts in first 2 cycles of portion b auc0-tlast auc0-âˆž cmax tmax tlag Î»z t1/2 cl/f vz/f auc0-âˆž plasma resminostat/total radioactivity ratio auc0-âˆž blood/plasma ratio aeu cumulative aeu feu cumulative feu aef cumulative aef fef cumulative fef. defervescence (without hypothermia) safety analysis - number of participants with dose limiting toxicities (dlt) in the dlt evaluation phase safety analysis - number of participant deaths safety analysis - number of participants with adverse advents safety analysis - number of participants with serious adverse events safety analysis - number of participants with adverse events leading to discontinuation safety analysis - number of participants with adverse events leading to dose delay or reduction safety analysis - number of participants with drug related adverse events safety analysis - percentage of participants with thyroid test abnormalities safety analysis - percentage of participants with liver test abnormalities objective response rate (orr) phase i : maximal tolerated dose (mtd) determination phase ii = fraction of responding patients according to lugano classification (metabolic complete response) tolerance and safety as measured by any â‰¥ grade iv granulocyte toxicity or any grade iii toxicity thought to be drug related at 1 week after each course determine the maximally-tolerated dose (mtd) and/or maximum-feasible dose (mfd) of jx-594 determine the safety/toxicity of jx-594 administered by it injection in this patient population mtd of lenalidomide after allogeneic hematopoietic stem cell transplantation graded according to the national cancer institute common terminology criteria for adverse events (nci ctcae) v4.0 number of subjects with adverse events as assessed by ctcae 4.03 maximum tolerated dose of sra737 recommended phase 2 dose of sra737 disease control rate (dcr) of sra737 time to progression (ttp) progression free survival (pfs) overall survival (os) 1. to establish the maximum tolerated dose (mtd)of chilob 7/4 ; 2. to determine the biologically active dose of chi lob 7/4, which is defined as the dose level at which peripheral blood b-cells are reduced by the end of therapy to 10% or less of the starting number. 3. to determine the toxicity profile of chi lob 7/4 (ctcae version 3.0) and to identify the dose limiting toxicity 4. to propose a safe dose for phase ii evaluation incidence of prolonged hematologic toxicity started in cycle 1 complete response to determine the effect of rifampin on the pharmacokinetics of navitoclax. maximum tolerated dose safety toxicity feasibility of haploidentical hsct change in tumor poly (adp-ribose) (par) levels from baseline to 3-6 hours after abt-888 administration pharmacokinetics safety and tolerability of asp3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ecgs) and clinical observations safety tolerability maximum tolerated dose (mtd) incidence of adverse event post transplant success of hematopoietic stem cell engraftment maximum tolerated dose (mtd) of natural killer (nk) cells with lenalidomide and lymphodepleting chemotherapy number of patients with adverse events as a measure of safety and tolerability serum concentration of cnto 328 number of infusion reaction number of graft failure safety and tolerability of â¸â¹zr-df-iab22m2c assessed by local and systemic signs and symptoms of infusion reactions,incidence of adverse events,changes in laboratory test results,dose limiting toxicities,vital signs and 12-lead electrocardiogram findings number of participants with dose limiting toxicities number of participants with relapsed disease number of participants with grades iii-iv acute gvhd number of non-relapse participant mortalities number of participants who experienced graft failure phase ib- incidence of dose limiting toxicities (dlt) during the first cycle phase ii- overall response rate (orr) = complete response (cr) + partial response (pr) according to the non-hodgkin\\'s lymphoma international working group criteria adverse events evaluated by the national cancer institute common terminology criteria for adverse events (ctcae) v4.0 safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests dose-limiting toxicity and maximum tolerated dose of urelumab (bms-663513) as determined by the incidence of dose-limiting toxicities maximum tolerated dose of aurora kinase inhibitor at9283 (at9283) recommended phase ii dose of at9283 safety, tolerability, toxicity profile, and dose-limiting toxicity of at9283 pharmacokinetic profile of at9283 estimate the maximum tolerated dose of dexamethasone given for 5 consecutive days when combined with fixed doses of irinotecan and vincristine in children with relapsed hematologic malignancies safety and tolerability of ct-322 mtd of photodynamic therapy mtd of silicon phthalocyanine 4 defined as the dose immediately below the dose in which 2 or more of 6 patients experience a grade 4 toxicity assessed using national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 complete remission rate incidence of adverse events (aes) recommended phase 2 dose (rp2d) of brigatinib objective response rate (orr) safety pharmacokinetic profile safety and feasibility maximum tolerated dose (mtd) and/or recommended dose (rd) of ldk378 objective response rate (orr) based on evaluation by image assessment committee number of participants with treatment-emergent adverse events (teaes) number of participants with dose-limiting toxicities eastern cooperative oncology group (ecog) performance status at each visit define the mtd number of participants with treatment emergent adverse events (aes) to determine the maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of the combination npi-0052 and vorinostat non-myeloablative maximum tolerated dose of i-131 tositumomab that can be given to patients with relapsed/refractory hodgkin\\'s lymphoma. overall and complete response rates maximum tolerated dose (mtd) of recombinant human interleukin 15 (il-15) (rhil-15) number of grade 1-4 treatment related adverse events changes in vital signs, ecgs, and clinical laboratory results incidence and nature of dose-limiting toxicities and adverse events of special interest incidence, nature, and severity of all adverse events and serious adverse events toxicity analysis efficacy analysis define the toxicity spectrum of marqibo in children with cancer determine of marqiboÂ® administered as a 60 minute intravenous infusion weekly (every 28 days constitute 1 cycle), in children and adolescents with refractory solid tumors and hematologic malignancies. determine dose limiting toxicities (dlt) of marqiboÂ® administered as a 60 minute intravenous infusion weekly (every 28 days constitute 1 cycle), in children and adolescents with refractory solid tumors and hematologic malignancies. maximum tolerated dose (mtd) to recommend a dose for future trials with a new drug called di-b4 by finding the highest safe dose which can be given to patients number of participants with one or more drug (or procedure)-related adverse events (aes) or any serious aes dose limiting toxicity (dlt) safety, tolerability,and dose limiting toxicities will be determined using aes,pe,ophthalmologic examinations,clinical laboratory tests,vital signs, ecgs and echocardiograms/muga scans. number of participants having treatment-emergent adverse events time to maximum plasma concentration (tmax) of venetoclax maximum plasma concentration (cmax) of venetoclax area under the plasma concentration-time curve from 0 to 24 hours (auc24) post-dose of venetoclax objective response rate (phase 2) maximum tolerated dose (mtd) of vorinostat that can be combined with fludarabine phosphate, cyclophosphamide and rituximab (fcr) (phase i) percentage of patients with progression-free survival at 2 years overall survival treatment safety: monitored through recordings of ecg, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis. safety measures: injection site and systemic reactions auc (0-168) auc cmax qtcf survival pharmacokinetic measures of cmax and area under the curve by analysis of blood samples for the amount of each drug present at different timepoints. maximum tolerated dose (mtd) of crizotinib number of patients with dose limiting toxicity (dlt) area under the concentration to determine safety & tolerability by adverse event rates in order to determine recommended phase ii dose number of patients with dose limiting toxicities (dlts) recommended dose level of flavopiridol maximum tolerated dose phase i: maximum tolerated dose (mtd) phase ii: overall response rate (orr) number of subjects with adverse events as a measure of safety and tolerability number of participants with dose-limiting toxicities (dlts) maximum observed plasma concentration of carfilzomib (cmax) time to maximum observed plasma concentration of carfilzomib (tmax) area under the concentration-time curve to last measureable timepoint (auclast) for carfilzomib area under the concentration-time curve extrapolated to infinity (aucinf) for carfilzomib determine safety of carfilzomib by evaluating the toxicity profile. safety and tolerability incidence of primary graft failure number of participants with dose limiting toxicities (dlts) recommended dose of ly3039478 in combination with dexamethasone number of participants who achieve complete remission (cr) or cr with incomplete blood count recovery (cri): overall remission rate (orr) phase 1b: number of participants with dose-limiting toxicities (dlt) phase 2: percentage of participants with an overall response after 4 treatment cycles occurrence of adverse events (aes) occurrence of serious adverse events (saes) occurrence of dose-limiting toxicities (dlts) number of patients with changes in laboratory parameters from baseline number of patients with changes in vital signs from baseline number of patients with changes in electrocardiogram (ecg) results from baseline percentage of patients with changes in laboratory parameters from baseline maximum tolerated dose of lenalidomide when combined with ibrutinib maximum tolerated dose and recommended phase ii dose of metformin hydrochloride when administered with temsirolimus incidence rate of dose limiting toxicities (dlt) characterize the adverse events associated with cdx-1127 administration the primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality. generate autologous, ebv-specific, cytotoxic t cell lines (ctls) from individuals receiving or having received a solid organ transplant (sot). administer autologous, ebv-specific ctls to patients, to determine the safety of intravenous injections in these individuals evaluate the antiviral and immunological efficacy of the infused ctls maximum tolerated dose (mtd) defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities dlt graded according to common terminology criteria for adverse events (ctcae) version 3.0 dose limiting toxicity (dlt), maximum tolerated dose (mtd) for phase i objective response rate for phase ii incidence of adverse events and laboratory abnormalities identify the maximum tolerated dose of lenalidomide when combined with bendamustine and rituximab in cll/sll adverse events to determine if there is significant toxicity associated with the administration of cd34-tk75 transduced donor lymphocytes after allogeneic bmt for relapsed hematologic malignancies perform pet imaging to allow us to locate the donor t cells within the recipient as they exert anti-leukemic effects, and the t cells can then be eliminated in response to administration of ganciclovir, before morbidity and mortality from gvhd occurs to determine if there is significant toxicity associated with the administration of cd34-tk75 transduced donor lymphocytes after allogeneic bmt for relapsed hematologic malignancies minimal effective dose (med) of azacitidine with phenylbutyrate incidence of grade ii-iv acute graft vs. host disease (gvhd) to evaluate the safety, tolerability, maximum tolerated dose (mtd), and efficacy pharmacokinetics of cpi-613 given twice weekly for three consecutive weeks in cancer patients to determine the recommended phase ii dose and schedule of gsk214179 using the following information: safety and tolerability, pharmacokinetic (single and repeat dose administration) and pharmacodynamic data number of phase i participants with dose-limiting toxicity events (phase i) proportion of complete response defined to be a cr or cri noted as the objective status (phase ii) incidence rate of dose limiting toxicities (dlts) occurring during first cycle of treatment to estimate the dose for a given oral formulation that would yield similar exposure [area under the curve (auc)] to 75 mg/m2 of the subcutaneous formulation. maximum tolerated dose overall response rate time to reach maximum observed plasma concentration (tmax) maximum observed plasma concentration (cmax) area under the plasma concentratio-time curve from time 0 to the time of the last measurable concentration (auclast) area under the concentration-time curve from time 0 to infinity (aucinf) percentage of aucinf based on extrapolation (aucextrap) observed elimination rate constant associated with the terminal portion of the curve (Î» z) observed terminal elimination half-life (t1/2) time of last measurable concentration (tlast) last quantifiable drug concentration (clast) mean residence time (mrtinf) safety and feasibility of donor cord blood transplant safety and tolerability of cdx-1140 as assessed by ctcae v5.0 cutaneous toxicity of combining tseb and brentuximab vedotin in patients with mf or ss (cohorts a and b). number of patients who achieved complete response (cr) and partial response(pr) the primary out come is to assess the diagnostic quality of [18f]iso-1-pet/ct images at the proposed 8 mci dose. incidence of grade 3-5 infusional toxicity efficacy of nonmyeloablative preparative regimen change in lymphocyte count change in quality of life change in inflammation change in metabolic profiles change in autophagy status immune cell gene expression profiles maximum tolerated dose (mtd) of t-cells photochemically treated with psoralen and ultraviolet a determine the safety and feasibility of performing donor umbilical cord blood transplantation (ucbt) in patients with advanced hematologic malignancies to describe dose limiting toxicities (dlt) of prt1419 to determine the maximally tolerated dose (mtd) and/or optimal biological dose (obd) to determine the recommended phase 2 dose (rp2d) and schedule of prt1419 percentage of participants with grade ii-iv acute graft versus host disease (gvhd) percentage of participants with chronic graft versus host disease (cgvhd) recovery of naÃ¯ve cluster of differentiation 4 (cd4) t cells recovery of naÃ¯ve cluster of differentiation 8 (cd8) t cells changes in cluster of differentiation 4 (cd4) t cell receptor vbeta repertoire changes in cd8 t cell receptor vbeta repertoire maximum tolerated dose (mtd) dose limiting toxicities (dlt) recommended phase 2 dose (rp2d) dose limited toxicities evaluated with nci ctcae v4.03 clinical response (complete or partial remission) number of participants with dose-limiting toxicities test the safety and tolerability of the combination of everolimus and alemtuzumab. incidence of all adverse events graded according to nci ctcae, v4.0 incidence of dose limiting toxicities (dlts) pharmacokinetic property of gdc-0425: determination of plasma drug concentration pharmacokinetic property of gdc-0425: exposure pharmacokinetic property of gdc-0425: half-life severity of all adverse events graded according to nci ctcae, v4.0 adverse events number of patients with aes and saes to assess the safety and tolerability of sns-032 the number of days from the date of the stem cell infusion to engraftment of absolute neutrophils (anc) and platelets (plt) will be determined based on daily cbc and differential counts. rate of non-engraftment and secondary graft failure dose-limiting toxicities (dlts) for nk cells infusions after non-myeloablative transplantation for lymphoid malignancies number of participants with serious adverse events (saes) and common (>=5%) non-serious adverse events- part 1 number of participants with saes and common (>=5%) non-serious adverse events- part 2 (mm) number of participants with saes and common (>=5%) non-serious adverse events- part 2 (nhl) number of participants with dose-limiting toxicities (dlts) during the determinative period- part 1 number of participants with grade change from baseline in vital signs-dbp & sbp-part 1 number of participants with grade change from baseline in vital signs-dbp & sbp-part 2 (mm) number of participants with grade change from baseline in vital signs-dbp & sbp-part 2 (nhl) number of participants with change from baseline in heart rate and temperature-part 1 number of participants with change from baseline in heart rate and temperature-part 2 (mm) number of participants with change from baseline in heart rate and temperature-part 2 (nhl) number of participants with grade change from baseline in clinical chemistry data-part 1 number of participants with grade change from baseline in clinical chemistry data-part 2 (mm) number of participants with grade change from baseline in clinical chemistry data-part 2 (nhl) number of participants with change from baseline in clinical chemistry data with respect to normal range-part 1 number of participants with change from baseline in clinical chemistry data with respect to normal range-part 2 (mm) number of participants with change from baseline in clinical chemistry data with respect to normal range-part 2 (nhl) number of participants with grade change from baseline in hematology data-part 1 number of participants with grade change from baseline in hematology data-part 2 (mm) number of participants with grade change from baseline in hematology data-part 2 (nhl) number of participants with change from baseline in hematology data with respect to normal range-part 1 number of participants with change from baseline in hematology data with respect to normal range-part 2 (mm) number of participants with change from baseline in hematology data with respect to normal range-part 2 (nhl) number of participants with worst-case urinalysis results post-baseline relative to baseline by dipstick method -part 1 number of participants with worst-case urinalysis results post-baseline relative to baseline by dipstick method -part 2 (mm) number of participants with worst-case urinalysis results post-baseline relative to baseline by dipstick method -part 2 (nhl) change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 0.06 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 0.03 mg/kg and 0.12 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 0.24 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 0.48 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 0.96 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 1.92 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 2.50 mg/kg change from baseline in urine protein excretion (24 hour)-part 1: gsk2857916 3.40 mg/kg and 4.60 mg/kg change from baseline in urine protein excretion (24 hour)-part 2 (mm) change from baseline in urine protein excretion (24 hour)-part 2 (nhl) safety and tolerability of urelumab in combination with rituximab as measured by incidence of adverse events (aes), serious aes, death, vital sign changes, electrocardiograms (ecgs), physical examination results, and laboratory test abnormalities safety and tolerability of urelumab in combination with rituximab as measured by incidence of adverse events (aes), serious aes, death, vital sign changes, electrocardiograms (ecgs), physical examination results, and laboratory test abnormalities area under the plasma concentration-time curve from time 0 to 8 hours post-dose area under the plasma concentration-time curve from time zero to the last quantifiable time point area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration of azacitidine (cmax) time to maximum plasma concentration of azacitidine (tmax) terminal phase half-life of azacitidine (tÂ½) apparent total clearance of azacitidine (cl/f) apparent volume of distribution of azacitidine (vz/f) area under the plasma concentration-time curve from time 0 to 8 hours post-dose after single and multiple doses of azacitidine area under the plasma concentration-time curve from time 0 to the last quantifiable time point after single and multiple doses of azacitidine area under the plasma concentration-time curve from time 0 to infinity after single and multiple doses of azacitidine maximum plasma concentration of azacitidine (cmax) after single and multiple doses of azacitidine time to maximum plasma concentration of azacitidine (tmax) after single and multiple doses of azacitidine terminal phase half-life of azacitidine (tÂ½) after single and multiple doses of azacitidine apparent total clearance of azacitidine (cl/f) after single and multiple doses of azacitidine apparent volume of distribution of azacitidine (vz/f) after single and multiple doses of azacitidine number of participants with adverse events (aes) incidence of adverse events maximum tolerated dose the primary outcome of this study is to determine the mtd of daily oral bmn 673 in patients with aml and mds (arm 1) and patients with cll and mcl (arm 2). occurrence of drug-related grade 3 or 4 systemic or local adverse events (defined using the nci ctcae version 3.0) occurrence of local skin reactions considered related to the vaccination occurrence of drug-related systemic reactions (e.g., transient fever) demonstration by elispot assays of the frequency of t-lymphocytes recognizing major histocompatibility complex (mhc) class i and ii-restricted epitopes within ebna1 and lmp2 in peripheral blood at sequential time-points before, during, and up to 9 mo ... maximum tolerated dose (mtd))/recommended phase 2 dose of trigriluzole number of participants with engraftment within 42 days mean time to engraftment standardized measure of [18f]-fludarabine uptake in tumor tissue. to determine the maximum tolerated dose of fenretinide to describe the toxicities of fenretinide maximum tolerated dose (mtd) incidence of adverse events (aes) cd34+ cells dose limiting toxicities dose limiting toxicities dose-limiting toxicity and maximum tolerated dose intensity of adverse events (aes) incidence of adverse events incidence of adverse events dose limiting toxicities maximum tolerated dose maximal tolerated dose (mtd) of sar260301 in monotherapy (study part a) maximal tolerated dose (mtd) of sar260301 in combination with vemurafenib (study part b) percentage of participants achieving response safety during dose-limiting toxicity (dlt) observation period pharmacodynamic biomarker p70s6k determine the maximum tolerated dose auc during a dosing interval for rituximab number of patients with adverse events safety and toxicity assessment of study treatment feasibility assessment of study treatment feasibility toxicity part a: number of participants with dose-limiting toxicities maximum observed plasma concentration (cmax) of cc-223 time to maximum concentration (tmax) of cc-223 area under the plasma concentration-time curve from time 0 to the last measurable concentration (auct) for cc-223 area under the concentration time-curve from 0-24 hours after a dose (auc0-24) for cc-223 area under the plasma concentration-time curve from time 0 extrapolated to infinity (aucinf) for cc-223 part a: terminal elimination phase half-life (t1/2) of cc-223 apparent total body clearance (cl/f) of cc-223 apparent volume of distribution (vz/f) of cc-223 part b: progression free survival (pfs) rate at 6 months for gbm participants incidence, severity and relationship of treatment-emergent adverse events incidence, severity and relationship of treatment-emergent adverse events safety and tolerability of sch 727965, including maximum administered dose and dose-limiting toxicity. in participants with advanced solid tumors, non hodgkin\\'s lymphoma or multiple myeloma, pharmacodynamic effects of sch 727965 with an ex vivo lymphocyte stimulation assay of participant\\'s peripheral blood lymphocytes. adverse events (aes) and changes in laboratory values and vital signs. pharmacokinetic parameter values for gsk2126458, change from baseline in protein markers in tumor and/or blood. blood glucose and insulin levels. tumor response, recist defined number of participants with dose limiting toxicities (dlts) mtd of lenalidomide when combined with alvocidib, defined as the maximum dose level with fewer than 2 of 6 patients experiencing dose limiting toxicity (dlt) incidence of dlt in patients treated with alvocidib and lenalidomide graded according to nci ctcae version 4.0 number of solid tumor participants with first-cycle dose-limiting toxicity (dlt) number of t-all/lbl participants with first-cycle dlt incidence and nature of adverse events (aes) number of participants with a dose limiting toxicity (dlt) maximum tolerated dose (mtd) or recommended phase 2 dose (r2pd) of entinostat frequency of adverse events for entinostat half-life of entinostat peak plasma concentration of entinostat: c-max total area under the plasma concentration curve of entinostat: auc time to reach maximum plasma concentration of entinostat: t-max maximum-tolerated dose of dinaciclib when given in combination with ofatumumab, defined as a dose level where at most one of 6 evaluable patients has a dose limiting toxicity (phase ia) number of patients with dose-limiting toxicity incidents graded according to the nci ctcae v4.0 (phase i) percentage of patients who achieve an overall response, defined as achieving a complete response, an unconfirmed complete response (sll only), or a partial response (phase ii) safety of escalating doses on01910.na at day 28. number of participants with dose limiting toxicities (dlts) dose-escalation cohort: maximum tolerated dose (mtd) of crizotinib dose-escalation cohort: recommended phase 2 dose (rp2d) of crizotinib dose-escalation and recommended phase 2 dose (rp2d) cohort: area under the curve from time zero to extrapolated infinite time (aucinf) of crizotinib on day -7 dose-escalation and recommended phase 2 dose (rp2d) cohort: area under the curve from time zero to end of dosing interval (auctau) of crizotinib on day -7 dose-escalation and recommended phase 2 dose (rp2d) cohort: area under the curve from time zero to end of dosing interval (auctau) of crizotinib on cycle 1 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: area under the curve from time zero to end of dosing interval (auctau) of crizotinib on cycle 1 day 15 dose-escalation and recommended phase 2 dose (rp2d) cohort: area under the curve from time zero to end of dosing interval (auctau) of crizotinib on cycle 2 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: trough concentration (ctrough) of crizotinib cycle 1 day 15 dose-escalation and recommended phase 2 dose (rp2d) cohort: trough concentration (ctrough) of crizotinib on cycle 2 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: maximum observed plasma concentration (cmax) of crizotinib on day -7 dose-escalation and recommended phase 2 dose (rp2d) cohort: maximum observed plasma concentration (cmax) of crizotinib on cycle 1 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: maximum observed plasma concentration (cmax) of crizotinib on cycle 1 day 15 dose-escalation and recommended phase 2 dose (rp2d) cohort: maximum observed plasma concentration (cmax) of crizotinib on cycle 2 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: time to reach maximum observed plasma concentration (tmax) of crizotinib on day -7 dose-escalation and recommended phase 2 dose (rp2d) cohort: time to reach maximum observed plasma concentration (tmax) of crizotinib on cycle 1 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: time to reach maximum observed plasma concentration (tmax) of crizotinib on cycle 1 day 15 dose-escalation and recommended phase 2 dose (rp2d) cohort: time to reach maximum observed plasma concentration (tmax) of crizotinib cycle 2 day 1 dose-escalation and recommended phase 2 dose (rp2d) cohort: plasma decay half-life (t1/2) of crizotinib on day -7 dose-escalation and recommended phase 2 dose (rp2d) cohort: number of participants with treatment emergent adverse events (teaes) and serious adverse events (saes) dose-escalation cohort: number of participants with dose-limiting toxicities (dlt) midazolam interaction cohort: maximum observed plasma concentration (cmax) of midazolam when taken alone or taken with crizotinib area under the curve from time zero to extrapolated infinite time (aucinf) of midazolam when taken alone or taken with crizotinib rp2d cohort: area under the curve from time zero to last quantifiable concentration [auc (0-24)] of crizotinib when taken with food rp2d cohort: maximum observed plasma concentration (cmax) of crizotinib when taken with food area under the curve from time zero to end of dosing interval (auctau) of crizotinib alone and when taken with rifampin rifampin cohort: maximum observed plasma concentration (cmax) of crizotinib alone and when taken with rifampin rifampin cohort: ctrough of crizotinib alone and when taken with rifampin itraconazole cohort: area under the curve from time zero to end of dosing interval (auctau) of crizotinib when taken alone and when taken with itraconazole itraconazole cohort: maximum observed plasma concentration (cmax) of crizotinib when taken alone and when taken with itraconazole itraconazole cohort: trough plasma concentration (ctrough) of crizotinib when taken alone and when taken with itraconazole recommended phase 2 dose (rp2d) cohort: percentage of participants with objective response (or) recommended phase 2 dose (rp2d) cohort: duration of response (dor) recommended phase 2 dose (rp2d) cohort: time to response (ttr) recommended phase 2 dose (rp2d) cohort: percentage of participants with disease control at week 8 recommended phase 2 dose (rp2d) cohort: percentage of participants with disease control at week 16 recommended phase 2 dose (rp2d) cohort: progression free survival (pfs) recommended phase 2 dose (rp2d) cohort: probability of being event free at month 6 recommended phase 2 dose (rp2d) cohort: overall survival (os) probability of participant survival at month 6 probability of participant survival at month 12 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 1 day 15 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 2 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 4 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 6 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 9 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 12 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 15 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 18 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 21 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 24 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 27 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 30 day 1 geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin (shbg), luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at end of treatment maximum tolerated dose of targeted marrow irradiation defined as the dose level immediately below that in which greater than or equal to 2/6 subjects experience a dose limiting toxicity assessed using nci ctcae version 4.0 - to determine the maximum tolerated dose of gsk1120212 safety dose limiting toxicity assessment at the end of the first 28 day cycle. to evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma. to evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy. three-year relapse-free survival (rfs) rate at the maximum tolerated dose identified during phase i of the trial (target auc 6912) number of participants with dose limiting toxicities (dlts) number of patients who are surviving at 100-days post-transplant pharmacokinetics cmax - stage i (bioequivalence) pharmacokinetics tmax - stage i (bioequivalence) pharmacokinetics auc-t - stage i (bioequivalence) pharmacokinetics auc-infinity - stage i (bioequivalence) pharmacokinetics Î»z (terminal rate) - stage i (bioequivalence) pharmacokinetics terminal half-life (tÂ½) - stage i (bioequivalence) pharmacokinetics apparent total clearance (cl/f) - stage i (bioequivalence) pharmacokinetics apparent volume of distribution (vd/f) - stage i (bioequivalence) pharmacokinetics cmax - stage ii (food effect bioavailability) pharmacokinetics tmax - stage ii (food effect bioavailability) pharmacokinetics auc-t - stage ii (food effect bioavailability) pharmacokinetics auc-infinity - stage ii (food effect bioavailability) pharmacokinetics Î»z (terminal rate) - stage ii (food effect bioavailability) pharmacokinetics terminal half-life (tÂ½) - stage ii (food effect bioavailability) pharmacokinetics apparent total clearance (cl/f) - stage ii (food effect bioavailability) pharmacokinetics apparent volume of distribution (vd/f) - stage ii (food effect bioavailability) to determine the dose-limiting toxicity and maximum tolerated dose of plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure. subjects with treatment emergent adverse events number of participants who experienced dose-limiting toxicities (dlts) rate of toxicity in study participants receiving protocol therapy determination of the maximum tolerated dose (mtd) in study participants receiving protocol therapy mtd of inotuzumab ozogamicin with cvp for patients with relapsed or refractory cd22+ acute leukemia dose limiting toxicity number of participants with dose limiting toxicities (dlts): phase i recommended phase ii dose (rp2d): phase i percentage of participants with objective response according to response evaluation criteria in solid tumors version 1.1 (recist v1.1) by independent review committee (irc): phase ii safety and tolerability as monotherapy safety and tolerability as monotherapy safety as assessed by a non-relapse mortality < 30% within day 100 number of patients with dose limiting toxicities change from baseline local immune effects after repeated t-vec injections safety of dli following a non-myeloablative transplant, defined as incidence of grade iv acute gvhd can il-2 be administered with gm-csf to efficiently mobilize autologous peripheral blood stem cells. this study will determine the maximum tolerated dose of il-2 and the optimal biological dose with gm-csf for stem cell mobilization. dose limiting toxicity number of participants and severity of aes determination of non tolerated dose (ntd) and maximum tolerated dose (mtd) adverse events and other safety assessments to assess the safety of chemotherapy and il-2 administration to facilitate transient nk-cell engraftment in research participants with chemotherapy refractory non-acute myelogenous leukemia (non-aml) hematologic malignancies to evaluate the safety of cal-101 and determine the dose limiting toxicity in patients with hematologic malignancies. to describe dose limiting toxicities (dlt) of prt543 to determine the maximally tolerated dose (mtd) to determine the recommended phase 2 dose (rp2d) and schedule of prt543 response rate acute toxicity associated with the infusion of nicord proportion of patients with neutrophil engraftment dose-limiting toxicity and maximum tolerated dose determination of dose limiting toxicities of 4sc-202 determination of safety of 4sc-202 determination of pharmacokinetic profile of 4sc-202 determination of maximum tolerated dose of 4sc-202 determination of tolerability of 4sc-202 recommended phase 2 dose (rp2d) of alectinib percentage of participants with dose limiting toxicities (dlts) percentage of participants achieving objective response (complete response [cr] or partial response [pr]) as assessed by independent radiological review committee (irc) in response evaluable (re) population percentage of participants achieving objective response (cr or pr) as assessed by irc in chemotherapy-pretreated participants event-free survival by disease assessment overall survival dose limiting toxicity maximum dose tolerated of mln 9708 number of participants with adverse events (aes), serious adverse events (saes), and aes leading to discontinuation number of participants who died number of participants with on-treatment laboratory abnormalities in specific hepatics tests objective response rate (orr) - part d duration of response (dor) - part d number of participants with merestinib dose-limiting toxicities (dlts) phase 1 study: percentage of participants experiencing adverse events defined as dose limiting toxicities (dlts) of chidamide. phase 1 study: maximum tolerable dose of chidamide among participants phase 1 study: maximum tolerable dose(mtd) and recommended phase 2 dose (rp2d) of chidamide among participants phase 2 safety management study efficacy of sintilimab plus chidamide in refractory and relapsed enktcl recommended phase 2 dose safety and tolerability of cb-839: incidence of adverse events neutrophil engraftment/chimerism duration of plasmatic asparagin depletion (< 2Âµmol/l) maximum tolerated dose (mtd) of ps-341 in combination with doxil (phase i) response rate of the combination of velcade and doxil in patients with metastatic breast cancer change in leukemia cell death examination of potential food-effect on pharmacokinetics of ro5045337 evaluation of relative bioavailability of ro5045337 regimen-related toxicities non-relapse mortality maximum tolerated dose of genetically modified, cd19-specified t cells phase 1, part 1: number of participants with dose limiting toxicities (dlts) phase 1, part 2: number of participants with dose limiting toxicities (dlts) phase 1, parts 1 and 2: number of participants with at least one treatment-emergent adverse event (teae) phase 2: objective response rate (orr) in participants with select solid tumors per response evaluation criteria in solid tumors (recist) v 1.1 for participants with solid tumors and per cheson criteria for participants with dlbcl phase 2: progression free survival (pfs) phase 2: overall survival (os) rate of proportion with glioblastoma feasibility of expansion of frozen donor mononuclear cells into cik toxicity including gvhd and marrow aplasia toxicity number of participants with graft versus host disease (gvhd) greater than or equal to grade 3 to determine the maximum tolerated dose of expanded nk cells in research participants with relapsed or refractory hematologic malignancies and sarcomas. bioequivalence maximum tolerated dose (mtd) determination maximum observed plasma concentration (cmax) of ibrutinib minimum observed plasma concentration (cmin) of ibrutinib time to reach maximum observed plasma concentration (tmax) of ibrutinib area under the plasma concentration-time curve from time zero to 24 hours (auc[0-24]) of ibrutinib metabolite to parent (m/p) ratio of ibrutinib to evaluate the safety and tolerability of escalating doses of twice weekly emd 121974 in patients with cancer. maximum tolerated dose maximum tolerated dose/dose-limiting toxicities safety: incidence of adverse events comparison of daily versus twice daily dosing: incidence of adverse events percentage of participants with grades ii to iv acute graft-versus-host disease (agvhd) summary of participants reporting adverse events maximum tolerated dose (mtd) proportion of donors from whom a sufficient number of cells for transplantation are collected in no more than 2 lp procedures following mobilization with amd3100 (donor only) proportion of recipients who experience grade 2-4 acute gvhd (recipient only) proportion of recipients who successfully engraft by day +21 after transplant (recipient only) molecular pharmacodynamic effect of low dose daunorubicin on beta-catenin phosphorylation as assessed by quantitative immunohistochemistry assay performed on serial bone marrow samples of patients with relapsed leukemia. number of participants with dose limiting toxicity (dlt) events number of participants experiencing potential efficacy of alt 803 to determine the maximum tolerated dose of cxd101 administered twice daily for 5 consecutive days every 21 days determine the maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of epz-5676. to assess the safety and tolerability of epz-5676 administered as a continuous intravenous (civ) infusion determine maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of npi-0052 number of patients with adverse events physical exam electrocardiogram (ecg) vital signs transthoracic echocardiogram (tte)/multiple gated acquisition (muga) scans clinical laboratory assessments ecog peformance status pk - maximum observed plasma concentraion (cmax) pk - time to cmax [tmax] (maximum observed plasma concentration) pk - area under the plasma concentration-time curve (auc(0-t)) pk - apparent terminal phase elimination rate constant pk - apparent terminal phase half-life (t1/2) pk - oral clearance (cl/f) cumulative incidence of grade 2-4 acute graft-versus-host disease immune reconstitution (quantitative evaluation of lymphocyte subsets in the peripheral blood, quantitative evaluation of pathogen-specific immune response by elispot assay) overall response (cr for all patients), (cr + crp for aml patients) safety maximum tolerated dose (mtd) of ipilimumab according to the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (phase i) maximum tolerated dose (mtd) of nivolumab according to the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (phase i) incidence of adverse events as assessed by national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (phase ib) maximum tolerated dose (mtd) risk of true graft rejection in patients with and without preceding chemotherapy risk of grades ii-iv acute gvhd in those patients with sustained engraftment dose limiting toxicity to establish the dlt and the mtd of ridaforolimus administered daily x 5 every 14 days in pediatric patients with recurrent/refractory solid tumors, including lymphoma and tumors of the central nervous system. number of participants with treatment-emergent adverse events (teaes) and treatment-emergent serious adverse events (tesaes) recommended phase 2 dose (rp2d) of selinexor maximum tolerated dose (mtd) of a 5-day continuous infusion schedule of nelarabine maximum tolerated dose of abbv-075 time to cmax (peak time, tmax) for abbv-075 number of participants with adverse events maximum observed plasma concentration (cmax) of abbv-075 area under the curve (auc) safety and tolerability of asp3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ecgs) and clinical observations maximum tolerated dose of donor natural killer (nk) cells safety effectiveness of donor nk cell infusion in preventing tumor relapse and graft failure after hla-haploidentical familial donor bone marrow transplantation number of subjects with treatment-emergent adverse events (teaes) number of subjects with best overall tumor response by immune-related response evaluation criteria in solid tumors (irrecist) safety of car nk-cd19 cell cell count of car nk-cd19 cmax of car nk-cd19 tmax of car nk-cd19 auc of car nk-cd19 other pharmacokinetic of car nk-cd19 cell incidence of adverse events after pcar-19b infusion [safety and tolerability] obtain the maximum tolerated dose of pcar-19b cells[safety and tolerability] maximum tolerated dose (mtd), dose limiting toxicity (dlt) and recommended phase ii dose (rp2d) safety of cnct19 therapy incidence of dose limiting toxicities (dlt) of the combination of palbociclib and dexamethasone maximum tolerated dose (mtd) of the combination of palbociclib and dexamethasone defined as the highest dose level where a dlt occurs in at most one out of six patients treated dose limiting toxicities (dlt): number of patients with grade 3-5 toxicities occurring within the dose limiting toxicity (dlt) period of auto3 infusion number of patients with dose limiting toxicity (dlt) of auto3 number of patients achieving morphological remission (complete response(cr) or complete response with incomplete count recovery (cri) and minimal residual disease (mrd)-negative response in the bone marrow (pcr)). cardiorespiratory exercise test the complete remission (cr) rate incidence and severity of adverse events dose escalation part: dose limiting toxicities (dlts) occurence. dose expansion part: ae throughout the study. phase 1b: number of participants with dose-limiting toxicities phase 2: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment expansion cohort: number of participants with treatment-emergent adverse events (teaes) and treatment-related teaes safety safety and feasibility phase i: number of participants with dose-limiting toxicities (dlts) percentage of participants with complete remission in the first two cycles maximum tolerated dose (mtd) local reactions after each vaccination systemic reaction maximum tolerated dose (mtd) safety as evaluated by adverse events (incidence, severity, duration, causality, seriousness, type) pharmacokinetics as measured by maximum drug serum concentration (cmax) pharmacokinetics as measured by time to maximum serum concentration (tmax) pharmacokinetics as measured by area under the drug-concentration curve (auc) pharmacokinetics as measured by half life (t1/2) pharmacokinetics as measured by renal clearance (clr) to determine the maximum tolerated dose (mtd) and dose limiting toxicity (dlt) this study will determine the maximum tolerated dose of genetically modified nk cells in research participants with relapsed or refractory b-lineage all the incidence of dlts (dose limiting toxicities) experienced with 1 cycle of this 5-drug regimen in this patient population (in all patients who receive any doses of study drugs) maximum tolerated dose [mtd] determination by number of participants with dose limiting toxicity (dlt) overall response rate (or) where or = cr + crp + cri compare changes in gene expression signatures in steroid alone versus steroid plus rapamycin treated patients. compare biologic measures of \"pro-apoptotic state\" in steroid alone versus steroid plus rapamycin treated patients aall08p1 safety outcome aall08p1 feasibility outcome partial and complete remission, overall response rates optimum dose of deglycosylated ricin a chain-conjugated anti-cd19 and anti-cd22 immunotoxins (combotox) efficacy of treatment occurrence of a dose-limiting toxicity (phase 1) achievement of complete remission (cr) to determine the safety and tolerability of 5-aza-2\\'-deoxycytidine (decitabine) administered daily for 5 days every other week in patients with relapsed or refractory acute lymphocytic leukemia (all). to determine the clinical activity of this schedule of decitabine in this patient population. to determine the safety and tolerability of decitabine in combination with hypercvad based chemotherapy in patients with relapsed or refractory all. to determine the clinical activity of this schedule of decitabine in combination with hypercvad in this patient population. in this phase i study the endpoint is the determination of the maximum tolerable dose without toxicity. response rate safety profile and tolerability mtd of vsli remission re-induction (cr2) rate event-free survival rate rate of minimal residual disease (mrd) < 0.01% toxicity treatment failure safety maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) for abbv-621 area under the serum/plasma concentration time curve (auc) of abbv-621 area under the serum/plasma concentration time curve (auc) of venetoclax maximum observed serum concentration (cmax) of abbv-621 maximum observed serum concentration (cmax) of venetoclax time to cmax (tmax) of abbv-621 time to cmax (tmax) of venetoclax terminal phase elimination rate constant (Î²) for abbv-621 terminal phase elimination rate constant (Î²) for venetoclax terminal phase elimination half-life (t1/2) of abbv-621 in plasma terminal phase elimination half-life (t1/2) of venetoclax in plasma part 1 : number of participants experiencing adverse events part 1: number of participants with clinical laboratory abnormalities part 1: number of deaths part 1: number of participants experiencing dose-limiting toxicity (dlt) part 1 and part 2: number of participants achieving a best response of partial response maximum tolerated dose of romiplostim determine maximum tolerated dose (mtd) of bp31510 number of treatment-emergent adverse events (teaes) safety and tolerability of cb-839: incidence of adverse events dose limiting toxicity (dlt) is defined as grade 4 acute gvhd within the first 90 days following infusion. maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone percentage of participants with a minimally durable clinical response rate circulating cd3+ve t cell count at 4 months post-sct dose-limiting toxicity non-tolerated dose maximum tolerated dose maximum observed concentration in plasma of cc-115 area under the concentration-time curve for cc-115 time to maximum concentration of cc-115 terminal half-life for cc-115 apparent total body clearance of cc-115 apparent volume of distribution of cc-115 accumulation index of cc-115 occurrence of adverse events grade 4 or grade 5 as assessed by ctcaev4 graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3 to determine the mtd and the recommended final dose (rd) to be used for further investigations. the maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of epz-5676 as determined by incidence of protocol-specified dose-limiting adverse events. to determine the dose of dasatinib that can be safely administered with cytarabine, and high-dose mitoxantrone in patients with ph+ all / lymphoid blast crisis of known chronic myelogenous leukemia. number of patients experiencing regimen-related toxicity events in study population number of patients experiencing graft failure incidence (percent of participants) with nonrelapse mortality (nrm) by day 200 (secondary phase only) maximum tolerated dose (mtd) of alemtuzumab (phase i) number of participants who proceed to course v within 2-6 weeks of the last dose of alemtuzumab (phase ii) to determine the maximum tolerated dose(mtd)of tak-901 in subjects with advanced hematologic malignancies. to further assess the safety and tolerability of tak-901 at or below the mtd in an expanded cohort of subjects in order to select a dose for future studies. toxicity phase i: maximum tolerated dose (mtd) of carfilzomib phase ii: kaplan-meier estimate of the percentage of patients who are alive and have not developed any \"event\" the identification of the maximum tolerated dose for twice or once weekly dosing, on three weeks out of four incidence of treatment-emergent adverse events pharmacokinetics (pk) of cpx-351 the frequency of grade 4 crs phase i study - safety and tolerability of pol6326 as a mobilization agent. phase ii study - determine the number of allogeneic donors who require a second leukapheresis maximum tolerated dose as a measure of safety and tolerability mtd of brentuximab vedotin when administered with a gvhd prophylaxis regimen engraftment one month after transplantation maximum tolerated dose (mtd) in phase 1 participants with dose limiting toxicity in phase 1 percentage of participants achieving a response over the first two treatment cycles in phase 2 to evaluate the toxicity and maximum tolerated dose of 9-ac administered as a 72 hour infusion in patients with relapsed/refractory leukemia. maximum tolerated dose maximum tolerated dose (mtd) dose limited toxicity (dlt) safety and tolerability of treatment with tkm-080301 determine dose-limiting toxicities and maximum tolerated dose of tkm-080301 maximum tolerated dose (mtd) of total marrow irradiation (tmi) determination of the safety and tolerability of bbi608 administered as monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib by assessing dose-limiting toxicities (dlts) proportion of subjects who start a targeted drug maximal tolerated dose (mtd) dose limiting toxicity (dlts) maximum tolerated dose (mtd) of combination selinexor, fludarabine and cytarabine dose limiting toxicity of combination selinexor, fludarabine and cytarabine number of participants who experienced a dose limiting toxicity (dlt) occurrence and severity of side effects of donor natural killer cell infusion the dose of ac220 that is safe and biologically active when given in sequential combination with ara-c/etoposide proportion of major adverse cardiac events (mace) proportion of other significant clinical events subjects with events precluding their receipt of product subjects who receive less than 20 injections during spi subjects who did not receive the study product (either 100 million cells or placebo) subjects who have at least one cardiac mri endpoint measure that is uninterpretable subjects who fail to complete follow-up to determine the maximum tolerated dose (mtd) and/or the safe, tolerated dose of clofarabine in combination with ara-c and tbi followed by allosct in children with all and anll. to define the toxicity and safety of the conditioning regimen of clofarabine, ara-c, tbi followed by allosct in children with all and anll. to define the pharmacokinetics of clofarabine given in combination with ara-c and tbi followed by allosct in children with all and anll. maximum tolerable dose toxicities of lenalidomide engraftment rate maximum tolerated dose (mtd) of vemurafenib with carboplatin and paclitaxel phase i: maximum tolerated dose phase ii: antitumour activity tolerance of low transfusion threshold as assessed by the percentage of participants who crossed over from the low arm to the high arm. safety of escalating nk cell doses of adoptively infused ex vivo expanded autologous nk cells in subjects with treatment refractory metastatic tumors or hematological malignancies that are sensitized to nk cell toxicity with bortezomib. to obtain high resolution spectra from tumors using surface coils to improve sensitivity. maximum tolerated dose (mtd) oxaliplatin phase 1: percentage of participants with treatment-emergent adverse events (teae) and serious treatment-emergent adverse events phase 2: objective response rate (orr) engraftment the maximum tolerated dose (mtd)/recommended phase ii dose (rp2d) is the dose at which less than or equal to 1 of 6 patients experience a dose limiting toxicity (dlt) with the next higher dose having at least 2 of 3 or 2 of 6 patients experiencing a dlt. to study the highest tolerable dose of vnp40101m that can be given to patients with a form of leukemia, mds, lymphoma, or myeloma in preparation for an autologous stem cell transplant. the incidence of participants with dose limiting toxicities (dlts) within each dose level cohort. to determine the safety, tolerability and recommended phase 2 dose (rp2d) of arq 621 administered intravenously. safety of bp1001 safety of bp1001 in combination with ldac summary of nilotinib non-compartmental pk parameters: cmax summary of nilotinib non-compartmental pk parameters: tmax summary of nilotinib non-compartmental pk parameters: auclast (last = 24h) summary of nilotinib non-compartmental pk parameters: auc0-12h summary of nilotinib steady-state pk parameters: aucss summary of nilotinib steady-state pk parameters: clf (body surface area (bsa) adjusted) summary of nilotinib steady-state pk parameters: cmin evaluate the safety and feasibility of administering prophylactic donor lymphocyte infusion (dli) after non-myeloablative transplant (nmt). to determine the maximum tolerated dose (mtd) and dose limiting toxicity (dlt) of inno-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant ph+ leukemias. to determine the safety profile (including acute and chronic toxicities) and tolerability of inno-406 in this patient population. recommended phase 2 dose (rp2d) of bez235 in acute lymphoblastic leukemia (all), acute myeloid leukemia (aml) and chronic myeloid leukemia in blastic phase (cml-bp) incidence of dose-limiting toxicity (dlt) incidence of serious adverse reactions adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using common terminology criteria for adverse events version 4 phase 1: number of participants with dose-limiting toxicities (dlts) as a measure of safety profile to determine recommended dose of ponatinib phase 2, cp-cml participants: percentage of participants with major cytogenetic response (mcyr) phase 2, bp-cml and ph+all: percentage of participants with major hematologic response (mahr) assess safety and feasibility of monoclonal abs directed to cd45 and cd52 antigens, fludarabine and low dose tbi, as a non-myeloablative preparatory regimen for allo hsct. this will be determined by 100d non-relapse mortality and 100d graft rejection recommended phase ii doses for the combination of bortezomib and belinostat number of participants with adverse events (aes), serious adverse events (saes), deaths, and discontinuation determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-hodgkin\\'s lymphoma. maximum tolerated dose (mtd) of bosutinib all phase i participants number of participants with a major hematologic response trm, defined as death occurring in a patient from causes other than disease relapse rate of grade ii/iii organ toxicity, defined by the bearman regimen-related toxicities scale maximum tolerated dose toxicity as assessed by nci ctcae v3.0 response rate objective tumor response survival time to treatment failure duration of response establishment of mtd and recommended phase ii dose. safety as determined by the number of participants with treatment-related adverse events identify maximum tolerated (mtd) and/or recommended dose (rd) and schedule for xmab14045 dosing dose limiting toxicity (dlt) change in bone marrow blast cell and peripheral blood counts at 5, 13 and 25 weeks to assess efficacy in subjects with aml, all and blast-phase cml based on standard response criteria incidence and nature of adverse events pharmacokinetic parameter for total antibody (tab), antibody drug conjugate (adc), and monomethyl auristatin e (mmae): concentration at the end of infusion (ceoi) pharmacokinetic parameter for total antibody (tab), antibody drug conjugate (adc), and monomethyl auristatin e (mmae): maximum observed concentration (cmax) pharmacokinetic parameter for monomethyl auristatin e (mmae): time to maximum concentration (tmax) pharmacokinetic parameter for total antibody (tab), antibody drug conjugate (adc), and monomethyl auristatin e (mmae): partial area under the serum concentration-time curve after first dose and as appropriate (auc0-21) pharmacokinetic parameter for total antibody (tab), antibody drug conjugate (adc), and monomethyl auristatin e (mmae): terminal or apparent terminal half-life (t1/2) pharmacokinetic parameter for total antibody (tab), antibody drug conjugate (adc), and monomethyl auristatin e (mmae): systemic clearance (cl) pharmacokinetic parameter for total antibody (tab), antibody drug conjugate (adc), and monomethyl auristatin e (mmae): volume of distribution at steady state (vss) the primary endpoint is all cause mortality at day 200, and the proportion of subjects who have survived at day 200 will be used to determine the sample size. define human intra-patient bioavailability of clofarabine; compare the pharmacokinetics of intravenously-administered clofarabine when administered alone, with the pharmacokinetics of clofarabine when co-administered with cimetidine, an oct2 inhibitor. non-relapse mortality at 1 year maximum tolerated dose (mtd) number of patients with treatment-related dose limiting toxicity in cycle 1 by dose level number of patients with treatment-related adverse events area under the plasma concentration versus time curve (auc) of sorafenib clearance (cl) of sorafenib half-life of sorafenib maximum serum concentration (cmax) of sorafenib number of patients with treatment-related dose limiting toxicities in later cycles by dose level area under the plasma concentration versus time curve (auc) of sorafenib clearance (cl) of sorafenib half-life of sorafenib volume of distribution at steady state (vss) of sorafenib maximum serum concentration (cmax) of sorafenib safety of uld il-2 as gvhd proph determine the safety profile (adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of abt-348 as monotherapy or in combination study the pharmacokinetic interaction (plasma concentrations and pharmacokinetic parameter values) of abt-348 as monotherapy and in combination to determine the maximum tolerated dose of th-302 to determine the dose-limiting toxicity of th-302 to determine the number of participants with adverse events as a measure of safety and tolerability safety and tolerability phase i: maximum tolerated dose (mtd) phase ii: major cytogenetic response number of participants with major cytogenetic response (mcyr) number of participants confirmed overall hematological response (phase ii) number of participants with treatment safety failure safety data, including laboratory parameters and adverse events, will be collected for all patients in order to determine the qualitative and quantitative toxicity, and reversibility of toxicity, of on 01910.na. percentage of participants with cumulative incidence of grade ii to iv agvhd through day +100 based on investigator assessment the mtd of radiation delivered via 90y-dota-bc8 when combined with flu and 2 gy tbi as a preparative regimen for patients aged â‰¥ 18 with advanced aml, all, and high-risk mds. pharmacokinetic interaction dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib maximum tolerable dose (mtd) of photofrinÂ® in pediatric subjects the safety and toxicity of alt-801 in patients with progressive metastatic malignancies the maximum-tolerated dose (mtd) of alt-801 toxicity rate associated with infusing donor cd8+ ctl clones specific for wt1 in patients at high risk for post transplant relapse of cml, aml, or all maximum tolerated dose of belinostat in combination with azacitidine safety maximum tolerated dose of genotype-based dosing of folfiri with or without monoclonal antibody therapy incidence of dlt, defined as recurring grade 2 or greater non-hematological or grade 3 or greater hematological toxicities or skin rash graded using common terminology criteria for adverse events version 3.0 (ctcae-v3) mtd defined as the dose level at which fewer than 2 out of 6 patients experience dlt graded using ctcae-v3 safety of ebola and marburg vaccines assessed by clinical observation. safety of ebola and marburg vaccines assessed by clinical observation. safety of ebola and marburg vaccines assessed by change from baseline in levels of complete blood count (cbc). safety of ebola and marburg vaccines assessed by change from baseline in levels of creatinine. safety of ebola and marburg vaccines assessed by change from baseline in levels of alanine transaminase (alt). safety of ebola and marburg vaccines assessed by adverse experiences. safety of ebola and marburg vaccines assessed by serious adverse experiences. correlation analysis of pd-l1 expression of tumor objective response rate (orr) by irrc and recist 1.1 to determine the overall response rate to evaluate the safety to evaluate the pharmacokinetics of allogeneic nk cells ae/sae incidences changes from baseline in clinical laboratory test (hematology, biochemistry, coagulation factors and urinalysis) results, vital sign measurements, physical examination findings, and ecg and 2d echocardiogram/multiple-gated acquisition (muga) scan results characterize the pk of d07001-f4 orr(objective response rate) and tumor response pharmacokinetics anti-cancer activity of 4sc-205 after 6 weeks of treatment. effects of eg5 inhibition on biomarker modulation. overall response rates best response number of participants with serious and non-serious adverse events assessed by the common terminology criteria in adverse events (ctcae v4.0). overall response rate progression-free survival overall survival duration of response pharmacodynamics response assess the pharmacokinetic profile (cmax, auc, and half-life) of arq 092 assess pharmacodynamic activity determine preliminary evidence of activity as defined by recist v 1.1 determine recommended phase 2 dose objective response rate (orr) tumor response assessment summary of participants with treatment emergent adverse events (teaes) summary of participants with treatment emergent adverse events (teaes) estimate response rate in children and adolescents with recurrent solid tumors and lymphomas. auc0-inf cmax t1/2 cd19 positive b cells cd20 positive b cells antidrug antibodies of hlx01 best overall response (bor), progression free survival (pfs) serum concentration profiles of gwn323 as a single agent: cmax serum concentration profiles of gwn323 in combination with pdr001 and derived pk parameters: cmax presence and titer of anti-gwn323 antibodies measurement of the effector/regulatory t cell ratio serum concentration profiles of gwn323 as a single agent: auc serum concentration profiles of gwn323 in combination with pdr001 and derived pk parameters: auc presence and titer of anti-pdr001 antibodies determination of overall response rates determination of duration of response. determination of duration of stable disease (sd) as measured from time of 1st evidence of response to time of 1st evidence of progressive disease as measured by ct or mri. evaluate progression-free survival (pfs) evaluate overall survival (os) evaluate the mean plasma concentrations of ff-10502-01 evaluate ff-10502-01 incorporation into whole blood cellular dna by lc-ms/ms as a pharmacodynamic marker area under the concentration-time curve (auc) maximum tolerated dose (mtd) response rate (rr) dose limiting toxicity (dlt) progression free survival (pfs) recommended phase 2 dose (rp2d) evaluate the pharmacokinetic of each agent alone and in combination; determine the effects of the study treatment on the level of parp inhibition and dna damage in pbmcs and tumor samples. severity of the adverse events response rate progression-free survival(pfs) persistence of car t cells in vivo number of participants with adverse events (aes) and serious adverse events (saes) objective tumor response to characterize safety profile and feasibility, pharmacokinetics, drug-drug interactions. to obtain information on antitumor activity. best overall response rate based on investigator assessment duration of response concentrations of relevant tumor markers to perform a pharmacokinetic study of orally administered cz48 in the plasma. to assess responses by recist criteria and to follow patients for survival. pharmacokinetic (pk) profile of ca-170 pharmacokinetic (pk) profile of ca-170 preliminary anti-tumor activity of ca-170 based on recist and immune related response criterion (irrc) for solid tumors or cheson for lymphoma safety and tolerability of lee011, as assessed by grade and frequency of adverse events, serious adverse events, and changes in lab values, vital signs and ecgs. the pharmacokinetics (pk) of lee011 (auc inf, cmax, tmax, t1/2) any pharmacodynamic activity of lee011 treatment, as assessed by changes from baseline in biomarkers associated with the pharmacologic activity of lee011 antitumor activity that may be associated with lee011 treatment, as assessed by ct/mri response evaluation criteria for solid tumors (recist) criteria v1.0 or cheson criteria 2007 for lymphomas. relationship between qtc prolongation and exposure to lee011 and/or any of its relevant metabolites. efficacy tumour response pharmacokinetic analysis immunological monitoring pharmacokinetic (pk) parameter: cmax of alobresib pk parameter: ctau of alobresib pk parameter: auc0-24 of alobresib pk parameter: auctau of alobresib pk parameter: tmax of alobresib pk parameter: t1/2 of alobresib 1: assessment of anti-tumor activity: mri k-trans in [ 10^-3/min] and/or ceus in [arbitrary units]; 2: pharmacokinetic profile: auc in [ng*h/ml] area under the curve (auc) of vorinostat after single oral dosing remission rate after 4 cycles and 8 cycles mean peak and trough concentrations of medi551 mean peak and trough concentrations of medi0680 terminal half-life (t1/2) of medi551 terminal half-life (t1/2) of medi0680 number of participants with positive anti-drug antibodies (ada) for medi-551 and medi0680 duration of complete response number of participants with disease control duration of disease control progression-free survival (pfs) overall survival (os) time to response (ttr) response of participants treated at lenalidomide 20 mg objective response rate of participants treated with lenalidomide 20 mg: overall response as % of participants with complete or partial response efficacy of carfilzomib (cfz) after autologous stem cell transplantation (asct) objective response rate based on lugano classification criteria complete response rate based on lugano classification criteria duration of response progression-free survival overall survival plasma concentrations of dtrmwxhs-12 overall survival progression free survival phase 1: orr, defined as the percentage of participants achieving either a cr or a pr, per the modified lugano classification for dlbcl phase 2: duration of response (dor): time from the first overall response contributing to an objective response (cr or pr) to the earlier of the participant\\'s death and the first overall response of progressive disease, per the lugano classification phase 2: durable response rate (drr) phase 2: progression-free survival (pfs), defined as the time from the first dose to the earlier date of death due to any cause or disease progression determined by objective radiographic disease assessments phase 2: number of participants with any teae phase 2: number of participants with any grade 3 or higher teae obinutuzumab minimum serum concentration (cmin) percentage of participants with adverse events (aes) graded according to the national cancer institute (nci) common terminology criteria for adverse events version 4.0 (ctcae v4.0) percentage of participants with anti-therapeutic antibody response to atezolizumab and obinutuzumab atezolizumab maximum serum concentration (cmax) atezolizumab minimum serum concentration (cmin) obinutuzumab maximum serum concentration (cmax) percentage of participants with best overall response according to lugano classification percentage of participants with objective response (complete response or partial response) according to lugano classification progression free survival (pfs) according to lugano classification overall survival (os) duration of objective response (dor) according to lugano classification tazemetostat plasma concentrations rate of efs overall response rate, cr rate, overall survival, pfs, and duration of response percentage of participants with cr at eoi, as determined by investigator on the basis of ct scans alone percentage of participants with objective response (cr + pr) at eoi, as determined by the investigator on the basis of pet-ct scans percentage of participants with objective response (cr + pr) at eoi, as determined by the investigator on the basis of ct scans alone percentage of participants with best response of cr or pr during the study, as determined by the investigator on the basis of ct scans alone percentage of participants with adverse events and serious adverse events serum obinutuzumab concentration serum rituximab concentration serum atezo concentration serum pola concentration percentage of participants with human anti-human antibodies (hahas) to obinutuzumab percentage of participants with human anti-chimeric antibodies (hacas) to rituximab percentage of participants with anti-therapeutic antibodies (atas) to atezo percentage of participants with atas to pola antibody and t-cell responses against cd20 antitumor response overall survival progression-free survival (pfs) time to disease progression duration of response, defined as date at which the patient\\'s objective status is first noted to be either a cr or partial remission to the date progression is documented survival time frequency and severity of adverse events assessed by ctcae v3.0 progression free survival at 1 year percentage change in tumour size safety of azd1152 overall response rate overall survival progression free survival clinical response toxicities of pralatrexate progression free survival overall survival evaluate the safety profile of multiple simultaneous microinjections using custom syringe after these drugs are given for 2 courses, a second goal is to see how long a remission lasts. a third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted. complete response (cr) rate overall response rate (cr + pr) time to response (ttr) duration of response (dor) time to progression (ttp) changes in degree of pruritus quality of life during therapy changes in skin related symptoms phase ii: percentage of participants with aes arms a and c (phase ii): percentage of participants with treatment emergent adas to polatuzumab vedotin arms e and f (phase ii): percentage of participants with treatment emergent adas to polatuzumab vedotin and obinutuzumab phase ii: percentage of participants with cr at pra based on pet-ct as determined by the investigator phase ii expansion cohorts and arm g (phase ii nf cohort): percentage of participants with cr at pra based on pet-ct as determined by the irc phase ii: percentage of participants with objective response (or) at pra based on pet-ct as determined by investigator phase ii: percentage of participants with or at pra based on pet-ct as determined by irc phase ii: percentage of participants with cr at pra based on ct only as determined by investigator phase ii: percentage of participants with cr at pra based on ct only as determined by irc phase ii: percentage of participants with or at pra based on ct only as determined by investigator phase ii: percentage of participants with or at pra based on ct only as determined by irc phase ii: percentage of participants with best objective response (bor) based on pet-ct or ct only as determined by the investigator dlbcl cohorts: percentage of participants with bor based pet-ct or ct only as determined by irc dlbcl cohorts: duration of response (dor) based on pet-ct or ct only as determined by the investigator dlbcl cohorts: dor based on pet-ct or ct only as determined by the irc dlbcl cohorts: progression free survival (pfs) based on pet-ct or ct only as determined by the investigator dlbcl cohorts: pfs based on pet-ct or ct only as determined by the irc phase ii nf cohort: percentage of participants with cr at pra based on pet-ct as determined by the investigator phase ii nf cohort: percentage of participants with or at pra based on pet-ct as determined by investigator phase ii nf cohort: percentage of participants with or at pra based on pet-ct as determined by irc phase ii nf cohorts: percentage of participants with bor based on pet-ct or ct only as determined by the investigator phase ii nf cohorts: percentage of participants with bor based on pet-ct or ct only as determined by the irc phase ii nf cohort: dor based on pet-ct or ct only as determined by the investigator phase ii nf cohort: dor based on pet-ct or ct only as determined by the irc phase ii nf cohort: pfs based on pet-ct or ct only as determined by the investigator phase ii nf cohort: pfs based on pet-ct or ct only as determined by the irc phase ii nf cohort: event-free survival (efs) based on pet-ct or ct only, as determined by the investigator phase ii nf cohorts: overall survival (os) arm g (phase ii nf cohort): percentage of participants with cr at pra based on pet-ct as determined by the irc arm g (phase ii nf cohort): percentage of participants with cr at pra based on ct only as determined by investigator arm g (phase ii nf cohort): percentage of participants with cr at pra based on ct only as determined by irc arm g (phase ii nf cohort): percentage of participants with or at pra based on ct only as determined by investigator arm g (phase ii nf cohort): percentage of participants with or at pra based on ct only as determined by irc plasma concentration of of polatuzumab vedotin analyte: acmmae arm g+h (phase ii nf cohorts): plasma concentration of of polatuzumab vedotin analyte: acmmae serum concentration of of polatuzumab vedotin analyte: total ab arm g+h (phase ii nf cohorts): plasma concentration of polatuzumab vedotin analyte: total ab plasma concentration of polatuzumab vedotin analyte: unconjugated mmae arm g+h (phase ii nf cohorts): plasma concentration of polatuzumab vedotin analyte: unconjugated mmae plasma concentration of bendamustine serum concentration of rituximab serum concentration of obinutuzumab phase ib: cmax of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a phase ib: cmax of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b phase ii: cmax of polatuzumab vedotin, bendamustine, and rituximab in arms a and c phase ii: cmax of bendamustine and rituximab in arms b and d phase ii: cmax of polatuzumab vedotin, obinutuzumab and bendamustine in arms e and f arm h (phase ii nf cohort): cmax of polatuzumab vedotin (lyophilized) phase ib: auc from time zero to infinity (aucinf) of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a phase ib: aucinf of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b phase ii: aucinf of polatuzumab vedotin, bendamustine, and rituximab in arms a and c phase ii: aucinf of bendamustine and rituximab in arms b and d phase ii: aucinf of polatuzumab vedotin, bendamustine, and obinutuzumab in arms e and f arm h (phase ii nf cohort): auc of polatuzumab vedotin (lyophilized) phase ib: cl of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a phase ib: cl of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b phase ii: cl of polatuzumab vedotin, bendamustine and rituximab in arms a and c phase ii: cl of bendamustine and rituximab in arms b and d phase ii: cl of polatuzumab vedotin, bendamustine and obinutuzumab in arms e and f arm h (phase ii nf cohort): cl of polatuzumab vedotin (lyophilized) phase ib: vss of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1a phase ib: vss of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b phase ii: vss of polatuzumab vedotin, bendamustine and rituximab in arms a and c phase ii: vss of bendamustine and rituximab in arms b and d phase ii: vss of polatuzumab vedotin, bendamustine and obinutuzumab in arms e and f arm h (phase ii nf cohort): vss of polatuzumab vedotin (lyophilized) symptom severity and interference according to therapy-induced neuropathy assessment score (tinas) in arms a-f optimal dose intensity of the intervention. clinical efficacy (radiological assessment by ct), biological efficacy (reconstitution of ebv-specific ctl immunity & anti-viral efficacy), safety & efficacy of the 1st treatment schedule vs the 2nd schedule clinical efficacy adverse events according to nci ctcae v. 3.0 event-free survival (phase ii) response duration (phase ii) time to progression (phase ii) overall survival (phase ii) quality of life usefulness and feasibility of the sakk c-sga association between who performance status, qol indicators, and sakk c-sga scores progression free survival (pfs) overall response rate duration of response progression free survival overall survival part i: total drug exposure (area under the concentration curve, auc[0-24 hours]) part i: maximum drug concentration (cmax) part i: time at which cmax occurs (tmax) part i: the amount of time it takes for the drug concentration to decrease by half (t1/2) number of participants who respond to treatment progression free survival (pfs) overall survival (os) t-cell response after every 3 courses of treatment and every month for up to a year after completion of study treatment progression-free survival (pfs) fcÎ³-receptor polymorphism response to treatment quantitative t-, b-, and nk-cell subsets using flow cytometry access pharmacokinetics through auc0-âˆž (area under curve) access pharmacokinetics through cmax monitor human anti-veltuzumab antibodies and human anti-milatuzumab (haha) comparing high-dose beam or beac chemo. with autologous hsct and radioimmunotherapy and high-dose beam or beac chemo. with autologous hsct safety and tolerability of cpi-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, echo and ecog score pharmacokinetic parameters of cpi-0610: auc(0-t), auc(0-inf), auctau,ss, tmax, cmax, ctrough, t1/2, vd/f, cl/f pharmacodynamic effects of cpi-0610: changes in the expression of myc and other genes in tumor tissue; changes in cellular proliferation and in the extent of apoptosis; changes in tumor metabolism changes in the expression of a set of genes in peripheral blood mononuclear cells (pbmcs) that are sensitive to bet inhibition anti-lymphoma activity associated with cpi-0610 treatment pharmacokinetic (pk) profile of av-299, and erlotinib (for subjects enrolled in the phase 1b only). evaluate the effects of av-299 and combination of av-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow. study the preliminary antineoplastic activity of av-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of av 299 in combination with erlotinib in subjects with advanced solid tumor. investigate the effect of av-299 and of the combination of av-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow. assess dosing schedules of av-299 (e.g. every 2-week and every 3-week schedules). assess safety and tolerability of the rp2d of av-299 in expansion cohort(s). to evaluate the safety and tolerability of the treatment combination to estimate the time to progression and the duration of overall response determine the optimal phase ii dose of doxorubicin hcl liposome to be administered with the combination chemotherapy regimen. determine the effect of this regimen on hiv viral load in these patients determine the clinical response to this regimen by these patients evaluate the toxicities of atc infusions armed with cd20bi evaluate immune b-cell recovery after atc infusion evaluate response rates of infusions and compare relapse rates and overall survival to historical controls partial response rate at 20 weeks overall response rate (complete and partial responses) at 20 weeks progression free survival (pfs) rate at 2 years overall survival (os) rate at 2 years survival days to neutrophil and platelet engraftment response rate c0: initial plasma concentration after bolus intravenous administration auc(0-168): area under the plasma concentration-time curve from time 0 to 168 hours postdose for ixazomib terminal phase elimination half-life (t1/2) for ixazomib rac: accumulation ratio for ixazomib ae (0-4): amount of drug excreted in urine from 0 to 4 hours postdose fe (0-4): fraction of dose excreted unchanged in urine from 0 to 4 hours postdose clr: renal clearance emax: maximum observed effect for ixazomib temax: time to maximum observed effect (emax) for ixazomib overall best response median overall survival at 1 year impact of bortezomib alone and in combination with rituximab, ifosfamide, carboplatin, and etoposide ([r]ice) on serum hiv viral loads and apobec3g levels impact of bortezomib alone and in combination with (r)ice on ebv and hhv-8 lytic activation using serum viral loads safety of bortezomib alone in patients with relapsed or refractory aids-associated lymphomas correlation of ebv/hhv-8 viral load changes with lymphoma response comparison of above outcomes to a parallel protocol employing ice +/- rituximab in patients with ebv/hhv-8-negative aids-nhl to assess whether bortezomib has additional effects beyond (r)ice alone toxicity event occurrence up to 100 days after transplantation complete remission 100 days after transplantation overall survival overall survival overall response rate (orr) median duration of response median progression free survival (pfs) median time to next therapy part 2: overall survival (os). part 2: progression-free survival (pfs). part 2: pk parameters for amg 655 on a 3 week dosing schedule. part 2: subject incidence of anti-amg 655 antibody formation. part 2: duration of response. part 1: subject incidence of anti-amg 655 antibody formation. part 1: best tumor response, objective response rate and duration of response. part 1: maximum tolerated dose of amg 655 administered with bortezomib or vorinostat, if reached. part 1: pk parameters for amg 655 on a 3 week dosing schedule. an estimate of the overall response rate (orr)(complete response [cr] + cr unconfirmed [cru] + partial response [pr]) to bortezomib and rituximab (vr)-chop according to international workshop to standardize response criteria (iwrc) criteria progression free survival evaluate incidence and severity of aes, serious aes, trph-222-related aes, aes leading to death or discontinuation from treatment tumor activity trph-222 pharmacokinetics (pk) trph-222 anti-drug antibodies (ada) to assess the safety and tolerability of sb1518, administered orally once daily in subjects with advanced lymphoid malignancies. to assess the pharmacokinetic and pharmacodynamic profile of sb1518. incidence rate of dose limiting toxicities (dlts) exposure to bcl201 and idelalisib as measured by auc0-24h at c1d15 plasma concentration of bcl201, idelalisib and gs-563117 (metabolite of idelalisib) auc pharmacokinetics (pk) parameter for bcl201, idelalisib and gs-563117 objective response rate (orr) best overall response (bor) duration of response (dor) complete response (cr) partial response (pr) stable disease (sd) cmax pharmacokinetics (pk) parameter for bcl201, idelalisib and gs-563117 adverse events (aes) laboratory safety variables complete response (cr) overall response (or) based on best response observed during combination therapy. duration of response progression free survival (pfs) preliminary anti-tumour activity overall survival at day 100 post-transplant overall survival at day 365 post-transplant transplant-related mortality disease response following salvage chemotherapy disease response 30 days post-transplant disease response at 1 year post-transplant progression-free survival after stem cell transplant efficacy - overall survival efficacy - progression free survival efficacy - overall survival efficacy - disease progression percentage of participants with complete response (cr/cru/cri) in phase ii of the study percentage of participants with partial response (pr) in phase ii of the study progression-free survival (pfs) in phase ii of the study duration of response by disease type in phase ii of the study participants with event-free survival (efs) in phase ii of the study pharmacodynamics: participants with peripheral b-cell recovery after having had depletion at end of treatment during phase ii of the study percentage of retreated participants with response maximum plasma concentration (cmax) of obinutuzumab in nhl participants area under the concentration-time curve of obinutuzumab administered on day 1 of cycle 1 in phase i of the study determine efficacy: best overall response define the duration of response identify immunohistochemistry biomarkers polymerase chair reaction (pcr) analysis of biomarkers identify phosphorylation biomarkers identify scd30 and tarc biomarkers occurrence of adverse events grade â‰¥ 3 as assessed by ctcaev5 severity and duration of grade â‰¥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea. time to neutrophil engraftment time to platelet engraftment time to lymphoid recovery progression-free survival non-relapse mortality overall survival immune responses overall response rate (orr) duration of response (dor) progression-free survival (pfs) overall survival (os) maximum observed serum concentration (cmax) for camidanlumab tesirine time to reach the maximum serum concentration (tmax) for camidanlumab tesirine area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration (auc0-last) for camidanlumab tesirine area under the serum concentration-time curve from time 0 to the end of the dosing interval (auc0-t) for camidanlumab tesirine area under the serum concentration-time curve from time 0 to infinity (aucâˆž) for camidanlumab tesirine accumulation index (ai) for camidanlumab tesirine volume of distribution for camidanlumab tesirine apparent terminal half-life (t1/2) of camidanlumab tesirine clearance of camidanlumab tesirine number of participants with anti-drug antibody response (ada) against camidanlumab tesirine assessment of humoral idiotype-specific immune responses assessment of cellular idiotype-specific immune responses long-term safety/tolerability as determined by the proportion of patients with toxicities as assessed by the fda cber guidance for industry toxicity grading scale in preventive vaccine clinical trials and the nci/ctcae version 4.02 grade >/= 3 flow cytometric measurement of constitutive or inducible phosphorylation of akt (at s473) and s6 within tumor b cells flow cytometric measurement of tumoral and peripheral blood t and nk cells changes in concentration of peripheral blood chemokines and cytokines changes in liver imaging as assessed by magnetic resonance imaging (mri) and gadoxetic acid (gd-eob-dtpa) contrast response rate pharmacodynamic responses orr assessed by investigator duration of response (dor) progression-free survival (pfs) disease control rate (dcr) minimum observed concentration (cmin) of ak105 at steady state number of subjects who develop detectable anti-drug antibodies (adas) investigate the effects of snx-5422 on hsp90 client proteins using pharmacodynamic (pd) assays. evaluate the level of top1 in tumor biopsies pre and post- administration of lmp400 complete response rate and overall response rate at the end of treatment complete and overall response rates after induction progression-free survival and overall survival duration of response collection of adverse events area under the plasma concentration versus time curve (auc) cd19+ peak plasma concentration (cmax) elimination half-life (t1/2) frequency of grade 3 or higher treatment-related adverse events by ctcae 4.03 duration of response (dor) time to progression (ttp) progression-free survival (pfs) overall survival (os) percentage of participants achieving cr at eoi, as determined by the investigator using modified lugano 2014 criteria percentage of participants achieving cr at eoi, as determined by the irc and investigator using lugano 2014 criteria percentage of participants with objective response (cr or pr) at eoi as determined by the irc and investigator on the basis of pet-ct scans percentage of participants with objective response (cr or pr) at eoi as determined by the irc and investigator on the basis of ct scans alone percentage of participants with best response (cr or pr) during the study as determined by the investigator on the basis of ct scans alone percentage of participants with adverse events and serious adverse events number of participants with dose-limiting toxicities (dlts) during cycle 2 of study treatment serum concentration of obinutuzumab (mcg/ml) serum concentration of atezolizumab (mcg/ml) serum concentration of lenalidomide (ng/ml) number of participants positive for human anti-human antibodies (haha) to obinutuzumab number of participants positive for anti-therapeutic antibodies (atas) to atezolizumab duration of response (dor) (phase 1) progression free survival (pfs) (phase 1) overall survival (os) (phase 2) auc of bi 695500 and rituximab (mabtheraÂ®) over the fourth dosing interval (pre-infusion on day 22 to day 29) (auc day 22-day 29) maximum measured concentration of bi 695500 and rituximab (mabtheraÂ®) in plasma (cmax) following dose 1 maximum measured concentration of rituximab (mabtheraÂ®) and bi 695500 in plasma (cmax) following dose 4 area under the depletion-time curve of the cluster of differentiation (cd)19+ b-cell count (% change from baseline (cfb)) in peripheral blood from pre-infusion on day 1 until last measurement on day 8 (pre-infusion) change from baseline (%) of cd19+ b-cells in peripheral blood measured after seven days on day 8 (day 8 pre-infusion time point) overall response rate (orr) (complete response (cr) plus partial response (pr)) evaluated approximately one month after last dose of bi 695500 or rituximab (mabtheraÂ®) percentage of patients with treatment emergent adverse events (teaes) selected for comparability assessment of bi 695500 and rituximab (mabtheraÂ®) serum concentrations of antibody-drug conjugate (adc) serum concentration of total antibody (tab) number of participants reporting one or more treatment-emergent adverse events (teaes) and serious adverse events (saes) number of participants with anti-therapeutic antibodies (ata) to brentuximab vedotin number of participants with markedly abnormal laboratory values number of participants with clinically significant change from baseline in vital signs area under the curve from time zero to end of dosing interval (auctau) maximum observed plasma concentration (cmax) time to reach maximum observed plasma concentration (tmax) plasma decay half-life (t1/2) percentage of participants with adverse events (aes) or serious adverse events (saes) investigate the effect of food on the absorption, break down and elimination of jnj-26481585 and its metabolite, jnj-26395018. monitor the antitumor activity of jnj-26481585. pharmacodynamic effects duration of in vivo persistence of adoptively transferred cd20-specific cd8+ t cell clones by flow cytometry and quantitative polymerase chain reaction (qpcr) during each infusion, weekly for 4 weeks, and then monthly for a year trafficking of cd8+ cd20-specific t cell clones to lymph nodes by gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year development of host anti-scfvfc:zeta (and anti-neor) immune responses by elisa and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year tumor responses to cyclophosphamide, vincristine, and prednisone (cvp) and to cytotoxic t-lymphocyte (ctl) infusions by cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year safety profile of the combination of lenalidomide and brentuximab vedotin treatment intensity. objective response rate cytostatic response. event free survival. overall survival plasma pharmacokinetics of daily oral administration of xl147 in two treatment schedules pharmacodynamic effects of xl147 on tumor tissue when administered at the maximum tolerated dose in two treatment schedules plasma pharmacokinetics of xl147 capsule and tablet formulations adverse events by frequency, severity, and duration; pharmacokinetics; immunogenicity; response duration; time to progression therapeutic activity of dt2219arl frequency of grade 3 or higher treatment-related adverse events by ctcae 4.03 duration of response (dor) progression-free survival (pfs) overall survival (os) determine the pharmacokinetic (pk) profile; determine the pd profile. overall response rate (orr) objective response rate duration of complete response duration of objective response progression-free survival post-autologous stem cell transplant number and frequency of adverse events objective response rate (orr) response rate (overall and complete) progression-free survival overall survival (os) at 2 years in vivo survival of ari-0001 cells in peripheral blood, bone marrow and cerebrospinal fluid in vivo survival of ari-0001 cells in peripheral blood, bone marrow and cerebrospinal fluid quality of life of included patients toxicity assessment progression-free survival duration of response (mean and median) event-free survival overall survival toxicity of participants receiving bortezomib, rituximab, cyclophosphamide, and prednisone for treatment of non-hodgkin\\'s lymphoma overall response rate (orr) progression free survival (pfs) overall response rate number of participants with serious adverse events plasma concentration time profiles objective response rate preliminary estimate of overall response rate (orr) progression-free survival (pfs), and overall survival (os) objective response according to revised response criteria for malignant lymphoma (cheson 2007) duration of response overall survival blood concentration of sgn-cd19a and metabolites incidence of antitherapeutic antibodies safety and tolerability assessment of immunogenicity objective response rate, disease control rate, and progression free survival. change in solcd30 to determine the obd (optimal biological dose) or mtd (maximum tolerated dose) of afm13 to define the pharmacokinetic profile of afm13. to analyse immunological markers of activity to assess the immunogenicity of afm13. to assess the activity of afm13 adverse event rate tumor status (assessed by ct) after chemotherapy tumor status (assessed by pet) after chemotherapy cmax: maximum observed plasma concentration for tak-659 and venetoclax tmax: time to reach the maximum plasma concentration (cmax) for tak-659 and venetoclax aucÏ„: area under the plasma concentration-time curve from time 0 to time over the dosing interval for tak-659 and venetoclax oral clearance (cl/f) for tak-659 and venetoclax peak-trough ratio (ptr) for tak-659 and venetoclax accumulation ratio (rac) for tak-659 and venetoclax trough concentration (c trough) for tak-659 and venetoclax overall response rate (orr) duration of overall response cr rate duration of cr time to progression (ttp) progression-free survival (pfs) overall response rate as assessed by the investigator [phase 1] complete response rate [phase 2] duration of response (dor) [phase 2] progression free survival (pfs) [phase 2] number of participants with treatment-emergent adverse events [phase 2] number of participants with clinically significant vital signs findings [phase 2] number of participants with clinically significant changes in electrocardiograms (ecgs) [phase 2] number of participants with clinically significant changes in multigated acquisition (muga)/ echocardiogram (echo) [phase 2] number of participants with clinically significant laboratory tests reported as adverse events [phase 2] cmax: maximum plasma concentration for alisertib tmax: time to first occurrence of cmax fo alisertib auct: area under the concentration time curve over the dosing interval from time 0 to time t for alisertib cmax: maximum plasma concentration for vincristine auct: area under the concentration-time time curve over the dosing interval from time 0 to time t for vincristine aucâˆž: area under the concentration-time curve from time 0 to infinity for vincristine t1/2: terminal disposition phase half-life for vincristine progression-free survival (pfs) time to response (ttr) response duration (rd): cr rate and the overall response rate, determination by independent review committee percentage of participants with failure free survival (ffs) area under the curve (auc) at 0 to 120 hours area under the curve (auc) at 0 to 168 hours area under the curve (auc) at 0 to infinity (extrapolated) maximum concentration (cmax) values mean residence times from day 0 to day 7 mean absorbed dose in the source organs and the target organs number of participants with expected distribution of radioactivity in the circulatory system compared with uptake by other organs. percentage of participants evaluable for confirmed response with complete response (cr), cr unconfirmed (cru), partial response (pr), stable disease (sd), and progressive disease (pd) duration of response progression-free survival overall survival evaluate the pharmacokinetics of abt-888 when administered combination with cyclophosphamide. evaluate for anti-tumor response. overall response rate (complete response + partial response) complete response rate assessed by cheson 2014 criteria duration of overall response duration of complete response overall survival progression-free survival incidence of adverse events assessed objective disease response to tisagenlecleucel objective disease response to tisagenlecleucel objective disease response to tisagenlecleucel objective disease response to tisagenlecleucel overall survival rate progression free survival rate overall response rate progression-free survival time to treatment failure to define the rate of tumor response (cr plus pr) in the brain, spine, eye, or csf. pharmacodynamics of ha20 pharmacokinetics ha20 assess efficacy pharmacokinetics- cmax pharmacokinetics - auc pharmacokinetics - tmax pharmacokinetics - t1/2 pharmacokinetics cl/f pharmacokinetics - vz/f overall response rate (orr) complete response (cr) rate progression free survival (pfs) number of participants with mild, moderate and/or severe chronic graft versus host disease (cgvhd) disease-free survival overall survival since date of transplant number of occurrences of viral infection and/or reactivation in allogeneic peripheral blood stem cell transplant (pbsct) followed by natural killer-donor lymphocyte infusion (nk-dli) number of participants with a decline in interleukin 7 (il-7) and interleukin 15 (il-15) cell numbers post-transplant number of participants with presence of killer-cell immunoglobulin-like receptors (kir) gene mismatch number of participants with serious and non-serious adverse events assessed by the common terminology criteria in adverse events (ctcae v4.0) brentuximab vedotin concentration in blood antitherapeutic antibodies in blood best clinical response progression-free survival overall survival phase i-ii participants treated at the rp2d (3mg): overall response rate (orr) all phase i-ii participants: progression-free survival (pfs) all phase i-ii participants: overall survival (os) all phase i-ii participants: safety phase i participants treated at the rp2d (3mg): overall response rate (orr) phase i participants: progression-free survival (pfs) all phase i participants: overall survival (os) phase i participants: safety safety attributable to 99mtc-1-thio-d-glucose injections (physical findings) safety attributable to 99mtc-1-thio-d-glucose injections (laboratory tests) safety attributable to 99mtc-1-thio-d-glucose injections (incidence and severity of adverse events) safety attributable to 99mtc-1-thio-d-glucose injections determine pharmacokinetic parameters of alrn-6924 when administered to patients with advanced solid tumors or lymphomas determine pharmacokinetic parameters of alrn-6924 when administered to patients with advanced solid tumors or lymphomas determine pharmacokinetic parameters of alrn-6924 when administered to patients with advanced solid tumors or lymphomas assess additional measures of anti-tumor activity, including duration of response, progression free survival, overall survival and time to response assess additional pharmacologic properties, including biomarkers and immunogenicity to characterize the pharmacokinetic (pk) and pharmacodynamic (pd) profiles of pazopanib and metabolites (gsk1071306, gsk1268992, gsk1268997, and gw700201) in patients with varying degrees of hepatic dysfunction. secondary graft failure of t-cell infusions occurrence of treatment related mortality (trm) occurrence of disease response number of patients alive without progression frequency of adverse events pharmacokinetic parameters of cpi-1205: auc(0-t), auc(0-inf), auctau,ss, tmax, cmax, ctrough, t1/2, vd/f, cl/f pharmacodynamic effects of cpi-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3; changes in the expression of genes whose transcription may be altered by ezh2 inhibition pharmacodynamic effects of cpi-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3 (h3k27me3) disease response assessment will be performed using the 2014 lugano response criteria for hodgkin and non-hodgkin lymphoma estimate tazemetostat absolute bioavailability (f) after repeated oral administration of 800 mg bid (auc 0-12 and auc 0-~) compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14c] tazemetostat (auc 0-t, auc 0-12, auc 0-~) determine peak plasma concentration (cmax) after oral administration of [14c] tazemetostat determine the plasma terminal half-life (t1/2) after oral administration of [14c] tazemetostat plasma pk of tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 Âµci (14.8 mbq) of radioactivity (plasma auc 0-t, auc 0-12) determine the peak plasma concentration (cmax) of tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 Âµci (14.8 mbq) of radioactivity determine the time to peak plasma concentration (tmax) tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 Âµci (14.8 mbq) of radioactivity phase 1b/ 2: duration of response phase 1b/ 2: progression-free survival (pfs) phase 1b/2: overall survival phamacokinetics: mean maximum observed plasma concentration (cmax) for ibrutinib pharmacokinetics: mean time to maximum observed plasma concentration (tmax) for ibrutinib pharmacokinetics: mean area under the plasma concentration-time curve from time 0-24 hours (auc0-24h) for ibrutinib pharmacokinetics: mean terminal elimination half-life (t1/2,term) for ibrutinib pharmacokinetics: mean peak plasma concentration (cmax) for medi4736 pharmacokinetics: mean trough plasma concentration (ctrough) for medi4736 pharmacokinetics: medi4736 accumulation ratio for cmax pharmacokinetics: medi4736 accumulation ratio for ctrough bruton tyrosine kinase (btk) occupancy pharmacodynamics of ibrutinib in subjects with relapsed or refractory lymphomas pharmacodynamics of medi4736 in subjects with relapsed or refractory lymphomas number of participants who completed six cycles of study treatment response rate complete response rate maximum number of cycles received number of dose delays at the mtd overall response rate (orr) of the study population duration of response (dor) of the combination in patients with t-cell lymphoma overall survival (os) of patients with t-cell lymphoma on study progression free survival (pfs) of the combination in patients with t-cell lymphoma number of dose reductions at the mtd progression free survival (pfs) of the study population duration of response (dor) of the study population. rate of disease response anti-tumor responses b cell depletion antitumor activity progression-free survival relapse-free survival(rfs ) overall-survival(os) persistence of car-t cells in vivo clinical response following administration of rp6530 percentage of participants with cr at eoi, as determined by the investigator using lugano 2014 criteria percentage of participants with cr at eoi, as determined by the irc using modified cheson 2007 criteria percentage of participants with cr at eoi, as determined by the investigator using modified cheson 2007 criteria percentage of participants with objective response (cr or pr) at eoi, as determined by the irc using modified cheson 2007 criteria percentage of participants with objective response (cr or pr) at eoi, as determined by the investigator using modified cheson 2007 criteria percentage of participants with objective response (cr or pr) at eoi, as determined by the irc using lugano 2014 criteria percentage of participants with objective response (cr or pr) at eoi, as determined by the investigator using lugano 2014 criteria percentage of participants with best response of cr or pr during study, as determined by investigator using modified cheson 2007 criteria observed serum obinutuzumab concentration observed serum atezolizumab concentration observed serum rituximab concentration percentage of participants with human anti-human antibodies (hahas) to obinutuzumab percentage of participants with human anti-chimeric antibodies (hacas) to rituximab percentage of participants with anti-therapeutic antibodies (atas) to atezolizumab concentration of drug in plasma objective response rate (orr) complete response rate (crr) duration of response (dor) progression free survival (pfs) overall survival (os) toxicity profile assessed by nci ctcae version 4.0 or rate assessed up to 10 years cr rate assessed up to 10 years pfs assessed up to 10 years to measure the response rate tumor measurement by bone marrow biopsy, blood counts, and/or pet/ct scan serum levels of biomarkers (troponin-1, troponin-t, and b-type natriuretic) of cardiac injury. apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib time to severe graft versus host disease (gvhd) or death toxicity number of participants with teaes and saes overall response rate duration of response (dor) progression free survival (pfs) number of participants with anti-drug antibodies (adas) to tislelizumab peak percentage and persistence at 1 month of peripheral blood mononuclear cells (pbmc) that expressed the chimeric antigen receptor (car) t-cells number of participants with complete response (cr), partial response (pr), stable disease (sd), or progression as their best response overall response rate (orr) with tenalisib and romidepsin combination duration of response (dor) with tenalisib and romidepsin combination maximum observed plasma concentration (cmax) tolerability of study treatment as measured by dose interruptions, dose reductions, and treatment discontinuation due to aes complete response (cr) based on pet/ct as determined by the investigator according to the 2014 lugano response criteria objective response rate (orr), defined as the proportion of participants with a best overall response of partial response (pr) or cr, as determined by the investigator according to the 2014 lugano response criteria maximum serum concentration (cmax) of glofitamab response rates duration of response progression-free survival (pfs) time to next anti-lymphoma treatment (ttnlt) overall survival (os) incidence of grade â‰¥ 2 renal toxicities, grade â‰¥ 2 neuropathy, and grade â‰¥ 3 toxicities all adverse events or adverse reactions, during the treatment cycle (twenty one days) pharmacokinetics profile percentage of participants with cr at eoi, determined by the investigator on the basis of pet-ct scans percentage of participants with cr at eoi, determined by the irc on the basis of ct scans alone percentage of participants with cr at eoi, determined by the investigator on the basis of ct scans alone percentage of participants with objective response (or) at eoi, determined by an irc on the basis of pet and ct scans percentage of participants with or at eoi, determined by the investigator on the basis of pet and ct scans percentage of participants with or at eoi, determined by an irc on the basis of ct scans alone percentage of participants with or at eoi, determined by the investigator on the basis of ct scans alone percentage of participants with best overall response (bor) of cr or pr, determined by the investigator on the basis of ct scans alone observed serum obinutuzumab concentration observed serum rituximab concentration observed serum concentration of total antibody to polatuzumab vedotin observed plasma concentration of polatuzumab vedotin antibody-conjugated mono-methyl auristatin e (mmae) (acmmae) observed plasma concentration of polatuzumab vedotin unconjugated mmae observed plasma venetoclax concentration number of participants with human anti-human antibodies (hahas) to obinutuzumab number of participants with anti-therapeutic antibodies (atas) to polatuzumab vedotin observe the activity of the combination against mantle cell lymphoma (mcl) in patients treated in this phase i study. number of participants who had a best response of complete remission (cr), partial remission (pr), stable disease (sd), and progressive disease (pd) number of participants with a duration of best response in months number of participants that had any grade 2, 3, 4 and 5 adverse events median peak chimeric antigen receptor (car) t cells level for participants treated number of participants who had a second or third infusion of chimeric antigen receptor (car)+ t cells number of participants who had anti-lymphoma activity number of participants with evidence of immunogenicity of the chimeric antigen receptor (car) t-cell product to obtain preliminary evidence of anti-tumor activity of cddo in this population. overall response rate (orr) duration of response (dor) overall survival (os) progression-free survival (pfs) maximum observed serum concentration (cmax) for adct-402 time to reach the maximum serum concentration (tmax) for adct-402 area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration (auclast) for adct-402 area under the serum concentration-time curve from time 0 to the end of the dosing interval (auctau) for adct-402 area under the serum concentration-time curve from time 0 to infinity (aucinf) for adct-402 terminal half-life (thalf) of adct-402 apparent clearance (cl) at steady state for adct-402 volume of distribution at steady state (vss) for adct-402 accumulation index (ai) for adct-402 number of participants with anti-drug antibody response (ada) against adct-402 tumor/organ dosimetry at the indicated predoses of 475 mg, 95 mg, and 0 mg (initial treatment) number of participants (par.) with the indicated response as assessed by the investigator number of participants (par.) with confirmed response as assessed by the investigator duration of response for all unconfirmed responders (cr, ccr, or pr) as assessed by the investigator time to progression of disease or death overall survival half-life: initial half-life (t1/2 alpha) and terminal half-life (t1/2 beta) of i 131 tst for the antibody predose levels of 0 mg, 95 mg, and 475 mg clearance (cl) of i 131 tst for the indicated antibody predose levels area under the concentration time curve (auc) of i 131 tst for the indicated antibody predose levels maximum blood concentration (cmax) of i 131 tst for the indicated antibody predose levels volume of distribution at steady state (vss) of i 131 tst for the indicated antibody predose levels number of participants who developed human anti-mouse antibodies (hama postivitiy) after receiving tositumomab time to hama positivity from the first dosimetric dose (time from baseline [dosimetric dose] to the first reported presence of hama) number of participants with the indicated type of infection time to nadir for the indicated hematologic laboratory parameters time to recovery to baseline for the indicated hematologic laboratory parameters nadir values for the hematologic parameters anc, platelets, and wbc count nadir values for hemoglobin, a hematologic parameter progression-free survival(pfs) number of participants who were administered intensive chemotherapy prior to cluster of differentiation (cd)19-chimeric antigen receptor (car): cd19 car infusion mean percentage cluster of differentiation 19 (cd19) - chimeric antigen-receptor (car) t-cells in blood, bone marrow (bm) and cerebrospinal fluid (csf) number of patients with a complete response (cr) number of participants with grade 4 cytokine release syndrome (crs) number of participants with serious and non-serious adverse events determine pharmacokinetics of alemtuzumab determine immunosuppressive properties of alemtuzumab + chop determine if fc receptor-gamma (fcÎ³r) polymorphism is predictive of response or toxicity with alemtuzumab treatment. clinical response rate time to progression (ttp) maximum observed plasma concentration (cmax) of recombinant human interleukin-15 (rhil-15) concentration of drug in plasma at steady state (css) area under the curve (auclast) inflammatory cytokines part i and part ii: area under the plasma concentration-time curve from zero to the last measurable concentration (auclast) for single-dose zanubrutinib part i and part ii: area under the plasma concentration-time curve zero to infinity (auc0-inf) for single-dose zanubrutinib part i and part ii: maximum plasma concentration (cmax) for single-dose zanubrutinib part i and part ii: time to maximum plasma concentration (tmax) for single-dose zanubrutinib part i and part ii: apparent terminal half life (t1/2) for single-dose zanubrutinib part i and part ii: apparent plasma clearance (cl/f) for single-dose zanubrutinib part i and part ii: terminal apparent volume of distribution (vz/f) for single-dose zanubrutinib part i and part ii: area under the plasma concentration-time curve for steady state (aucss) zanubrutinib part i and part ii: maximum plasma concentration at steady state (cmax,ss) for zanubrutinib part i and part ii: time to steady plasma concentration (tmax,ss) for zanubrutinib part i: percentage of btk occupied in peripheral blood mononuclear cells in participants who received zanubrutinib part ii: number of participants experiencing treatment-emergent adverse events and treatment-emergent serious adverse events auc for gb241 and rituximab concentrations maximum observed concentration of the gb241 and rituximab degree of clearance from baseline of cd19+ , cd20+ b-cells between the two study arms comparison of aes between the two study arms comparison of the incidence rate of hacaï¼ˆhost anti-chimeric antibodyï¼‰ between the two study arms overall response rate (orr) of phase i and phase ii participants overall response rate (orr) of previously treated and previously untreated participants time to best response of phase i and phase ii participants time to best response of previously treated and previously untreated participants duration of response (dor) of phase i and phase ii participants duration of response (dor) of previously treated and previously untreated participants progression free survival (pfs) of phase i and phase ii participants progression free survival (pfs) of previously treated and previously untreated participants overall survival of phase i and phase ii participants overall survival of previously treated and previously untreated participants phase ii: time to progression phase ii: major response rate phase ii: minor response rate phase ii: time to response phase ii: duration of response phase ii: time to next therapy phase ii: overall survival pharmacokinetics - cmax of cc-95775 pharmacokinetics - auc of cc-95775 pharmacokinetics - tmax of cc-95775 pharmacokinetics - t1/2 of cc-95775 pharmacokinetics - cl/f of cc-95775 pharmacokinetics - vz/f of cc-95775 evaluate the pharmacodynamic (pd) effects of cc-95775 on gene expression in peripheral blood and in tumor tissue. incidence and severity of adverse events overall response rate complete response rate progression-free survival overall survival assessment of the number of events and number and percentage of patients with treatment-emergent aes time to progression overall survival concentration (mg/ml) of ka2237 in serum/plasma over time (hours) concentration (mg/ml) of ka2237 in urine over time (hours) concentration (ng/ml) of key cytokine and intracellular signalling markers in immune cell subsets frequency of ka2237 related adverse events and laboratory abnormalities establish safety profile the percentage of subjects experiencing anti-cancer activity (orr) at various dose levels when given multiple doses of cx-072 as a monotherapy or in combination with ipilimumab or vemurafenib number of patients who experienced adverse events area under the concentration versus time curve (auc) peak plasma concentration (cmax) time of cmax (tmax) objective response rate complete response rate disease control rate time to progression progression free survival duration of response adverse events any single mutation of oncogene and copy number variation in ctdna(single gene analysis) mutation of polygene and copy number variation in signal pathway(multi-gene analysis) number of participants with clinical response rates cmax tmax auc t1/2 cl vss vz excretion profile of total and free (ultrafiltrate) platinum (pt) overall response (or), complete response (cr), their duration, absorbed dose to normal organ and tumours, relapse pattern, the effect of radioimmunotherapy (rit) in its own right as assessed by positron emission tomography (pet) toxicity according to the ctc criteria stem cell mobilization capacity transplant-related mortality (trm) overall survival (os) progression free survival (pfs) event-free survival time to hl progression disease-free survival response duration lymphoma-specific survival time to next treatment progression-free survival (pfs) percentage of participants with objective response duration of response (dr) time to tumor progression (ttp) correlation coefficient between plasma pd 0332991 concentration and change from baseline in biomarkers and suvmax at cycle 1 day 21 parts 1 and 2: ulevostinag area under the plasma drug concentration-time curve from time zero to 24 hours (auc0-24) parts 1 and 2: ulevostinag minimum plasma concentration (cmin) parts 1 and 2: ulevostinag maximum plasma concentration (cmax) parts 1 and 2: pembrolizumab minimum plasma concentration (cmin) parts 1 and 2: objective response rate (orr) as assessed by response evaluation criteria in solid tumors version 1.1 (recist 1.1) duration of overall response peak plasma concentration (cmax) percentage and absolute value of cd19+ percentage and absolute value of cd20+ b-cell positive rate of ada positive rate of nab safety profiles area under the plasma concentration versus time curve (auc) aucï¼ˆ0-tï¼‰ of ibi301 and rituximab percentage of participants with a best or of cr or pr according to international response criteria for nhls in the de cohorts kaplan-meier estimate of the progression-free survival (pfs) in the de cohorts kaplan-meier estimates of the probability of being alive and free from pd or new anticancer therapy at 6, 12, and 24 months in the de cohorts kaplan-meier estimate of the pfs in the mtd confirmation/ee cohorts kaplan-meier estimates of the probability of being alive and free from pd or new anticancer therapy at 6, 12, and 24 months in the mtd confirmation/ee cohorts. kaplan-meier estimate of the overall survival (os) in the de cohorts kaplan-meier estimates of the probability of being alive at 6, 12, and 24 months in the de cohorts kaplan-meier estimate of the os in the mtd confirmation/ee cohorts kaplan-meier estimates of the probability of being alive at 6, 12, and 24 months in the mtd confirmation/ee cohorts mean inotuzumab ozogamicin serum concentrations progression-free survival (pfs) (phase ii) overall survival (os) (phase ii) progression-free survival according to the international workshop to standardize response criteria for nhl event-free survival according to the international workshop to standardize response criteria for nhl area under the plasma concentration-time curve from time 0 to day 28 (auc0-28) of ocrelizumab area under the plasma concentration-time curve from time 0 to infinity auc(0-inf) of ocrelizumab percentage of participants with overall response according to the international workshop to standardize response criteria for nhl maximum plasma concentration (cmax) of ocrelizumab systemic clearance (cl) of ocrelizumab steady state volume of distribution (vss) of ocrelizumab terminal elimination half-life (t1/2) of ocrelizumab number of participants with peripheral blood b-cell depletion number of participants with peripheral blood b-cell recovery objective response according to modified response criteria for acute myeloid leukemia (cheson 2003) or revised response criteria for malignant lymphoma (cheson 2007) duration of response overall survival blood concentrations of sgn-cd19a and metabolites incidence of antitherapeutic antibodies pharmacokinetic parameter: area under the plasma concentration-time curve (auc) measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours. pharmacokinetic parameter: maximum observed plasma concentration (cmax) measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours. pharmacokinetic parameter: time of maximum observed plasma concentration (tmax) at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours. pharmacokinetic parameter: apparent terminal half-life (t1/2) at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours. anti-tumor activity of hbi-8000 by overall response status based on cheson\\'s response criteria for nhl and japan clinical oncology group (jcog) response criteria for adult t-cell lymphoma (atl) safety of hbi-8000 in japanese patients with nhl for whom no other standard therapy is suitable with incidence and severity of adverse events graded according to the nci-ctcae version 4.03 progression-free survival (pfs): evaluable population- part 2 (lead-in + expanded cohorts) progression-free survival (pfs): intent-to-treat population-part 2 (lead-in + expanded cohorts) overall survival (os): evaluable population- part 2 (lead-in + expanded cohorts) overall survival (os): intent-to-treat population: part 2 (lead-in + expanded cohorts) number of participants with best overall response (bor): part 2 (expanded cohorts) duration of overall response (dor): part 2 (lead-in + expanded cohorts) time-to-tumor progression: part 2 (expanded cohorts) complete response rates orr overall survival progressive-free survival number of participants with overall response rate overall survival pd parameter pd parameter pd parameter to evaluate the biologic effects of sb-485232 given in combination with ofatumumab to seek preliminary evidence of efficacy in this population percentage of participants with complete response (cr), unconfirmed cr (cru), or partial response (pr) kaplan-meier estimates of progression free survival (pfs) kaplan-meier estimates of the probability of being progression free at 6 months kaplan-meier estimates of overall survival (os) kaplan-meier estimates of the probability of survival at 6 months kaplan-meier estimates of time to tumor progression (ttp) kaplan-meier estimates of the probability of being event free at 6 months duration of response (cr+cru+pr) area under the serum concentration-time profile from time zero extrapolated to infinite time (aucinf) of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 auclast of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time of the last quantifiable serum concentration in a dosing interval (tlast) of inotuzumab ozogamicin in participants receving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 area under the steady-state serum concentration-time curve (auctau) of inotuzumab ozogamicin in participants receving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 peak serum concentration (cmax) of inotuzumab ozogamicin in participants receving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time to reach maximum concentration (tmax) of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 average serum concentration at steady state (cav) of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 minimum observed serum trough concentration (cmin) of inotuzumab ozogamicin in participants receiving inotuzumab+rituximab on dosing day 30 and day 58 clearance (cl) of serum inotuzumab ozogamicin in participants receiving inotuzumab+rituximab on dosing day 30 and day 58 steady-state volume of distribution (vss) of inotuzumab ozogamicin in serum in participants receiving inotuzumab mtd+rituximab 375 mg/m^2 on dosing day 30 and day 58 mrt of inotuzumab ozogamicin in serum in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 serum decay half-life (t1/2) of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 aucinf of total calicheamicin (conjugated + unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 auclast of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time of the last quantifiable concentration in a dosing interval (tlast) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 area under the steady-state serum concentration-time curve (auctau) for total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30, and day 58 peak serum concentration (cmax) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time of observed maximum concentration (tmax) of total calicheamicin (conjugated+unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 average serum concentration (cav) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 minimum observed serum trough concentration (cmin) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 clearance (cl) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 steady-state volume (vss) of total calicheamicin (conjugated plus unconjugated) distribution in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 mean residence time (mrt) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 serum decay half-life (t1/2) of total calicheamicin (conjugated plus unconjugated) in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 area under the steady-state serum concentration-time curve (auclast) of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time of the last quantifiable concentration in a dosing interval (tlast) of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 peak serum concentration (cmax) of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time of observed maximum concentration (tmax) of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin + rituximab on dosing day 1, day 30 and day 58 minimum observed serum trough concentration (cmin) of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin+rituximab on dosing day 30 and day 58 area under the serum concentration-time profile from time zero extrapolated to infinite time (aucinf) of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m2 on dosing day 30 and day 58 area under the steady-state concentration-time curve (auclast) of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time of the last quantifiable concentration in a dosing interval (tlast) of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 serum decay half-life (t1/2) of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab on dosing day 30 and day 58 area under the steady-state serum concentration-time curve (auctau) of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd+ rituximab 375 mg/m^2 on dosing day 1, day 30, and day 58 peak concentration (cmax) of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 time to reach maximum concentration (tmax) of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58 average serum concentration (cav) of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 minimum observed serum trough concentration (cmin) of inotuzumab ozogamicin antibody in participants receiving inotuzumab mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 clearance (cl) of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 steady-state volume (vss) of inotuzumab ozogamicin antibody distribution in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58 tumor response (according to the international response criteria for non-hodgkin\\'s lymphomas). cumulative dlt(s) incidence of adverse events and laboratory abnormalities tumor response (complete response, partial response) and duration of the response pharmacokinetics parameters lack of immunogenicity pharmacodynamics pharmacokinetics efficacy number of participants with anti-drug antibodies (ada) to pinatuzumab vedotin number of participants with ada to polatuzumab vedotin number of participants with ada to obinutuzumab percentage of participants with pd as determined by modified response and progression criteria for nhl or death due to any cause: rituximab containing regimens (arms a and b, cohort c) progression-free survival (pfs) as determined by modified response and progression criteria for nhl: rituximab containing regimens (arms a and b, cohort c) percentage of participants who died due to any cause: rituximab containing regimens (arms a and b, cohort c) overall survival (os): rituximab containing regimens (arms a and b, cohort c) percentage of participants with cr at eot based on pet/ct assessment as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e, g, and h) percentage of participants with or at eot based on pet/ct assessment as determined by irc per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e, g, and h) percentage of participants with or at eot based on pet/ct assessment as determined by the investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e, g, and h) percentage of participants with cr at eot based on ct assessment alone as determined by irc per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e + h and e + g) percentage of participants with cr at eot based on ct assessment alone as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e + h and e + g) percentage of participants with or at eot based on ct assessment alone as determined by irc per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e + h and e + g) percentage of participants with or at eot based on ct assessment alone as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e + h and e + g) percentage of participants with best or based on pet/ct or ct assessment as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts (cohorts e, g, and h) area under the concentration-time curve from time zero to infinity (aucinf) of rituximab: rituximab containing regimens (arms a and b, cohort c) maximum observed concentration (cmax) of rituximab: rituximab containing regimens (arms a and b, cohort c) systemic clearance (cl) of rituximab: rituximab containing regimens (arms a and b, cohort c) half-life (t1/2) of rituximab: rituximab containing regimens (arms a and b, cohort c) volume of distribution at steady state (vss) of rituximab: rituximab containing regimens (arms a and b, cohort c) aucinf of total antibody for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab aucinf of antibody conjugated monomethyl auristatin e (acmmae) for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab area under the concentration-time curve from time zero to last measurable concentration (auclast) of unconjugated mmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab cmax of total antibody for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab cmax of acmmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab cmax of unconjugated mmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab aucinf of total antibody for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab aucinf of acmmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab auclast of unconjugated mmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab cmax of total antibody for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab cmax of acmmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab cmax of unconjugated mmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab aucinf of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab aucinf of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab auclast of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab cmax of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab cmax of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab cmax of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab aucinf of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab aucinf of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab auclast of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab cmax of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab cmax of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab cmax of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab cmax of obinutuzumab: obinutuzumab-containing cohorts (cohorts e + h and e + g) overall survival (os): obinutuzumab-containing cohorts (cohorts e + h and e + g) percentage of participants who died due to any cause: obinutuzumab containing cohorts (cohorts e + h and e + g) progression-free survival (pfs) as determined by modified response and progression criteria for nhl: obinutuzumab containing cohorts (cohorts e + h and e + g) percentage of participants with pd as determined by modified response and progression criteria for nhl or death due to any cause: obinutuzumab containing cohorts (cohorts e + h and e + g) complete response rate to rituximab and a combination of vorinostat with cyclophosphamide, etoposide, and prednisone in elderly pts with relapsed diffuse large b-cell lymphoma who aren\\'t candidates for autologous stem cell transplantation. evaluate preliminary data regarding progression-free survival when abt-199 is administered in combination with bendamustine and rituximab evaluate preliminary data regarding overall survival and duration of overall response when abt-199 is administered in combination with bendamustine and rituximab. evaluate preliminary data regarding objective response rate when abt-199 is administered in combination with bendamustine and rituximab evaluate preliminary data regarding time to tumor progression when abt-199 is administered in combination with bendamustine and rituximab. peripheral blood counts; bone marrow aspirates and biopsies; transfusion and growth factor requirements disease response by the international workshop to standardize response criteria for non-hodgkin\\'s lymphomas 2 weeks after completion of the first treatment cycle immunogenicity by incidence of anti-ril-21 antibodies up to 1 month after treatment number of participants with objective response: evaluable population number of participants with objective response: intent-to-treat (itt) population progression-free survival (pfs) overall response rate: proportion of patients with confirmed complete response (cr) and partial response (pr) overall disease control rate: proportion of patients who have a best response rating of cr, pr or stable disease (sd) the number of serious drug-related teaes (treatment-emergent adverse events) the number of non-serious drug-related teaes cmax (cycle 1 day 1) of m-1 metabolite auc(0-24) (cycle 1 day 1) of m-1 metabolite auc(0-tlast) (cycle 1 day 1) of m-1 metabolite cmax (cycle 1 day 15) of m-1 metabolite auc(0-24) (cycle 1 day 15) of m-1 metabolite steady state serum concentration (css) of blinatumomab after civ administration systemic clearance (cl) of blinatumomab after civ administration maximum observed concentration (cmax) of blinatumomab after sc administration time at which cmax (tmax) occurred of blinatumomab after sc administration area under the concentration-time curve (auc) of blinatumomab after sc administration for a dosing interval t (auct) minimum observed concentration (cmin) of blinatumomab after sc administration apparent clearance (cl/f) of blinatumomab after sc administration volume of distribution based on terminal phase (vz/f) of blinatumomab after sc administration terminal half-life (t1/2,z) of blinatumomab after sc administration accumulation ratio of blinatumomab after sc administration bioavailability (f) of sc blinatumomab maximum tolerated dose (mtd) of sc blinatumomab number of participants with anti-blinatumomab antibody formation after sc administration overall response rate (orr) after sc administration adverse events response rate progression free survival biomarkers phase i: overall frequency of response overall complete response (cr) and partial response (pr) rate overall progression-free survival total overall survival for transplant vs non-transplant overall proportion of patients who are able to undergo stem cell transplant (sct) overall safety and tolerability of the combination of bendamustine, ofatumumab, carboplatin, and etoposide disease response overall response progression free survival toxicity overall survival response rate duration of response relapse-free survival time to treatment failure safety as measured by adverse events, severity of hematologic toxicity, the use of supportive care and the percentage of human anti-murine antibody positivity overall response rate (orr) safety will be evaluated by: - physical exam at screen & then d1 for each cycle - 12 lead ecg & telemetry at screen & wk 1 to 3 for schedule 1 & 2, & wk 1 & 2 (ecg only) for schedule 3. - lab tests & ae monitoring throughout the study. tumour size reduction best overall response based on all assessment best overall response based on imaging data progression free survival (pfs) failure free survival (ffs) area under the serum concentration-time curve (auc) for dcds0780a total antibody maximum observed serum concentration (cmax) for dcds0780a total antibody total clearance (cl) of dcds0780a total antibody half-life (t1/2) of dcds0780a total antibody volume of distribution under steady-state conditions (vss) of dcds0780a total antibody area under the plasma concentration-time curve (auc) for dcds0780a conjugate (antibody-conjugated monomethyl auristatin e [acmmae]) maximum observed plasma concentration (cmax) for acmmae total clearance (cl) of acmmae half-life (t1/2) of acmmae volume of distribution under steady-state conditions (vss) of acmmae area under the plasma concentration-time curve (auc) for unconjugated monomethyl auristatin e (mmae) maximum observed plasma concentration (cmax) for unconjugated mmae total clearance (cl) of unconjugated mmae half-life (t1/2) of unconjugated mmae volume of distribution under steady-state conditions (vss) of unconjugated mmae obinutuzumab serum concentration rituximab serum concentration percentage of participants with anti-dcds0780a antibodies absolute lymphocyte count change from baseline in intra-patient absolute lymphocyte counts time to cd19+ b-cell count recovery to baseline value percentage of participants with best overall response of complete response (cr) or partial response (pr) assessed according to lugano classification duration of response assessed according to lugano classification progression-free survival (pfs) assessed according to lugano classification relative dose intensity (di) calculated as ratio of amount of drug actually administered to the amount planned phase i and phase ii: event free survival and overall survival 12 patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin\\'s lymphoma will receive a dosimetric dose of fission-derived iodine i 131 tositumomab to evaluate pk to monitor presence of human anti galiximab antibody to evaluate efficacy to identify nk functional assays that may predict galiximab efficacy overall response rate (orr) with rp6530 duration of response (dor) with rp6530 peak plasma concentration (cmax) overall survival progression free survival to assess pharmacokinetics (pk) of fimepinostat when administered in combination with anti-cancer regimens as measured by area under the concentration-time curve (auc). to assess pharmacokinetics (pk) of fimepinostat when administered in combination with anti-cancer regimens as measured by maximum plasma concentration (cmax). to assess pharmacokinetics (pk) of fimepinostat when administered in combination with anti-cancer regimens as measured by half-life (t1/2). to assess pharmacokinetics (pk) of fimepinostat when administered in combination with anti-cancer regimens as measured by clearance (cl). to assess pharmacokinetics (pk) of fimepinostat when administered in combination with anti-cancer regimens as measured by volume of distribution (vd). to assess pk of venetoclax when administered in combination with fimepinostat as measured by area under the concentration-time curve (auc). to assess pk of venetoclax when administered in combination with fimepinostat as measured by maximum plasma concentration (cmax). to assess pk of venetoclax when administered in combination with fimepinostat as measured by half-life (t1/2). to assess pk of venetoclax when administered in combination with fimepinostat as measured by clearance (cl). to assess pk of venetoclax when administered in combination with fimepinostat as measured by volume of distribution (vd). to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by os. to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by pfs. to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by orr. to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by dor. to evaluate biomarkers of fimepinostat activity percentage of participants with objective response as determined using response evaluation criteria in solid tumors (recist) v1.1 progression-free survival (pfs) as determined using recist v1.1 duration of objective response as determined using recist v1.1 disease response relapse rate disease free survival overall survival graft versus host disease (gvhd) immunoreconstitution number of participants reporting one or more treatment-emergent adverse events (teaes) and serious adverse events (saes) number of participants with clinically significant teaes related to laboratory abnormalities number of participants with clinically significant vital sign abnormalities percentage of participants with best overall response maximum observed plasma concentration (cmax) of jnj-42756493 minimum observed plasma concentration (cmin) of jnj-42756493 time to reach maximum observed plasma concentration (tmax) of jnj-42756493 area under the curve from time zero to end of dosing interval (auctau) elimination half life of jnj-42756493 apparent volume of distribution at steady-state (vss) of jnj-42756493 total clearance of jnj-42756493 accumulation index (ai) of jnj-42756493 number of participants with objective tumor response progression free survival (pfs) duration of objective response number of participants with an adverse event percentage of participants with objective response (cr or partial response [pr]), as assessed by investigator using cheson criteria for dlbcl population percentage of participants with objective response (cr or partial response [pr]), as assessed by investigator using cheson criteria for non-dlbcl population number of participants with anti-polatuzumab vedotin antibodies number of participants with anti-obinutuzumab antibodies area under the concentration-time curve (auc) of polatuzumab vedotin maximum concentration (cmax) of polatuzumab vedotin clearance (cl) of polatuzumab vedotin terminal half-life (t1/2) of polatuzumab vedotin steady-state volume of distribution (vss) of polatuzumab vedotin plasma levels of cyclophosphamide plasma levels of doxorubicin peripheral neuropathy symptom severity: therapy-induced neuropathy assessment scale (tinas) overall neuropathy severity score peripheral neuropathy symptom interference: tinas numbness/tingling item score duration of response, as assessed by investigator using cheson criteria for dlbcl population duration of response, as assessed by investigator using cheson criteria for non-dlbcl population progression free survival, as assessed by investigator using cheson criteria for dlbcl population progression free survival, as assessed by investigator using cheson criteria for non-dlbcl population event free survival, as assessed by investigator using cheson criteria for dlbcl population event free survival, as assessed by investigator using cheson criteria for non-dlbcl population relative dose intensity of polatuzumab vedotin (ratio of the amount of drug actually administered to the amount planned) for dlbcl population relative dose intensity of polatuzumab vedotin (ratio of the amount of drug actually administered to the amount planned) for non-dlbcl population overall survival for dlbcl population overall survival for non-dlbcl population plasma and urine concentrations of dzd8586 the number of patients who had disease response assessed by deauville scales among those in phase i with dose level 2. percentage of patients who achieved overall response (or) as measured by complete response (cr) and partial response (pr) the number of patients who had successful peripheral blood stem cell (pbsc) collection plasma level of thymus and activation-regulated chemokine (tarc) correlation between micro ribonucleic acid (mirna) and disease response to protocol treatment number of patients with fcyriiia-158 v/f (valine/phenylalanine) polymorphism venetoclax plasma pk: area under the plasma concentration-time curve (auc) venetoclax plasma pk: time to maximum observed plasma concentration (tmax) venetoclax plasma pk: maximum observed plasma concentration (cmax) venetoclax plasma pk: minimum plasma concentration (cmin) within the dosing interval prednisone plasma pk: auc prednisone plasma pk: tmax prednisone plasma pk: cmax rituximab pk: cmax rituximab pk: cmin within the dosing interval obinutuzumab pk: cmax cyclophosphamide pk: cmax doxorubicin pk: cmax vincristine pk: cmax percentage of participants with objective response defined as partial response (pr) or complete response (cr) defined by positron emission tomography-computed tomography (pet/ct) using the modified lugano classification assessed by irc percentage of participants who are alive and without disease progression at month 12 percentage of participants with cr defined by computed tomography (ct) scan using the modified lugano classification safety: percentage of participants with adverse events safety: percentage of participants maintaining relative dose intensity of chop chemotherapy relative dose intensity of venetoclax incidence of treatment-emergent adverse events as a measure of safety part a: pk of tazemetostat and its metabolites after administration alone and with fluconazole (auc0-t, auc0-8) part a: tmax of tazemetostat after administration alone and with fluconazole part a: t1/2 of tazemetostat after administration alone and with fluconazole part a: cmax of tazemetostat metabolites after administration alone and with fluconazole part a: tmax of tazemetostat metabolites after administration alone and with fluconazole part a: t1/2 of tazemetostat metabolites after administration alone and with fluconazole part a: exposure of fluconazole after administration of 400 mg once daily for 4 days (auc0-8) part a: cmax of fluconazole after administration of 400mg once daily for 4 days part a: tmax of fluconazole after administration of 400mg once daily for 4 days the antitumor activity of tazemetostat will be assessed in patients with diffuse large b-cell lymphoma (dlbcl), marginal zone lymphoma (mzl), follicular lymphoma (fl) or advanced solid tumors . toxicity efficacy doe-limiting toxicity and pharmacogenomics event free survival proportion of leukemia participants with positive minimal residual disease plasma concentration of bendamustine percentage of participants with end of induction response, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population percentage of participants with end of induction response, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - first-line population percentage of participants with best overall response, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population percentage of participants with best overall response, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - first-line population percentage of participants with best overall response of complete response, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population percentage of participants with best overall response of complete response, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - first-line population number of participants with progression-free survival (pfs) events (disease progression/relapse or death), according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population number of participants with pfs events (disease progression/relapse or death), according to 2007 revised response criteria for non hodgkin\\'s lymphoma - first-line population pfs, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population pfs, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - first-line population number of participants with event-free survival (efs) event (disease progression, death, or initiation of a new anti-lymphoma therapy), according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population number of participants with efs event (disease progression, death, or initiation of a new anti-lymphoma therapy), according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population efs, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - relapsed/refractory population efs, according to 2007 revised response criteria for non hodgkin\\'s lymphoma - first-line population pharmacokinetics of obinutuzumab: area under the concentration-time curve from time zero to last quantifiable concentration (auclast) - relapsed/refractory population pharmacokinetics of obinutuzumab: auclast - first-line population pharmacokinetics of obinutuzumab: maximum observed plasma concentration (cmax) - relapsed/refractory population pharmacokinetics of obinutuzumab: cmax - first-line population pharmacokinetics of obinutuzumab: systemic clearance at steady state (clss) - relapsed/refractory population pharmacokinetics of obinutuzumab: clss - first-line population pharmacokinetics of obinutuzumab: auc from time zero to 7 days (auc7d) - relapsed/refractory population pharmacokinetics of obinutuzumab: auc7d - first-line population pharmacokinetics of obinutuzumab: volume of distribution at steady state (vss) - relapsed/refractory population pharmacokinetics of obinutuzumab: vss - first-line population pharmacokinetics of obinutuzumab: plasma half-life (t1/2) - relapsed/refractory population pharmacokinetics of obinutuzumab: t1/2 - first-line population pharmacokinetics of obinutuzumab: plasma trough concentration (ctrough) - relapsed/refractory population pharmacokinetics of obinutuzumab: ctrough - first-line population pharmacodynamics of obinutuzumab: number of participants with peripheral blood b-cell depletion - relapsed/refractory population pharmacodynamics of obinutuzumab: number of participants with peripheral blood b-cell depletion - first-line population pharmacodynamics of obinutuzumab: time from end of treatment to b-cell recovery - relapsed/refractory population pharmacodynamics of obinutuzumab: time from end of treatment to b-cell recovery - first-line population to evaluate pk to evaluate efficacy to monitor for the presence of human anti galiximab antibody and human antichimeric antibody formation evaluate pk samples during c1, identify and use biomarkers to characterize the pd effects in surrogate and tumor tissue, establish a biologically active dose range, assess preliminary anti-tumor activity in cancer patients. tumor response (complete response, partial response, stable disease) according to cheson criteria and duration of response incidence of adverse events change from the time-matched baseline in the fridericia correction of qtc (qtcf) number of participants with adverse events (aes) and serious adverse events (saes) determine the pharmacokinetics of oral pxd101 when dosed once or twice daily at various dose levels explore anti-tumor activity determine the safety, tolerability, and anti-tumor activity of orally administered pxd101 to patients with lymphoma number of subjects with adverse events percentage of subjects with adverse events change in physical exam finding, including vital signs change in clinical laboratory test results change in cardiac assessment findings changes in vital signs, physical examination findings, and clinical laboratory results incidence, nature, and severity of adverse events pharmacokinetic parameters patient\\'s best response as assessed by the investigator duration of response event-free survival assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- describe engraftment kinetics-- describe the response rate-- describe relapse rate and event-free survival-- assess clofarabine p auc(0-168) of copanlisib after each copanlisib iv infusion during 2 cycles of copanlisib monotherapy aes as characterized by type, frequency, severity (as graded by ctcae) and relationship to study drug maximum change from baseline in insulin during 2 cycles of copanlisib maximum change from baseline in c-peptide during 2 cycles of copanlisib fdg pet early response (decreased suvmax compared to baseline) after dosing with copanlisib for non-diabetic patients with detectable fdg tumor uptake at baseline change from baseline in expression and / or phosphorylation of pi3k pathway proteins in paired tumor biopsies percentage of participants experiencing teaes and saes beyond 28 days of idelalisib exposure percentage of participants experiencing teaes related to idelalisib beyond 28 days of idelalisib exposure percentage of participants experiencing treatment-emergent laboratory abnormalities beyond 28 days of idelalisib exposure by worst grade at postbaseline percentage of participants who permanently discontinued idelalisib due to a teae beyond 28 days of idelalisib exposure characterize the pk profile of emd 521873 alone or in combination with fixed lowdose cpa evaluate the immunogenicity of emd 521873 alone or in combination with cpa measured by the induction of o specific antibodies against the genetically modified il-2 o fc-il2-specific antibodies o anti-idiotype antibodies collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with emd 521873 alone or in combination with cpa evaluate survival evaluate biological responses to emd 521873 alone or in combination with cpa as measured by o absolute cell numbers and ratios of lymphocyte subsets in defined combinations o change in serum level of sil2r and neopterin treatment-related mortality event-free survival overall survival response rate measured by tumor imaging estimate progression free survival, clinical response rates to treatment, and overall survival to determine efficacy. the toxicity of vtp195183 pretreatment when used with g-csf number of participants with a response to therapy overall progression free survival (pfs) overall survival (os) incidence of adverse events, graded according to ctcae 4.0 overall response rate defined as number of patients with an objective status of complete response (cr), complete response/unconfirmed (cru), or partial response (pr) divided by total number of evaluable patients overall survival time progression-free survival response pk-time to maximum plasma concentration (tmax) pk-apparent total body clearance (cl/f) pk-apparent volume of distribution (vz/f) pk-terminal half-life (t1/2) pk-area under the plasma concentration time curve (auc) accumulation ratio (cmax) accumulation ratio (aucÏ„) pk-maximum concentration in plasma (cmax) dose limiting toxicity pharmacokinetics objective response rate progression free survival overall response rate objective response rate (orr) in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) overall survival (os) overall survival (os) in participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) overall survival (os) in participants pooled from cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide) relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) duration of response (dor) in cohort 1: myelodysplastic syndrome (mds) duration of response (dor) in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) duration of response (dor) in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) duration of response (dor) in participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) duration of response (dor) in the cohort 4 non-hodgkin lymphoma (nhl) individual sub-cohorts (cohorts 4a, 4b, 4c, and 4d) duration of response (dor) in participants pooled from cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide) relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) positive participants in cohort 1: myelodysplastic syndrome (mds) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) negative participants in cohort 1: myelodysplastic syndrome (mds) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) indeterminate participants in cohort 1: myelodysplastic syndrome (mds) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) positive participants in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) negative participants in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) indeterminate participants in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) positive participants in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) negative participants in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) indeterminate participants in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) positive participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) negative participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) indeterminate participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) positive participants in the cohort 4 non-hodgkin lymphoma (nhl) individual sub-cohorts (cohorts 4a, 4b, 4c, and 4d) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) negative participants in the cohort 4 non-hodgkin lymphoma (nhl) individual sub-cohorts (cohorts 4a, 4b, 4c, and 4d) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) indeterminate participants in the cohort 4 non-hodgkin lymphoma (nhl) individual sub-cohorts (cohorts 4a, 4b, 4c, and 4d) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) positive participants pooled from cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide): relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) negative participants pooled from cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide): relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) objective response rate (orr) in programmed cell death ligand 1 (pd-l1) indeterminate participants pooled from cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide): relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) progression-free survival (pfs) in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) progression-free survival (pfs) in cohort 3: relapsed/refractory (r/r) hodgkin lymphoma (hl) progression-free survival (pfs) in participants pooled from the cohort 4 non-hodgkin lymphoma (nhl) sub-cohorts (cohorts 4a+4b+4c+4d) progression-free survival (pfs) in the cohort 4 non-hodgkin lymphoma (nhl) individual sub-cohorts (cohorts 4a, 4b, 4c, and 4d) progression-free survival (pfs) in participants pooled from the cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide) relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl) marrow complete response (mcr) in cohort 1: myelodysplastic syndrome (mds) cytogenic complete response in cohort 1: myelodysplastic syndrome (mds) cytogenic partial response in cohort 1: myelodysplastic syndrome (mds) erythroid response in cohort 1: myelodysplastic syndrome (mds) neutrophil response in cohort 1: myelodysplastic syndrome (mds) platelet response in cohort 1: myelodysplastic syndrome (mds) time to progression (ttp) in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) stringent complete remission (scr) in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) complete response (cr) in cohort 2: relapsed refractory/refractory (rr/r) multiple myeloma (mm) assess blood values of combination treatment for 4 weeks assess blood values of sb-485232 for additional 8 weeks pharmacokinetic parameters for sb-485232 and rituxan: auctau, cmax, and cmin. pharmacodynamic biomarker responses: plasma ifn-Î³, gmcsf, ip-10, mig, and mcp-1 changes plasma il-18bp change pbmc phenotype changes activated nk cells (cd16+/cd56+/cd3-/cd69+/fasl+ or il-18ra+) activated cytolytic t cells (cd8+/cd4-/cd3+/cd69+ fasl+ or il- 18ra+) activated b cells (cd19+/cd25-/cd3-/cd69+) activated neutrophils/monocytes (cd11b+/cd16+/cd64+/cd14+/cd45+/cd69+) regulatory t-cells (foxp3+/cd25+/cd4+/cd127+) immunogenicity (anti-sb-485232 and anti-rituximab antibodies) anti-tumor activity (radiographic tumor assessments) cd16 (fcÎ³riiia) 158v/f genotyping adverse events complete response rate duration of response progression free survival objective response rate overall survival area under the concentration versus time curve (auc) peak plasma concentration (cmax) time of cmax (tmax) number of patients with adverse events define incidence and severity of adverse events, defined according to ctcae v 4.0. overall response rate complete response rate event-free survival progression free survival overall survival overall response rate (orr) of bendamustine hydrochloride and gemcitabine hydrochloride in patients with relapsed or refractory hodgkin lymphoma (phase ii) efficacy evaluate the clinical responses (i.e., effectiveness) by the mna-d number of participants with non-serious treatment-emergent adverse events (teaes) and serious adverse events (saes) as a measure of safety and tolerability of denileukin diftitox maximum serum concentration (cmax) of denileukin diftitox time to cmax (tmax) of denileukin diftitox in serum area under the serum concentration-time curve from time 0 to time of last quantifiable concentration (auc(0-t)) area under the serum concentration-time curve from time 0 to infinity (auc(0-inf)) terminal phase rate constant (Î»z) terminal elimination phase half-life (t1/2) volume of distribution at terminal phase (vz) volume of distribution at steady state (vss) total clearance (cl) recommended dose phase 1a or phase 1b safety assessment phase 1a, phase 1b, or phase 2a pharmacokinetic profile evaluation phase 1a effect of food on bioavailability complete response rate(cr) at the end of treatment progression-free survival (pfs) duration of response safety of association romidepsin-chop overall response at the end of treatment overall survival (os) secondary efficacy endpoints include disease response assessed by the pga, duration of overall response, duration of ccr, duration of pr, time to response and time to progression of disease. complete response rate partial response rate overall response rate progression free survival duration of response complete response (cr) rate overall response rate (antitumor effect : â‰¥ partial response [pr]) progression-free survival (pfs) the maximum concentration (cmax) of unchanged syb l-0501 the maximum drug concentration time (tmax) of unchanged syb l-0501 the area under the curve (auc) for unchanged syb l-0501 the half-life period (t1/2) of unchanged syb l-0501 overall response rate (orr) characterize the safety profile of pralatrexate in patients with relapsed or refractory ctcl. toxicity of the combination of romidepsin and carfilzomib best overall response at the mtd maximum percentage change in the radiological sum of the product of the diameters from baseline, assessed using the revised response criteria for malignant lymphoma duration of response from time of first documented response until relapse or progression progression free survival overall survival change in absolute number of cmv-induced adaptive nk cells response to cmv-mva triplex vaccine in cmv seropositive vs. seronegative patients progression free survival (pfs) response to cmv-mva triplex vaccine in lymphoma vs. myeloma patients pharmacokinetic parameter maximum plasma concentration (cmax) of milademetan in participants receiving milademetan pharmacokinetic parameter area under the curve (auc) of milademetan in participants receiving milademetan pharmacokinetic parameter time to reach maximum plasma concentration (tmax) of milademetan in participants receiving milademetan pharmacokinetic parameter apparent clearance (cl/f) of milademetan in participants receiving milademetan pharmacokinetic parameter elimination terminal half life half-life (t1/2) of milademetan in participants receiving milademetan mean fold change from baseline in serum mic-1 levels in participants receiving milademetan overall response rate progression-free survival overall survival pharmacokinetics (pk) in humans of intravenously administered cx-3543. evaluate evidence of antitumor activity of cx-3543 by objective radiographic assessment. pharmacodynamic evaluation of antitumor activity to evaluate the pharmacokinetic profile of tak-901 and its primary metabolite (m-i). to evaluate disease response. to investigate the effect of tak-901 on tumor proliferation. determine the cmax profile of ds 3078a effect on glucose metabolism assess pharmacodynamic effects tumor glucose uptake assess tumor response assess pharmacodynamic effects v-akt murine thymoma viral oncogene determine the auc of ds 3078a determine the tmax of ds 3078a determine the terminal half-life of ds 3078a secondary end points: efficacy- cailds score secondary end points: efficacy- swat score to determine the plasma pharmacokinetics of pemetrexed and assess drug penetration into the csf. to provide preliminary evidence of pemetrexed activity against brain lymphoma my mri criteria of clearance of csf lymphoma cells. to identify the time to complete response. to provide a measure of reduction of enhancing tumor volume as compared to our nomogram of reduction of tumor volume for methotrexate recipients with brain lymphoma. overall remission rate (orr), which includes complete remission (cr) and partial remission (pr) overall remission rate (orr), which includes complete remission (cr) and partial remission (pr) overall remission rate (orr), which includes complete remission (cr) and partial remission (pr) overall remission rate (orr), which includes complete remission (cr) and partial remission (pr) best overall response (bor) time to initial response (ttr) progression-free survival (rfs) duration of remission (dor) overall survival (os) safety and tolerance overall response rate effectiveness of study drug tumor response (overall response) plasma concentration-time profile overall response rate (orr); percentage of participants who achieve a pr or cr according to the lugano criteria. orr by predictive gene signature progression-free survival (pfs) event-free survival (efs) overall survival (os) adverse events (aes) pharmacokinetics (pk): maximum plasma concentration (cmax) of abemaciclib pharmacokinetics (pk): area under the plasma concentration versus time curve (auc) of abemaciclib percentage of participants with a tumor response: objective response rate (orr) number of participants with adverse events (aes) and serious adverse events (saes) number of participants with clinically significant change in laboratory parameters reported as aes number of participants with clinically significant change in vital sign reported as aes tumor response (overall response) plasma concentration-time profile progression-free survival duration of response assessment of the efficacy of each treatment by evaluation of overall response rate using recil 2017 response criteria duration of response (dor) using recil 2017 response criteria for the anti-tumour activity of each therapy. progression free survival (pfs) using recil 2017 response criteria for the anti-tumour activity of each therapy. overall survival (os) peak plasma concentration (cmax) of study drug a (arm 1) peak plasma concentration (cmax) of study drug b (arm 2) area under the plasma concentration versus time curve (auc) of study drug a (arm 1) area under the plasma concentration versus time curve (auc) of study drug b (arm 2) presence of anti-drug antibody (ada) titres in subjects treated with study drug a peak plasma concentration (cmax) of acalabrutinib (arm 1) area under the plasma concentration versus time curve (auc) for acalabrutinib (arm 1) peak plasma concentration (cmax) of acalabrutinib (arm 2) area under the plasma concentration versus time curve (auc) for acalabrutinib (arm 2) number of participants with serious and non-serious adverse events assessed by the common terminology criteria in adverse events (ctcae v3.0). best overall response (bor) per international myeloma working group (imwg) criteria for myeloma; and per revised criteria for staging of the international working group (iwg) guidelines for lymphoma area under curve (auc) maximum plasma concentration (cmax) terminal elimination half-life (t1/2) apparent volume of distribution (vz) clearance (cl) duration of response (dor)per international myeloma working group (imwg) criteria for myeloma; and per revised criteria for staging of the international working group (iwg) guidelines for lymphoma progression free survival (pfs) per international myeloma working group (imwg) criteria for myeloma; and per revised criteria for staging of the international working group (iwg) guidelines for lymphoma clinical benefit duration of response time to progression tumor response incidence of human anti-human antibody (haha) formation determine the pharmacokinetics of ds-8273a abscopal response rate time to response of bexarotene with ecp in patients with ctcl, at month 4 (follow-up visit) patient\\'s response by organ system involvement, with an overall assessment: complete response, partial response, no change, or progressive disease, flare. another secondary outcome is whether combination of instruments provides relevant information on ctcl patients\\' health related quality of life during therapy to define antitumor activity, assess biological activity of bortezomib by measuring nf-kb activity in pbmc and to assess the biologic activity of bortezomib by measuring endoplasmic reticulum stress response using grp78 molecular chaperone marke... progress free survival (pfs) overall survival (os) participants with treatment-emergent adverse events (teaes) associated with romidepsin area under the plasma concentration-time curve from time zero to the last measurable concentration (auc0-t) of romidepsin in phase 1 area under the plasma concentration-time curve from time zero to infinity (aucâˆž) of romidepsin in phase 1 maximum plasma concentration (cmax) of romidepsin in phase 1 time to maximum plasma concentration of romidepsin (tmax) in phase 1 terminal phase half-life of romidepsin (tÂ½) in phase 1 apparent total clearance of romidepsin (cl/f) of romidepsin in phase 1 apparent volume of distribution (vz/f) of romidepsin in phase 1 auc0-t, at steady state (ss) of romidepsin in phase 1 at cycle 1, day 15 cmax, ss of romidepsin in phase 1 at cycle 1, day 15 tmax,ss of romidepsin in phase 1 at cycle 1, day 15 terminal phase half-life of romidepsin (tÂ½) in phase 1 at cycle 1, day 15 auc0-t, accumulation ratio of romidepsin in phase 1, cycle 1 cmax accumulation ratio of romidepsin in phase 1, cycle 1 the percentage of participants with abnormal q-wave and t wave intervals percentage of ptcl participants with the best response in accordance with the modified 2007 international workshop response criteria as assessed by ier time to response (ttr) for ptcl participants with at least a pr based on the modified 1999 iwc as assessed by ier time to response (ttr) for ptcl participants with at least a pr based on the modified 2007 iwc as assessed by ier kaplan meier estimate of duration of response (dor) for ptcl responders based on the modified 1999 iwc as assessed by the ier. kaplan meier estimate of duration of response (dor) for ptcl responders based on the modified 2007 iwc as assessed by the ier. kaplan meier estimate of time to progression (ttp) in ptcl participants based on the 1999 iwc as assessed by ier kaplan meier (k-m) estimate of time to progression (ttp) in ptcl participants based on the modified 2007 iwc as assessed by ier overall survival disease free survival ae cmax tmax t1/2 auc0-24h auc0-last cl/f vd orr dcr pfs duration of donor nk cells in the recipient\\'s blood patient survival at 100 days and at one year post treatment (all cause mortality) occurrence of new cancer during the first year post infusion of allogeneic nk-cells documented systemic infections during the first 30 days post infusion of allogeneic nk-cells. occurrence of other possible nk-infusions related complications such as,fever, capillary leak syndrome and/or allergic reaction. pharmacokinetics, pharmacodynamics, efficacy efficacy (to see if the study drug works) in patients with nhl and cll pharmacokinetics (how the drug is processed by the body) pharmacodynamics (how the study drug is absorbed by the body)\\' immunogenicity optimal dose immunogenicity as a result of di-leu16-il2 administration pharmacokinetics of di-leu16-il2 administration clinical responses and survival preliminary assessment of the efficacy of this regimen ability to proceed to peripheral blood stem cell (pbsc) collection following treatment (impact of this regimen on stem cell reserve) percentage of participants with adverse events (aes) - part 2 percentage of participants with clinically significant changes in vital signs, physical examination, clinical laboratory results and electrocardiogram (ecg) findings- part 2 maximum concentration (cmax) of ro6870810 and its potential metabolites- part 1 and part 2 trough serum concentration (cmin) of ro6870810 and its potential metabolites- part 1 and part 2 time of maximum concentration (tmax) of ro6870810 and its potential metabolites- part 1 and part 2 clearance (cl) of ro6870810 and its potential metabolites- part 1 and part 2 volume of distribution (vd) of ro6870810 and its potential metabolites- part 1 and part 2 area under the curve (auc) of ro6870810 and its potential metabolites- part 1 and part 2 complete response (cr) rate as determined by the investigator based on the modified lugano response criteria- part 1 and part 2 complete response (cr) rate, as determined by the icr and by the investigator on the basis of ct scans alone- part 1 and part 2 objective response rate, as determined by the icr and by the investigator on the basis of modified lugano response criteria- part 1 and part 2 objective response rate, as determined by the icr and by the investigator on the basis of ct scans alone- part 1 and part 2 duration of response (dor)- part 1 and part 2 progression-free survival (pfs)- part 1 and part 2 event-free survival (efs)- part 1 and part 2 disease-free survival (dfs)- part 1 and part 2 overall survival (os)- part 1 and part 2 half-life (t1/2) of ro6870810 and its potential metabolites- part 1 and part 2 percentage of ant-drug antibodies (ada) against rituximab - part 1 and part 2 antitumor activity based on cheson criteria complete response rate(cr) after 4 cycles and at the end of treatment progression-free survival (pfs) duration of response overall response at the end of treatment overall survival (os) safety of association temsirolimus with the three chemotherapy regimens to assess the safety and tolerability of rhukgf in subjects with hematologic malignancies undergoing tbi and high-dose chemotherapy followed by pbpc transplantation. to assess oral mucositis in subjects receiving rhukgf. clinical response pharmacokinetics pharmacodynamics (histone acetylation; biomarkers) phospho-akt level in circulating cll cells number of patients with clinical/radiological response estimated dose to tumor sites based on the tumor to normal organ ratios derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of yttrium y 90 anti-cd45 monoclonal antibody bc8 the lowest antibody (yttrium 90-bc8-dota) dose (mg/kg) that is consistent with a favorable biodistribution rate >= 80% in lymphoma patients incidence of grade 3 or greater adverse events summarized using the nci ctcae version 4.0 overall response rate (orr) evaluated by computed tomography (ct) or positron emission tomography (pet)/ct change in correlative markers in blood, bone marrow and tumor tissue ecg parameters blood mmae levels incidence of proarrhythmic adverse events incidence of adverse events and laboratory abnormalities event-free survival overall survival number of subjects with serious and non-serious adverse events pk profile immunogenicity (anti-sgn-35 antibodies) anti-tumor activity pharmacokinetic profile of snx-5422 tumor response measured by x-rays or scans markers of kidney toxicity markers of fluid overload effects on therapy delays effects on development of severe mucositis to evaluate the safety profile of px-478 when administered orally on days one to five of a 21 day cycle to evaluate pharmacodynamic measures of the effects of px 478 on the hif 1-alpha pathway, and related tumor markers to determine the pk profile of px 478 when administered orally on days one to five of a 21 day cycle to evaluate the effects of px 478 on tumor blood flow and vascular permeability as measured by dce mri to evaluate the anti-tumor activity of px 478 in patients with advanced malignancies response rate at the completion of 1 cycle of study treatment minimum residual disease (mrd) levels present at end of cycle 1 therapy in patients percentage of alisertib metabolites in plasma following a single dose of [^14c]-alisertib oral solution percentage of alisertib metabolites in urine following a single dose of [^14c]-alisertib oral solution percentage of alisertib metabolites in feces following a single dose of [^14c]-alisertib oral solution number of participants with treatment-emergent adverse events and serious adverse events number of participants with clinically significant changes or abnormalities in clinical laboratory values reported as aes number of participants with clinically significant changes or abnormalities in vital sign measurements overall response rate duration of response time to response progression-free survival overall survival plasma concentration of idela (cohort 1, cohorts 2 and 3, cohort 5) plasma concentration of idela (cohort 4) plasma concentration of idela (cohort 6) plasma concentration of idela (cohort 7) sub-study: plasma concentration of idela (cohorts 1-4) plasma concentration of bendamustine plasma concentration of everolimus plasma concentration of lenalidomide time to tumor progression (ttp) overall survival clinical benefit rate progression-free survival (pfs) blood concentrations of sgn-cd70a and metabolites incidence of antitherapeutic antibodies objective response rate progression-free survival duration of response number of subjects with treatment emergent adverse events pharmacokinetics (cmax) of sar245409 pharmacokinetics (tmax) of sar245409 pharmacokinetics (auc0-12h) of sar245409 pharmacokinetics (ctrough) of sar245409 pharmacokinetics (auc) of bendamustine pharmacokinetics (auclast) of bendamustine pharmacokinetics (ceoi) of bendamustine pharmacokinetics (tmax) of bendamustine pharmacokinetics (cl) of bendamustine pharmacokinetics (vss) of bendamustine pharmacokinetics (auc0-7h) of rituximab pharmacokinetics (ceoi) of rituximab pharmacokinetics (tmax) of rituximab efficacy as determined by objective response rate (orr) objective response rate (orr) event free survival (efs) number of participants who experienced adverse events ixazomib and metabolites as percent of total radioactivity in plasma ixazomib and metabolites as percent of total dose administered in urine ixazomib and metabolites as percent of total dose administered in feces number of participants reporting one or more treatment emergent adverse events (teaes) and serious adverse events (saes) number of participants with teaes related to investigations system organ class for laboratory values number of participants with teaes related to vital signs percentage of participants with best overall response maximum observed plasma concentration (cmax) under steady state of mil62 area under the plasma concentration versus time curve (auc) of mil62 under steady state systemic clearance of mil62 under steady state volume of distribution under steady state (vss) of mil62 terminal plasma half-life (t1/2) of mil62 under steady state change in cluster of differentiation 19 (cd19+) b cells change in cluster of differentiation 20 (cd20+) b cells percentage of participants with positive anti-drug antibodies to mil62 progression-free survival (pfs) in the study overall survival (os) in the study duration of response (dor) disease control rate (dcr) participants with event-free survival (efs) part a only: define either the maximum tolerated dose (mtd), if possible, or maximum feasible dose (mfd) part b only: preliminary assessment of the effect of food on the pharmacokinetic (pk) parameters of azd6738 via plasma analysis parts a&b: establish pharmacokinetics characteristics of azd6738 and its active metabolite from plasma analysis part a and b: anti tumour activity by assessing tumour response via ct or mri scans part a and b: measuring 4 beta-hydroxy cholesterol concentration for assessment of cyp3a4 induction potential part b: pharmacokinetic profile of azd6738 and its active metabolite from urinalysis part b only: preliminary assessment of the effect of food on the pk parameters of azd6738 via urinalysis part a: determine the extent of atr target inhibition using pharmacodynamic biomarkers part a and b: biomarker analysis using lymph node biopsies part a and b: confirmation of tumour response assessment by analysing bone marrow / aspirate part a and b: bone marrow biopsy or aspirate will be analysed for biomarkers part a and b: determination of 11q del status to investigate any potential changes in fish cytogenetic\\'s post treatment parts a and b: identify patients with atm deficient status, determine atm mutation load and correlate this with clinical efficacy in order to better understand patient population which will most likely benefit from azd6738 treatment part b: the extent of atr target inhibition identified using pharmacodynamic biomarkers duration of response (dor) progression free survival (pfs) overall survival (os) in vivo cellular kinetics of tisagenlecleucel in blood, bone marrow, lymph nodes and other tissues by qpcr and flow cytometry impact of pembrolizumab dosing strategy on the cellular kinetics of tisagenlecleucel by qpcr and flow cytometry immunogenicity measured by antibody titres specific to tisagenlecleucel molecule and by the presence of t lymphocytes activated by the tisagenlecleucel protein summary of adverse events (aes) and serious adverse events (saes) dose-limiting toxicities (dlts) treatment-related adverse events (all grades) with an overall incidence greater than or equal to 10% best overall response (bor) maximum plasma concentration (cmax) of lenvatinib time to maximum plasma concentration (tmax) of lenvatinib apparent plasma half-life (t1/2) of lenvatinib area under the plasma concentration curve from time 0 to infinity (auc(0-inf)) area under the plasma concentration curve from time 0 to 24 hours (auc(0-24)) clearance corrected for the fraction of lenvatinib absorbed (cl/f) apparent volume of distribution (vz/f) fraction of unchanged lenvatinib excreted in the urine (fe) renal clearance (clr) of lenvatinib effect of food on the area under the curve from zero to 24 hours (auc(0-24)) effect of food on the maximum plasma concentration (cmax) of lenvatinib effect of food on time to maximum concentration (tmax) of lenvatinib serum concentration of blinatumomab objective tumor response according to the cheson criteria (without minimal response) objective tumor response according to the cheson criteria (with minimal response) response rate monitor for minimal residual disease pharmacodynamics identification of the mtd evaluation of the immunogenicity of sym023. evaluation of objective response (or) or stable disease (sd) by recist v1.1 evaluation of objective response (or) or stable disease (sd) by irecist evaluation of objective response (or) or stable disease (sd) by recil 2017. time to progression (ttp) of disease. area under the concentration-time curve in a dosing interval (auc). maximum concentration (cmax) time to reach maximum concentration (tmax) trough concentration (ctrough) terminal elimination half-life (tÂ½) clearance (cl) response will be evaluated every 2 cycles (8 weeks), according to the revised recist guideline, version 1.1 maximum plasma concentration (cmax) of apg-115 on day 1-3 and day 21-23 post apg-115 treatment on cycle 1 area under the plasma concentration versus time curve (auc) of apg-115 on day 1 -3 and day 21 - 23 post apg-115 treatment on cycle 1 tumor response median time to progression (ttp) characterization of pk (cmax) of sb-743921 administered as a 1-hour intravenous infusion on day 1 characterization of pk (tmax) of sb-743921 administered as a 1-hour intravenous infusion on day1 characterization of pk (clast) of sb-743921 administered as a 1-hour intravenous infusion on day 1 characterization of pk (auclast) of sb-743921 administered as a 1-hour intravenous infusion on day 1 characterization of pk (cmax) of sb-743921 administered as a 1-hour intravenous infusion on day 15 characterization of pk (tmax) of sb-743921 administered as a 1-hour intravenous infusion on day 15 characterization of pk (clast) of sb-743921 administered as a 1-hour intravenous infusion on day 15 characterization of pk (auclast) of sb-743921 administered as a 1-hour intravenous infusion on day 15 overall survival for all eligible patients progression-free survival for all eligible patients duration of response for all eligible patients time to treatment failure for all eligible patients evaluation of the immunogenicity of sym022. evaluation of objective response (or) or stable disease (sd). time to progression (ttp) of disease. area under the concentration-time curve in a dosing interval (auc). maximum concentration (cmax) time to reach maximum concentration (tmax) trough concentration (ctrough) terminal elimination half-life (tÂ½) clearance (cl) incidence of neutrophil recovery within 42 days incidence of platelet recovery within six months frequency of expanded unit predominance at day 100 (ducbt recipients only) incidence of transplant related mortality (trm) within 100 days and one year incidence of acute graft versus host disease (agvhd) within 100 days and chronic graft versus host disease (cgvhd) within 1 year incidence of relapse within one year overall survival (os) within one year disease free survival (dfs) within one year overall response rate complete response number of participants with treatment emergent adverse events (teaes) using ctcae version 4.03 objective response rate plasma concentration of pralatrexate in combination with chop pharmacokinetics: area under the curve (auc) pharmacokinetics: maximum concentration (cmax) pharmacokinetics: time to maximum concentration (tmax) pharmacokinetics: clearance (cl) safety profile safety profile safety profile safety profile safety profile safety profile tumor-specific immune response tumor-specific immune response tumor-specific immune response tumor-specific immune response tumor-specific immune response tumor-specific immune response number of clinical and laboratory adverse events (aes) . objective response rate (orr) as assessed by recist version 1.1 and immune-related recist (irrecist) for solid tumor and the lugano classification for non-hodgkin lymphoma duration of response (dor) as assessed by recist version 1.1 and immune-related recist (irrecist) for solid tumor and the lugano classification for non-hodgkin lymphoma time to progression (ttp) as assessed by recist version 1.1 and immune-related recist (irrecist) for solid tumor and the lugano classification for non-hodgkin lymphoma disease control rate (dcr) as assessed by recist version 1.1 and immune-related recist (irrecist) for solid tumor and the lugano classification for non-hodgkin lymphoma progression-free survival (pfs) as assessed by recist version 1.1 and immune-related recist (irrecist) for solid tumor and the lugano classification for non-hodgkin lymphoma peak plasma concentration (cmax) plasma concentration at the end of a dosing interval (ctrough) time to reach cmax (tmax) area under the curve from time zero to the last timepoint (auc0-last) auc from time zero to infinity (auc0-âˆž) auc during a dosing interval (auctau) clearance (cl) volume of distribution at steady state (vss) ada levels for adg106. serum biomarkers linked to immunomodulation and cytokine release: such as tnfÎ±, ifn-Î³, il 10, il-6, il-4, il-2. cell counts for circulating t, natural killer (nk), and b cells. area under the concentration-time curve (auc) from 0 to 24 hours post azd3965 dosing auc from 0 to 12 hours post azd3965 dosing maximum observed plasma concentration of azd3965 time to maximum observed concentration of azd3965 elimination half life for azd3965 plasma level of cell death marker m30 (caspase-cleaved ck18; part 1 only) plasma level of cell death marker m65 (total plus caspase-cleaved ck18; part 1 only) plasma level of nucleosomal dna (ndna) as a measure of apoptosis (part 1 only) number of patients who experienced a complete response, partial response or stable disease according to recist 1.1 or a complete remission, partial remission or stable disease according to the iwg criteria for lymphoma (part 2 only) the area under the curve (auc) of plasma concentration of drug maximum concentration (cmax) time at which maximum concentration (tmax) lowest plasma concentration (c[trough]) overall response rate complete response survival of subjects treated with kpt-330 + rice progression-free survival of subjects treated with kpt-330 + rice number of patients who demonstrate a response to kpt-330+rice number of patients who undergo stem cell collection after induction therapy with kpt-330 + rice to define the extent of cerebrospinal fluid (csf) penetration of lenalidomide. to assess the clinical efficacy lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular (for patients with intraocular lymphoma) response criteria. to define the immunological effects of lenalidomide using flow-cytometry csf as well as genomic markers of recurrent/refractory cns lymphoma. to assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria. to determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the csf after intraventricular rituximab administration. objective response rate as measured by cd30 expression overall response rate duration of response progression-free survival (pfs) overall survival (os) os rate at 12 months os follow-up time time to response (ttr) clinical benefit rate (cbr) number of participants with antitherapeutic antibodies (ata) and neutralizing ata (nata) (phase 1 and 2) overall response rate (orr) (phase 1) time to progression (ttp) (phase 1 and 2) time to response (phase 1 and 2) duration of response (dor) (phase 1 and 2) event free survival (efs) (phase 1 and 2) progression free survival (pfs) (phase 1 and 2) overall survival (os) (phase 1 and 2) number of participants with adverse events (aes) and serious adverse events (saes) (phase 1 and 2) number of participants with abnormal clinical laboratory values reported as aes (phase 1 and 2) number of participants with clinically significant vital signs reported as aes (phase 1 and 2) antibody-drug conjugate (adc) serum concentrations (phase 1 and 2) serum concentration of total antibodies (conjugated and unconjugated) monomethyl auristatin e (mmae) plasma concentrations (phase 1 and 2) pharmacokinetics: maximum observed drug concentration (cmax) at steady state of enzastaurin, its principle metabolites and total analyte pharmacokinetics: time of maximal plasma concentration (tmax) of enzastaurin, its principle metabolites and total analyte pharmacokinetics: area under concentration-time curve over a dosing interval at steady state (aucss) of enzastaurin, its principle metabolites and total analyte pharmacokinetics: average concentration during a dosing interval steady state (cav,ss) of enzastaurin, its principle metabolites and total analyte pharmacodynamics: maximum international normalised ratio (inrmax) following warfarin alone pharmacodynamics: area under international normalised ratio-time curve auc(inr) following warfarin alone pharmacodynamics: maximum international normalised ratio (inrmax) following concomitant administration of warfarin and enzastaurin pharmacodynamics: area under international normalised ratio-time curve auc(inr) following concomitant administration of warfarin and enzastaurin pharmacodynamics: international normalised ratio (inr) following enzastaurin alone cmax of incb053914 in combination with incb050465 tmax of incb053914 in combination with incb050465 cmin of incb053914 in combination with incb050465 auc0-t of incb053914 in combination with incb050465 cl/f of incb053914 in combination with incb050465 overall response rate duration of response progression-free survival response rate incidence of aes/saes assessment of safety procedures findings pk parameter for metabolite m1: auc0-t pk parameter for metabolite m1: auc0-inf pk parameter for metabolite m1: cmax number of participants with adverse events graded according to ctc (phase ii) overall survival progression-free survival overall survival (os) (phase ii) overall response rate (partial or complete response) (phase ii) evaluation of the immunogenicity of sym021 as a single agent and in combination with sym022 and sym023. evaluation of objective response (or) or stable disease (sd). time to progression (ttp) of disease. area under the concentration-time curve in a dosing interval (auc) maximum concentration (cmax) time to reach maximum concentration (tmax) trough concentration (ctrough) terminal elimination half-life (tÂ½) clearance (cl) time to maximum observed serum concentration (tmax) of obinutuzumab at cycle 8 apparent terminal half-life (t1/2) volume of distribution at steady state (vss) of obinutuzumab at cycle 8 total systemic clearance at steady state (clss) of obinutuzumab at cycle 8 minimum observed serum concentration of obinutuzumab percentage of participants with complete response (cr), cr unconfirmed (cru) at end of treatment (1 month after cycle 8) in nhl participants (dlbcl and fl participants) per cheson 1999 criteria percentage of participants with partial response (pr), stable disease (sd), and progressive disease (pd) at end of treatment (1 month after cycle 8) in nhl participants (dlbcl and fl participants) per cheson 1999 criteria percentage of participants with best overall response (bor) of cr, cru at anytime during study in nhl participants (dlbcl and fl participants) per cheson 1999 criteria percentage of participants with bor of pr, sd, and pd at anytime during study in nhl participants (dlbcl and fl participants) per cheson 1999 criteria percentage of participants with complete remission (cre), cre with incomplete bm recovery (cri) at end of treatment (1 month after cycle 8) in cll participants according to international workshop on chronic lymphocytic leukemia (iwcll) 2008 guidelines percentage of participants with pr, sd, and pd at end of treatment (1 month after cycle 8) in cll participants according to iwcll 2008 guidelines percentage of participants with bor of cre, cri at anytime during the study in cll participants according to iwcll 2008 guidelines percentage of participants with bor of pr, sd, and pd at anytime during study in cll participants according to iwcll 2008 guidelines number of participants with positive human anti-human antibodies (haha) number of participants with positive human anti-chimeric antibodies (haca) number of participants with b-cell depletion or recovery duration of depletion of cd19+ b-cell time to recovery of cd19+ b-cell preliminary efficacy signals of the cc-292 + lenalidomide combination observed maximum plasma concentration time to reach maximum observed plasma concentration (tmax) terminal phase rate constant (Î»z) plasma decay half-life (t1/2) area under the curve from time zero to the last quantifiable concentration [auc(0-t)] area under the curve from time zero to extrapolated infinity [auc(0-âˆž)] btk receptor occupancy duration of response (dor) progression-free survival (pfs) the number of participants affected by an adverse event maximum observed plasma concentration of jnj-40346527 trough plasma concentration of jnj-40346527 minimum observed plasma concentration of jnj-40346527 time of maximum observed plasma concentration of jnj-40346527 area under the plasma concentration-time curve of jnj-40346527 total drug clearance of jnj-40346527 accumulation index of jnj-40346527 duration of response progression-free survival (pfs) time safety profile of osi-027 pharmacokinetic profile of osi-027 preliminary pharmacodynamic relationship with osi-027 systemic exposure preliminary antitumor activity of osi-027 pharmacokinetic pharmacodynamic efficacy correlation of efficacy to pharmacokinetic and/or pharmacodynamic effects of debio 1143 (at-406) incidence of aes, change in safety and efficacy parameters number of participants with complete responses (cr) and partial responses (pr) as a measure of efficacy number of subjects with adverse events as a measure of safety and tolerability progression free survival (pfs) and overall survival (os) as a measure of efficacy duration of response (dor) the best overall tumour response dosimetry clinical activity of ionis-stat3rx pharmacokinetics-cmax stat3 and other biomarkers pharmacokinetics - tmax phase i of the study: to analyze the adverse events of lr-eshap (frequency and severity of the adverse events) phase i of the study: preliminarily analyze effectiveness (response rates (cr and pr), duration of response and survival (dfs and os) phase i of the study: evaluate haematopoietic progenitor cells mobilization after treatment with lr-eshap (evaluate cd34+ cell count) phase i of the study: evaluate hematologic recovery after hsct (recovery of blood parameters) phase ii of the study: analyze effectiveness (complete remission (cr) rate (determined by positron emission tomography [pet]/ct), event-free survival (efs) and overall survival (os) phase ii of the study: rate of transplanted patients (number of patients that undergo hsct) phase ii of the study: to analyze the adverse events of lr-eshap and asct. (frequency and severity of the adverse events) phase ii of the study: evaluate mobilization after treatment with lr-eshap (number of stem cells (2 x 106/kg hematopoietic progenitor cell antigen (cd34)+ cells) collected after the salvage therapy.) phase ii of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological (such as cell of origin) prognostic factors on response rates and survival.) complete response (cr) to study treatment (phase iia) duration of remission (phase iia) overall survival (phase iia) pharmacokinetic parameters of veliparib (phase ib) progression-free survival using recist version 1.1 (phase iia) participants with dose limiting toxicities time to neutrophil engraftment time to platelet engraftment total number of subjects with grade ii-iv acute graft-versus-host-disease (gvhd) total number of subjects that experienced transplant-related mortality (trm) frequency of grade 3 or higher treatment-related adverse events by ctcae 4.03 duration of response (dor) progression-free survival (pfs) overall survival (os) percentage of subjects experiencing grade 3 or 4 thrombocytopenia duration of grade 3 or 4 thrombocytopenia percentage of subjects that received platelet transfusions clinical benefit duration of response time to progression participants evaluated for toxicity maximum observed plasma concentration of jnj-42756493 minimum observed plasma concentration of jnj-42756493 time correspondent to the maximum observed plasma concentration of jnj-42756493 area under the plasma concentration-time curve from time 0 to 24 hours of jnj-42756493 half-life of jnj-42756493 apparent volume of distribution of jnj-42756493 total clearance of drug of jnj-42756493 accumulation index of jnj-42756493 number of participants with complete response number of participants with partial response number of participants with stable disease number of participants with progressive disease best overall response rate based on investigator\\'s assessment duration of response (dor) number of participants with polymorphisms in gene encoding enzyme ugt1a1 number of participants with polymorphisms in aurora a kinase response as per investigator assessment for patients with acute myelogenous leukemia (aml) response as per investigator assessment for patients with acute myelogenous leukemia (aml) in expansion phase response as per investigator assessment for patients with hodgkin\\'s lymphoma (hd) response as per investigator assessment for patients with myelodysplastic syndromes (mds) maximum plasma concentration of panobinostat after the first dose in arms 1 and 2 half life of panobinostat after the first dose in arms 1 and 2 maximum plasma concentration of panobinostat after multiple doses in arm 1 on day 15 half life of panobinostat after multiple doses in arm 1 on day 15 geometric mean ratio (gmr) comparing treatment days in arm 1 percentages of participants with histone acetylation induction in peripheral blood in arm 1 (mwf every week), group x percentages of participants with histone acetylation induction in peripheral blood in arm 1 (mwf every week), group y percentages of participants with histone acetylation induction in peripheral blood in arm 2 (mwf every other week), group x percentage of participants with histone acetylation induction in peripheral blood in arm 2 (mwf every other week), group y highest percent change in fetal hemoglobin from baseline in arm 1 (mwf every week) highest percent change of fetal hemoglobin from baseline in arm 2 (mwf every other week) tumor response 12-week objective response rate 12-week non-progression rate phase â…°, safety/tolerability: incidence and severity of treatment emergent adverse events (teae) phase â…°, safety/tolerability: incidence and severity of study treatment related ae phase â…°, safety/tolerability: cytokine (il-2, il-6,il-8,il-10,ifn-Î³,tnf-Î± ) concentration (pg/ml) by msd and cba method phase â…°: the number of copies of car-cd19 t cells in peripheral blood genomes by qpcr method and car-cd19 t cells by flow cytometry method phase â…°, efficacy: overall remission rate (orr) phase â…±, efficacy: complete response (cr) rate phase â…±, efficacy: duration of response (dor) phase â…±, efficacy: time to response (ttr) phase â…±, efficacy: progression-free survival (pfs) phase â…±, efficacy: overall survival (os) phase â…±, safety/tolerability: incidence and severity of treatment emergent adverse events (teae) incidence and severity of o study treatment related ae phase â…±, safety/tolerability: incidence and severity of aes of special interest (crs, cres) phase â…±, safety/tolerability: cytokine (il-2, il-6,il-8,il-10,ifn-Î³,tnf-Î± ) concentration (pg/ml) by msd and cba method phase â…±: the number of copies of car-cd19 t cells in peripheral blood genomes by qpcr method and car-cd19 t cells by flow cytometry method pharmacokinetics of cep-18770 following single and multiple dose administration. profile and time course of inhibition and recovery of proteasome activity antineoplastic activity evaluated with internationally accepted response criteria overall survival disease-free survival incidence of relapse lymphocyte and hematopoietic reconstitution characteristics of the stem cell grafts characteristics of the natural killer cell grafts. overall survival of patients treated without stem cell manipulation or nk cell infusion due to off therapy criteria kinetics of stem cell mobilization using iv amd3100 as measured by median fold change in the number of cd34+ cells after amd3100 iv administration pharmacodynamic response to a dose of sc amd3100 as measured by mean percentage of the circulating cd34+ count with the 34+ra-123+/- phenotype toxicity of the combination iv amd3100 and g-csf to mobilize â‰¥ 2 x 106 cd34+ cells/kg as measured by number of participants who experience grade 3 or higher adverse event broken down by adverse event incidence of toxicities produced by alisertib in combination with vorinostat assessed by the nci ctcae version 4.0 clinical response rate number of participants with adverse events as a measure of dose limiting toxicities of the combination of methoxyamine and fludarabine number of participants with adverse events as a measure of dose limiting toxicities of the combination of methoxyamine and fludarabine pharmacokinetics of methoxyamine when given in combination with fludarabine as determined by methoxyamine levels at different time points. number of apurinic/pyrimidinic (ap) sites. change in mirna profiles in cll cells in a cohort of cll patients number of dna strand breaks determination by comet assay to monitor drug effects on dna damage in clinical studies. measure of proteins (bcl-2, bax, cleaved parp, topoisomerase i and ii, gammah2ax) progression free survival (pfs) overall survival (os) igvh level delayed cr overall response rate (orr) neutrophil recovery primary graft failure secondary graft failure platelet recovery donor cell engraftment progression-free survival infections the maximum concentration (cmax) of the hlx01 and rituximab presence of anti-drug antibodies against hlx01 change from baseline of cd19+ b-cells objective response rate (orr) at the end of treatment (eot) metabolic, pet-negative complete response (cr) rate at the end of treatment incidence and severity of adverse events (aes) in the follow-up (fu) period best objective response rate (orr) until the end of study (eos) metabolic, pet-negative complete response (cr) rate until the end of study progression-free survival (pfs) at 12 and 24 months event-free survival (efs) at 12 and 24 months time to next anti-lymphoma treatment (ttnt) overall survival at 12 and 24 months anti-tafasitamab antibodies formation overall response rate progression-free survival event free survival overall survival complete response rate overall response rate (orr) duration of remission (dor) progression free survival (pfs) overall survival rateï¼ˆosrï¼‰ area under the plasma concentration versus time curve (auc) of sct400 pharmacokinetics: maximum concentration (cmax) of ly3039478 pharmacokinetics: time to maximum concentration (tmax) of ly3039478 part a: number of participants with tumor response part b, c, d, e and f: duration of response (dor) part b, c, d, e and f: progression free survival (pfs) part b, c, d, e and f: overall survival (os) phase 1b: orr phase 1b: complete response (cr) rate phase 2: cr rate phase 2: duration of response (dor) phase 2: progression free survival (pfs) phase 2: overall survival (os) phase 2: number of participants with teaes, serious teaes, and discontinuations due to teaes best overall response, duration of objective response, and progression-free survival for patients with measurable disease according to recist pet response for patients with detectable fdg tumor uptake at baseline incidence of adverse events and laboratory abnormalities incidence of adverse events by nci ctcae v4.0 grade and associated dose of gdc-0349 incidence of grade 3 and 4 abnormalities in safety related laboratory parameters and associated dose of gdc-0349 time to progression effects of on htlv-1 dna after treatment as measured by proviral loads relation of nfÎºb gene expression profile on response effects of htlv-1 rna load after treatment as measured by hbz messenger rna effects of htlv-1 integrase gene sequence after treatment as measured by nucleotide divergence effects of htlv-1 integration sites after treatment number of subjects who develop anti-drug antibodies (ada) time to response duration of response progression free survival time to progression event free survival overall survival medi4736 maximum plasma concentration (cmax) tremelimumab maximum plasma concentration (cmax) azd9150 maximum plasma concentration (cmax) medi4736 minimum plasma concentration (cmin) tremelimumab minimum plasma concentration (cmin) azd9150 minimum plasma concentration (cmin) individual medi4736 concentrations individual tremelimumab concentrations individual azd9150 concentrations change from baseline of stat3 rna (signal transducer and activator of transcription) baseline pd-l1 protein expression within the tumor overall survival (os) progression free-survival (pfs) incidence and severity of adverse events as defined by the nci ctcae version 4.03 response rates (complete response, partial response, stable disease) best overall response, duration of objective response, and progression-free survival for patients with measurable disease long-term safety/tolerability of xl184 after oral administration for up to 1 year evaluate preliminary tumor response after repeated xl184 administration in mtd expanded cohort: progression-free survival and duration of response in subjects with advanced or recurrent medullary thyroid cancer best overall tumor response maximum concentration (cmax) of ridaforolimus area under the curve (auc[0 to infinity]) of ridaforolimus apparent terminal half-life (t1/2) of ridaforolimus clearance (cl) of ridaforolimus volume of distribution at steady state (vss) of ridaforolimus phosphorylated 4e binding protein 1 (phospho-4e-bp1) blood levels rate of remission rate of minimal residual disease (mrd) in bone marrow aspirate samples rate of mrd in bone marrow aspirate samples objective response rate (orr) duration of response for tazemetostat as a single agent or in combination with prednisolone (phase 2 only) progression free survival for tazemetostat as a single agent or in combination with prednisolone (phase 2 only) two-year overall survival for all cases. five year overall survival for all cases stage i - dose limiting toxicity incidence rate stage ii - 1 year progression free survival (pfs) stage ii - 2 year progression free survival (pfs) stage ii - 1 year overall survival (os) stage ii - 2 year overall survival (os) stage iii - progression free survival (pfs) rate post transplant stage iii - overall survival (os) erythrocyte 6mp cytosol metabolite levels myelotoxicity severe hepatotoxicity including sinusoidal obstruction syndrome overall response rate correlation of the biological activity of azacitidine as a demethylating agent with clinical endpoints and plasma pharmacokinetics biological activity of bortezomib as a potential demethylating agent correlation of intracellular concentration of azacitidine-triphosphate with global dna methylation and other biological endpoints as well as clinical response biologic role of micrornas in determining clinical response to the bortezomib plus azacitidine combination and achievement of the other pharmacodynamic endpoints positron emission tomography (pet) response for patients with detectable fdg tumor uptake at baseline best overall response, duration of objective response, and progression-free survival (pfs) for patients with measurable disease according to recist obtain preliminary evidence of anti-tumor activity of batracylin in patients with solid tumors or lymphoma. percentage of participants with cr at eoi, determined by the investigator on the basis of pet-ct scans percentage of participants with cr at eoi, determined by the irc on the basis of ct scans alone percentage of participants with cr at eoi, determined by investigator on the basis of ct scans alone percentage of participants with objective response (or) at eoi, determined by the irc on the basis of pet-ct scans percentage of participants with objective response at eoi, determined by investigator on the basis of pet-ct scans percentage of participants with objective response at eoi, determined by the irc on the basis of ct scans alone percentage of participants with objective response, determined by the investigator on the basis of ct scans alone percentage of participants with best response of cr or pr, determined by the investigator on the basis of ct scans alone observed serum obinutuzumab concentration observed serum rituximab concentration serum concentration of polatuzumab vedotin analyte: total antibody plasma concentration of polatuzumab vedotin analyte: antibody-conjugated mmae (acmmae) plasma concentration of polatuzumab vedotin analyte: unconjugated mmae observed plasma lenalidomide concentration number of participants with human anti-human antibodies (hahas) to obinutuzumab number of participants with human anti-chimeric antibodies (hacas) to rituximab number of participants with anti-therapeutic antibodies (atas) to polatuzumab vedotin tumor response measurement of pathway biomarkers in plasma change in cd8 cell counts (phase i) changes in absolute cd4 cell counts (phase i) changes in epstein-barr virus (ebv) viral load changes in human herpes virus (hhv)-8 viral load changes in human immunodeficiency virus (hiv) viral load event-free survival (efs) (phase ii) overall survival (os) (phase ii) change in plasma associated human immunodeficiency virus (hiv)-1 ribonucleic acid (rna) (phase i) pharmacokinetic clearance (phase i) tumor response (phase i) car19 t-cell engraftment b cell compartment cytokine profile clinical complete response eligibility to allogeneic transplantation maximum tolerated dose, assessed according to nci ctcae v4.0 response response duration time to progression survival the greatest number of cycles received in each treatment group the number of dose delays and reductions at the mtd the prevalence of anti-tumor activity pharmacodynamic markers of target effect in paired tissue biopsies overall survival time (phase ii) progression-free survival (phase ii) duration of response (phase ii) evaluation of wp1220 applied topically to index lesions via standard measurement scale at-101 level (bound and unbound) paclitaxel level (bound and unbound) pharmacokinetics of at-101 pharmacokinetics of paclitaxel plasma concentration over time number of participants with adverse events tumor response objective response rate to asp4132 duration of response to asp4132 disease control rate to asp4132 maximum concentration (cmax) of asp4132 time of the maximum concentration (tmax) of asp4132 area under the concentration-time curve from time of dosing to the last measurable concentration (auclast) of asp4132 auc from the time of dosing to 24 hours (auc24) of asp4132 auc from the time of dosing extrapolated to time infinity (aucinf) of asp4132 apparent terminal elimination half-life (t1/2) of asp4132 accumulation ratio of asp4132 apparent total systemic clearance after single or multiple extravascular dosing (cl/f) of asp4132 apparent volume of distribution during the terminal elimination phase after single or multiple extravascular dosing (vz/f) of asp4132 progression-free survival evaluate the safety and tolerability of cep-9722 in combination with gemcitabine and cisplatin cmax pharmacokinetics parameter auc pharmacokinetics parameter pharmacodynamics assessment efficacy - will be assessed by tumor response evaluation of each patient peak plasma concentration (cmax) the urine concentration of azd5153 and its co-former (if appropriate). the effect of azd 5153 on qtc interval. antitumor activity of azd5153 in patients by assessing the disease control rate (dcr). antitumor activity of azd5153 in patients by assessing progression free survival (pfs). antitumor activity of azd5153 in patients by assessing overall response rate (orr). antitumor activity of azd5153 in patients by assessing duration of response (dor). area under the plasma concentration versus time curve (auc). time to reach peak plasma concentration (tmax). elimination half-lfe (t1/2). volume of distribution (vd). clearance (cl). to measure changes in tumor definition with breathing synchronized pet compared to standard free breathing pet, and determine the fraction of patients whose radiation treatment plans would be modified based on this information. chronic gvhd response measured as change in physical exam and laboratory testing chronic gvhd response measured as change in daily corticosteroid requirement chronic gvhd response measured as frequency of treatment failure defined as discontinuation of study drug due to severe adverse effects or initiation of a new treatment for cgvhd chronic gvhd response measured as change in cgvhd symptom burden pharmacokinetic profile of pnt2258 percentage of participants experiencing acute gvhd percentage of participants experiencing chronic gvhd disease relapse non-relapse mortality use of immunosuppression survival chimerism engraftment adverse event,clinical laboratory tests,immunoglobulin,haha,objective response rate,duration of response,progression free survival,cd5,19,20,cd23 positive cells,complement (ch50),pk parameters, antitumor effect time to progression (ttp) duration of persistence of adoptively transferred cd19 chimeric antigen receptor (car)-t cells migration of adoptively transferred cd19 chimeric antigen receptor (car)-t cells document any preliminary efficacy information from the nk-92 cell infusion. assess any immune response directed against the infused nk-92 cells. determine kinetics of infused nk92 cells. to evaluate efficacy of gp2013 to evaluate the incidence of immunogenicity (ada formation) against gp2013 to evaluate peripheral cd19+ b-cell count duration of response (dor) efficacy: progression-free survival (pfs) car-t proliferation car-t proliferation cytokine release pharmacokinetics (pk) indicators: pharmacodynamic (pd) indicators: overall response rate disease control rate to assess the safety and tolerability of cn1 in patients with advanced solid tumor or b-cell lymphoma through physical exam to assess the safety and tolerability of cn1 in patients with advanced solid tumor or b-cell lymphoma through adverse events/serious adverse events to assess the pharmacokinetic (pk) profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through area under the plasma concentration-time curve to assess the pharmacokinetic (pk) profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through tmax to assess the pharmacokinetic (pk) profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through apparent volume of distribution at steady state to assess the pharmacokinetic (pk) profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through accumulation factor based on auc 0-Ï„ to assess the immunogenicity to cn1 in patients with advanced solid tumor or b-cell lymphoma through ada testing to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through orr analysis to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through dcr analysis. to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through dor analysis. hematological toxicity (i.e., number of courses of therapy associated with neutrophils < 0.5 x 10e9/l or platelets < 50 x 10e9/l as measured by routine blood counts) incidence of infection (i.e., number of days with fever â‰¥ 38 cÂ° measured by clinical examination and days of intravenous antibiotics taken from patients\\' medical records) number of inpatient days taken from patients\\' medical records disease response and remission rates measured by serial mri scanning (and eye examination and lumbar puncture if necessary) disease outcome, time to progression, and overall survival at 2 years from start of therapy measured by clinical examination and serial mri scanning relative dose intensity methotrexate levels post-glucarpidase (expressed as a clinically important reduction, which is defined as a methotrexate level of < 1 Î¼mol/l in all post-glucarpidase samples) incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy mean progression free survival (pfs) mean event-free survival (efs) mean overall survival (os) overall response in participants with greater than or equal to 50% programmed death-ligand 1 (pd-l1) expressing tumor cells number of participants with overall best response mean duration of response (dor) evaluation of response (e.g., cr, cr*) in patients with bone marrow involvement. overall response rate, defined as the sum of partial and complete responses as determined by revised international working group criteria for malignant lymphoma pk parameters of ibrutinib in the presence of r-ice as a measure of potential drug-drug interaction percentage of participants who experienced at least 1 treatment-emergent adverse event percentage of participants who experienced at least 1 serious adverse event percentage of participants with clinically significant laboratory values percentage of participants with clinically significant vital signs cmax: maximum observed plasma concentration for alisertib metabolites m1 and m2 tmax: time of first occurrence of cmax for alisertib metabolites m1 and m2 auclast: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib metabolites m1 and m2 dose-normalized trough concentration of alisertib on cycle 1 day 14 to determine the maximum tolerated dose (mtd) adverse events overall response rate (orr) in the cll, dlbcl, inhl, mcl, and ptld cohorts duration of response (dor), time to progression (ttp) and progression-free survival (pfs) in the cll, dlbcl, inhl, mcl, ptld cohorts overall survival (os) rate in the cll, dlbcl, inhl, mcl, ptld cohorts cmax: maximum observed plasma concentration for tak-659 tmax: time to reach the maximum plasma concentration (cmax) for tak-659 auc(0-24): area under the plasma concentration-time curve from time 0 to time 24 hour for tak-659 auclast: area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration for tak-659 t1/2: terminal disposition half-life overall response rate (orr) during durvalumab treatment overall response rate during the entire study time to first response kaplan-meier estimate of duration of response kaplan-meier estimate of progression-free survival (pfs) maximum observed plasma concentration (cmax) of durvalumab time to maximum plasma concentration (tmax) of durvalumab area under the plasma concentration-time curve from time zero to the last measurable concentration (auclast) of durvalumab area under the plasma concentration-time curve from time zero to infinity (aucinf) of durvalumab terminal elimination phase half-life (tÂ½) of durvalumab clearance (cl) of durvalumab volume of distribution (vz) of durvalumab maximum observed plasma concentration (cmax) of lenalidomide time to maximum observed plasma concentration (tmax) of lenalidomide area under the plasma concentration-time curve from time zero to the last measurable concentration (auclast) of lenalidomide maximum observed plasma concentration (cmax) of ibrutinib time to maximum observed plasma concentration (tmax) of ibrutinib area under the plasma concentration-time curve from time zero to the last measurable concentration (auclast) of ibrutinib change from baseline in soluble programmed cell death ligand-1 (spd-l1) concentration evaluate immunomodulatory activity. quantify antitumor effects cl/f: oral clearance of alisertib in presence and absence of itraconazole in part a tmax: time to reach maximum plasma concentration of alisertib in presence and absence of itraconazole in part a terminal phase elimination half-life of alisertib in presence and absence of itraconazole in part a cmax: maximum observed plasma concentration for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a tmax: time to reach the maximum plasma concentration (cmax) for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a number of participants with treatment emergent adverse events (teaes) and serious adverse events (saes) number of participants with abnormal laboratory values reported as aes number of participants with clinically significant change in weight reported as aes number of participants with clinically significant change in vital sign reported as aes progression-free survival (pfs) partial response (pr) rate number of participant who proceed to stem cell transplantation or chimeric antigen receptor t-cell (car-t) therapy overall survival (os) objective response rate (orr) complete response (cr) rate overall response rate (orr) number of patients with treatment-related adverse events (aes) and serious aes (saes) pharmacokinetic parameters best clinical response duration of response, progression-free survival blood concentrations of sgn-75 and metabolites incidence of antitherapeutic antibodies objective response rate progression-free survival (pfs) food effect - cmax preliminary efficacy assessment minimal residual disease collection (mrd) food effect - tmax food effect - auc toxicity profile progression-free survival overall response rate complete response rate immune response as measured by the frequency of activated t-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of b-cell depletion clinical anti-tumor response (complete response and partial response as per international workshop lymphoma response criteria [cheson 2007]) progression-free survival percentage of paticipants with anti therapeutic antibodies (atas) against polatuzumab vedotin progression free survival (pfs), as assessed by using modified response criteria for non-hodgkin lymphoma (nhl) or chronic lymphocytic leukemia (cll) percentage of participants with objective response [complete response (cr) or partial response (pr)], as assessed by using modified response criteria for nhl or cll duration of response, as assessed by using modified response criteria for nhl or cll percentage of participants with best overall response (bor), as assessed by using modified response criteria for nhl or cll area under the curve (auc) from time 0 to the last quantifiable time point (auclast)-polatuzumab vedotin monotherapy auc extrapolating to time of infinity (aucinf)-polatuzumab vedotin monotherapy percentage of aucinf (aucextrap)-polatuzumab vedotin monotherapy maximum plasma concentration (cmax)-polatuzumab vedotin monotherapy clearance-polatuzumab vedotin monotherapy volume of distribution at steady state-polatuzumab vedotin monotherapy auclast - polatuzumab vedotin combined with rituximab aucinf-polatuzumab vedotin combined with rituximab aucextrap-polatuzumab vedotin combined with rituximab cmax-polatuzumab vedotin combined with rituximab clearance-polatuzumab vedotin combined with rituximab volume of distribution at steady state-polatuzumab vedotin combined with rituximab auclast of rituximab when given in combination with polatuzumab vedotin aucinf of rituximab when given in combination with polatuzumab vedotin aucextrap of rituximab when given in combination with polatuzumab vedotin cmax of rituximab when given in combination with polatuzumab vedotin clearance of rituximab when given in combination with polatuzumab vedotin volume of distribution at steady state-of rituximab when given in combination with polatuzumab vedotin determination of peak concentration (cmax) of abt-199 and/or rituximab. assess the exploratory efficacy of the combination abt-199 and rituximab. determination of trough concentration (ctrough) of abt-199 and/or rituximab determination of area under the concentration versus time curve (auc) of abt-199 and/or rituximab assess the exploratory efficacy of the combination abt-199 and rituximab assess the exploratory efficacy of the combination abt-199 and rituximab assess the exploratory efficacy of the combination abt-199 and rituximab assess the exploratory efficacy of the combination abt-199 and rituximab number of participants with adverse events possibly related to study drugs graded 3, 4, and 5 orr (overall response rate) clinical benefit rate (cbr) progression free survival (pfs) overall survival (os) number of patients alive and progression free at 24 weeks objective response, defined as a partial response (pr) or complete response (cr) minimal effective dose of vorinostat in combination with decitabine by bone marrow and/or peripheral blood (for leukemia) pharmacokinetics of vorinostat in conjunction with decitabine antitumor activity methylation status of gene promoter regions and gene expression altered response of leukemic cells to ppar and rar ligands number of participants with positive anti-drug antibody (ada) and neutralizing antibody cd22 expression cells in peripheral blood by best response number of participants with potential biomarkers of predicting capillary leak syndrome (cls) percentage of participants with complete response (cr) duration of complete response percentage of participants with partial response (pr) percentage of participants with objective response (or) time to response (ttr) duration of objective response (dor) duration of stable disease (sd) maximum plasma concentration (cmax) of moxetumomab pasudotox area under concentration-time curve from dosing extrapolated to infinity (aucinf) of moxetumomab pasudotox clearance (cl) of moxetumomab pasudotox elimination half life (t1/2) of moxetumomab pasudotox number of participants with positive anti-drug antibody number of participants with cd22 expression levels number of capillary leak syndrome (cls) participants with weight changes, albumin, hypotension, edema, hypoxia, and pulmonary adverse events (aes) percentage of participants with stable disease (sd) metabolism biodistribution radiation dosimetry mk-8776 maximum plasma concentration (cmax) mk-8776 area under the curve of the plasma concentration versus time from time zero to the time of the last analytically quantifiable concentration (auc0-last) time of mk-8776 cmax (tmax) mk-8776 terminal phase half-life (t1/2) acetylation of histones in peripheral blood tumor response by ct scan every 12 weeks biomarker: incidence of cd70+ tumors in target population overall response rate (orr) progression-free survival (pfs) incidence of adverse events overall safety profile plasma pharmacokinetics preliminary antitumor activity the number of subjects with a successful product manufactured number of subjects with complete remission (cr). number of subjects with complete remission with incomplete blood count recovery (cri). determine and monitor clinical and biological responses in patients treated with intranodal injections of ad-isf35. determine pharmacodynamic (pd) parameters in patients treated with intranodal injections of isf35. level of fenretinide in normal peripheral blood mononuclear cells overall response summary to determine the safety of tpi 287 to determine the antitumor activity of tpi 287 to determine the pharmacokinetic profile of tpi 287 anti-tumor responses to tancart19/20 cell infusions phase 1: number of participants achieving overall response rate (partial response [pr] plus complete response [cr]) as assessed by the investigator phase 1: number of participants achieving clinical benefit phase 1 and phase 2: number of participants with an adverse event (ae) or a serious adverse event (sae) phase 1: area under the plasma concentration-time curve from 0 to 12 hours (auc0-12) of cerdulatinib phase 2a: median time to progression-free survival (pfs) phase 2a: number of participants achieving clinical benefit phase 2a: number of participants achieving dominant mass response (dmr) to determine the safety of tpi 287 to determine the antitumor activity of tpi 287 to determine the pharmacokinetic profile of tpi 287 to determine the pharmacodynamic profile of tpi 287 overall response rate the number of participants affected by a dose-limiting toxicity number of participants with potential drug-drug interactions between ibrutinib and vincristine overall response rate duration of response progression-free survival mean plasma concentrations of ibrutinib maximum observed plasma concentration of ibrutinib time to reach the maximum plasma concentration of ibrutinib area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of ibrutinib elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of vincristine partial area under the plasma concentration versus time curve of vincristine the number of participants with pharmacodynamic markers of ibrutinib in peripheral blood mononuclear cells the number of participants with biomarkers predictive of clinical response the number of participants affected by an adverse event overall response rate pharmacokinetic (pk) parameter: cmax of tirabrutinib pk parameter: auctau of tirabrutinib survival time progression free survival progression free survival overall survival efficacy of nk dli infusions overall survival (os) event free survival progression free survival response duration response rate at the end of maintenance treatment complete response rate after induction complete response rate after 3 cycles pharmacokinetic and correlative studies response rate according to the harmonization project (protocol 8.5.1) or recist criteria. grade iii-iv toxicity rate in participants receiving an extended dosage regimen according to the nci common toxicity criteria (ctcae) version 2.0 and the method of przepiorka et. al. (protocol appendix i). evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated immunological response incidence of serious adverse events phase ii : duration of response disease-free survival overall survival time to relapse/progression phase ii: pre-irradiation chemotherapy tumor response rate (including phase i patients at same dose) phase ii: progression-free survival (including phase i patients at same dose) preliminary antitumor activity of treatment in patients with measurable disease overall response (complete and partial response) rate response duration (median and range) concentration-time curve of b001 pd results of b001 immunogenicity of b001 orr of b001 pharmacokinetics (part ii) progression symptomatic deterioration determine maximum tolerated dose (mtd) evaluate the immunogenicity and safety of repeated infusions of 90y-hll2 in nhl patients. determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in nhl patients. number of participants with a clinical response progression free survival (pfs) percentages of circulating lymphocytes (t and nk cells) and the t-cell subsets plasma levels of pro-inflammatory cytokines number of adverse events possibly caused by Î±-tea blood serum levels of Î±-tea tumor load overall response rate number of participants with treatment emergent adverse events (teaes) and serious adverse events (saes) cmax: maximum plasma concentration of tazemetostat and its metabolite er-897387 tmax: time to reach maximum plasma concentration (cmax) of tazemetostat and its metabolite er-897387 auc(0-12 hours): area under the plasma concentration-time curve from time zero to 12 hours post-dose of tazemetostat and its metabolite er-897387 auc(0-t hours): area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of tazemetostat and its metabolite er-897387 auc(0-infinity): area under the plasma concentration-time curve from time 0 to infinity of tazemetostat and its metabolite er-897387 lambda z: terminal phase elimination rate constant of tazemetostat and its metabolite er-897387 t1/2: terminal half-life of tazemetostat and its metabolite er-897387 cl/f: apparent total body clearance of tazemetostat vz/f: apparent volume of distribution at terminal phase of tazemetostat mrt: mean residence time of tazemetostat and its metabolite er-897387 auc(0-tau): area under the plasma concentration-time curve over the dosing interval of tazemetostat and its metabolite er-897387 css,av: average steady state plasma concentration of tazemetostat and its metabolite er-897387 css,max: maximum steady state plasma concentration of tazemetostat and its metabolite er-897387 css,min: minimum steady state plasma concentration of tazemetostat and its metabolite er-897387 ptf: peak-trough fluctuation ratio of tazemetostat and its metabolite er-897387 tss,max: time to reach the maximum plasma concentration (cmax) at steady state of tazemetostat and its metabolite er-897387 clss/f: apparent total body clearance of tazemetostat at steady state rac (cmax): accumulation ratio of cmax for tazemetostat and its metabolite er-897387 rac (auc): accumulation ratio of auc for tazemetostat and its metabolite er-897387 rss: steady state accumulation ratio of tazemetostat and its metabolite er-897387 ae: amount of unchanged drug tazemetostat excreted in urine fe: fraction of tazemetostat dose excreted in urine clr: renal clearance of tazemetostat percentage of participants with objective response tumor response to treatment dosimetry model incidence of serious adverse events overall survival time to progression pharmacokinetics (pk): minimum concentration (cmin) of ramucirumab, merestinib and abemaciclib proportion of participants who exhibit complete response (cr) or partial response (pr) [overall response rate (orr)] progression free survival (pfs) area under the plasma concentration vs. time curve (auc) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously peak plasma concentration (cmax) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously trough plasma concentration (ctrough) of cobomarsen following each 4-week cycle of dosing skin disease severity (index lesions) - mf only skin disease severity (whole body) - mf only overall response rate in the skin - mf overall response rate - cll minimal residual disease (mrd) - cll only overall response rate - dlbcl overall response rate - atll duration of response time to progression progression free survival (pfs) overall survival (os) safety and response to a repeated dosage regimen analysis of immune function of ctls number of patients with an ebv and/or disease response to the ctls to evaluate the peripheral blood cd34+ count after second mobilization. to evaluate cd34+ cells/kg from apheresis after second mobilization. to evaluate the percent of patients for whom adequate numbers of cd34+ cells are obtained. to evaluate transfusion support. to evaluate the days to neutrophil engraftment (anc >500) post autologous transplant. to evaluate the days to platelet engraftment (platelet count > 20,000 unsupported). to evaluate the 6 month transplant related (non-relapse) mortality. to evaluate the days to neutrophil engraftment (anc > 500). to evaluate the days of platelet engraftment (platelet count > 20k unsupported). to evaluate the risk of acute and chronic graft versus host disease. to evaluate percent donor chimerism - contribution of each cord unit. to evaluate relapse rate. to evaluate overall survival. to evaluate transfusion support needed to cord blood transplant recipients. overall response rate (orr) defined according to standard criteria for the relevant malignancy [phase1b] duration of response (dor) progression-free survival (pfs) overall survival (os) disease response as assessed by complete remission, partial remission, stable disease, and progressive disease from radiographic and cellular or tissue samples incidence of donor-specific chimerism assessed by str analysis safety: incidence of adverse events pharmacokinetics: area under the concentration-time curve (auc) of gdc-0853 pharmacokinetics: maximum concentration (cmax) of gdc-0853 objective response to gdc-0853 progression-free survival the principal toxicities and dose limiting toxicities of plerixafor when combined with rituximab time to maximal plasma concentration (tmax) when plerixafor is combined with rituximab area under the concentration-time curve from time zero to the last observed concentration (auc 0-last) when plerixafor is combined with rituximab area under the concentration-time curve over the dosing interval (Ï„) (auc 0-Ï„) when plerixafor is combined with rituximab area under the concentration-time curve from time zero to infinity (auc 0-âˆž ) when plerixafor is combined with rituximab half-life (tÂ½) when plerixafor is combined with rituximab volume of distribution (vz/f for subcutaneous (sc) administration; vz for intravenous (iv) administration); preliminary indication of response as defined by nci 1996 criteria in part 3, area under the plasma concentration versus time curve and maximum concentration of sch 727965 administered as a 2 hour intravenous infusion with or without aprepitant in participants with advanced malignancies. measurement of pk parameter maximum observed serum concentration (cmax) for bi-1206 measurement of pk parameter area under the serum concentration-time curve from time 0 to the last time point (auclast) for bi-1206 measurement of pk parameter half-life (t1/2) for bi-1206 measurement of pk parameter total body clearance (cl) for bi-1206 measurement of pk parameter volume of distribution (vss) for bi-1206 measurement of anti-drug antibody (ada) response to bi-1206 during the bi-1206 treatment period using elisa measurement of peripheral blood b-lymphocyte depletion during the bi-1206 treatment period using flow cytometry. assessment of best disease response according to criteria for malignant lymphoma (cheson, 2014) waldenstrÃ¶m macroglobulinaemia assessment criteria (owen 2013, kimby 2006) or nci chronic lymphocytic leukaemia (cll) criteria (hallek, 2008). measure progression free survival at 1 year after the first bi-1206 administration on the study for all patients measure overall survival at 1 year after the first bi-1206 administration on the study for all patients overall survival (os) adverse event profile conversion of partial response/stable disease post-asct to complete response. evaluate immune response event-free survival (efs) progression-free survival (pfs) skin clinical response duration of response relapse free and progression free survival number of participants (relapsed or refractory solid tumors or anaplastic large cell lymphoma (alcl))with response to crizotinib number of participants (relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (alcl)) with response to crizotinib number of participants with minimum residual disease (mrd) pharmacokinetics antitumor effectiveness association of the histone deacetylase (hdac)-inhibiting activity with the dose administered, toxicity, and treatment response safety duration of response in responding patients number of participants with clinical responses number of participants with best overall response number of participants with treatment-emergent adverse events (aes) and serious adverse events (saes) in portion a number of participants with treatment-emergent aes by maximum national cancer institute common terminology criteria for adverse event (nci ctcae) grade in portion a number of participants with hematology laboratory abnormalities by maximum nci ctcae grade in portion a number of participants with chemistries laboratory abnormalities by maximum nci ctcae grade in portion a number of participants with clinically significant vital sign abnormalities in portion a pf-05082566 maximum observed serum concentration (cmax) in portion a pf-05082566 pre-dose trough concentration during multiple dosing (ctrough) in portion a pf-05082566 time for maximum observed serum concentration (tmax) in portion a pf-05082566 area under the serum concentration-time profile (auc) from time 0 to the time of the last measurable concentration (auclast) in portion a pf-05082566 auc from time 0 to infinity (aucinf) in portion a pf-05082566 auc from time 0 to time of dosing interval (auctau) in portion a pf-05082566 clearance (cl) in portion a pf-05082566 volume of distribution at steady state (vss) in portion a number of participants with positive anti-drug antibody (ada) for pf-05082566 in portion a number of participants with qtc interval meeting categorical summarization criteria in portion a percentage of participants achieving objective response per response evaluation criteria in solid tumor (recist) version 1.1 in portion a duration of response in portion a time to response in portion a progression-free survival in portion a overall survival in portion a number of participants with treatment-emergent aes and saes in portion b number of participants with treatment-emergent aes by maximum nci ctcae grade in portion b number of participants with hematology laboratory abnormalities by maximum nci ctcae grade in portion b number of participants with chemistries laboratory abnormalities by maximum nci ctcae grade in portion b number of participants with clinically significant vital sign abnormalities in portion b pf-05082566 cmax in portion b pf-05082566 ctrough in portion b pf-05082566 tmax in portion b pf-05082566 auclast in portion b pf-05082566 aucinf in portion b pf-05082566 auctau in portion b pf-05082566 cl in portion b pf-05082566 vss in portion b rituximab cmax and ctrough in portion b number of participants with positive ada for pf-05082566 and rituximab in portion b number of participants with qtc interval meeting categorical summarization criteria in portion b percentage of participants achieving objective response per cheson 2007 criteria in portion b duration of response in portion b time to response in portion b progression-free survival in portion b overall survival in portion b safety and tolerability heart rhythm ventricular rate pr-interval (synonymous: pq interval) qrs complex qt interval qtcf interval vital signs (body temperature) vital signs (blood pressure) physical examination metabolic profiles of resminostat identification and quantification of resminostat metabolites clinical success or failure need for additional antimicrobials mortality (in-house) time to defervescence hospital length of stay successful treatment of baseline infection duration of response (dor) complete response rate (crr) duration of complete response progression free survival (pfs) overall survival (os) phase i : number of participants with treatment-related adverse events as assessed by ctcae v4.03 phase i = preliminary overall response rate (orr) phase ii = orr phase ii : number of participants with treatment-related adverse events as assessed by ctcae v4.03 phase ii = number of patients with hematological recovery after each cycle phase ii = feasibility of autologous stem cell transplant (asct) after bv-ice = fraction of patients for whom harvest is possible phase ii = fraction of patients eligible for asct phase ii = number of patients positron emission tomography (pet) 4- after pet 2+ phase ii = progression free survival (pfs) phase ii = overall survival (os) determine the jx-594 pharmacokinetics and pharmacodynamics over time following it injection in this patient population determine the immune response to jx-594 following it injection in this patient population overall response in patients treated with lenalidomide according to the international working group (iwg) criteria 1. to examine the biological effects of chilob 7/4 treatment 2. to examine the pharmacokinetics of chilob 7/4 treatment: (measurement of serum chi lob 7/4) 3. to examine the possible anti-tumour activity of chi lob 7/4 (recist 1.0 criteria) incidence of adverse events requiring dose delay or discontinuation of ibrutinib overall incidence of grade â‰¥3 adverse events (aes) per nci ctcae v4.0 overall incidence of serious adverse events (saes) overall response rate (complete response [cr] + complete response with incomplete marrow recovery [cri] + nodular partial response [npr] + partial response [pr]) sustained hematologic improvement in subjects with neutropenia, anemia, or thrombocytopenia at baseline progression free survival rate at 12 months to determine the safety of navitoclax when administered alone and in combination with rifampin in these patients. hematopoietic cell recovery and engraftment rates infection rates and complications overall survival (os) event-free survival safety of administering 1 dose of abt-888 changes in par levels in peripheral blood mononuclear cells from baseline to after abt-888 administration pharmacokinetic assessment through analysis of blood and urine samples objective response rate (orr) pharmacokinetics pharmacodynamics response evaluation criteria in solid tumors (recist) overall survival absence of detection of vector-derived replication competent lentivirus (rcl) frequency and severity of clinical adverse events absence of tropism shift from r5 to dual/mixed or x4 at any point after day 0 quantify gene transfer efficiency and expression time to restart antiretroviral therapy response rate of natural killer (nk) cells with lenalidomide and lymphodepleting chemotherapy determined by bone marrow biopsy/aspiration pharmacodynamics of cnto 328 plasma antibodies to cnto 328 number of participants with castleman\\'s disease who achieved tumor response number of participants with multiple myeloma who achieved disease response number of participants with b-cell non-hodgkin\\'s lymphoma and multiple myeloma who achieved clinical benefit (cb) number of participants with castleman\\'s disease who achieved clinical benefit number of participants with b-cell non-hodgkin\\'s lymphoma who achieved disease response time to neutrophil engraftment time to platelets engraftment number of transplant-related mortality (trm) number of disease free survivals number of overall survivals number of participants at risk of gvhd number of infectious complications time to myeloid engraftment time to lymphoid engraftment change in t cell count evaluate imaging time window with â¸â¹zr-df-iab22m2c evaluate protein dose for imaging with â¸â¹zr-df-iab22m2c evaluate the radioactive pharmacokinetics of â¸â¹zr-df-iab22m2c by determining the time-activity curves for serum (% injected dose/liter), auc, clearance, volume of distribution, tmax and cmax. evaluate the dosimetry of a single dose of â¸â¹zr-df-iab22m2c number of subjects surviving post-transplant. number of participants who experienced chronic extensive gvhd occurrence of adverse events (aes), serious adverse events (saes) assessments of clinical laboratory values and vital sign measurements. best overall response (bor) duration of response (dor) progression free survival (pfs) overall survival (os) concentration-time profiles of pharmacokinetics (pk) parameters - phase ib maximum plasma concentration (cmax) time to reach plasma cmax (tmax) area under the plasma concentration-time curve (auc) terminal elimination half-life (tÂ½) recommended study phase ii dose (rp2d) disease control rate objective response rate maximum observed serum concentrations (cmax) of urelumab (bms-663513) minimum observed serum concentrations (cmin) of urelumab (bms-663513) time of maximum observed serum concentration (tmax) of urelumab (bms-663513) area under the concentration-time curve in 1 dosing interval [auc(tau)] of urelumab (bms-663513) plasma half-life (t-half) of urelumab (bms-663513) total body clearance (clt) of urelumab (bms-663513) volume of distribution at steady-state (vss) of urelumab (bms-663513) human anti-human antibodies tumor response and progression as determined by proportion of patients with best overall response (bor), progression-free survival (pfs), objective response rate (orr), time to response, and duration of response efficacy of at9283 to evaluate the pharmacokinetics of ct-322 in these patients; to assess whether antibodies to this drug develop in these patients; and to make a preliminary assessment of the biological activity of ct-322 to alter tumor growth. incidence of dose-limiting toxicities overall best response rate duration of response progression-free survival number of participants who had at least one treatment-emergent adverse event (teae) maximum tolerated dose (mtd) assessed in dose escalation phase of the study number of participants with dose limiting toxicities (dlts) assessed in dose escalation phase of the study cmax: maximum observed plasma concentration for brigatinib at cycle 1 day 1 cmax: maximum observed plasma concentration for brigatinib at cycle 2 day 1 tmax: time to reach the maximum observed plasma concentration (cmax) for brigatinib at cycle 1 day 1 tmax: time to reach the maximum observed plasma concentration (cmax) for brigatinib at cycle 2 day 1 auc(0-24): area under the plasma concentration-time curve from time 0 to 24 hours post-dose for brigatinib at cycle 1 day 1 auc(0-24): area under the plasma concentration-time curve from time 0 to 24 hours post-dose for brigatinib at cycle 2 day 1 t1/2: terminal phase elimination half-life for brigatinib at cycle 2 day 1 best overall response duration of response progression free survival (pfs) overall survival (os) intracranial objective response rate duration of intracranial response intracranial progression free survival (pfs) level of insulin-like growth factor receptor-1 (igf-1r) on peripheral blood cells tumor response measured by modified recist tumor glucose metabolism as measured by fludeoxyglucose f 18-pet/ct scan anti-amg-479 antibody formation the incidence of dose-limiting toxicities and the severity of adverse events levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase (may also include tartrate-resistant acid phosphatase 5b) in blood circulating levels of igf-1r and igf-bp3 the safety and tolerability of ldk378, including both acute and chronic toxicities plasma concentration of ldk378 preliminary anti-tumor activity of ldk378 pk parameter: auclast pk parameter: auctau pk parameter: cmax pk parameter: tmax pk parameter: the apparent elimination half-life (t1/2) pk parameter: accumulation ratio (racc) maximum observed plasma concentration (cmax) after a single dose of enasidenib on day -3 time of maximum plasma concentration (tmax) of enasidenib after a single dose on day -3 area under the plasma concentration time curve from time zero to 10 hours postdose (auc0-10) of enasidenib after a single oral dose on day -3 area under the plasma concentration time curve from time zero to 72 hours postdose (auc0-72) of enasidenib after a single dose on day -3 maximum observed plasma concentration (cmax) of metabolite agi-16903 after a single dose of enasidenib on day -3 time of maximum plasma concentration (tmax) of metabolite agi-16903 after a single dose of enasidenib on day -3 area under the plasma concentration-time curve from time 0 to 10 hours postdose (auc0-10) for metabolite agi-16903 after a single dose of enasidenib on day -3 area under the plasma concentration-time curve from time 0 to 72 hours postdose (auc0-72) for agi-16903 after a single dose of enasidenib on day -3 area under the plasma concentration-time curve from time 0 to 10 hours postdose (auc0-10) for enasidenib after multiple doses maximum observed plasma concentration (cmax) of enasidenib after multiple doses time of maximum plasma concentration (tmax) of enasidenib after multiple doses area under the plasma concentration-time curve from time 0 to 10 hours postdose (auc0-10) for metabolite agi-16903 after multiple doses of enasidenib maximum observed plasma concentration (cmax) of metabolite agi-16903 after multiple doses of enasidenib time of maximum plasma concentration (tmax) of metabolite agi-16903 after multiple doses of enasidenib percentage of participants with solid tumors (excluding glioma) who achieved an objective response percentage of participants with glioma who achieved an objective response percentage of participants with aitl who achieved an objective response tumor burden according to response evaluation criteria in solid tumors (recist)/revised response criteria malignant lymphoma translational biomarkers and pharmacokinetics food effect cohort assessments progression free survival rate at 24 months percentage of participants achieving response to evaluate the pharmacokinetics and pharmacodynamics of npi-0052 and vorinostat to evaluate the safety and toxicity profile of the combination of npi-0052 and vorinostat to evaluate the anti-tumor activity of npi-0052 and vorinostat median time to progression following i-131 tositumomab therapy. frequency of visualization of hodgkin\\'s lymphoma with i-131 tositumomab imaging and tumor radiation absorbed dose event free survival progression-free survival number of participants overall response pharmacokinetic parameters of gdc-0917 (including total exposure, maximum and minimum serum concentration, time to maximum observed plasma concentration, elimination of half-life, accumulation at steady-state) progression free survival complete response rate evaluate the plasma pharmacokinetics of marqibo in children with cancer. drug safety pharmacokinetics measuring of pk parameter values for di-b4 including auc, cmax, tmax, and half life t1/2. to evaluate the effect of di-b4 on the depletion of peripheral blood and bone marrow b-cells. to look for signs of anti-tumour activity of di-b4 in patients with relapsed or refractory indolent b-cell malignancies. to assess immunogenicity of di-b4 in patients with relapsed or refractory indolent b-cell malignancies to measure the time to disease progression and eighteen month survival pharmacokinetics (pk): maximum concentration (cmax) of ly2875358, erlotinib and gefitinib pharmacokinetics (pk): area under the concentration time curve (auc) of ly2875358, erlotinib and gefitinib number of participants with a tumor response maximum plasma concentration (cmax) time to cmax (tmax) area under the curve (auc) plasma half life (t1/2) volume of distribution (v/f) plasma clearance (cl/f) exploratory surrogate biomarker preliminary tumor response establish recommended phase 2 dose, after completing dose escalation in part 1 and evaluating accumulated safety,pk,and pd data from the dose escalation phase (part1) evaluate the pharmacokinetic parameters of avl-292 evaluate the pharmacodynamics of avl-292 by measurement of free btk characterize preliminary anti-tumor efficacy of avl-292 in relapsed and/or refractory b-nhl, cll and wm objective response rate (phase 1) minimal residual disease (mrd) duration of response time to disease progression complete response or remission (cr) rate partial response or remission (pr) rate progression free survival (pfs) to eliminate residual disease (documented by flow cytometry and/or polymerase chain reaction [pcr]) in patients who have achieved complete response (cr) after fludarabine, cyclophosphamide, and rituximab (fcr) plus vorinostat to estimate the rate of conversion of partial response (pr) to complete response (cr) after fludarabine, cyclophosphamide and rituximab (fcr) plus vorinostat main efficacy for ctcl main efficacy for cgvhd immunogencity measures: antigen-specific antibodies and cellular immune response auc(0-tlast) tmax tlast t1/2 urine [ae,ur(0-24)] number of participants with adverse events as a measure of safety and tolerability pr intervals qrs intervals ecg waveform morphology left ventricular ejection fraction (lvef) qtcb changes in vital signs and the number adverse events measure the extent of the disease by ct scan or flow cytometry analysis response rate alk status and response to crizotinib mrd status and response to crizotinib alk expression for crizotinib acceptability of crizotinib capsule formulation palatability acceptability of crizotinib microsphere formulation palatability pharmacokinetics and pharmacodynamics overall response rate (cr + pr) of flavopiridol in patients evaluated utilizing the revised national cancer institute-sponsored working group guidelines number of patients with detectable treg cells number of patients with grade ii-iv and grade iii-iv acute graft versus host disease (gvhd) number of patients with sustained donor engraftment number of patients with double chimerism incidence of neutrophil recovery after umbilical cord blood (ucb) transplantation number of patients with chronic graft versus host disease (gvhd) number of patients with disease-free survival number of patients with fungal and viral infections incidence of platelet recovery after umbilical cord blood (ucb) number of patients with disease relapse percent of patients with immune cell recovery incidence of grade 3 or higher treatment-related toxicity median progression free survival (pfs) disease assessments in bone marrow & by computed tomography (ct)/ magnetic resonance imaging (mri) pharmacokinetics of bms-906024 and its metabolite bms-911557: maximum observed concentration (cmax) pharmacokinetics of bms-906024 and its metabolite bms-911557: minimum observed concentration (cmin) pharmacokinetics of bms-906024 and its metabolite bms-911557: area under the concentration-time curve (auc) pharmacokinetics of bms-906024 and its metabolite bms-911557: time to reach maximum observed concentration (tmax) pharmacokinetics of bms-906024 and its metabolite bms-911557: terminal phase elimination half-life (t-half) pharmacokinetics of bms-906024 and its metabolite bms-911557: accumulation index (ratio of auc at steady state to auc after first dose) pharmacodynamics (percent change from baseline in mrna expression of notch pathway-related genes in blood cells) best clinical response to treatment duration of response time to progression progression-free survival to evaluate the efficacy of carfilzomib therapy in relapsed or refractory chromic lymphocytic leukemia (cll)/small lymphocytic leukemia (sll)/prolymphocytic leukemia (pll) neutrophil and platelet recovery persistence of clt-008 derived cells graft-versus-host disease (gvhd) non-relapse mortality infections incidence of hyperacute gvhd incidence of grade d acute gvhd incidence of adverse events pharmacokinetics (pk): area under the concentration-time curve (auc[0-âˆž]) of ly3039478 in combination with dexamethasone in day 1 pharmacokinetics (pk): area under the concentration-time curve (auc[0- 48]) of ly3039478 in combination with dexamethasone in day 8 number of participants with cr or cri and notch-1 or fbxw7 mutations phase 2: number of participants who achieve cr, cri or partial remission (pr): overall remission rate (orr) plus pr phase 2: number of participants who achieve pr phase 2: duration of remission (dor) phase 2:relapse free survival (rfs) phase 2: event free survival (efs) phase 2: overall survival (os) phase 2: change from baseline in the functional assessment of cancer therapy-leukemia-general (fact-leu-g) score percentage of participants with an overall response throughout the study duration of response progression-free survival time to progression maximum observed plasma concentration of carfilzomib time to maximum observed plasma concentration (tmax) of carfilzomib area under the plasma concentration-time curve from time zero to the last concentration measured (auc0-last) for carfilzomib area under the plasma concentration-time curve from time zero to infinity (auc0-inf) for carfilzomib elimination half-life (tÂ½) of carfilzomib clearance (cl) of carfilzomib volume of distribution at steady state (vss) of carfilzomib mean residence time (mrt) extrapolated to infinity for carfilzomib medi7247 maximum observed concentration for pk medi7247 area under the concentration-time curve for pk medi7247 clearance for pk medi7247 terminal half-life for pk number of subjects who develop anti-drug antibodies (adas) best overall response (bor) objective response rate (orr) time to response (ttr) duration of response (dor) progression-free survival (pfs) overall survival (os) response rates remission/response duration toxicity and safety, with particular reference to glucose and lipid deregulation antitumor activity, including tumor response rate and time to progression objective response survival frequency and severity of adverse events number of patients with adverse events changes in laboratory values assessments of electrocardiograms assessments of dose interruptions, reductions, and dose intensity plasma pk parameter of ldk378 and auy922: tmax overall response rate (orr) duration of response (dor) time to response (ttr) progression free survival (pfs) number of patients with serious adverse events plasma pk parameter of ldk378 and auy922: cmax plasma pk parameter of ldk378 and auy922: auclast plasma pk parameter of ldk378 and auy922: auctau plasma pk parameter of ldk378 and auy922: cmin plasma pk parameter of ldk378 and auy922: racc levels of anti-cd27 antibodies in circulating blood. levels of cdx-1127 in circulating blood. activity evaluations immune system effects (eg: lymphoid cell populations and serum cytokine levels) the secondary objective will be to estimate the proportion of patients developing acute and chronic graft-versus-host disease, 100 day treatment-related mortality, and to measure disease-free survival. the tertiary objective will be to measure the time to immunologic reconstitution as defined by normal numbers of t and b cells, normal t-cell proliferative responses, normal natural killer (nk) cell function, and normal immunoglobulin synthesis. the proportion of patients who demonstrate each polymorphism adverse events progression-free survival (pfs) overall survival (os) brentuximab vedotin concentration in blood antitherapeutic antibodies in blood best clinical response define dose limiting toxicities of bendamustine, rituximab and lenalidomide in cll clinical efficacy pk-cmax pk-tmax pk-Î»z pk-t1/2 pk-auc (0-t) pk-auc0-âˆž efficacy to determine if the patient develops any evidence of anti-leukemic effect from the administration of cd34-tk75 transduced donor lymphocytes to determine if gcv administration to patients who develop gvhd results in clinical improvement after infusions of cd34-tk75 transduced lymphocytes. toxicity as assessed by number of participants experiencing adverse events grade 3 or higher as defined by ctcae v2.0 pharmacokinetics of azacitidine combined with phenylbutyrate as measured by maximal plasma concentration (cmax) gene-re-expression of epigenetic modulation in peripheral blood mononuclear cells (pbmc) as measured by change in epstein-barr virus (ebv) viral load (number of copies per 1 million cells) after treatment with azacitidine incidence of chronic gvhd overall survival (os) progression free survival (pfs) to evaluate pharmacokinetics, toxicity profile, biological activity, and anti-tumor activity of cpi-613 given twice weekly for three consecutive weeks in cancer patients â€¢ to explore the clinical efficacy of gsk2141795 in subjects with solid tumor malignancies or lymphomas to characterize the metabolite profile of oral gsk2141795 after repeat dose administration in subjects with solid tumor malignancies or lymphoma biomarker analysis (igvh gene mutation) biomarker analysis (cd38, cd49d, and zap-70) fluorescent in situ hybridization (fish) biomarker analysis duration of response minimal-residual disease overall response rate treatment-free survival summary of best overall response by overall response rate (orr) per investigator assessment duration of response (dor) per investigator assessment progression free survival (pfs) based on investigator assessment plasma concentration time profiles by treatment group in escalation phase plasma concentration time profiles by treatment group in expansion phase pharmacokinetics (pk) parameters: auc0 - 24h & auclast in cycle 1 day 1 - dose escalation phase (single dose) pharmacokinetics (pk) parameters: auc0 - 24h & auclast in cycle 2 day 1 - dose escalation phase (single dose) pharmacokinetics (pk) parameters: auc0 - 24h & auclast in cycle 2 day 1 - dose expansion phase (multiple dose) pk parameter: cmax in cycle 1 day 1 - dose escalation phase (single dose) pk parameter: cmax in cycle 2 day 1 - dose escalation phase (single dose) pk parameter: cmax in cycle 2 day 1 - dose expansion phase (multiple dose) pk parameter: tmax in cycle 1 day 1 - dose escalation phase (single dose) pk parameter: tmax in cycle 2 day 1 - dose escalation phase (single dose) pk parameter: tmax in cycle 2 day 1 - dose expansion phase (multiple dose) pk parameter: racc in dose escalation phase cycle 2 day 1 to determine the oral bioavailability of up to 6 different oral formulations in comparison to the subcutaneous formulation to assess the safety and tolerability of subcutaneous and oral formulations of azacitidine to assess response rates to assess rbc transfusion independence to investigate the pharmacokinetics of oral azacitidine to assess the pharmacodynamic effects of oral azacitidine safety pharmacokinetics biological effects changes in agt (o6-alkylguanine dna alkyltransferase) activity changes in agt (o6-alkylguanine dna alkyltransferase) activity changes in agt (o6-alkylguanine dna alkyltransferase) activity changes in agt (o6-alkylguanine dna alkyltransferase) activity changes in the apoptosis changes in the apoptosis changes in the cell cycle/proliferation changes in the cell cycle/proliferation changes in dna damage- cytotoxicity changes in dna damage- cytotoxicity changes in agt inactivation in non-responding patients changes in agt inactivation in non-responding patients objective response rate clinical benefit rate duration of response progression-free survival overall survival immunogenicity evaluation pharmacokinetic evaluation duration of complete skin response (cohorts a and b) tumor response in lymph nodes (cohort b) tumor response in blood (cohort b) overall toxicity (cohorts a and b) skin-related quality of life (qol) (cohorts a and b) patient-reported chemotherapy-induced peripheral neuropathy (cipn) (cohort a) duration of clinical benefit (docb) secondary outcome is to quantitatively determine the relationship between tumor [18f]iso-1 uptake and ki-67, s-phase, mitotic index and sigma-2 receptors content of the tumor. cumulative incidence of grade ii-iv acute graft-versus-host disease (gvhd) incidence of chronic graft-versus-host disease (gvhd) relapse of disease survival survival number of participants who experienced acute gvhd grades ii-iv number of participant who experienced chronic graft versus host disease number of participants that experienced graft failure overall response number of participants who experienced transplant related mortality number of participants overall survival number of participants that remained disease-free number of participants that experienced engraftment number of participants that experienced platelet recovery number of participants that experienced red blood cell recovery median time in months to achieve full myeloid and full donor t-cell chimerism change in gut microbiome (optional) to describe the adverse event profile and tolerability of prt1419 to describe the pharmacokinetic profile of prt1419 to describe any anti-tumor activity of prt1419 percentage of participants with grade iii-iv acute graft versus host disease (gvhd) toxicities days to engraftment of neutrophils days to engraftment of platelets days to engraftment of lymphocytes overall survival early treatment related mortality percentage of participants with late treatment related mortality decline in homeostatic cytokine interleukin 7 (il-7) post-transplant immune reconstitution of normal killer (nk) cells immune reconstitution of cluster of differentiation 4 (cd4) t cell populations immune reconstitution of cluster of differentiation 8 (cd8) t cell populations area under the plasma concentration versus time curve (auc) peak plasma concentration (cmax) time of peak plasma concentration (tmax) time for half of the drug to be absent in blood stream following dose (t 1/2) rate at which drug is removed from blood stream (cl/f) rate of drug distribution within the blood stream (vd/f) observe patients for any evidence of anti-leukemic or anti-myelodysplastic activity of ft-1101 maximum plasma concentration calculated with blood samples time to reach maximum concentration calculated with blood samples objective response rate adverse events evaluated by nci ctcae v4.03 survival time progression-free survival duration of response time to subsequent therapy antitumor activity of gdc-0425 in combination with gemcitabine: determination of tumor response using recist v1.1 for patients with measurable disease percentage of participants who have received some form of response pk-cmax pk-tmax pk-Î»z pk-t1/2 pk-auc (0-t) pk-auc0-âˆž pharmacokinetics: auc pharmacokinetics: cmax immunogenicity: percentage of ada positive patients preliminary anti-tumor activity of ibi188 (objective response rate) to characterize the pharmacokinetic profile of sns-032 identify a recommended phase 2 dose and schedule of administration percentage of subjects who develop acute graft-versus-host disease. assess the maximum overall grades 0- iv of acute gvhd and maximum severity (0-4) by involved organ system in patients who develop acute graft-versus-host disease. percentage of subjects who develop chronic graft-versus-host disease. assess the maximum grade: limited versus extensive; maximum severity: mild, moderate or severe) of chronic gvhd in patients who develop chronic graft-versus- disease-free survival time to relapsed disease immune reconstitution area under the concentration-time curve from time zero extrapolated to infinite time (auc[0-infinity]) of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1 auc[0-infinity] of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg area under the concentration-time curve over the dosing interval (auc[0-tau]) of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1 auc[0-tau] of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg area under the concentration-time curve from zero to time of last quantifiable concentration (auc[0-tlast]) of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1 auc[0-tlast]) of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg clearance (cl) of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1 cl of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg maximum observed concentration (cmax) of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1 cmax of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg trough plasma concentration (ctrough) of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1 ctrough of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg terminal half-life (t1/2) of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1 t1/2 of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg volume of distribution at steady state (vss) of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1 vss of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg time to reach maximum observed concentration (tmax) of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1 tmax of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg ctrough of gsk2857916 following iv dose in participants with relapsed/refractory mm-part 2 ctrough of gsk2857916 following iv dose in participants with nhl-part 2 auc(0-tlast) of cys monomethyl auristatin f (cys-mcmmaf) following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1 auc(0-tlast) of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg cmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1 cmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg ctrough of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1 ctrough of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg tmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1 tmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm-part 1: gsk2857916 2.50 mg/kg number of participants with at least one confirmed positive post-baseline anti-drug antibody result- part 1 number of participants with at least one confirmed positive post-baseline anti-drug antibody result- part 2 (mm) number of participants with at least one confirmed positive post-baseline anti-drug antibody result- part 2 (nhl) number of participants with antibodies to gsk2857916 in serum over time- part 1 number of participants with antibodies to gsk2857916 in serum over time- part 2 (mm) number of participants with antibodies to gsk2857916 in serum over time - part 2 (nhl) overall response rate (orr)- part 1 orr-part 2 (mm) orr-part 2 (nhl) clinical benefit rate (cbr)- part 1 cbr- part 2 efficacy-antitumor activity of urelumab in combination with rituximab as measured by best overall response, progression-free survival, time to response, and duration of response maximum observed serum concentration (cmax) of urelumab and rituximab time of maximum observed serum concentration (tmax) of urelumab area under the serum concentration-time curve from time zero to time of last quantifiable concentration (auc(0-t)) of urelumab trough observed serum concentration (cmin) of urelumab and rituximab area under the concentration-time curve (auc) in one dosing interval (auc(tau)) of urelumab immunogenicity of urelumab in combination with rituximab as determined by blood sample measurements of anti-drug antibodies (ada) maximum plasma concentration of iacs-010759 [cmax] overall response rate duration of response number of participants with adverse events determine the pharmacokinetic (pk) profile of bmn 673 determine the recommended phase 2 dose (rp2d) of oral daily bmn 673 assess preliminary efficacy of bmn 673 by evaluating per response publications measurement of ebv-genome levels in plasma number of participants who experienced dose-limiting toxicities (dlt) objective response rate assessed according to response evaluation criteria in solid tumors version 1.1 overall survival time to next therapy or death freedom from new metastases landmark survival rates at 1 year landmark survival rate at 2 years duration of response for responding patients progression free survival time to treatment failure calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body plasma concentration of s 55746 the pharmacokinetic (pk) profile of s 55746: area under the curve [auc] the pk profile of s 55746: maximal concentration [cmax] apoptotic activity from blood samples objective response rate (orr) clinical benefit rate (cbr) duration of response progression free survival (pfs) primary and secondary graft failure acute and chronic gvhd overall survival (os) and disease-free survival tcr alfa beta cells number of patients with treatment-emergent adverse events maximum sar245408 plasma concentration area under the sar245408 plasma concentration versus time curve number of patients with treatment-emergent adverse events maximum sar245409 plasma concentration area under the sar245409 plasma concentration versus time curve ratio of maximum sar245409 plasma concentration between fed and fasted dosing ratio of area under the sar245409 plasma concentration versus time curve between fed and fasted dosing area under the plasma concentration-time curve (auc) over the dosing interval overall response rate (complete response [cr] and partial response [pr]) time to response maximum observed plasma concentration of azd4573 area under the concentration-time curve for plasma concentrations of azd4573 volume of distribution (vd). clearance (cl). antitumor activity of azd4573 in patients by assessing overall response rate (orr). duration of response (dor) antitumor activity of azd4573 in patients by assessing overall survival (os). minimal residual disease (mrd) progression free survival (pfs) number of patients with treatment emergent events assessment of pk parameters for sar260301 and vemurafenib, including tmax, cmax, auc, rac (day 28/day1), half-life, cl, ctrough assessment of pk parameters for sar260301 including tmax, cmax, auc fasting and fed (food effect)(only part a) assessment of urine excretion of sar2690301 (part a) assessment of potential for cyp induction (4beta-hydroxycholesterol)(part a) assessment of pk parameter rac (day 28/day 1) on auc and cmax assessment of pd parameter serine/threonine protein kinase akt (akt) phosphorylation in blood platelets assessment of pd parameter akt phosphorylation in tumor (expansion phase only) assessment of preliminary antitumor activity as documented by tumor response (defined by recist1.1 criteria for solid tumors, international working group (iwg) and revised response for lymphomas, and tumor markers when relevant) number of participants with treatment emergent adverse events (aes) progression free survival (pfs) at 12 months pharmacodynamic biomarkers p4ebp1 and pakt tolerability - full physical exam fasting serum glucose and triglycerides evaluate non-dose limiting toxicity pk anti-tumor effects pk and pd parameters area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (auclast) area under the plasma concentration-time curve from time 0 to infinity time (aucâˆž) maximum plasma concentration (cmax) time to reach maximum plasma concentration (tmax) terminal elimination half-life (t1/2) pharmacodynamic evaluations tumor response anti-tumor efficacy and duration of persistence, migration, and function of adoptively transferred bi-specific effector cells extent, degree, and duration of donor chimerism complete response rate part a: percent change from baseline in levels of phosphorylated ribosomal protein s6 (ps6rp) in stimulated b cells part a: percent change from baseline in levels of phosphorylated elongation i initiation binding protein (p4e-bp1) in stimulated t cells part a: percent change from baseline in levels of phosphorylated protein kinase b (pakt) in stimulated monocytes part b: percent change from baseline in p4e-bp1 in monocytes by tumor cohort part b: percent change from baseline in p4e-bp1 in monocytes in the hcc and net cohorts by dose part b: percent change from baseline in levels of pakt in monocytes by tumor cohort part b: percent change from baseline in levels of pakt in monocytes in the hcc and net cohorts by dose part b: percent change from baseline in ps6rp levels in tumor tissue by tumor type part a: overall response rate part b: overall response rate maximum observed concentration (cmax) of metabolite m1 time to maximum concentration (tmax) of metabolite m1 area under the plasma concentration-time curve from time 0 to the last measurable concentration (auct) for metabolite m1 area under the concentration time-curve from 0-24 hours after a dose (auc0-24) for metabolite m1 pharmacodynamics single-dose and steady-state cmax single-dose and steady-state auc steady-state elimination half-life (t1/2) metabolic profile in plasma at the maximum tolerated dose number of participants who experienced at least one adverse event (ae) number of participants who discontinued study therapy due to aes number of participants whose best response was partial response (pr) or complete response (cr) maximum concentration (cmax) of mk-8628/otx015 time to maximum concentration (tmax) of mk-8628/otx015 apparent terminal half-life (t1/2) of mk-8628/otx015 area under the concentration time curve of mk-8628/otx015 from time 0 to infinity (auc 0-inf) apparent total body clearance (cl/f) of mk-8628/otx015 volume of distribution at steady state (vz/f) of mk-8628/otx015 pharmacokinetic parameters of alvocidib and lenalidomide alone and in combination in plasma samples plasma il-6 and selected cytokine levels b-cell activation as assessed by surface antigen (cd40, cd80, cd86, hla-dr, and cd95) expression intracellular pharmacodynamic targets including stat3, mcl-1, and nuclear factor kappa-light-chain-enhancer of activated b cells (nf-kb) response assessed by national cancer institute-sponsored working group guidelines progression-free survival (pfs) toxicity graded according to nci ctcae version 4.0 presence of minimal residual disease number of participants with treatment-emergent adverse events (teaes) (all causality) number of participants with teaes (treatment-related) number of participants with treatment-emergent adverse events (teaes) (all causality) by severity (by maximum common terminology criteria for adverse events [ctcae] grade) number of participants with teaes (treatment-related) by severity (by maximum ctcae grade) number of participants with potentially clinical significant categorical changes from baseline in electrocardiogram (ecg) findings in qtc interval number of participants with laboratory tests abnormalities meeting the criteria of potential clinical concern (hematology and chemistries, all cycles) maximum observed serum concentration (cmax) after a single dose on cycle 1 day 1 dose-normalized cmax [cmax (dn)] after a single dose on cycle 1 day 1 area under the time-concentration curve from time 0 to the dosing interval (auctau) after a single dose on cycle 1 day 1 dose-normalized auctau [auctau (dn) ] after a single dose on cycle 1 day 1 time to reach cmax (tmax) after a single dose on cycle 1 day 1 cmax after multiple dose on cycle 1 day 21 time to reach cmax (tmax) after multiple dose on cycle 1 day 21 auctau after multiple dose on cycle 1 day 21 apparent volume of distribution (vz/f) on cycle 1 day 21 serum decay half-life (t1/2) after multiple dose on cycle 1 day 21 apparent oral clearance (cl/f) on cycle 1 day 21 minimum observed serum concentration (cmin) after multiple dose on cycle 1 day 21 average serum concentration (cavg) at steady state on cycle 1 day 21 accumulation ratio (rac) on cycle 1 day 21 dose-normalized auctau [auctau (dn)] after multiple dose on cycle 1 day 21 dose-normalized cmax [cmax (dn)] after multiple dose on cycle 1 day 21 auctau in the fasted state for solid tumor participants auctau in the fed state for solid tumor participants cmax in the fasted state for solid tumor participants cmax in the fed state for solid tumor participants dose-normalized auctau [auctau(dn)] in the fasted state for solid tumor participants dose-normalized auctau [auctau(dn)] in the fed state for solid tumor participants dose-normalized cmax [cmax(dn)] in the fasted state for solid tumor participants dose-normalized cmax [cmax(dn)] in the fed state for solid tumor participants auctau on cycle 2 day 1 dose-normalized auctau [auctau (dn)] on cycle 2 day 1 cmax on cycle 2 day 1 dose-normalized cmax [cmax (dn)] on cycle 2 day 1 tmax on cycle 2 day 1 percentage of solid tumor participants with objective response (or) time to tumor progression (ttp) for solid tumor participants duration of response (dr) for solid tumor participants progression-free survival (pfs) for solid tumor participants percentage of t-all/lbl participants with or relapse free survival (rfs) for t-all/lbl participants peripheral blast count reduction (pbr) for t-all/lbl participants changes in expression levels of notch 1 target genes in tumor biopsies for solid tumor participants: hairy and enhancer of split-4 (hes4) gene expression levels on cycle 1 day 21 relative to that at baseline changes from baseline in expression levels of notch 1 target genes in peripheral blood for t-all/lbl participants: hes4 gene expression levels on cycle 1 day 8, cycle 1 day 15, cycle 1 day 21 relative to that at baseline changes in expression levels of notch 1 target genes in peripheral blood for solid tumor participants: hes4 gene expression level on cycle 1 day 8 and cycle 1 day 21 relative to that at baseline changes from baseline in notch intracellular domain (nicd) levels in peripheral blood for t-all/lbl participants changes from baseline in notch intracellular domain (nicd) levels in bone marrow for t-all/lbl participants objective response rate (orr) disease control rate (dcr) maximum observed concentration (cmax) of ak117 as monotherapy or in combination with ak104 and minimum observed concentration (cmin) of ak117 at steady stateconcentration (cmin) of ak117 at steady state number of subjects who develop detectable anti-drug antibodies (adas) of ak117 as monotherapy or in combination with ak104 area under the curve (auc) of ak117 as monotherapy or in combination with ak104 for assessment of pharmacokinetics receptor occupancy (ro) of ak117 as monotherapy or in combination with ak104 to evaluate target engagement antitumor activity of entinostat change in histone h3 acetylation of entinostat change in histone h4 acetylation of entinostat complete response rate overall survival progression free survival time to treatment failure the reduction in lymph nodes, quantification of circulating lymphoma cells, assessment of extranodal disease sites, and/or measurement of the malignant monoclonal proteins in the serum or urine after 4 cycles of therapy (day 56). overall response rate (orr) based on investigator assessment overall response rate based on blinded independent review committee (birc) assessment duration of response (dor) based on investigator assessment duration of response (dor) based on birc progression-free survival based on investigator assessment progression-free survival based on birc assessment primary pharmacokinetics (pk) parameter: auc0-last primary pharmacokinetics (pk) parameter: auc0-24h primary pharmacokinetics (pk) parameter: tmax primary pharmacokinetics (pk) parameter: cmax secondary pharmacokinetics (pk) parameter: t1/2 secondary pharmacokinetics (pk) parameter: cl/f secondary pharmacokinetics (pk) parameter: vz/f secondary pharmacokinetics (pk) parameter: clss/f secondary pharmacokinetics (pk) parameter: racc incidence of toxicities assessed using nci ctcae version 4.0 patient mortality organ avoidance target coverage planning time treatment delivery time disease response status, assessed by standard criteria for the presence of relapse rates of acute gvhd, graded and staged according to the blood and marrow transplant clinical trials network manual of operations - to characterize the pk of gsk1120212 after single and repeat-dose administration - to evaluate the pharmacodynamic response in tumors after treatment with gsk1120212 - to explore relationships between gsk1120212 pk, mapk signalling inhibition and clinical endpoints - to explore the clinical tumor response after treatment with gsk1120212 - to determine the association of clinical and pk endpoints with genetic and protein profiles from tumor tissue measure: adverse event assessed through 30 days after last dose of study drug measure: tumor response measure: pharmacokinetic/pharmacodynamic assessments capacity of test dosing of busulfan that would result in the desired area under the curve concentration exposure of patients receiving a full-dose busulfan regimen incidence of graft vs host disease in patients between one month and two years post transplant incidence of dna chimerism in patients between one month post transplant overall survival time to marrow engraftment assessing all subjects\\' response to treatment at 100 days post-transplant assessing all subjects\\' response to treatment at 1 year post-transplant assessing all subjects\\' survival at 1 year post-transplant assessing the mortality rate of patients in the first 100 days post-transplant assessing the number of treatment-related adverse events collecting the incidents of gvhd experienced by patients post-transplant assessing the donor-chimerism at 30, 60 and 90 days post-transplant adverse events (aes) treatment response rate of clinical response in study participants receiving protocol therapy pharmacodynamics (pd): expression levels of endoplasmic reticulum (er) stress response and unfolded protein response (upr) in primary all cells to pevonedistat therapy pharmacokinetics (pk): maximum (peak) plasma concentration (cmax) of pevonedistat pharmacokinetics (pk): single-dose time to reach maximum (peak) concentration (tmax) of pevonedistat pharmacokinetics (pk): area under the curve (auc) of plasma concentration of pevonedistat pharmacokinetics (pk): terminal disposition phase half-life (t1/2) of plasma concentration of pevonedistat response rate (cr+cri) among expansion cohort frequency and severity of toxicities anti tumour activity in injected tumour complete response (ircr) and partial response (irpr) overall response rate (or) disease control rate (cr + pr + sd) progression free survival (pfs) percentage of participants with objective response according to recist v1.1 by investigator: phase i duration of response (dor) according to recist v1.1 by investigator: phase i percentage of participants with objective response according to recist v1.1 by investigator: phase ii percentage of participants with disease control according to recist v1.1 by investigator: phase ii percentage of participants with disease progression according to recist v1.1 by irc or death : phase ii progression-free survival (pfs) according to recist v1.1 by irc: phase ii percentage of participants with disease progression according to recist v1.1 by investigator or death : phase ii pfs according to recist v1.1 by investigator: phase ii percentage of participants who died due to any cause: phase ii overall survival (os) time: phase ii dor according to recist v1.1 by irc: phase ii dor according to recist v1.1 by investigator: phase ii percentage of participants with central nervous system objective response (cor) according to recist v1.1 by irc: phase ii percentage of participants with cor according to response assessment in neuro-oncology (rano) criteria by irc: phase ii cns duration of response (cdor) according to recist v1.1 by irc: phase ii cdor according to rano criteria by irc: phase ii percentage of participants with cns progression according to recist v1.1 by irc: phase ii percentage of participants with cns progression according to rano criteria by irc: phase ii maximum observed plasma concentration (cmax) after single dose of alectinib: phase i cmax after multiple dose of alectinib: phase i area under the plasma concentration (auc) versus time curve extrapolated to infinity (aucinf) after single dose of alectinib: phase i auc from time zero to last measurable concentration (auclast) after multiple dose of alectinib: phase i ctrough after multiple dose of alectinib: phase ii change from baseline in european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq-c30): phase ii change from baseline in eortc quality of life questionnaire lung cancer 13 (eortc qlq-lc13): phase ii safety, as measured by vital signs, clinical laboratory tests,ecog performance status, physical exams, 12 lead ecgs incidence and severity of adverse events efficacy- including best overall response (bor) derived from changes in tumor burden and metabolic response based on fdg-pet (for dlbcl) immunogenicity measurement for human anti human antibodies (haha) -characterizing the immunogenicity of bms-936564 maximum observed serum concentration (cmax) of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time trough observed serum concentration (cmin) of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time time of maximum observed concentration (tmax) of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time area under the concentration-time curve from time zero extrapolated to infinite time [auc(inf)] of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time area under the concentration-time curve from time zero to the time of the last quantifiable concentration [auc(0-t)] of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time area under the concentration-time curve in one dosing interval [auc(tau)] of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time half life (t-half) of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time total body clearance(clt) of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time volume of distribution at steady-state (vss) of bms-936564 (mdx-1338) will be derived from serum concentration versus actual time biomarker- characterizing the pharmacodynamic (pd) profiles of bms-936564 (mdx-1338). the main pd biomarkers are cell trafficking exploratory biomarkers- are detection of apoptosis, cytokine analyses, cxcr4 expression, zap-70 and cd38 expression hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion pharmacokinetic profiles of parent drug and metabolite number of patients with adverse events as a measure of tolerability detection of tumor regression using world health organization (who) response criteria systemic immune response analysis of adverse events incidence of graft rejection incidence of relapse/progression incidence of grade ii-iv gvhd in patients undergoing dli following a non-myeloablative transplant incidence of infections in patients undergoing dli following a non-myeloablative transplant overall survival progression-free survival will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and apbsct. objective response adverse events according to nci ctcae v.4.0 cc-122 plasma concentrations when administered alone or in combination with ibrutinib or obinutuzumab ibrutinib plasma concentrations when administered in combination with cc-122 best overall response (bor) minimal residual disease response rate duration of response progression free survival (pfs) cmax when administered alone or in combination with ibrutinib tmax of cc-122 when administered alone or in combination with ibrutinib auc of cc-122 when administered alone or in combination with ibrutinib tumor response measured by x-rays or scans to study the persistence, phenotype and function of donor natural killer (nk) cells after infusion in research participants with chemotherapy refractory hematologic malignancies. to explore the efficacy of nk cell infusion in research participants with chemotherapy refractory hematologic malignancies to evaluate the pharmacokinetic parameters, pharmacodynamic effects and clinical response rate following cal-101 treatment in patients with hematologic malignancies. to describe the adverse event profile and tolerability of prt543 to determine the maximum observed plasma concentration (cmax) of prt543 to determine the time to reach maximum observed plasma concentration (tmax) of prt543 the recist criteria will be used for patients with all leukemias and myelodysplastic syndromes. patients with lymphoma or myeloma will be assessed by the international workshop to standardize response criteria for non-hodgkin\\'s lymphomas. ebmt, ibmtr and abmtr criteria for definition of response, relapse and progression in patients with multiple myeloma . proportion of patients who developed acute gvhd grade ii-iv and iii-iv non-relapse mortality pharmacokinetics confirmed complete or partial response percentage of patients with 6-month progression-free survival assessment of potential anticancer activity of 4sc-202 histone deacetylase (hadac) inhibition in peripheral mononuclear cells histone acetylation in peripheral mononuclear cells gene expression analysis in peripheral blood cytokine and mirna levels in plasma percentage of participants achieving objective response (cr or pr) as assessed by irc in chemotherapy-naive participants percentage of participants achieving objective response (cr or pr) as assessed by investigator in re population percentage of participants achieving objective response (cr or pr) as assessed by investigator in chemotherapy-pretreated participants percentage of participants achieving objective response (cr or pr) as assessed by investigator in chemotherapy-naive participants duration of response (dor) as assessed by irc in re population percentage of participants with pd as assessed by irc according to recist v1.1 or death from any cause in safety population progression free survival (pfs) as assessed by irc in safety population percentage of participants who died of any cause overall survival (os) percentage of participants achieving cr, pr or stable disease (sd) according to recist v1.1 in re population percentage of participants achieving central nervous system (cns) objective response as assessed by irc according to recist v1.1 percentage of participants achieving cns objective response as assessed by irc according to radiology assessment in neuro-oncology (rano) criteria cns duration of response (cdor) as assessed by irc according to recist v1.1 cdor as assessed by irc according to rano criteria percentage of participants with cns progression as assessed by irc according to recist v 1.1 maximum observed plasma concentration (cmax) of alectinib time to cmax (tmax) of alectinib time to last measurable plasma concentration (tlast) of alectinib area under the plasma concentration-time curve from time 0 to 10 hours post-dose (auc[0-10]) of alectinib area under the plasma concentration-time curve from time 0 to tlast (auc[0-last]) of alectinib cmax of alectinib metabolite tmax of alectinib metabolite tlast of alectinib metabolite auc(0-10) of alectinib metabolite auc(0-last) of alectinib metabolite metabolite to parent ratio based on auc(0-10) metabolite to parent ratio based on auc(0-last) trough plasma concentration (ctrough) of alectinib ctrough of alectinib metabolite peak to trough ratio of alectinib accumulation ratio of alectinib accumulation ratio of alectinib metabolite umbilical cord blood donor engraftment by chimerism and complete blood count (cbc) disease free survival at 2 years disease progression incidence of acute gvhd incidence of chronic gvhd median time to anc>500/mm3 median time to platelets>20k/mm3 severity of acute gvhd severity of acute gvhd severity of acute gvhd severity of acute gvhd severity of chronic gvhd severity of chronic gvhd antitumor activity biologic efects of drug combination antiangiogenic properties of drug combination percentage of patient with complete remission (cr) rate at the end of induction therapy percentage of participants with disease free survival rate of overall survival (os) complete remission rate rate of toxicity bms-986016 maximum observed serum concentration (cmax) bms-986016 time of maximum observed serum concentration (tmax) bms-986016 area under the concentration-time curve in one dosing interval (auc(tau)) bms-986016 concentration at the end of a dosing interval (ctau) bms-986016 effective elimination half-life that explains the degree of auc accumulation observed (t 1/2eff auc) bms-986016 total body clearance (cl/t) bms-986016 cmax accumulation index (ai_cmax) bms-986016 accumulation index (ai_auc) bms-986016 ctau accumulation index (ai_ctau) bms-986016 average concentration over a dosing interval ([auc(tau)/tau] (css,avg) bms-986016 trough observed serum concentration (ctrough) number of participants with anti-bms-986016 antibodies (ada) number of participants with anti-nivolumab antibodies (ada) pharmacokinetics (pk): maximum concentration (cmax) of merestinib and its metabolites pk: area under the concentration time curve (auc) of merestinib and its metabolites objective response rate (orr): percentage of participants with a complete or partial response disease control rate (dcr): percentage of participants with a best overall response of complete response, partial response, and stable disease progression-free survival (pfs) duration of response (dor) overall survival (os) pharmacokinetics: maximum concentration (cmax) pharmacokinetics: time of maximal concentration number of participants with tumor response potential of ly3023414 to inhibit cyp3a4-mediated metabolism pharmacokinetics: area under the curve (auc) of cb-839 concentration in blood pharmacodynamics: % inhibition of glutaminase in blood clinical activity: change in tumor size from baseline safety immune reconstitution donor search percentage of recently born leukemia cells mobilized into the blood by pci-32765 treatment evaluation of safety and tolerability of ro5045337 evaluation of pharmacodynamics and biomarkers overall survival progression-free survival relapse mortality acute graft-versus-host disease (agvhd) outcome chronic graft-versus-host disease (cgvhd) outcome the proportion of patients for which a t cell product could not be prepared proportion of patients experiencing response (complete response and partial response) phase 1, part 2: orr per recist v1.1 and for participants with advanced or metastatic scchn and advanced or metastatic nsclc phase 1, part 1: orr per recist v1.1 for participants with solid tumors; per cheson criteria for participants with b-cell nhl; and per rano and mrano criteria for participants with gbm phase 1, part 2: duration of response (dor) for participants with advanced or metastatic scchn and advanced or metastatic nsclc phase 1, part 2: pfs for participants with advanced or metastatic scchn and advanced or metastatic nsclc phase 2: duration of response phase 2: duration of disease control, defined as cr, pr, and stable disease (sd) phase 2: safety and tolerability measured by the number of adverse events (aes), serious adverse events (saes), and fatal treatment emergent aes efficacy in terms of disease response as compared to previous treatment modality ie unmanipulated dli time to immune response wilm\\'s tumor 1 (wt1) enzyme-linked immunospot (elispot) wilm\\'s tumor (wt1) delayed-type hypersensitivity (dth) keyhole limpet hemocyanin (klh) delayed-type hypersensitivity (dth) number of participants with progressive disease pharmacokinetics (pk) parameters of auc (0-inf) calculated by plasma concentration of vinorelbine[ pharmacokinetics (pk) parameters of auc (0-inf) calculated by plasma concentration of majormetabolite, 4-o-deacetylvinorelbine pharmacokinetics (pk) parameters of auc(0 - last) calculated by plasma concentration ofvinorelbine pharmacokinetics (pk) parameters of auc(0 - last) calculated by plasma concentration of majormetabolite, 4-o-deacetylvinorelbine pharmacokinetics (pk) parameters of cmax calculated by plasma concentration of vinorelbine pharmacokinetics (pk) parameters of tmax calculated by plasma concentration of vinorelbine pharmacokinetics (pk) parameters of tmax calculated by plasma concentration of major metabolite,4-o-deacetylvinorelbine pharmacokinetics (pk) parameters of t1/2 calculated by plasma concentration of vinorelbine pharmacokinetics (pk) parameters of t1/2 calculated by plasma concentration of 4-o-deacetylvinorelbine pharmacokinetics (pk) parameters of mrt(0-inf) calculated by plasma concentration of vinorelbine pharmacokinetics (pk) parameters of mrt(0-inf) calculated by plasma concentration of 4-o-deacetylvinorelbine dose exposure relationship in patients with advanced malignancies treated with single and multipledoses of lipovnb number of participants with treatment-related adverse events as assessed by ctcae v4.03 incidence of treatment-emergent adverse events lipovnb antitumor activity assessed by response rate lipovnb antitumor activity assessed by duration of response progression free survival (pfs) of patients with advanced malignancies treated with lipovnb partial area under the plasma concentration-time curve between 2 defined timepoints (auc [t1 and t2]) of voriconazole number of participants with adverse events (aes) and serious adverse events (saes) asparaginase activity in serum pharmacokinetics: blood/urine concentrations pharmacodynamics: blood leukemia cells/mic-1 protein level/cd33+cd34 markers clinical response: clinical/hematologic malignancy assessments uric acid levels number of participant with adverse events (ae) graft-versus-host and host-versus-graft immune responses pharmacokinetics anti-imc-3g3 antibody assessment antitumor activity of imc-3g3 as monotherapy pharmacodynamics proportion of recipients who experience chronic gvhd (recipient only) proportion of recipients who experience mortality before day 100 after transplant (recipient only) quality of life during stem cell mobilization (recipients only) proportion of donors who experience infusional toxicity (donor only) to determine the pharmacokinetics of iv amd3100 (iv donor arm only) as measured by cmax to determine the pharmacokinetics of iv amd3100 (iv donor arm only) as measured by mean auc from time 0 to infinity number of participants with treatment-related adverse events and/or toxicity as assessed by ctcae 4.03. maximum plasma concentration [cmax] area under the curve [auc] number of participants with excessive toxicity number of participants with incidence of acute graft versus host disease number of participants with incidence of chronic graft versus host disease to determine the pharmacokinetic (pk) profile of cxd101 following single and multiple dosing to enable a preliminary assessment of the anti-tumour activity of cxd101 to evaluate the tissue expression of the biomarker hr23b to assess the pharmacodynamic effect of cxd101 determine the pharmacokinetic (pk) and pharmacodynamic (pd) profile of epz-5676 evaluate early evidence of anti-tumor activity to evaluate the pharmacokinetics activity of npi-0052 to evaluate the safety and tolerability of npi-0052 to evaluate the pharmacodynamics of npi-0052 metabolite profiling 1-year survival transplant-related mortality incidence of chronic graft-versus-host disease safety and tolerability as measured by ctcae v3.0 correlate the expression of apoptosis specific genes clinical efficacy of donor nk cell infusion, in terms of tumor response, response duration, and survival clinical response progression-free survival (pfs) overall survival (os) overall safety pharmacokinetic parameters of gs-9820 as measured by cmax, tmax, ctrough, and auc pharmacodynamics to measure changes in the phosphatidylinositol 3-kinase (p13k) delta pathway activation and changes in plasma concentration of disease-associated chemokines and cytokines tumor control patient well-being assessed using changes in baseline in hrql (health related quality of life questionnaire) domain and symptom scores based on the functional assessment of cancer therapy: lymphoma (fact-lym) drug exposure incidence of reversing impending graft rejection (less than 40% donor cluster of differentiation [cd]3+ t cell chimerism) overall survival progression-free survival immune response to determine the pharmacokinetic and pharmacodynamic properties of ridaforolimus in pediatric patients with recurrent/refractory solid tumors, including tumors of the central nervous system. screening at day 1-18, cycle 2 day 1, cycle 2 day 15. to evaluate the safety and efficacy data of ridaforolimus when administered at the mtd or recommended phase ii dose and schedule in an expanded cohort of patients when administered daily x 5 every 14 days to assess pharmacogenomic parameters from archival tumor specimens that may correlate with response to ridaforolimus. maximum observed plasma concentration (cmax) of selinexor time to maximum observed concentration (tmax) of selinexor average concentration from time 0 to 24 hours (cavg0-24h) of selinexor area under the concentration-time curve from time 0 to t (auc0-t) of selinexor area under the concentration-time curve from time 0 extrapolated to infinity (auc0-inf) of selinexor apparent volume of distribution uncorrected for fraction absorbed (vd/f) of selinexor apparent total body clearance, uncorrected for fraction absorbed (cl/f) of selinexor terminal half-life (tÂ½) of selinexor number of participants with overall response of selinexor duration of response progression-free survival duration of at least stable disease overall survival duration of overall response (dor) objective response rate (orr) progression free survival (pfs) pharmacokinetics of asp3026 by assessment of area under the curve over the time (auc) and maximum concentration (cmax) in plasma and urine objective response rate (orr) survival rates median progression-free survival (pfs) by immune-related response evaluation criteria in solid tumors (irrecist) as estimated using the kaplan-meier method overall disease control rate as measured by immune-related response evaluation criteria in solid tumors (irrecist) number of subjects with best overall tumor response by response evaluation criteria in solid tumors (recist 1.1) median pfs by response evaluation criteria in solid tumors (recist 1.1) as estimated using the kaplan-meier method overall disease control rate as measured by response evaluation criteria in solid tumors (recist 1.1) median overall survival (os) as estimated using the kaplan-meier method the overall response rate (orr) concentration of anti-drug antibody (ada) the changes of cytokines objective response rate after pcar-19b infusion [effectiveness] aucs of pcar-19b cells [cell dynamics] cmax of pcar-19b cells [cell dynamics] tmax of pcar-19b cells [cell dynamics] pharmacodynamics of pcar-19b cells[cell dynamics] immunogenicity of pcar-19b cells overall remission rate (orr), which includes complete remission (cr) and complete remission with incomplete blood count recovery (cri) overall remission rate (orr) overall remission rate (orr) with minimal residual disease (mrd) negative bone marrow overall remission rate (orr) with minimal residual disease (mrd) negative bone marrow overall remission rate (orr) overall remission rate (orr) with minimal residual disease (mrd) negative bone marrow duration of remission (dor) relapse-free survival (rfs) overall survival (os) clinically relevant responses to therapy determined by bone marrow biopsy feasibility of generating auto3: number of patients\\' cells successfully manufactured as a proportion of the number of patients undergoing leukapheresis event-free survival (efs) by morphological analysis number of patients with cd19- and/or cd22-negative relapse relapse-free survival (rfs) by morphological analysis overall survival (os) expansion of auto3 following adoptive transfer persistence of auto3 following adoptive transfer duration of b cell aplasia echocardiography functional mobility functional mobility strength flexibility level of physical activity disease-free survival (dfs) number of adverse event of cd19 car t cells treatment grade of adverse event of cd19 car t cells treatment duration of in vivo survival of cd19 car t cells. molecular remission rate incidence and severity of adverse events as a measure of safety and tolerability objective remission rate duration of remission time to remission progression free survival (pfs) overall survival (os) phase 1b adults: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment phase 1b pediatric: percentage of participants with m1 remission within 2 cycles of treatment phase 1b and phase 2: duration of response phase 1b and phase 2: relapse-free survival phase 1b and phase 2: overall survival phase 2: best overall response within 2 cycles of treatment phase 2: percentage of participants who received an allogeneic hematopoietic stem cell transplant (hsct) during blinatumomab induced remission phase 2: 100-day mortality after allogeneic hsct phase 1b and phase 2: number of participants with teaes phase 1b and phase 2: serum blinatumomab concentration at steady state phase 1b and phase 2: systemic clearance of blinatumomab phase 1b and phase 2: terminal half-life of blinatumomab phase 1b and phase 2: volume of distribution of blinatumomab phase 1b and phase 2: number of participants who developed anti-blinatumomab antibodies phase 1b and phase 2: interleukin-2 concentration phase 1b and phase 2: interleukin-6 concentration phase 1b and phase 2: interleukin-10 concentration phase 1b and phase 2: tumor necrosis factor-alpha (tnfÎ±) concentration phase 1b and phase 2: interferon gamma (ifn-Î³) concentration expansion cohort adult: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment expansion cohort pediatric: percentage of participants with m1 remission within 2 cycles of treatment complete and partial resolution of graft-vs-host disease (gvhd) cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute gvhd clinical activity impact on biologic markers determinants of response number of participants with adverse events steady state concentration of blinatumomab time to hematological relapse (duration of response) overall survival relapse-free survival percentage of participants who received an allogeneic hematopoietic stem cell transplant during blinatumomab induced remission number of participants who developed anti-blinatumomab antibodies serum cytokine peak levels the number of participants with complete remission the number of participants with biological response to treatment the number of participants with adverse events as a measure of safety and feasibility immunogenicity: number of participants with a post-titer greater than or equal to a fourfold titer rise immunogenicity:number of participants with a pre-titer â‰¥1:40 immunogenicity: number of participants with a post-titer â‰¥1:40 immunogenicity: the geometric mean titers pre-vaccine in study participants immunogenicity: geometric mean titers post-vaccine in study participants to determine the rate of morphologic complete remission (cr) to determine the rates of cytogenetic complete remission (crc) morphologic complete remission with incomplete count recovery (cri), overall response rate (cr+ cri), partial remission (pr), stable disease and hematologic improvement. to determine the time to response, remission duration, progression-free survival, event-free survival and overall survival of patients treated with carfilzomib. to determine the safety and tolerability of carfilzomib by evaluating the number of participants with adverse events as a measure of safety and tolerability. to prospectively collect serum and bone marrow specimens to determine biomarkers of response and correlative ex vivo studies of the anti-leukemic activity of carfilzomib. this study will determine the persistence and phenotype of genetically modified nk cells in research participants with relapsed or refractory b-lineage all. this study will explore the efficacy of genetically modified nk cells in research participants with relapsed or refractory b-lineage all. overall toxicity profile documented by incidence of aes, saes, and/or dlts efficacy as documented by complete remission (cr), time and duration of remission, event-free survival (efs), 4-month efs, disease-free survival (dfs), and overall survival participant responses by daily dose level assignment (rad001 5 mg, 10 mg and mtd 5 mg) assess clinical response by percent reduction of peripheral leukemia blasts at day 2 of therapy and at completion of the 5-day investigational window valuation of tolerance, more particularly targeted at the immunodeficiency shortage, contagious complications and neurotoxicity assessed according to the nci (national cancer institute) classification. valuation of the response waiting time, from the first day of the induction treatment to the reevoluting. to determine the effects of decitabine administration on dna methylation and gene expression in this patient population. a decrease in leukemic blasts. the study will be terminated if unacceptable dosesecondary endpoints are a decrease in leukemic blasts. the study will be terminated if unacceptable dose limiting toxicity is found. this is a phase i trial to study safety. pharmacokinetics time to development of cytomegalovirus (cmv) specific immune reconstitution cmv dna levels time during post-infusion follow up at which the dominant cmv pp65 epitope for the donor is recognized by the cytotoxic t-cell lymphocyte recipient qtcf change from baseline number of participants with dose-limiting toxicities (dlts) part 1 and part 2: number of participants achieving a best response of complete response part 1 and part 2: progression-free survival (pfs) part 1 and part 2: duration of response (dor) part 1 and part 2: time to response (ttr) part 1 and part 2: overall survival (os) part 1 and part 2: hematologic improvement in participants with cll part 1: area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (auclast) of zanubrutinib part 1: area under the plasma concentration-time curve from time 0 to infinity time (auc) of zanubrutinib part 1: maximum plasma concentration (cmax) of zanubrutinib part 1: time to maximum plasma concentration (tmax) of zanubrutinib part 1: terminal elimination half-life (t1/2) of zanubrutinib part 1: apparent clearance (cl/f) of zanubrutinib part 1: apparent volume of distribution (vz/f) of zanubrutinib part 1 and part 2: steady state auclast of zanubrutinib part 1 and part 2: steady state cmax of zanubrutinib part 1 and part 2: steady state tmax of zanubrutinib part 2: number of participants experiencing adverse events part 2: number of participants with clinical laboratory abnormalities part 2: number of deaths platelet recovery thrombocytopenia bone marrow fibrosis to evaluate plasma pharmacokinetics (pk) of bpm31510 to estimate renal clearance of bpm31510 cmax of incagn02385 tmax of incagn02385 cmin of incagn02385 auc0-t of incagn02385 objective response rate (orr) in participants with advanced or metastatic solid tumors disease control rate (dcr) in participants with advanced or metastatic solid tumors duration of response (dor) in participants with advanced or metastatic solid tumors progression-free survival (pfs) in participants with advanced or metastatic solid tumors orr in participants with diffuse large b-cell lymphoma (dlbcl) dor in participants with dlbcl pfs in participants with dlbcl pharmacokinetics: area under the curve (auc) of cb-839 concentration in blood pharmacodynamics: % inhibition of glutaminase in blood clinical activity: % of tumor cells in bone marrow efficacy of clofarabine used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone event free survival peak level of lmb-2 in adult t-cell lymphoma progression free survival (pfs) overall survival (os) number of participants with serious and non-serious adverse events number of participants with dose limiting toxicity (dlt) soluble cluster of differentiation 25 (scd25) between responders and nonresponders area under the plasma concentration (auc) - lmb2 post treatment effects of lmb-2 + fludarabine and cyclophosphamide (fc) on normal b and t cell subsets by flow cytometry percentage of patients who developed neutralizing antibodies after one or more cycles of lmb-2 duration of response (complete response + partial response) plasma clearance (cl) of lmb-2 volume of distribution of lmb-2 half life (t1/2) of lmb-2 count of participants with grades 3-5 adverse events of > 1 adult t-cell leukemia (atl) patients treated with 20+200, 25+250, and 30+300 mg/m^2 lmb-2/fludarabine and cyclophosphamide count of participants with adverse events attributed at least possibly to patients treated with fludarabine and cyclophosphamide dose levels 20+200, 25+250, and 30+300 mg/m^2 incidence of grade ii-iv acute and chronic gvhd time to recovery of normal t-cell (>700/ul) and cd4 (>300/ul) counts and normal tcr diversity as assessed by vb spectratyping in vitro anti-viral responses of circulating pbmc transplant related mortality at 1 year post-sct disease-free survival at 1 year post-sct pharmacodynamics anti-tumor efficacy time to neutrophil engraftment cumulative incidence of sustained donor-derived neutrophil engraftment cumulative incidence of sustained donor-derived neutrophil engraftment cumulative incidence of sustained donor-derived neutrophil engraftment incidence of engraftment syndrome cumulative incidence of graft failure cumulative incidence of graft failure presence of post-transplant phenotype in hematopoietic cells of donor origin cumulative incidence of grade ii - iv acute graft versus host disease (agvhd) cumulative incidence of grade ii - iv acute graft versus host disease (gvhd) cumulative incidence of chronic gvhd cumulative incidence of chronic gvhd time to lymphoid recovery cumulative incidence of transplant related mortality (trm) cumulative incidence of transplant related mortality (trm) overall survival (os) overall survival (os) disease free survival (dfs) disease free survival (dfs) number of adverse events. number of patients able to complete the study. time to complete enrolment. number and characteristics of immunologic modifications. number of patients who respond to treatment. number of patients alive after treatment conclusion. number of patients alive without progression. pharmacokinetic profile of epz-5676 the incidence of adverse events in patients treated with epz-5676 anti-leukemic activity of epz-5676 in patients with acute leukemia harboring a mll-rearrangement effects of epz-5676 on histone h3k79 methylation in peripheral blood mononuclear cells (pbmc). effects of epz-5676 on histone h3k79 methylation in leukemia cells to determine the toxicity of this combination in these patients. to determine abl-mutational status at baseline and at the time of disease progression as a possible mechanism of resistance. number of subjects who are without disease at one year as indicator of disease free survival. minimal residual disease (mrd) during treatment with alemtuzumab (phase ii) disease-free survival, for only complete response patients overall survival to evaluate the pharmacokinetic profile of tak-901 and its primary metabolite (m-i). to make a preliminary assessment of the clinical activity of tak-901. to make a preliminary assessment of the effects of tak-901 on pharmacodynamic biomarkers. to make a preliminary assessment of the association between selected genetic markers and tak-901 response and/or pharmacokinetic parameters. response presence of disease or antigen-specific lymphocytes phase ii: kaplan-meier estimate for progression/relapse-free survival time phase ii: kaplan-meier estimate for overall survival time number of regimen related toxicities (rrts) phase ii: cumulative incidence of acute gvhd phase ii: cumulative incidence of chronic gvhd phase ii: cumulative incidence of non-relapse mortality pharmacokinetic profile, safety and tolerability of maximum tolerated dose, pharmacodynamic effect, identify dose limiting toxicities days of persistence of adoptively-transferred haploidentical nk cells occurrence of disease response median time to leukocytes and platelets recovery number of t, b, nk, activated t and nk cells after immunotherapy pk parameter of the individual components of cpx-351, and their respective metabolites incidence of treatment emergent adverse events (teaes) tumor response phase i study - define maximum tolerated dose of pol6326 phase ii study - the proportion of hla-identical sibling donors who experience grade 3-4 infusional toxicity and the proportion who are safely mobilized phase ii study - pharmacokinetics and pharmacodynamics of iv pol6326 phase ii study - rate of acute gvhd and chronic gvhd in patients who receive iv pol6326 mobilized peripheral blood stem cells. phase ii study - kinetics of neutrophil and platelet engraftment in recipients of pol6326 mobilized peripheral blood stem cells. adverse event profile after single cycle decitabine post transplant grade 3 adverse events after decitabine safety and tolerability of brentuximab vedotin when administered with a gvhd prophylaxis regimen rate of acute gvhd rate of chronic gvhd progression-free survival overall survival. 1-year non-relapse mortality rate 2-year non-relapse mortality rate 1-year disease relapse rate 2-year disease relapse rate six months survival summary of participants with adverse events (aes) in phase 1 percentage of participants achieving a response over the first two treatment cycles in phase 1 time to remission for participants who had a response in phase 1 kaplan meier estimate of duration of remission (dor) for participants who achieved overall remission (or) in phase 1 kaplan meier estimates of event-free survival (efs) for participants in phase 1 number of participants with 4-month event free survival in phase 1 kaplan meier estimates of overall survival (os) for participants in phase 1 summary of participants with adverse events (aes) in phase 2 time to remission for participants who had a response in phase 2 kaplan meier estimate of duration of remission (dor) for participants who achieved overall remission (or) in phase 2 kaplan meier estimates of event-free survival (efs) for participants in phase 2 number of participants with 4-month event free survival in phase 2 kaplan meier estimates of overall survival (os) for participants in phase 2 to analyze the pharmacokinetics in these patients. disease control rate progression free survival overall survival characterize the pharmacokinetics of tkm-080301 assess preliminary evidence of anti-tumor activity incidence of neutrophil engraftment incidence of platelet engraftment incidence of complete donor chimerism incidence of transplantation-related mortality incidence of grade ii-iv and grade iii-iv acute graft-versus-host disease (gvhd) after transplantation incidence of chronic gvhd after transplantation incidence of relapse after transplantation disease-free survival after transplantation durability of remission based on presence of rapid early response after transplantation overall survival after transplantation pharmacokinetic profile of bbi608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by maximum plasma concentration and area under the curve pharmacodynamic activity of bbi608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by biomarker analysis assessment of the preliminary anti-tumor activity by performing tumor assessments incidence of any grade 3 or higher dose limiting toxicity graded (dlt) according to common terminology criteria for adverse events version 4.0 overall objective response rates defined as morphologic, cytogenetic and molecular complete response (cr) rates at the end of induction period proportion of patients who show sensitivity to each of the study kinase inhibitors overall survival safety and tolerability expressed by any grade adverse events (aes) pharmacokintetics (pk): maximum plasma concentration (cmax) response rate: complete remission + partial remission (cr + pr) phrmacokinetics (pk): area under the curve (auc) versus time curve maximum plasma concentration (cmax) of selinexor complete response rate overall response rate area under the curve (auc) of selinexor disease response rate after treatment anti-leukemia effect of donor natural killer cell infusion disease response count of participants according to inhibition of flt3 phosphorylation change from baseline in left ventricular ejection fraction (lvef) change from baseline in left ventricular ejection fraction (lvef)-trajectory change from baseline in global strain (harp mri) change from baseline in global strain (harp mri)-trajectory change from baseline in regional strain (harp mri) change from baseline in regional strain (harp mri)-trajectory change from baseline in left ventricular end diastolic volume index (lvedvi) change from baseline in left ventricular end diastolic volume index (lvedvi)-trajectory change from baseline in left ventricular end systolic volume index (lvesvi) change from baseline in left ventricular end systolic volume index (lvesvi)-trajectory change from baseline in left ventricular sphericity index change from baseline in left ventricular sphericity index-trajectory change from baseline in area of injury change from baseline in area of injury-trajectory change from baseline in exercise tolerance (six minute walk test) change from baseline in exercise tolerance (six minute walk test)-trajectory change from baseline in minnesota living with heart failure questionnaire score change from baseline in minnesota living with heart failure questionnaire score-trajectory change from baseline in n-terminal pro-brain natriuretic peptide (nt-probnp) change from baseline in n-terminal pro-brain natriuretic peptide (nt-probnp)-trajectory cumulative days alive and out of hospital for heart failure to determine the event-free, disease-free and overall survival of the conditioning regimen of clofarabine, ara-c and tbi followed by allosct in children with all and aml. to estimate the time to hematopoietic reconstitution, stratified by cell source, following clofarabine, ara-c and tbi followed by allosct in children with all and aml. to measure the changes in minimal residual disease with all and aml following clofarabine, ara-c and tbi followed by allosct preliminary clinical activity plasma and cellular pharmacokinetics pharmacodynamics relapse rate analysis non-relapse mortality analysis incidence of acute gvhd, grades ii-iv incidence of chronic gvhd, moderate and severe (nih criteria) overall survival analysis event-free survival analysis toxicity (nci ctcae 4.03) infectious complications, including analysis of severe bacterial, fungal and viral infections incidence overall response rate phase i: study of the variation of radioactivity of 131i or 124i in whole blood, at several time intervals (pharmacokinetics) phase ii: adverse events as a measure of safety phase ii: overall response rate (orr) phase ii: progression free survival (pfs) phase ii: survival rate safety of low vs. high transfusion threshold as assessed by total difference in number of transfusions given per participant safety of low vs. high transfusion threshold as assessed by number of participants experiencing neutropenic infections safety of low vs. high transfusion threshold as assessed by number of grade 3-4 bleeding events as defined by ctcae 4.0 safety of low vs. high transfusion threshold as assessed by number of deaths attributed to induction chemotherapy safety of low vs. high transfusion threshold as assessed by number of participants with at least one grade 3-5 non-hematological toxicity by ctcae 4.0. feasibility as determined by percentage of participants consented feasibility as determined by percentage of participants who tolerate 7g/dl transfusion feasibility as determined by percentage of participants who crossed over from the low arm to the high arm number of transfusions neutropenic infections bleeding length of stay treatment-related mortality end organ dysfunction performance status scores incidence of crossover cost savings fatigue scores in some of these studies, to enhance our spectral resolution and obtain additional metabolic information, we propose to use decoupling, which will increase both signal quality (the signal to noise ratio) and spectral resolution. number of participants with a complete response or partial response phase 2: duration of response (dor) phase 2: progression free survival (pfs) phase 2: duration of disease control phase 2: overall survival (os) phase 2: ordinal categorical response score phase 2: percentage of participants with treatment-emergent adverse events (teae) and serious treatment-emergent adverse events objective-response rate (orr) duration of ft500 persistence to determine the pharmacokinetic profile of arq 621. to determine the pharmacodynamic profile (incl. biomarkers) of arq 621. to assess the preliminary anti-tumor activity of arq 621. optimal biologically active dose in vivo pharmacokinetics correlate pk data with historical experience number of ph+ cml participants with confirmed complete hematologic response (chr) number of ph+ cml participants with cytogenic response number of ph+ cml participants with major molecular response (mmr) efficacy endpoints for ph+ all patients to determine the pharmacokinetic (pk) profile of inno-406. to assess bcr-abl transcript levels and to analyze bcr-abl mutations. to assess leukemia response rates in this patient population. adverse events as graded by nci common terminology criteria for adverse events (ctcae) v4. investigator-reported best overall response (bor) as determined from the response categories during treatment period. time to progression remission duration biomarker evaluation bez235 and metabolite levels in plasma clinical laboratory tests as graded by nci ctcae v4. duration of neutropenia duration of thrombocytopenia duration of presence of clt-008 derived cells in blood duration of presence of clt-008 derived cells in bone marrow incidence of mucositis incidence of infections duration of fever duration of antibiotic use incidence of hospitalization duration of hospitalization pharmacokinetic parameters pharmacodynamic effects assess disease response heart corrected qt intervals recurrence-free survival overall survival cp-cml participants: percentage of participants with chr cp-cml, ap-cml, bp-cml, and ph+all participants: percentage of participants with confirmed mcyr cp-cml, ap-cml, bp-cml, and ph+all participants: percentage of participants with major molecular response (mmr) cp-cml, ap-cml, bp-cml, and ph+all participants: median time to response (ttr) cp-cml and advanced phase participants: median duration of response (dor) cp-cml and advanced phase participants: median progression-free survival (pfs) cp-cml and advanced phase participants: overall survival (os) cmax: maximum observed plasma concentration for ponatinib tmax: time to reach the cmax for ponatinib auc(0-24): area under the plasma concentration-time curve from time 0 to 24 hours post-dose for ponatinib t1/2: terminal phase elimination half-life for ponatinib to obtain a preliminary estimate of the efficacy of this therapy as defined by: complete remission at day 100 and one-year disease free survival. toxicity pharmacodynamic response activity of belinostat and bortezomib participants with chronic phase cml (cml-cp): percentage of participants with cytogenetic response participants with cml-accelerated or blast phase (ap/bp): percentage of participants with cytogenetic response participants with ph+ acute lymphoblastic leukemia (ph+ all): percentage of participants with cytogenetic response participants with cml-cp: time to complete cytogenetic response (ccyr) participants with cml-ap/bp and ph+ all: time to complete cytogenetic response (ccyr) participants with cml-cp: duration of complete cytogenetic response (ccyr) participants with cml-ap/bp and ph+all: duration of complete cytogenetic response (ccyr) participants with cml-cp: time to major cytogenetic response (mcyr) participants with cml-ap/bp and ph+all: time to major cytogenetic response (mcyr) participants with cml-cp: duration of major cytogenetic response (mcyr) participants with cml-ap/bp and ph+ all: duration of major cytogenetic response (mcyr) participants with cml-cp: percentage of participants with complete hematologic response (chr) participants with cml-ap/bp: percentage of participants with hematologic response participants with ph+ all: percentage of participants with hematologic response time to complete hematologic response (chr) in chronic phase cml, accelerated or blast phase cml, and ph+all duration of complete hematologic response (chr) in chronic phase cml, accelerated or blast phase cml, and ph+all time to major hematologic response (mahr) in accelerated or blast phase cml, and ph+all duration of major hematologic response (mahr) in accelerated or blast phase cml, and ph+all time to overall hematologic response (ohr) in accelerated or blast phase cml, and ph+all duration of overall hematologic response (ohr) in accelerated or blast phase cml, and ph+all participants with detectable mutations of rna (mrna) of bcr-abl at baseline and at best achievement status of point mutations of bcr-abl at baseline (bl) and end of study (eos) collection of blood samples for pharmacokinetic analysis of dasatinib twice daily (bid) that will contribute to population pharmacokinetic modeling duration of response overall survival (os) trm donor chimerism incidence of agvhd, graded according to ohio state university bone marrow transplant (osu bmt) program policy incidence of chronic gvhd, scored according to the osu bmt program policy cumulative incidence of grade ii organ toxicity incidence of hematopoietic recovery incidence of graft failure rate of infectious complications incidence of relapse overall survival progression-free survival immune reconstitution 1) hematologic response 2) cytogenetic response. concentration of on 01910.na in plasma to characterize the safety and tolerability of once-weekly sta-9090 (ganetespib) in subjects with aml, all and blast-phase cml incidence of anti-drug antibody (ada) formation to the fully human monoclonal antibody (ags67c) and antibody-drug conjugate (ags67e) incidence of tumor response objective response rate (orr) cumulative incidence of relapse secondary outcome measure: standard transplant outcome variables such as relapse, non-relapse mortality, neutrophil and platelet recovery kinetics, incidence and severity of acute gvhd and chronic gvhd. technical success rates and the use of dli... non relapse mortality days till anc greater than 500/ul days till platelet greater than 20 k/ul examine safety of orally-administered clofarabine; examine the safety of a combined intravenous and oral clofarabine regimen examine efficacy of orally-administered clofarabine explore the influence of oct2-encoding single nucleotide polymorphisms on clofarabine pharmacokinetics and pharmacodynamics engraftment disease free survival overall survival incidence of acute and chronic graft-versus-host disease incidence of infectious complication duration of hospitalization immune reconstitution after transplantation number of participants with graft versus host disease (gvhd) number of patients who respond using recist criteria mean concentration of vegf2 pharmacodynamics (pd) blood flow part c number of patients with demri leukemia mutations plasma inhibitory activity (pia) determine the maximum tolerated dose (mtd) and recommended phase 2 dose (rptd) of abt-348 when administered as a monotherapy and in combination in subjects with advanced hematologic malignancies to determine the efficacy of th-302 via specific response criteria pharmacokinetic profile duration of leukemia-free survival anti-tumor activity phase i: complete hematologic response phase i: major cytogenetic response phase i: safety and tolerability phase ii: complete hematologic response number of participants with overall major cytogenetic responses (phase ii) number of participants with complete hematologic response (phase ii) participants with (mmr) major molecular response (phase ii) time to progression (ttp) (phase ii) overall survival (os) (phase ii) number of participants with adverse events and serious adverse events to evaluate long term safety the proportion of patients at 1 year with treatment efficacy success survival patients alive with out relapse relapse to investigate the clinical pharmacology of on 01910.na including plasma pharmacokinetics, pharmacodynamics and biological effects on cell-cycle pathways. 1-year gvhd-free, relapse-free survival (grfs) percentage of subjects alive without relapse and without moderate or severe cgvhd at day +365 - mitt population achievement of remission disease-free survival duration of remission estimation of absorbed radiation doses to normal organs, marrow and tumor overall survival rates of acute gvhd rates of donor chimerism rates of engraftment rates of non-relapse mortality changes in apoptotic protein expression (bim, bax, akt) clinical efficacy (response rate) evaluated using the revised international working group criteria (iwg) for aml farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells brain tumor response clinical antitumor response to alt-801 alt-801 induced cell-mediated immune responses immunogenicity of alt-801 relapse of disease changes in pharmacodynamic variables (target gene expression, apoptosis) association of methylation status, categorized as positive or negative, with changes in target gene expression clinical activity (complete remission, partial remission, stable disease, hematologic improvement) donor chimerism engraftment survival relapse mortality response rate of genotype-based dosing in the subset of patients that has colorectal cancer change in molecular inhibition of the egfr signaling pathway obd defined as the dose at which either a >= 75% inhibition of phosphorylation of the egf receptor or of its downstream effectors p44/42 mapk or akt is observed, or ki67 is decreased by >= 25% antitumor effect observed evaluation of antibody response to cad3-ebo-s and cad3 marburg vaccines collection of sufficient post-vaccination plasma to support further development of filovirus assays.'"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['all_primary_terms'] = df['protocolSection_outcomesModule_primaryOutcomes'].apply(lambda x: create_all_terms(x))\n",
    "df[\"all_secondary_terms\"] = df['protocolSection_outcomesModule_secondaryOutcomes'].apply(lambda x: create_all_terms(x))\n",
    "all_terms = concatenate_strings([df['all_primary_terms'],df[\"all_secondary_terms\"]])\n",
    "primary_terms = concatenate_strings([df['all_primary_terms']])\n",
    "all_terms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def spacy_list(keyword:str, ref_text):\n",
    "    # Process the keyword and the large text\n",
    "    keyword_doc = nlp(keyword)\n",
    "    text_doc = nlp(ref_text)\n",
    "\n",
    "    # Set a threshold for similarity\n",
    "    similarity_threshold = 0.8\n",
    "\n",
    "    high_similarity_phrases = []\n",
    "    seen_phrases = set()  # Set to track unique words or phrases\n",
    "\n",
    "    # Check individual tokens\n",
    "    for token in text_doc:\n",
    "        # Skip stop words and punctuation\n",
    "        if not token.is_stop and not token.is_punct:\n",
    "            # Compute similarity\n",
    "            similarity_score = token.similarity(keyword_doc)\n",
    "            if similarity_score >= similarity_threshold and token.text not in seen_phrases:\n",
    "                high_similarity_phrases.append((token.text, similarity_score))\n",
    "                seen_phrases.add(token.text)  # Add to the set of seen phrases\n",
    "\n",
    "    # Check multi-word phrases\n",
    "    for chunk in text_doc.noun_chunks:\n",
    "        # Compute similarity with the keyword\n",
    "        similarity_score = chunk.similarity(keyword_doc)\n",
    "        if similarity_score >= similarity_threshold and chunk.text not in seen_phrases:\n",
    "            high_similarity_phrases.append((chunk.text, similarity_score))\n",
    "            seen_phrases.add(chunk.text)  # Add to the set of seen phrases\n",
    "    return high_similarity_phrases"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/t7/9qpt6ghx7x132zp3932q2fb80000gn/T/ipykernel_47647/1493651380.py:17: UserWarning: [W008] Evaluating Token.similarity based on empty vectors.\n",
      "  similarity_score = token.similarity(keyword_doc)\n",
      "/var/folders/t7/9qpt6ghx7x132zp3932q2fb80000gn/T/ipykernel_47647/1493651380.py:25: UserWarning: [W008] Evaluating Span.similarity based on empty vectors.\n",
      "  similarity_score = chunk.similarity(keyword_doc)\n"
     ]
    }
   ],
   "source": [
    "spacy_dict = {}\n",
    "lead_spacy_dict = {}\n",
    "terms = {\n",
    "    \"aes\": \"adverse events\",\n",
    "    \"osr\": \"overall survival rate\",\n",
    "    \"mtd\": \"maximally tolerated dose\",\n",
    "    \"dor\": \"duration of response\",\n",
    "    \"dlt\": \"dose limiting toxicity\",\n",
    "    \"cmax\": \"maximum measured concentration\"\n",
    "}\n",
    "for i in terms:\n",
    "    spacy_dict[i] = spacy_list(keyword=terms[i], ref_text=all_terms)\n",
    "\n",
    "lead_terms = {\n",
    "    \"aes\": \"adverse events\",\n",
    "    \"mtd\": \"maximally tolerated dose\",\n",
    "    \"dlt\": \"dose limiting toxicity\",\n",
    "}\n",
    "\n",
    "for i in lead_terms:\n",
    "    lead_spacy_dict[i] = spacy_list(keyword=terms[i], ref_text=primary_terms)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['outcome_measures'] = df['protocolSection_outcomesModule_primaryOutcomes'].apply(lambda x: x if isinstance(x, list) else [x]).fillna('') + \\\n",
    "                         df['protocolSection_outcomesModule_secondaryOutcomes'].apply(lambda x: x if isinstance(x, list) else [x]).fillna('')\n",
    "\n",
    "\n",
    "def check_terms_in_outcomes(outcomes, terms):\n",
    "    if isinstance(outcomes, list):  # Only proceed if 'outcomes' is a list\n",
    "        for outcome in outcomes:\n",
    "            if isinstance(outcome, dict):  # Ensure each item is a dictionary\n",
    "                for value in outcome.values():  # Check each value in the dictionary\n",
    "                    if isinstance(value, str) and any(term in value for term, _ in terms):\n",
    "                        return True\n",
    "    return False\n",
    "\n",
    "for i in terms:\n",
    "    df[f\"spacy_{i}_outcome\"] = df['outcome_measures'].apply(\n",
    "    lambda x: check_terms_in_outcomes(x, spacy_dict[i])\n",
    ")\n",
    "\n",
    "for i in lead_terms:\n",
    "    df[f\"spacy_{i}_lead_outcome\"] = df['protocolSection_outcomesModule_primaryOutcomes'].apply(\n",
    "    lambda x: check_terms_in_outcomes(x, lead_spacy_dict[i])\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "def check_tmax_in_outcomes(outcomes, terms):\n",
    "    if isinstance(outcomes, list):  # Only proceed if 'outcomes' is a list\n",
    "        for outcome in outcomes:\n",
    "            if isinstance(outcome, dict):  # Ensure each item is a dictionary\n",
    "                for value in outcome.keys():  # Check each value in the dictionary\n",
    "                    if value == terms:\n",
    "                        return True\n",
    "    return False\n",
    "\n",
    "df['tmax_outcome'] = df.loc[df[\"spacy_cmax_outcome\"] == True, 'outcome_measures'].apply(\n",
    "    lambda x: check_tmax_in_outcomes(x, \"timeFrame\"))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "tmax_outcome\n",
       "True     485\n",
       "False     18\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['tmax_outcome'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'measure': 'Dose Limiting Toxicity (DLTs)',\n",
       "  'description': 'A DLT was defined as an adverse event deemed possibly, probably, or definitely related to administration of study drugs and met the following criteria: gradeâ‰¥3 non-hematological toxicity (except grade â‰¥3 diarrhea, nausea, vomiting responsive to supportive therapy);gradeâ‰¥3 rise in creatinine (except grade 3 able to be corrected to grade 1 or baseline with intravenous fluids within 24hrs); gradeâ‰¥3 electrolyte toxicities (except those able to be corrected to grade 1 or baseline within 48hrs); grade 4 thrombocytopenia; grade 4 neutropenia for \\\\>5 days or febrile neutropenia; any neurotoxicity gradeâ‰¥2 not reversible to grade 1 or baseline within 2wks; or any delay in treatment by â‰¥2wks due to treatment-related toxicity. Worsening liver function, as defined by a rise in serum bilirubin not related to tumor progression, was considered a DLT if a patient with mild dysfunction became severe for 1wk, or if a patient in either the moderate/severe groups had a \\\\>1.5x increase in bilirubin for 1 wk.',\n",
       "  'timeFrame': 'First cycle of therapy, 28 days.'},\n",
       " {'measure': 'Maximum Tolerated Dose (MTD) of Belinostat According to Degree of Liver Dysfunction',\n",
       "  'description': 'In order to maintain consistent dosing across the hepatic dysfunction groups, the dose recommended for cohorts with greater liver dysfunction could be no greater than the dose for cohorts of lesser dysfunction. In other words, it was assumed that a particular group would not tolerate a dose not tolerated by a group with lesser dysfunction and conversely, will tolerate a dose tolerated by a group with greater dysfunction. If a higher dose was tolerated in a group of greater dysfunction, but not in the group of lesser dysfunction, the lower dose would be recommended for both groups. The highest dose to be explored was no greater than the recommended dose for patients with normal liver function.',\n",
       "  'timeFrame': 'First cycle of therapy, 28 days'},\n",
       " {'measure': 'Number of Participants Experiencing Adverse Events Considered to be at Least Possibly Related to the Study Drug',\n",
       "  'description': 'The number of participants experiencing each adverse event by liver function cohort at each dose level. The grade refers to the severity of the Adverse Event. Grade 1 Mild; Grade 2 Moderate; Grade 3 Severe or medically significant but not immediately life-threatening; Grade 4 Life-threatening consequences; Grade 5 Death related to adverse event.',\n",
       "  'timeFrame': 'From Cycle 1 Day -7 up to 12 (21-day) cycles'},\n",
       " {'measure': 'Pharmacokinetics (PK) of a Single-dose Belinostat (400 mg/m^2)) According to Degree of Liver Dysfunction: Maximum Plasma Concentrations (Cmax)',\n",
       "  'description': 'Maximum plasma concentrations (Cmax) for belinostat and five metabolites on Cycle 1 Day -7 as a function of degree of liver dysfunction.',\n",
       "  'timeFrame': 'Cycle 1 Day -7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf)',\n",
       "  'description': 'Area Under the Plasma Concentration Time Curve Extrapolated to Infinity (AUC0-inf) for belinostat and four metabolites on Cycle 1 Day -7 as a function of degree of liver dysfunction.',\n",
       "  'timeFrame': 'Cycle 1 Day-7 prior to infusion; 15 and 25 minutes after start of infusion; and 5, 10, 15, 60, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf) of Belinostat',\n",
       "  'description': 'Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf) for Belinostat glucuronide, a Belinostat Metabolite on Cycle 1 Day-7 as a function of degree of liver dysfunction.',\n",
       "  'timeFrame': 'Cycle 1 Day -7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Half-Life (t1/2)',\n",
       "  'description': 'Half-life Period (t1/2) of belinostat and five metabolites on Cycle 1 Day -7 as a function of degree of liver function.',\n",
       "  'timeFrame': 'Cycle 1 Day -7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Clearance (CL)',\n",
       "  'description': 'Clearance (CL) of Belinostat on Cycle 1 Day-7 as a function of degree of liver dysfunction',\n",
       "  'timeFrame': 'Cycle 1 Day-7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Volume of Distribution at Steady State (Vss)',\n",
       "  'description': 'Belinostat Apparent volume of distribution at steady state (Vss) on Cycle 1 Day-7 as a function of degree of liver dysfunction.',\n",
       "  'timeFrame': 'Cycle 1 Day-7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Metabolic Ratios of Maximum Plasma Concentrations (Cmax) for the Belinostat Metabolic Pathway',\n",
       "  'description': 'Metabolic ratios of Maximum Plasma Concentrations (Cmax), reported as a geometric mean (geometric standard deviation), for the belinostat metabolic pathway on Cycle 1 Day-7 as a function of degree of liver dysfunction.',\n",
       "  'timeFrame': 'Cycle 1 Day-7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Metabolic Ratios of Area Under the Plasma Concentration Time Curve Extrapolated to Infinity (AUC0-inf) for the Belinostat Metabolic Pathway',\n",
       "  'description': 'Metabolic ratios of Area Under the Plasma Concentration Time Curve Extrapolated to Infinity (AUC0-inf), reported as geometric mean (geometric standard deviation), for the belinostat metabolic pathway on Cycle 1 Day-7 as a function of degree of liver dysfunction.',\n",
       "  'timeFrame': 'Cycle 1 Day-7 prior to infusion; 15 and 25 minutes after the start of infusion; and 5, 10, 15, 30, 60, and 90 minutes, and 2, 4, 6, 8, and 24 hours after the end of infusion.'},\n",
       " {'measure': 'Best Response',\n",
       "  'description': 'Radiologic response assessments by computed tomography (CT) scans were performed at baseline and every two cycles of treatment based on the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Per RECIST v1.1 Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum diameters; Stable Disease (SD), neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for Progression of Disease (PD), taking as reference the smallest sum diameters while on study; PD, \\\\>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and an absolute increase of at least 5mm or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\<10 mm.',\n",
       "  'timeFrame': 'at baseline and every two 21-day cycles of treatment, up to 12 cycles'},\n",
       " {'measure': 'Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0).',\n",
       "  'description': 'Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.',\n",
       "  'timeFrame': 'From Cycle 1 Day -7 up to 12 (21-day) cycles.'}]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.loc[df['spacy_cmax_outcome'] == True, 'outcome_measures'][6]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('maximum', 0.8090030721371205),\n",
       " ('concentrations', 0.81027963764303),\n",
       " ('concentration', 0.8303335973368932),\n",
       " ('calculated', 0.8074786030082891),\n",
       " ('computed', 0.8074786030082891),\n",
       " ('measured', 0.8747061793695453),\n",
       " ('electrocardiograms', 0.8284184063789667),\n",
       " ('cumulative', 0.8176406506384377),\n",
       " ('measurement', 0.8492668723020855),\n",
       " ('measurements', 0.8284184063789667),\n",
       " ('measuring', 0.8376357442706482),\n",
       " ('the maximum tolerated dose', 0.8368078561671596),\n",
       " ('maximum plasma concentrations', 0.9041811556514319),\n",
       " ('maximum observed plasma concentration', 0.9270829311730717),\n",
       " ('apparent total plasma clearance', 0.800335450594177),\n",
       " ('adverse events maximum plasma concentration', 0.8516392714228507),\n",
       " ('maximum plasma concentration', 0.9163410801734877),\n",
       " ('maximum observed concentration', 0.959691836094287),\n",
       " ('accumulation ratio', 0.8021510996516491),\n",
       " ('the first treatment cycle maximum tolerated dose', 0.8082393935647026),\n",
       " ('treatment-emergent adverse events maximum observed plasma concentration',\n",
       "  0.8348397832474641),\n",
       " ('observed concentration', 0.8334249181173592),\n",
       " ('maximum concentration', 0.9636666982764991),\n",
       " ('the toxicity and maximum tolerated dose', 0.8384658990772706),\n",
       " ('postdose minimum observed plasma', 0.8404055780967639),\n",
       " ('combination maximum tolerated dose', 0.8292940115094987),\n",
       " ('relative excretion', 0.8225372027860116),\n",
       " ('concurrent chop and alemtuzumab maximum tolerated dose',\n",
       "  0.8111435145655038),\n",
       " ('asct complete response correlation coefficient', 0.8143612222119164),\n",
       " ('maximum standard uptake value', 0.8384920416071887),\n",
       " ('safety and tolerability maximum tolerated dose', 0.8367115162168822),\n",
       " ('gdc-0575 minimum observed plasma trough concentration', 0.8891610550201314),\n",
       " ('gdc-0575 accumulation ratio', 0.8021511589455942),\n",
       " ('the maximum plasma concentration', 0.8791735771072279),\n",
       " ('the maximum tolerable dose', 0.8354920052550664),\n",
       " ('idelalisib exposure plasma concentration', 0.809534640153517),\n",
       " ('their causality maximum tolerated dose maximum tolerated dose',\n",
       "  0.841755572785413),\n",
       " ('maximum observed drug concentration', 0.8343962261837644),\n",
       " ('maximal plasma concentration', 0.8305738144701331),\n",
       " ('average concentration', 0.8443375721681975),\n",
       " ('the maximum observed plasma concentration', 0.8919756684564888),\n",
       " ('maximum observed whole blood concentration', 0.8266898816033426),\n",
       " ('the maximum observed whole blood concentration', 0.8123658225657995),\n",
       " ('drug maximum observed plasma concentration', 0.8291815704361238),\n",
       " ('single dose maximum observed plasma concentration', 0.8576996412320129),\n",
       " ('multiple dose maximum observed plasma concentration', 0.874209607155828),\n",
       " ('overall response rate maximum tolerated dose', 0.8161610930268534),\n",
       " ('the maximum dose', 0.8059827297813009),\n",
       " ('gp2013 maximum observed concentration', 0.959691904982435),\n",
       " ('maximum tolerated dose percentage', 0.8026720638854037),\n",
       " ('maximum tolerated dose pharmacology and pharmacokinetics number',\n",
       "  0.8108847546005256),\n",
       " ('safety and tolerability maximum-tolerated dose', 0.8156875217972575),\n",
       " ('hematology and chemistry testing and toxicity evaluation maximum tolerated dose',\n",
       "  0.8108704964155017),\n",
       " ('feasibility maximum tolerated dose', 0.8212699744340763),\n",
       " ('venetoclax maximum plasma concentration', 0.8733863679346227),\n",
       " ('observed plasma concentration', 0.8185273760260995),\n",
       " ('baseline maximum tolerated dose', 0.817811443017616),\n",
       " ('the infused ctls maximum tolerated dose', 0.8190222395632925),\n",
       " ('maximum tolerated dose overall response rate time', 0.8030998038457331),\n",
       " ('infinity maximum plasma concentration', 0.8879430131330052),\n",
       " ('azacitidine maximum plasma concentration', 0.8658027087093495),\n",
       " ('standardized measure', 0.8264091741242223),\n",
       " ('the maximum tolerated dose auc', 0.8368078128444276),\n",
       " ('the maximum dose level', 0.8139939551634054),\n",
       " ('quantifiable concentration', 0.8116353391159263),\n",
       " ('maximum tolerated dose determination', 0.8451492039032251),\n",
       " ('maximum tolerable dose(mtd', 0.8546433381642362),\n",
       " ('ibrutinib minimum observed plasma concentration', 0.8794123037467015),\n",
       " ('selinexor maximum tolerated dose', 0.817811443017616),\n",
       " ('adverse events maximum observed plasma concentration', 0.8659983516104206),\n",
       " ('clinical observations maximum tolerated dose', 0.823257211408053),\n",
       " ('abbv-621 maximum observed serum concentration', 0.9065045405639937),\n",
       " ('partial response maximum tolerated dose', 0.834754018511687),\n",
       " ('the maximum tolerated dose(mtd)of tak-901', 0.8340830051880119),\n",
       " ('combination selinexor', 0.8127876478773739),\n",
       " ('lenalidomide engraftment rate maximum tolerated dose', 0.8124575241646859),\n",
       " ('overall survival plasma concentrations', 0.8105603879331714),\n",
       " ('classification tazemetostat plasma concentrations rate',\n",
       "  0.8247224927356293),\n",
       " ('initial plasma concentration', 0.8110741605201991),\n",
       " ('maximum observed effect', 0.8652135510240855),\n",
       " ('response maximum plasma concentration', 0.9020038823405544),\n",
       " ('the maximum serum concentration', 0.8631234500532227),\n",
       " ('cytometric measurement', 0.8347370647911572),\n",
       " ('the peak plasma concentration', 0.8054270455247581),\n",
       " ('medi4736 accumulation ratio', 0.8021511589455942),\n",
       " ('study treatment response rate complete response rate maximum number',\n",
       "  0.8015653322453496),\n",
       " ('maximum serum concentration', 0.8783882161496045),\n",
       " ('the indicated antibody predose levels volume', 0.8066355697294703),\n",
       " ('pembrolizumab minimum plasma concentration', 0.844973018201652),\n",
       " ('nhl maximum plasma concentration', 0.8544778307672678),\n",
       " ('observed maximum concentration', 0.959691836094287),\n",
       " ('58 minimum observed serum trough concentration', 0.8167976335329631),\n",
       " ('civ administration maximum observed concentration', 0.8603124087222344),\n",
       " ('minimum observed concentration', 0.9243782471721276),\n",
       " ('total antibody maximum observed serum concentration', 0.8824892119809713),\n",
       " ('best overall response maximum observed plasma concentration',\n",
       "  0.8762583560861696),\n",
       " ('jnj-42756493 minimum observed plasma concentration', 0.9061654084657383),\n",
       " ('polatuzumab vedotin maximum concentration', 0.8542393375426898),\n",
       " ('minimum plasma concentration', 0.8876649288018718),\n",
       " ('positive minimal residual disease plasma concentration',\n",
       "  0.8140900037254163),\n",
       " ('denileukin diftitox maximum serum concentration', 0.8783881829511411),\n",
       " ('the maximum concentration', 0.8565093078092959),\n",
       " ('pharmacokinetic parameter maximum plasma concentration',\n",
       "  0.9003564750834182),\n",
       " ('overall survival plasma concentration', 0.8181324763091492),\n",
       " ('either the maximum tolerated dose', 0.8327523336472801),\n",
       " ('version 1.1 maximum plasma concentration', 0.8168303940480516),\n",
       " ('maximum international normalised ratio', 0.887591015918809),\n",
       " ('international normalised ratio', 0.8092683384193644),\n",
       " ('maximum plasma concentration time', 0.8613458298575933),\n",
       " ('jnj-40346527 minimum observed plasma concentration', 0.9061654084657383),\n",
       " ('toxicity maximum observed plasma concentration', 0.8982015062020405),\n",
       " ('overall survival medi4736 maximum plasma concentration',\n",
       "  0.9007021727483234),\n",
       " ('tremelimumab maximum plasma concentration', 0.9163410790707667),\n",
       " ('medi4736 minimum plasma concentration', 0.887664994776107),\n",
       " ('tremelimumab minimum plasma concentration', 0.887664994776107),\n",
       " ('azd9150 minimum plasma concentration', 0.887664994776107),\n",
       " ('individual tremelimumab concentrations', 0.8215157201508493),\n",
       " ('azd9150 concentrations', 0.81027963764303),\n",
       " ('best overall tumor response maximum concentration', 0.8118856536046536),\n",
       " ('total antibody plasma concentration', 0.8039881427807248),\n",
       " ('asp4132 maximum concentration', 0.9636666943435934),\n",
       " ('asp4132 accumulation ratio', 0.8021511589455942),\n",
       " ('each patient peak plasma concentration', 0.805936709599108),\n",
       " ('durvalumab maximum observed plasma concentration', 0.8929263999390391),\n",
       " ('lenalidomide maximum observed plasma concentration', 0.8935000393941801),\n",
       " ('aucextrap)-polatuzumab vedotin monotherapy maximum plasma concentration',\n",
       "  0.8019671716035487),\n",
       " ('ibrutinib maximum observed plasma concentration', 0.8974184923904907),\n",
       " ('average steady state plasma concentration', 0.8307787586407869),\n",
       " ('maximum steady state plasma concentration', 0.8714804584078543),\n",
       " ('minimum steady state plasma concentration', 0.8444102164151269),\n",
       " ('steady state accumulation ratio', 0.8001500862786388),\n",
       " ('minimum concentration', 0.9070922566234305),\n",
       " ('bi-1206 measurement', 0.8492668723020855),\n",
       " ('maximum observed serum concentration', 0.9065046332392142),\n",
       " ('-3 maximum observed plasma concentration', 0.8574764939539833),\n",
       " ('multiple doses maximum observed plasma concentration', 0.8778070444834416),\n",
       " ('enasidenib maximum observed plasma concentration', 0.9270829831114102),\n",
       " ('maximum and minimum serum concentration', 0.908257902765249),\n",
       " ('progression maximum observed plasma concentration', 0.9229041925794281),\n",
       " ('carfilzomib medi7247 maximum observed concentration', 0.9173312860888653),\n",
       " ('ft-1101 maximum plasma concentration', 0.9163410790707667),\n",
       " ('maximum severity', 0.8531366934329911),\n",
       " ('response maximum observed serum concentration', 0.8945604359175875),\n",
       " ('treatment-emergent adverse events maximum sar245409 plasma concentration area',\n",
       "  0.8134696407259308),\n",
       " ('maximum sar245409 plasma concentration', 0.9163410790707667),\n",
       " ('overall response rate maximum observed concentration', 0.8856124229417233),\n",
       " ('the maximum tolerated dose number', 0.8348405074583045),\n",
       " ('bms-936564 maximum', 0.8090030721371205),\n",
       " ('1.1 maximum observed plasma concentration', 0.8882114366080354),\n",
       " ('last measurable plasma concentration', 0.8081699953269356),\n",
       " ('alectinib accumulation ratio', 0.8021511589455942),\n",
       " ('bms-986016 concentration', 0.8303335973368932),\n",
       " ('maximal concentration number', 0.8474994023191476),\n",
       " ('cb-839 concentration', 0.8303335973368932),\n",
       " ('selinexor average concentration', 0.8717904030934812),\n",
       " ('selinexor duration', 0.8178460810125712),\n",
       " ('safety and tolerability objective remission rate duration',\n",
       "  0.8200884982263387),\n",
       " ('engraftment cumulative incidence', 0.8153475243827978),\n",
       " ('time curve maximum plasma concentration', 0.8444965367018334)]"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "spacy_dict[\"cmax\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/t7/9qpt6ghx7x132zp3932q2fb80000gn/T/ipykernel_25717/1737469391.py:19: UserWarning: [W008] Evaluating Token.similarity based on empty vectors.\n",
      "  similarity_score = token.similarity(keyword_doc)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Phrase: adverse | Similarity Score: 0.81\n",
      "Phrase: events | Similarity Score: 0.91\n",
      "Phrase: events- | Similarity Score: 0.91\n",
      "Phrase: adverse events | Similarity Score: 1.00\n",
      "Phrase: emergent adverse events | Similarity Score: 0.97\n",
      "Phrase: adverse events maximum plasma concentration | Similarity Score: 0.85\n",
      "Phrase: serious adverse events number | Similarity Score: 0.91\n",
      "Phrase: adverse events number | Similarity Score: 0.92\n",
      "Phrase: adverse events cmax | Similarity Score: 1.00\n",
      "Phrase: adverse event profile | Similarity Score: 0.89\n",
      "Phrase: adverse events safety | Similarity Score: 0.92\n",
      "Phrase: adverse event monitoring | Similarity Score: 0.90\n",
      "Phrase: serious adverse events | Similarity Score: 0.96\n",
      "Phrase: adverse events incidence | Similarity Score: 0.97\n",
      "Phrase: treatment-emergent serious adverse events | Similarity Score: 0.82\n",
      "Phrase: adverse events change | Similarity Score: 0.94\n",
      "Phrase: adverse events intensity | Similarity Score: 0.95\n",
      "Phrase: adverse events determination | Similarity Score: 0.96\n",
      "Phrase: adverse events percentage | Similarity Score: 0.95\n",
      "Phrase: adverse event | Similarity Score: 0.92\n",
      "Phrase: serious adverse event | Similarity Score: 0.90\n",
      "Phrase: brentuximab vedotin adverse events | Similarity Score: 0.90\n",
      "Phrase: adverse events version | Similarity Score: 0.92\n",
      "Phrase: adverse event evaluation | Similarity Score: 0.90\n",
      "Phrase: adverse event number | Similarity Score: 0.87\n",
      "Phrase: related adverse events | Similarity Score: 0.94\n",
      "Phrase: systemic clinical and biological adverse events | Similarity Score: 0.83\n",
      "Phrase: toxicity events | Similarity Score: 0.92\n",
      "Phrase: treatment related adverse events | Similarity Score: 0.90\n",
      "Phrase: adverse events occurrence | Similarity Score: 0.97\n",
      "Phrase: adverse events tolerability incidence | Similarity Score: 0.93\n",
      "Phrase: adverse events efficacy | Similarity Score: 0.95\n",
      "Phrase: study related adverse events | Similarity Score: 0.87\n",
      "Phrase: study related adverse events phase | Similarity Score: 0.84\n",
      "Phrase: adverse reactions | Similarity Score: 0.85\n",
      "Phrase: adverse events toxicities | Similarity Score: 0.95\n",
      "Phrase: toxicity events number | Similarity Score: 0.85\n",
      "Phrase: adverse event measurement | Similarity Score: 0.90\n",
      "Phrase: serious adverse events safety analysis - number | Similarity Score: 0.80\n",
      "Phrase: adverse event post transplant success | Similarity Score: 0.81\n",
      "Phrase: adverse event reports | Similarity Score: 0.90\n",
      "Phrase: all adverse events | Similarity Score: 0.90\n",
      "Phrase: serious adverse events toxicity analysis efficacy analysis | Similarity Score: 0.83\n",
      "Phrase: procedure)-related adverse events | Similarity Score: 1.00\n",
      "Phrase: adverse event rates | Similarity Score: 0.84\n",
      "Phrase: the adverse events | Similarity Score: 0.90\n",
      "Phrase: adverse events dose limiting toxicities | Similarity Score: 0.84\n",
      "Phrase: adverse events safety and toxicity assessment | Similarity Score: 0.85\n",
      "Phrase: treatment-emergent adverse events incidence | Similarity Score: 0.81\n",
      "Phrase: emergent adverse events number | Similarity Score: 0.91\n",
      "Phrase: adverse events comparison | Similarity Score: 0.96\n",
      "Phrase: adverse events maximum observed plasma concentration | Similarity Score: 0.83\n",
      "Phrase: adverse events dose escalation part | Similarity Score: 0.84\n",
      "Phrase: adverse events dose | Similarity Score: 0.85\n",
      "Phrase: adverse events grade | Similarity Score: 0.87\n",
      "Phrase: other significant clinical events subjects | Similarity Score: 0.83\n",
      "Phrase: serious adverse reactions | Similarity Score: 0.82\n",
      "Phrase: adverse experiences | Similarity Score: 0.86\n",
      "Phrase: serious adverse experiences | Similarity Score: 0.82\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/t7/9qpt6ghx7x132zp3932q2fb80000gn/T/ipykernel_25717/1737469391.py:27: UserWarning: [W008] Evaluating Span.similarity based on empty vectors.\n",
      "  similarity_score = chunk.similarity(keyword_doc)\n"
     ]
    }
   ],
   "source": [
    "keyword = terms[0]\n",
    "large_text = ref_text\n",
    "\n",
    "# Process the keyword and the large text\n",
    "keyword_doc = nlp(keyword)\n",
    "text_doc = nlp(large_text)\n",
    "\n",
    "# Set a threshold for similarity\n",
    "similarity_threshold = 0.8\n",
    "\n",
    "high_similarity_phrases = []\n",
    "seen_phrases = set()  # Set to track unique words or phrases\n",
    "\n",
    "# Check individual tokens\n",
    "for token in text_doc:\n",
    "    # Skip stop words and punctuation\n",
    "    if not token.is_stop and not token.is_punct:\n",
    "        # Compute similarity\n",
    "        similarity_score = token.similarity(keyword_doc)\n",
    "        if similarity_score >= similarity_threshold and token.text not in seen_phrases:\n",
    "            high_similarity_phrases.append((token.text, similarity_score))\n",
    "            seen_phrases.add(token.text)  # Add to the set of seen phrases\n",
    "\n",
    "# Check multi-word phrases\n",
    "for chunk in text_doc.noun_chunks:\n",
    "    # Compute similarity with the keyword\n",
    "    similarity_score = chunk.similarity(keyword_doc)\n",
    "    if similarity_score >= similarity_threshold and chunk.text not in seen_phrases:\n",
    "        high_similarity_phrases.append((chunk.text, similarity_score))\n",
    "        seen_phrases.add(chunk.text)  # Add to the set of seen phrases\n",
    "\n",
    "# Display the results\n",
    "for phrase, score in high_similarity_phrases:\n",
    "    print(f\"Phrase: {phrase} | Similarity Score: {score:.2f}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('rate', 0.883419419137573),\n",
       " ('rates', 0.8236746847188752),\n",
       " ('objective response rate', 0.8845909278713904),\n",
       " ('overall response rate', 0.9478946439820523),\n",
       " ('vorinostat response rate maximum tolerated dose', 0.8374820756547168),\n",
       " ('safety and tolerability overall response rate', 0.8525315807412328),\n",
       " ('clinical benefit rate', 0.8694133560114623),\n",
       " ('overall objective response rate safety', 0.8953787208878509),\n",
       " ('the overall response rate', 0.8916665131257936),\n",
       " ('overall lymphoma response rate safety', 0.9059862162114447),\n",
       " ('overall response rate incidence rate', 0.9504811462063265),\n",
       " ('standard dose bortezomib objective response rate', 0.8308103466946615),\n",
       " ('response rate maximum tolerated dose overall response rate',\n",
       "  0.9083025379859421),\n",
       " ('complete remission rate number', 0.8607203392312581),\n",
       " ('toxicity rate', 0.8969271133475092),\n",
       " ('overall response rate - phase', 0.8289124002641589),\n",
       " ('severity incidence rate', 0.8988378967019364),\n",
       " ('overall response rate percentage', 0.9470755335205883),\n",
       " ('complete response rate', 0.887871807387932),\n",
       " ('partial response rate', 0.878172164304233),\n",
       " ('dose global response rate', 0.845921118829512),\n",
       " ('the response rate', 0.8515061016926194),\n",
       " ('rp6530 overall response rate incidence', 0.9388703653307024),\n",
       " ('the overall tumor response rate', 0.884276877778474),\n",
       " ('maximum tolerated dose response rate dlts', 0.8374820756547168),\n",
       " ('multiple dose terminal phase rate', 0.8008046205347797),\n",
       " ('overall response rate maximum tolerated dose', 0.8843694240398989),\n",
       " ('bendamustine hydrochloride response rate number', 0.8301292990209946),\n",
       " ('tolerated dose response rate', 0.8197892506109518),\n",
       " ('one-year overall survival rate', 0.8064973584821895),\n",
       " ('- overall response rate', 0.8404051678539136),\n",
       " ('gp2013 terminal elimination rate', 0.8744340145126923),\n",
       " ('the complete response rate', 0.8376290704403991),\n",
       " ('ventricular rate', 0.8980278758663528),\n",
       " ('overall survival rate', 1.0),\n",
       " ('dropout rate', 0.8017713436519602),\n",
       " ('sra737 disease control rate', 0.8585225437795295),\n",
       " ('4.0 complete remission rate incidence', 0.8571131901489756),\n",
       " ('ldk378 objective response rate', 0.8845910013217779),\n",
       " ('overall and complete response rates', 0.8294508790494795),\n",
       " ('venetoclax objective response rate', 0.8685730980599408),\n",
       " ('temsirolimus incidence rate', 0.9076785603511069),\n",
       " ('maximum tolerated dose overall response rate time', 0.8735963960034973),\n",
       " ('heart rate', 0.8192897256375322),\n",
       " ('prt543 response rate acute toxicity', 0.8450685634029554),\n",
       " ('response rate', 0.8904324028063836),\n",
       " ('overall response rates optimum dose', 0.8769832016393847),\n",
       " ('response rate safety profile', 0.8507504195984534),\n",
       " ('venetoclax terminal phase elimination rate', 0.8111663883371122),\n",
       " ('abbv-621 terminal phase elimination rate', 0.825738770967603),\n",
       " ('lenalidomide engraftment rate maximum tolerated dose', 0.8262771675458646),\n",
       " ('disease relapse rate', 0.8530216787689335),\n",
       " ('nci ctcae v3.0 response rate objective tumor response survival time',\n",
       "  0.8394307900240022),\n",
       " ('alt-801 toxicity rate', 0.8969271133475092)]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "aes = []\n",
    "for i in high_similarity_phrases:\n",
    "    if \"adverse events\" not in i[0] and \"adverse event\" not in i[0]:\n",
    "        aes.append(i)\n",
    "\n",
    "aes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "from matplotlib_venn import venn2\n",
    "\n",
    "# Define your two lists of strings\n",
    "list1 = [\n",
    "        'study_duration_days',\n",
    "        'study_eq_bins',\n",
    "        'study_eq_labels',\n",
    "        'num_oms',\n",
    "        'masking',\n",
    "        'number_of_intervention_types',\n",
    "        \"num_locations\",\n",
    "        'number_of_conditions',\n",
    "        'allocation',\n",
    "        'masking',\n",
    "        'enroll_count',\n",
    "        'biological_intervention',\n",
    "        'procedure_intervention',\n",
    "        'drug_intervention',\n",
    "        'radiation_intervention',\n",
    "        'treatment_purpose',\n",
    "        'prevention_purpose',\n",
    "        'us_led',\n",
    "        'us_included',\n",
    "        'nci_sponsor'\n",
    "    ]\n",
    "list2 = [\n",
    "        'protocolSection_identificationModule_nctId',\n",
    "        'primary_study_duration_days',\n",
    "        'study_duration_days',\n",
    "        'primary_eq_bins',\n",
    "        'study_eq_bins',\n",
    "        'study_eq_labels',\n",
    "        'primary_eq_labels',\n",
    "        'number_of_conditions',\n",
    "        'number_of_groups',\n",
    "        'age_group',\n",
    "        'num_locations',\n",
    "        'location',\n",
    "        'num_inclusion',\n",
    "        'num_exclusion',\n",
    "        # 'intervention_types',\n",
    "        'number_of_intervention_types',\n",
    "        'sponsor_type',\n",
    "        'intervention_model',\n",
    "        'resp_party',\n",
    "        'has_dmc',\n",
    "        'phase',\n",
    "        'allocation',\n",
    "        'masking',\n",
    "        'enroll_count',\n",
    "        'healthy_vol',\n",
    "        'treatment_purpose',\n",
    "        'diagnostic_purpose',\n",
    "        'prevention_purpose',\n",
    "        'supportive_purpose',\n",
    "        'procedure_intervention',\n",
    "        'device_intervention',\n",
    "        'behavioral_intervention',\n",
    "        'drug_intervention',\n",
    "        'radiation_intervention',\n",
    "        'biological_intervention',\n",
    "        'os_outcome_measure',\n",
    "        'dor_outcome_measure',\n",
    "        'ae_outcome_measure',\n",
    "        'primary_max_days',\n",
    "        'secondary_max_days',\n",
    "        'max_treatment_duration',\n",
    "        'min_treatment_duration',\n",
    "        'survival_5yr_relative',\n",
    "        # 'conditions_category_num'\n",
    "        # 'protocolSection_outcomesModule_primaryOutcomes',\n",
    "        # 'protocolSection_outcomesModule_secondaryOutcomes',\n",
    "        # 'protocolSection_eligibilityModule_eligibilityCriteria'\n",
    "    ]\n",
    "\n",
    "\n",
    "# Convert lists to sets and get unique and common items\n",
    "set1 = set(list1)\n",
    "set2 = set(list2)\n",
    "unique_to_list1 = set1 - set2\n",
    "unique_to_list2 = set2 - set1\n",
    "common_to_both = set1 & set2\n",
    "\n",
    "# Create the Venn diagram\n",
    "plt.figure(figsize=(8, 6))\n",
    "venn = venn2([set1, set2], set_labels=('Long, et al. Features', 'ClinicalAI Features'))\n",
    "\n",
    "# Update each section of the Venn with the items from each set\n",
    "venn.get_label_by_id('10').set_text(\"\\n\".join(unique_to_list1))  # Unique to List 1\n",
    "venn.get_label_by_id('01').set_text(\"\\n\".join(unique_to_list2))  # Unique to List 2\n",
    "venn.get_label_by_id('11').set_text(\"\\n\".join(common_to_both))   # Common to both\n",
    "\n",
    "# Display the plot\n",
    "plt.title(\"Model Features\")\n",
    "plt.show()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import spacy\n",
    "from itertools import combinations\n",
    "\n",
    "class DisjointSetUnion:\n",
    "    def __init__(self):\n",
    "        self.parent = {}\n",
    "        self.rank = {}\n",
    "\n",
    "    def find(self, item):\n",
    "        if self.parent[item] != item:\n",
    "            self.parent[item] = self.find(self.parent[item])\n",
    "        return self.parent[item]\n",
    "\n",
    "    def union(self, item1, item2):\n",
    "        root1 = self.find(item1)\n",
    "        root2 = self.find(item2)\n",
    "        \n",
    "        if root1 != root2:\n",
    "            if self.rank[root1] > self.rank[root2]:\n",
    "                self.parent[root2] = root1\n",
    "            elif self.rank[root1] < self.rank[root2]:\n",
    "                self.parent[root1] = root2\n",
    "            else:\n",
    "                self.parent[root2] = root1\n",
    "                self.rank[root1] += 1\n",
    "\n",
    "    def add(self, item):\n",
    "        if item not in self.parent:\n",
    "            self.parent[item] = item\n",
    "            self.rank[item] = 0\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "def group_similar_terms(terms, text, similarity_threshold=0.8):\n",
    "    dsu = DisjointSetUnion()\n",
    "\n",
    "    # Process the text with spaCy\n",
    "    doc = nlp(text)\n",
    "\n",
    "    # Create a spaCy document for each term to compare\n",
    "    term_docs = {term: nlp(term) for term in terms}\n",
    "\n",
    "    # Add terms to DSU\n",
    "    for term in terms:\n",
    "        dsu.add(term)\n",
    "\n",
    "    # Compare terms against each other for similarity\n",
    "    for term1, term2 in combinations(terms, 2):\n",
    "        similarity = term_docs[term1].similarity(term_docs[term2])\n",
    "        if similarity >= similarity_threshold:\n",
    "            dsu.union(term1, term2)\n",
    "\n",
    "    # Create groups based on the DSU\n",
    "    groups = {}\n",
    "    for term in terms:\n",
    "        root = dsu.find(term)\n",
    "        if root not in groups:\n",
    "            groups[root] = []\n",
    "        groups[root].append(term)\n",
    "\n",
    "    return groups"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>protocolSection_statusModule_dispFirstPostDateStruct_type</th>\n",
       "      <th>protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>protocolSection_designModule_designInfo_maskingInfo_whoMasked</th>\n",
       "      <th>protocolSection_oversightModule_isUsExport</th>\n",
       "      <th>protocolSection_designModule_designInfo_maskingInfo_maskingDescription</th>\n",
       "      <th>protocolSection_referencesModule_availIpds</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_nctId</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_statusForNctId</th>\n",
       "      <th>protocolSection_oversightModule_isUnapprovedDevice</th>\n",
       "      <th>similarity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.379698</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.381611</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.441973</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.396287</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.635230</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-0.126607</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.443009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-0.126607</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.494792</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.474961</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 87 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     protocolSection_statusModule_dispFirstPostDateStruct_type  \\\n",
       "0                                                   NaN          \n",
       "1                                                   NaN          \n",
       "2                                                   NaN          \n",
       "3                                                   NaN          \n",
       "4                                                   NaN          \n",
       "...                                                 ...          \n",
       "1095                                          ESTIMATED          \n",
       "1096                                                NaN          \n",
       "1097                                                NaN          \n",
       "1098                                                NaN          \n",
       "1099                                                NaN          \n",
       "\n",
       "     protocolSection_outcomesModule_otherOutcomes  \\\n",
       "0                                             NaN   \n",
       "1                                             NaN   \n",
       "2                                             NaN   \n",
       "3                                             NaN   \n",
       "4                                             NaN   \n",
       "...                                           ...   \n",
       "1095                                          NaN   \n",
       "1096                                          NaN   \n",
       "1097                                          NaN   \n",
       "1098                                          NaN   \n",
       "1099                                          NaN   \n",
       "\n",
       "     protocolSection_designModule_designInfo_maskingInfo_whoMasked  \\\n",
       "0                                                   NaN              \n",
       "1                                                   NaN              \n",
       "2                                                   NaN              \n",
       "3                                                   NaN              \n",
       "4                                                   NaN              \n",
       "...                                                 ...              \n",
       "1095                                                NaN              \n",
       "1096                                                NaN              \n",
       "1097                                                NaN              \n",
       "1098                                                NaN              \n",
       "1099                                                NaN              \n",
       "\n",
       "     protocolSection_oversightModule_isUsExport  \\\n",
       "0                                           NaN   \n",
       "1                                           NaN   \n",
       "2                                           NaN   \n",
       "3                                           NaN   \n",
       "4                                           NaN   \n",
       "...                                         ...   \n",
       "1095                                        NaN   \n",
       "1096                                        NaN   \n",
       "1097                                        NaN   \n",
       "1098                                        NaN   \n",
       "1099                                        NaN   \n",
       "\n",
       "     protocolSection_designModule_designInfo_maskingInfo_maskingDescription  \\\n",
       "0                                                   NaN                       \n",
       "1                                                   NaN                       \n",
       "2                                                   NaN                       \n",
       "3                                                   NaN                       \n",
       "4                                                   NaN                       \n",
       "...                                                 ...                       \n",
       "1095                                                NaN                       \n",
       "1096                                                NaN                       \n",
       "1097                                                NaN                       \n",
       "1098                                                NaN                       \n",
       "1099                                                NaN                       \n",
       "\n",
       "     protocolSection_referencesModule_availIpds  \\\n",
       "0                                           NaN   \n",
       "1                                           NaN   \n",
       "2                                           NaN   \n",
       "3                                           NaN   \n",
       "4                                           NaN   \n",
       "...                                         ...   \n",
       "1095                                        NaN   \n",
       "1096                                        NaN   \n",
       "1097                                        NaN   \n",
       "1098                                        NaN   \n",
       "1099                                        NaN   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_nctId  \\\n",
       "0                                                   NaN      \n",
       "1                                                   NaN      \n",
       "2                                                   NaN      \n",
       "3                                                   NaN      \n",
       "4                                                   NaN      \n",
       "...                                                 ...      \n",
       "1095                                                NaN      \n",
       "1096                                                NaN      \n",
       "1097                                                NaN      \n",
       "1098                                                NaN      \n",
       "1099                                                NaN      \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_statusForNctId  \\\n",
       "0                                                   NaN               \n",
       "1                                                   NaN               \n",
       "2                                                   NaN               \n",
       "3                                                   NaN               \n",
       "4                                                   NaN               \n",
       "...                                                 ...               \n",
       "1095                                                NaN               \n",
       "1096                                                NaN               \n",
       "1097                                                NaN               \n",
       "1098                                                NaN               \n",
       "1099                                                NaN               \n",
       "\n",
       "     protocolSection_oversightModule_isUnapprovedDevice similarity  \n",
       "0                                                   NaN   0.379698  \n",
       "1                                                   NaN   0.381611  \n",
       "2                                                   NaN   0.441973  \n",
       "3                                                   NaN   0.396287  \n",
       "4                                                   NaN   0.635230  \n",
       "...                                                 ...        ...  \n",
       "1095                                                NaN  -0.126607  \n",
       "1096                                                NaN   0.443009  \n",
       "1097                                                NaN  -0.126607  \n",
       "1098                                                NaN   0.494792  \n",
       "1099                                                NaN   0.474961  \n",
       "\n",
       "[1100 rows x 87 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "term_to_compare = terms[0]\n",
    "df['similarity'] = df['protocolSection_outcomesModule_primaryOutcomes'].astype(str).apply(lambda x: compute_similarity(term_to_compare, x))\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['protocolSection_conditionsModule_keywords']"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "x = [i for i in df.columns if 'keyword' in i]\n",
    "x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       [immunotherapy, check point inhibitor, PD-1 an...\n",
       "1         [Allogenetic NK cells, Lymphomas, Solid tumors]\n",
       "2                                                     NaN\n",
       "3             [4SC-205, Solid tumors, Lymphomas, Phase I]\n",
       "4       [Advanced solid malignancies, Malignant lymphoma]\n",
       "                              ...                        \n",
       "1095    [stage I colon cancer, stage II colon cancer, ...\n",
       "1096    [stage IIIB anal cancer, stage IV anal cancer,...\n",
       "1097    [stage III colon cancer, stage IV colon cancer...\n",
       "1098                                                  NaN\n",
       "1099    [Coronavirus Disease, Creatine phosphokinase, ...\n",
       "Name: protocolSection_conditionsModule_keywords, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['protocolSection_conditionsModule_keywords']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>protocolSection_designModule_designInfo_maskingInfo_maskingDescription</th>\n",
       "      <th>protocolSection_referencesModule_availIpds</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_nctId</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_statusForNctId</th>\n",
       "      <th>protocolSection_oversightModule_isUnapprovedDevice</th>\n",
       "      <th>start_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_study_duration_days</th>\n",
       "      <th>study_duration_days</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>2018-09-15</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>430.0</td>\n",
       "      <td>901.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2012-08-01</td>\n",
       "      <td>2013-03-01</td>\n",
       "      <td>700.0</td>\n",
       "      <td>912.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-04-01</td>\n",
       "      <td>2015-11-01</td>\n",
       "      <td>2016-03-01</td>\n",
       "      <td>944.0</td>\n",
       "      <td>1065.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2010-01-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>1916.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2012-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>730.0</td>\n",
       "      <td>730.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>1127.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2008-06-01</td>\n",
       "      <td>2010-11-01</td>\n",
       "      <td>2012-12-03</td>\n",
       "      <td>883.0</td>\n",
       "      <td>1646.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>1461.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>2343.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>342.0</td>\n",
       "      <td>342.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 91 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     protocolSection_designModule_designInfo_maskingInfo_maskingDescription  \\\n",
       "0                                                   NaN                       \n",
       "1                                                   NaN                       \n",
       "2                                                   NaN                       \n",
       "3                                                   NaN                       \n",
       "4                                                   NaN                       \n",
       "...                                                 ...                       \n",
       "1095                                                NaN                       \n",
       "1096                                                NaN                       \n",
       "1097                                                NaN                       \n",
       "1098                                                NaN                       \n",
       "1099                                                NaN                       \n",
       "\n",
       "     protocolSection_referencesModule_availIpds  \\\n",
       "0                                           NaN   \n",
       "1                                           NaN   \n",
       "2                                           NaN   \n",
       "3                                           NaN   \n",
       "4                                           NaN   \n",
       "...                                         ...   \n",
       "1095                                        NaN   \n",
       "1096                                        NaN   \n",
       "1097                                        NaN   \n",
       "1098                                        NaN   \n",
       "1099                                        NaN   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_nctId  \\\n",
       "0                                                   NaN      \n",
       "1                                                   NaN      \n",
       "2                                                   NaN      \n",
       "3                                                   NaN      \n",
       "4                                                   NaN      \n",
       "...                                                 ...      \n",
       "1095                                                NaN      \n",
       "1096                                                NaN      \n",
       "1097                                                NaN      \n",
       "1098                                                NaN      \n",
       "1099                                                NaN      \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_statusForNctId  \\\n",
       "0                                                   NaN               \n",
       "1                                                   NaN               \n",
       "2                                                   NaN               \n",
       "3                                                   NaN               \n",
       "4                                                   NaN               \n",
       "...                                                 ...               \n",
       "1095                                                NaN               \n",
       "1096                                                NaN               \n",
       "1097                                                NaN               \n",
       "1098                                                NaN               \n",
       "1099                                                NaN               \n",
       "\n",
       "     protocolSection_oversightModule_isUnapprovedDevice start_date  \\\n",
       "0                                                   NaN 2017-07-12   \n",
       "1                                                   NaN 2010-09-01   \n",
       "2                                                   NaN 2013-04-01   \n",
       "3                                                   NaN 2010-01-01   \n",
       "4                                                   NaN 2012-07-01   \n",
       "...                                                 ...        ...   \n",
       "1095                                                NaN 2000-01-01   \n",
       "1096                                                NaN 2008-06-01   \n",
       "1097                                                NaN 1999-03-01   \n",
       "1098                                                NaN 2007-01-01   \n",
       "1099                                                NaN 2021-01-06   \n",
       "\n",
       "     primary_completion_date completion_date primary_study_duration_days  \\\n",
       "0                 2018-09-15      2019-12-30                       430.0   \n",
       "1                 2012-08-01      2013-03-01                       700.0   \n",
       "2                 2015-11-01      2016-03-01                       944.0   \n",
       "3                 2015-04-01      2015-04-01                      1916.0   \n",
       "4                 2014-07-01      2014-07-01                       730.0   \n",
       "...                      ...             ...                         ...   \n",
       "1095              2003-02-01      2003-02-01                      1127.0   \n",
       "1096              2010-11-01      2012-12-03                       883.0   \n",
       "1097              2003-03-01      2003-03-01                      1461.0   \n",
       "1098              2013-06-01      2013-06-01                      2343.0   \n",
       "1099              2021-12-14      2021-12-14                       342.0   \n",
       "\n",
       "     study_duration_days  \n",
       "0                  901.0  \n",
       "1                  912.0  \n",
       "2                 1065.0  \n",
       "3                 1916.0  \n",
       "4                  730.0  \n",
       "...                  ...  \n",
       "1095              1127.0  \n",
       "1096              1646.0  \n",
       "1097              1461.0  \n",
       "1098              2343.0  \n",
       "1099               342.0  \n",
       "\n",
       "[1100 rows x 91 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['start_date'] = df['protocolSection_statusModule_startDateStruct_date'].apply(convert_to_datetime)\n",
    "df['primary_completion_date'] = df['protocolSection_statusModule_primaryCompletionDateStruct_date'].apply(convert_to_datetime)\n",
    "df['completion_date'] = df['protocolSection_statusModule_completionDateStruct_date'].apply(convert_to_datetime)\n",
    "df['primary_study_duration_days'] = (df['primary_completion_date'] - df['start_date']).dt.days\n",
    "df['study_duration_days'] = (df['completion_date'] - df['start_date']).dt.days\n",
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1786.860655737705"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#avg trial duration\n",
    "avg_dur = np.mean(df['study_duration_days'])\n",
    "avg_dur"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_nctId</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_statusForNctId</th>\n",
       "      <th>protocolSection_oversightModule_isUnapprovedDevice</th>\n",
       "      <th>start_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_study_duration_days</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>2018-09-15</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>430.0</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2012-08-01</td>\n",
       "      <td>2013-03-01</td>\n",
       "      <td>700.0</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-04-01</td>\n",
       "      <td>2015-11-01</td>\n",
       "      <td>2016-03-01</td>\n",
       "      <td>944.0</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2010-01-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2012-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>730.0</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2008-06-01</td>\n",
       "      <td>2010-11-01</td>\n",
       "      <td>2012-12-03</td>\n",
       "      <td>883.0</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>342.0</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 93 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_nctId  \\\n",
       "0                                                   NaN      \n",
       "1                                                   NaN      \n",
       "2                                                   NaN      \n",
       "3                                                   NaN      \n",
       "4                                                   NaN      \n",
       "...                                                 ...      \n",
       "1095                                                NaN      \n",
       "1096                                                NaN      \n",
       "1097                                                NaN      \n",
       "1098                                                NaN      \n",
       "1099                                                NaN      \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_statusForNctId  \\\n",
       "0                                                   NaN               \n",
       "1                                                   NaN               \n",
       "2                                                   NaN               \n",
       "3                                                   NaN               \n",
       "4                                                   NaN               \n",
       "...                                                 ...               \n",
       "1095                                                NaN               \n",
       "1096                                                NaN               \n",
       "1097                                                NaN               \n",
       "1098                                                NaN               \n",
       "1099                                                NaN               \n",
       "\n",
       "     protocolSection_oversightModule_isUnapprovedDevice start_date  \\\n",
       "0                                                   NaN 2017-07-12   \n",
       "1                                                   NaN 2010-09-01   \n",
       "2                                                   NaN 2013-04-01   \n",
       "3                                                   NaN 2010-01-01   \n",
       "4                                                   NaN 2012-07-01   \n",
       "...                                                 ...        ...   \n",
       "1095                                                NaN 2000-01-01   \n",
       "1096                                                NaN 2008-06-01   \n",
       "1097                                                NaN 1999-03-01   \n",
       "1098                                                NaN 2007-01-01   \n",
       "1099                                                NaN 2021-01-06   \n",
       "\n",
       "     primary_completion_date completion_date primary_study_duration_days  \\\n",
       "0                 2018-09-15      2019-12-30                       430.0   \n",
       "1                 2012-08-01      2013-03-01                       700.0   \n",
       "2                 2015-11-01      2016-03-01                       944.0   \n",
       "3                 2015-04-01      2015-04-01                      1916.0   \n",
       "4                 2014-07-01      2014-07-01                       730.0   \n",
       "...                      ...             ...                         ...   \n",
       "1095              2003-02-01      2003-02-01                      1127.0   \n",
       "1096              2010-11-01      2012-12-03                       883.0   \n",
       "1097              2003-03-01      2003-03-01                      1461.0   \n",
       "1098              2013-06-01      2013-06-01                      2343.0   \n",
       "1099              2021-12-14      2021-12-14                       342.0   \n",
       "\n",
       "     study_duration_days study_eq_bins study_eq_labels  \n",
       "0                  901.0           Low               0  \n",
       "1                  912.0           Low               0  \n",
       "2                 1065.0           Low               0  \n",
       "3                 1916.0          High               1  \n",
       "4                  730.0           Low               0  \n",
       "...                  ...           ...             ...  \n",
       "1095              1127.0           Low               0  \n",
       "1096              1646.0           Low               0  \n",
       "1097              1461.0           Low               0  \n",
       "1098              2343.0          High               1  \n",
       "1099               342.0           Low               0  \n",
       "\n",
       "[1100 rows x 93 columns]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['study_eq_bins'] = pd.cut(df['study_duration_days'], bins=[df['study_duration_days'].min(), avg_dur, df['study_duration_days'].max()], labels=['Low', 'High'], right=False)\n",
    "\n",
    "df['study_eq_labels'] = df['study_eq_bins'].cat.codes\n",
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['protocolSection_outcomesModule_primaryOutcomes',\n",
       " 'protocolSection_outcomesModule_secondaryOutcomes',\n",
       " 'protocolSection_outcomesModule_otherOutcomes']"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "oms = [col for col in df.columns if \"outcome\" in col]\n",
    "oms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "def list_to_lower_string(lst):\n",
    "    # Ensure the input is a list\n",
    "    if isinstance(lst, list):\n",
    "        # Convert each element to a lowercase string and join with spaces\n",
    "        return \", \".join(map(str, lst)).lower()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>start_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_study_duration_days</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>2018-09-15</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>430.0</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2012-08-01</td>\n",
       "      <td>2013-03-01</td>\n",
       "      <td>700.0</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-04-01</td>\n",
       "      <td>2015-11-01</td>\n",
       "      <td>2016-03-01</td>\n",
       "      <td>944.0</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2010-01-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>730.0</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2008-06-01</td>\n",
       "      <td>2010-11-01</td>\n",
       "      <td>2012-12-03</td>\n",
       "      <td>883.0</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>1999-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>342.0</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 96 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ... start_date  \\\n",
       "0                                           2017-07-12  ... 2017-07-12   \n",
       "1                                              2010-09  ... 2010-09-01   \n",
       "2                                              2013-04  ... 2013-04-01   \n",
       "3                                              2010-01  ... 2010-01-01   \n",
       "4                                              2012-07  ... 2012-07-01   \n",
       "...                                                ...  ...        ...   \n",
       "1095                                           2000-01  ... 2000-01-01   \n",
       "1096                                           2008-06  ... 2008-06-01   \n",
       "1097                                           1999-03  ... 1999-03-01   \n",
       "1098                                           2007-01  ... 2007-01-01   \n",
       "1099                                        2021-01-06  ... 2021-01-06   \n",
       "\n",
       "     primary_completion_date completion_date primary_study_duration_days  \\\n",
       "0                 2018-09-15      2019-12-30                       430.0   \n",
       "1                 2012-08-01      2013-03-01                       700.0   \n",
       "2                 2015-11-01      2016-03-01                       944.0   \n",
       "3                 2015-04-01      2015-04-01                      1916.0   \n",
       "4                 2014-07-01      2014-07-01                       730.0   \n",
       "...                      ...             ...                         ...   \n",
       "1095              2003-02-01      2003-02-01                      1127.0   \n",
       "1096              2010-11-01      2012-12-03                       883.0   \n",
       "1097              2003-03-01      2003-03-01                      1461.0   \n",
       "1098              2013-06-01      2013-06-01                      2343.0   \n",
       "1099              2021-12-14      2021-12-14                       342.0   \n",
       "\n",
       "     study_duration_days study_eq_bins study_eq_labels  \\\n",
       "0                  901.0           Low               0   \n",
       "1                  912.0           Low               0   \n",
       "2                 1065.0           Low               0   \n",
       "3                 1916.0          High               1   \n",
       "4                  730.0           Low               0   \n",
       "...                  ...           ...             ...   \n",
       "1095              1127.0           Low               0   \n",
       "1096              1646.0           Low               0   \n",
       "1097              1461.0           Low               0   \n",
       "1098              2343.0          High               1   \n",
       "1099               342.0           Low               0   \n",
       "\n",
       "     num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                                                     1   \n",
       "1                                                     1   \n",
       "2                                                     1   \n",
       "3                                                     1   \n",
       "4                                                     1   \n",
       "...                                                 ...   \n",
       "1095                                                  0   \n",
       "1096                                                  1   \n",
       "1097                                                  0   \n",
       "1098                                                  2   \n",
       "1099                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes  \n",
       "0                                                   0  \n",
       "1                                                   0  \n",
       "2                                                   0  \n",
       "3                                                   0  \n",
       "4                                                   0  \n",
       "...                                               ...  \n",
       "1095                                                0  \n",
       "1096                                                0  \n",
       "1097                                                0  \n",
       "1098                                                0  \n",
       "1099                                                0  \n",
       "\n",
       "[1100 rows x 96 columns]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "for i in oms:\n",
    "    df[i].apply(list_to_lower_string)\n",
    "    df[f\"num_{i}\"] = df[i].apply(lambda x: len(x) if isinstance(x, list) else 0)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['num_protocolSection_outcomesModule_primaryOutcomes',\n",
       " 'num_protocolSection_outcomesModule_secondaryOutcomes',\n",
       " 'num_protocolSection_outcomesModule_otherOutcomes']"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "num_om_cols = [col for col in df.columns if \"num\" in col and \"outcome\" in col]\n",
    "num_om_cols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_study_duration_days</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>2018-09-15</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>430.0</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-08-01</td>\n",
       "      <td>2013-03-01</td>\n",
       "      <td>700.0</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>2015-11-01</td>\n",
       "      <td>2016-03-01</td>\n",
       "      <td>944.0</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>730.0</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2010-11-01</td>\n",
       "      <td>2012-12-03</td>\n",
       "      <td>883.0</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>342.0</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 97 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     primary_completion_date completion_date primary_study_duration_days  \\\n",
       "0                 2018-09-15      2019-12-30                       430.0   \n",
       "1                 2012-08-01      2013-03-01                       700.0   \n",
       "2                 2015-11-01      2016-03-01                       944.0   \n",
       "3                 2015-04-01      2015-04-01                      1916.0   \n",
       "4                 2014-07-01      2014-07-01                       730.0   \n",
       "...                      ...             ...                         ...   \n",
       "1095              2003-02-01      2003-02-01                      1127.0   \n",
       "1096              2010-11-01      2012-12-03                       883.0   \n",
       "1097              2003-03-01      2003-03-01                      1461.0   \n",
       "1098              2013-06-01      2013-06-01                      2343.0   \n",
       "1099              2021-12-14      2021-12-14                       342.0   \n",
       "\n",
       "     study_duration_days study_eq_bins study_eq_labels  \\\n",
       "0                  901.0           Low               0   \n",
       "1                  912.0           Low               0   \n",
       "2                 1065.0           Low               0   \n",
       "3                 1916.0          High               1   \n",
       "4                  730.0           Low               0   \n",
       "...                  ...           ...             ...   \n",
       "1095              1127.0           Low               0   \n",
       "1096              1646.0           Low               0   \n",
       "1097              1461.0           Low               0   \n",
       "1098              2343.0          High               1   \n",
       "1099               342.0           Low               0   \n",
       "\n",
       "     num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                                                     1   \n",
       "1                                                     1   \n",
       "2                                                     1   \n",
       "3                                                     1   \n",
       "4                                                     1   \n",
       "...                                                 ...   \n",
       "1095                                                  0   \n",
       "1096                                                  1   \n",
       "1097                                                  0   \n",
       "1098                                                  2   \n",
       "1099                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms  \n",
       "0                                                   0       3  \n",
       "1                                                   0       4  \n",
       "2                                                   0       5  \n",
       "3                                                   0       4  \n",
       "4                                                   0       1  \n",
       "...                                               ...     ...  \n",
       "1095                                                0       0  \n",
       "1096                                                0       2  \n",
       "1097                                                0       0  \n",
       "1098                                                0       5  \n",
       "1099                                                0       9  \n",
       "\n",
       "[1100 rows x 97 columns]"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['num_oms'] = df[num_om_cols].sum(axis=1)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cols = [col for col in df.columns if \"nci\" in col]\n",
    "cols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       [{'type': 'BIOLOGICAL', 'name': 'Toripalimab',...\n",
       "1       [{'type': 'BIOLOGICAL', 'name': 'Allogeneic NK...\n",
       "2       [{'type': 'DRUG', 'name': 'Gemcitabine HCl Ora...\n",
       "3       [{'type': 'DRUG', 'name': '4SC-205', 'descript...\n",
       "4       [{'type': 'DRUG', 'name': 'AZD1208', 'descript...\n",
       "                              ...                        \n",
       "1095    [{'type': 'PROCEDURE', 'name': 'bowel obstruct...\n",
       "1096    [{'type': 'DRUG', 'name': 'fluorouracil'}, {'t...\n",
       "1097    [{'type': 'DRUG', 'name': 'capecitabine'}, {'t...\n",
       "1098    [{'type': 'DRUG', 'name': 'cetuximab', 'descri...\n",
       "1099    [{'type': 'BIOLOGICAL', 'name': 'cAd3-Marburg'...\n",
       "Name: protocolSection_armsInterventionsModule_interventions, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['protocolSection_armsInterventionsModule_interventions']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                    [Malignant Lymphoma]\n",
       "1                     [Malignant Lymphomas, Solid Tumors]\n",
       "2       [Advanced Solid Malignancies, Malignant Lympho...\n",
       "3       [Advanced and Incurable Solid Tumors, Malignan...\n",
       "4       [Advanced Solid Malignancies, Malignant Lymphoma]\n",
       "                              ...                        \n",
       "1095    [Colorectal Cancer, Constipation, Impaction, a...\n",
       "1096    [Anal Cancer, Carcinoma of the Appendix, Color...\n",
       "1097                                             [Cancer]\n",
       "1098    [Adenocarcinoma of the Colon, Adenocarcinoma o...\n",
       "1099         [Ebola Virus Disease, Marburg Virus Disease]\n",
       "Name: protocolSection_conditionsModule_conditions, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['protocolSection_conditionsModule_conditions']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_study_duration_days</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>us_included</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>430.0</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-03-01</td>\n",
       "      <td>700.0</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>2016-03-01</td>\n",
       "      <td>944.0</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>730.0</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-12-03</td>\n",
       "      <td>883.0</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>342.0</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 98 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ... completion_date  \\\n",
       "0                                           2017-07-12  ...      2019-12-30   \n",
       "1                                              2010-09  ...      2013-03-01   \n",
       "2                                              2013-04  ...      2016-03-01   \n",
       "3                                              2010-01  ...      2015-04-01   \n",
       "4                                              2012-07  ...      2014-07-01   \n",
       "...                                                ...  ...             ...   \n",
       "1095                                           2000-01  ...      2003-02-01   \n",
       "1096                                           2008-06  ...      2012-12-03   \n",
       "1097                                           1999-03  ...      2003-03-01   \n",
       "1098                                           2007-01  ...      2013-06-01   \n",
       "1099                                        2021-01-06  ...      2021-12-14   \n",
       "\n",
       "     primary_study_duration_days study_duration_days study_eq_bins  \\\n",
       "0                          430.0               901.0           Low   \n",
       "1                          700.0               912.0           Low   \n",
       "2                          944.0              1065.0           Low   \n",
       "3                         1916.0              1916.0          High   \n",
       "4                          730.0               730.0           Low   \n",
       "...                          ...                 ...           ...   \n",
       "1095                      1127.0              1127.0           Low   \n",
       "1096                       883.0              1646.0           Low   \n",
       "1097                      1461.0              1461.0           Low   \n",
       "1098                      2343.0              2343.0          High   \n",
       "1099                       342.0               342.0           Low   \n",
       "\n",
       "     study_eq_labels num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                  0                                                  1   \n",
       "1                  0                                                  1   \n",
       "2                  0                                                  1   \n",
       "3                  1                                                  1   \n",
       "4                  0                                                  1   \n",
       "...              ...                                                ...   \n",
       "1095               0                                                  0   \n",
       "1096               0                                                  1   \n",
       "1097               0                                                  0   \n",
       "1098               1                                                  2   \n",
       "1099               0                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms us_included  \n",
       "0                                                   0       3       False  \n",
       "1                                                   0       4       False  \n",
       "2                                                   0       5       False  \n",
       "3                                                   0       4       False  \n",
       "4                                                   0       1       False  \n",
       "...                                               ...     ...         ...  \n",
       "1095                                                0       0       False  \n",
       "1096                                                0       2       False  \n",
       "1097                                                0       0       False  \n",
       "1098                                                0       5       False  \n",
       "1099                                                0       9       False  \n",
       "\n",
       "[1100 rows x 98 columns]"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['us_included'] = df[\"protocolSection_contactsLocationsModule_locations\"].astype(str).apply(lambda x: True if x == \"USA\" or x == \"USA & non-USA\" else False)\n",
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_study_duration_days</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>us_included</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>430.0</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-03-01</td>\n",
       "      <td>700.0</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>2016-03-01</td>\n",
       "      <td>944.0</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2015-04-01</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>2014-07-01</td>\n",
       "      <td>730.0</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-02-01</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-12-03</td>\n",
       "      <td>883.0</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-03-01</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2013-06-01</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>2021-12-14</td>\n",
       "      <td>342.0</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 98 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ... completion_date  \\\n",
       "0                                           2017-07-12  ...      2019-12-30   \n",
       "1                                              2010-09  ...      2013-03-01   \n",
       "2                                              2013-04  ...      2016-03-01   \n",
       "3                                              2010-01  ...      2015-04-01   \n",
       "4                                              2012-07  ...      2014-07-01   \n",
       "...                                                ...  ...             ...   \n",
       "1095                                           2000-01  ...      2003-02-01   \n",
       "1096                                           2008-06  ...      2012-12-03   \n",
       "1097                                           1999-03  ...      2003-03-01   \n",
       "1098                                           2007-01  ...      2013-06-01   \n",
       "1099                                        2021-01-06  ...      2021-12-14   \n",
       "\n",
       "     primary_study_duration_days study_duration_days study_eq_bins  \\\n",
       "0                          430.0               901.0           Low   \n",
       "1                          700.0               912.0           Low   \n",
       "2                          944.0              1065.0           Low   \n",
       "3                         1916.0              1916.0          High   \n",
       "4                          730.0               730.0           Low   \n",
       "...                          ...                 ...           ...   \n",
       "1095                      1127.0              1127.0           Low   \n",
       "1096                       883.0              1646.0           Low   \n",
       "1097                      1461.0              1461.0           Low   \n",
       "1098                      2343.0              2343.0          High   \n",
       "1099                       342.0               342.0           Low   \n",
       "\n",
       "     study_eq_labels num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                  0                                                  1   \n",
       "1                  0                                                  1   \n",
       "2                  0                                                  1   \n",
       "3                  1                                                  1   \n",
       "4                  0                                                  1   \n",
       "...              ...                                                ...   \n",
       "1095               0                                                  0   \n",
       "1096               0                                                  1   \n",
       "1097               0                                                  0   \n",
       "1098               1                                                  2   \n",
       "1099               0                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms us_included  \n",
       "0                                                   0       3       False  \n",
       "1                                                   0       4       False  \n",
       "2                                                   0       5       False  \n",
       "3                                                   0       4       False  \n",
       "4                                                   0       1       False  \n",
       "...                                               ...     ...         ...  \n",
       "1095                                                0       0        True  \n",
       "1096                                                0       2        True  \n",
       "1097                                                0       0        True  \n",
       "1098                                                0       5        True  \n",
       "1099                                                0       9        True  \n",
       "\n",
       "[1100 rows x 98 columns]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['us_included'] = df[\"protocolSection_contactsLocationsModule_locations\"].astype(str).apply(trial_loc).apply(lambda x: True if x == \"USA\" or x == \"USA & non-USA\" else False)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       non-USA\n",
       "1       non-USA\n",
       "2       non-USA\n",
       "3       non-USA\n",
       "4       non-USA\n",
       "         ...   \n",
       "1095        USA\n",
       "1096        USA\n",
       "1097        USA\n",
       "1098        USA\n",
       "1099        USA\n",
       "Name: location0, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['location0'] = df[\"protocolSection_contactsLocationsModule_locations\"].astype(str).apply(trial_loc)\n",
    "df['location0']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "11    [{'facility': 'Florida Cancer Specialists', 'c...\n",
       "12    [{'facility': 'Florida Cancer Specialists', 'c...\n",
       "15    [{'facility': 'Novartis Investigative Site', '...\n",
       "17    [{'city': 'Goodyear', 'state': 'Arizona', 'cou...\n",
       "21    [{'facility': 'The Cancer Institute of New Jer...\n",
       "24    [{'facility': 'University of California San Fr...\n",
       "25    [{'facility': 'Dana Farber Cancer Institute DF...\n",
       "36    [{'facility': 'Banner Health', 'city': 'Gilber...\n",
       "43    [{'facility': 'City of Hope National Medical C...\n",
       "45    [{'facility': 'UCLA', 'city': 'Los Angeles', '...\n",
       "Name: protocolSection_contactsLocationsModule_locations, dtype: object"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.loc[df['location0'] == \"USA & non-USA\", \"protocolSection_contactsLocationsModule_locations\"][:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "x = df.loc[df['location0'] == \"USA & non-USA\", \"protocolSection_contactsLocationsModule_locations\"][15]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False\n"
     ]
    }
   ],
   "source": [
    "counter = {\"USA\": 0, \"non-USA\": 0}\n",
    "for i in x:\n",
    "    if i['country'] == 'United States':\n",
    "        counter[\"USA\"] += 1\n",
    "    else:\n",
    "        counter[\"non-USA\"] += 1\n",
    "\n",
    "if counter['USA'] > counter['non-USA']:\n",
    "    print(True)\n",
    "else:\n",
    "    print(False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>us_included</th>\n",
       "      <th>location0</th>\n",
       "      <th>us_led</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 100 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     study_duration_days study_eq_bins study_eq_labels  \\\n",
       "0                  901.0           Low               0   \n",
       "1                  912.0           Low               0   \n",
       "2                 1065.0           Low               0   \n",
       "3                 1916.0          High               1   \n",
       "4                  730.0           Low               0   \n",
       "...                  ...           ...             ...   \n",
       "1095              1127.0           Low               0   \n",
       "1096              1646.0           Low               0   \n",
       "1097              1461.0           Low               0   \n",
       "1098              2343.0          High               1   \n",
       "1099               342.0           Low               0   \n",
       "\n",
       "     num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                                                     1   \n",
       "1                                                     1   \n",
       "2                                                     1   \n",
       "3                                                     1   \n",
       "4                                                     1   \n",
       "...                                                 ...   \n",
       "1095                                                  0   \n",
       "1096                                                  1   \n",
       "1097                                                  0   \n",
       "1098                                                  2   \n",
       "1099                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms us_included  \\\n",
       "0                                                   0       3       False   \n",
       "1                                                   0       4       False   \n",
       "2                                                   0       5       False   \n",
       "3                                                   0       4       False   \n",
       "4                                                   0       1       False   \n",
       "...                                               ...     ...         ...   \n",
       "1095                                                0       0        True   \n",
       "1096                                                0       2        True   \n",
       "1097                                                0       0        True   \n",
       "1098                                                0       5        True   \n",
       "1099                                                0       9        True   \n",
       "\n",
       "     location0 us_led  \n",
       "0      non-USA  False  \n",
       "1      non-USA  False  \n",
       "2      non-USA  False  \n",
       "3      non-USA  False  \n",
       "4      non-USA  False  \n",
       "...        ...    ...  \n",
       "1095       USA   True  \n",
       "1096       USA   True  \n",
       "1097       USA   True  \n",
       "1098       USA   True  \n",
       "1099       USA   True  \n",
       "\n",
       "[1100 rows x 100 columns]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def trial_loc_counter(value):\n",
    "    # Initialize the counter\n",
    "    counter = {\"USA\": 0, \"non-USA\": 0}\n",
    "    \n",
    "    # Check if the value is a list of dictionaries\n",
    "    if isinstance(value, list):\n",
    "        for i in value:\n",
    "            if isinstance(i, dict) and 'country' in i:\n",
    "                if i['country'] == 'United States':\n",
    "                    counter[\"USA\"] += 1\n",
    "                else:\n",
    "                    counter[\"non-USA\"] += 1\n",
    "        # Return True if USA has more counts than non-USA\n",
    "        return counter['USA'] > counter['non-USA']\n",
    "    else:\n",
    "        # Return a default or handle the error case as appropriate\n",
    "        return False\n",
    "\n",
    "# Apply the function\n",
    "df['us_led'] = df[\"protocolSection_contactsLocationsModule_locations\"].apply(lambda x: trial_loc_counter(x))\n",
    "df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>us_included</th>\n",
       "      <th>location0</th>\n",
       "      <th>us_led</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>901.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>912.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>1065.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>1916.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>730.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>1127.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>1646.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>1461.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>2343.0</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>342.0</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 100 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ...  \\\n",
       "0                                           2017-07-12  ...   \n",
       "1                                              2010-09  ...   \n",
       "2                                              2013-04  ...   \n",
       "3                                              2010-01  ...   \n",
       "4                                              2012-07  ...   \n",
       "...                                                ...  ...   \n",
       "1095                                           2000-01  ...   \n",
       "1096                                           2008-06  ...   \n",
       "1097                                           1999-03  ...   \n",
       "1098                                           2007-01  ...   \n",
       "1099                                        2021-01-06  ...   \n",
       "\n",
       "     study_duration_days study_eq_bins study_eq_labels  \\\n",
       "0                  901.0           Low               0   \n",
       "1                  912.0           Low               0   \n",
       "2                 1065.0           Low               0   \n",
       "3                 1916.0          High               1   \n",
       "4                  730.0           Low               0   \n",
       "...                  ...           ...             ...   \n",
       "1095              1127.0           Low               0   \n",
       "1096              1646.0           Low               0   \n",
       "1097              1461.0           Low               0   \n",
       "1098              2343.0          High               1   \n",
       "1099               342.0           Low               0   \n",
       "\n",
       "     num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                                                     1   \n",
       "1                                                     1   \n",
       "2                                                     1   \n",
       "3                                                     1   \n",
       "4                                                     1   \n",
       "...                                                 ...   \n",
       "1095                                                  0   \n",
       "1096                                                  1   \n",
       "1097                                                  0   \n",
       "1098                                                  2   \n",
       "1099                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms us_included  \\\n",
       "0                                                   0       3       False   \n",
       "1                                                   0       4       False   \n",
       "2                                                   0       5       False   \n",
       "3                                                   0       4       False   \n",
       "4                                                   0       1       False   \n",
       "...                                               ...     ...         ...   \n",
       "1095                                                0       0        True   \n",
       "1096                                                0       2        True   \n",
       "1097                                                0       0        True   \n",
       "1098                                                0       5        True   \n",
       "1099                                                0       9        True   \n",
       "\n",
       "     location0 us_led  \n",
       "0      non-USA  False  \n",
       "1      non-USA  False  \n",
       "2      non-USA  False  \n",
       "3      non-USA  False  \n",
       "4      non-USA  False  \n",
       "...        ...    ...  \n",
       "1095       USA   True  \n",
       "1096       USA   True  \n",
       "1097       USA   True  \n",
       "1098       USA   True  \n",
       "1099       USA   True  \n",
       "\n",
       "[1100 rows x 100 columns]"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['us_led'] = df[\"protocolSection_contactsLocationsModule_locations\"].apply(trial_loc_counter)\n",
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0          OTHER\n",
       "1          OTHER\n",
       "2       INDUSTRY\n",
       "3       INDUSTRY\n",
       "4       INDUSTRY\n",
       "          ...   \n",
       "1095       OTHER\n",
       "1096       OTHER\n",
       "1097       OTHER\n",
       "1098         NIH\n",
       "1099       OTHER\n",
       "Name: protocolSection_sponsorCollaboratorsModule_leadSponsor_class, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['protocolSection_sponsorCollaboratorsModule_leadSponsor_class']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       SPONSOR\n",
       "1           NaN\n",
       "2       SPONSOR\n",
       "3           NaN\n",
       "4       SPONSOR\n",
       "         ...   \n",
       "1095    SPONSOR\n",
       "1096    SPONSOR\n",
       "1097    SPONSOR\n",
       "1098    SPONSOR\n",
       "1099    SPONSOR\n",
       "Name: protocolSection_sponsorCollaboratorsModule_responsibleParty_type, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['protocolSection_sponsorCollaboratorsModule_responsibleParty_type']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       Shanghai Junshi Bioscience Co., Ltd.\n",
       "1         Seoul National University Hospital\n",
       "2                           InnoPharmax Inc.\n",
       "3                                     4SC AG\n",
       "4                                AstraZeneca\n",
       "                        ...                 \n",
       "1095                 Northwestern University\n",
       "1096                             Mayo Clinic\n",
       "1097               Montefiore Medical Center\n",
       "1098         National Cancer Institute (NCI)\n",
       "1099       Albert B. Sabin Vaccine Institute\n",
       "Name: protocolSection_sponsorCollaboratorsModule_leadSponsor_name, Length: 1100, dtype: object"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['protocolSection_sponsorCollaboratorsModule_leadSponsor_name']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6       National Cancer Institute (NCI)\n",
       "18      National Cancer Institute (NCI)\n",
       "38      National Cancer Institute (NCI)\n",
       "50      National Cancer Institute (NCI)\n",
       "131     National Cancer Institute (NCI)\n",
       "                     ...               \n",
       "1022    National Cancer Institute (NCI)\n",
       "1076    National Cancer Institute (NCI)\n",
       "1088    National Cancer Institute (NCI)\n",
       "1092    National Cancer Institute (NCI)\n",
       "1098    National Cancer Institute (NCI)\n",
       "Name: protocolSection_sponsorCollaboratorsModule_leadSponsor_name, Length: 74, dtype: object"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.loc[df['protocolSection_sponsorCollaboratorsModule_leadSponsor_name']==\"National Cancer Institute (NCI)\", 'protocolSection_sponsorCollaboratorsModule_leadSponsor_name']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>study_eq_bins</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>us_included</th>\n",
       "      <th>location0</th>\n",
       "      <th>us_led</th>\n",
       "      <th>nci_sponsor</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>High</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>Low</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 101 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ... study_eq_bins  \\\n",
       "0                                           2017-07-12  ...           Low   \n",
       "1                                              2010-09  ...           Low   \n",
       "2                                              2013-04  ...           Low   \n",
       "3                                              2010-01  ...          High   \n",
       "4                                              2012-07  ...           Low   \n",
       "...                                                ...  ...           ...   \n",
       "1095                                           2000-01  ...           Low   \n",
       "1096                                           2008-06  ...           Low   \n",
       "1097                                           1999-03  ...           Low   \n",
       "1098                                           2007-01  ...          High   \n",
       "1099                                        2021-01-06  ...           Low   \n",
       "\n",
       "     study_eq_labels num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                  0                                                  1   \n",
       "1                  0                                                  1   \n",
       "2                  0                                                  1   \n",
       "3                  1                                                  1   \n",
       "4                  0                                                  1   \n",
       "...              ...                                                ...   \n",
       "1095               0                                                  0   \n",
       "1096               0                                                  1   \n",
       "1097               0                                                  0   \n",
       "1098               1                                                  2   \n",
       "1099               0                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms us_included  \\\n",
       "0                                                   0       3       False   \n",
       "1                                                   0       4       False   \n",
       "2                                                   0       5       False   \n",
       "3                                                   0       4       False   \n",
       "4                                                   0       1       False   \n",
       "...                                               ...     ...         ...   \n",
       "1095                                                0       0        True   \n",
       "1096                                                0       2        True   \n",
       "1097                                                0       0        True   \n",
       "1098                                                0       5        True   \n",
       "1099                                                0       9        True   \n",
       "\n",
       "     location0 us_led nci_sponsor  \n",
       "0      non-USA  False       False  \n",
       "1      non-USA  False       False  \n",
       "2      non-USA  False       False  \n",
       "3      non-USA  False       False  \n",
       "4      non-USA  False       False  \n",
       "...        ...    ...         ...  \n",
       "1095       USA   True       False  \n",
       "1096       USA   True       False  \n",
       "1097       USA   True       False  \n",
       "1098       USA   True        True  \n",
       "1099       USA   True       False  \n",
       "\n",
       "[1100 rows x 101 columns]"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['nci_sponsor'] = df['protocolSection_sponsorCollaboratorsModule_leadSponsor_name'].apply(lambda x: True if \"National Cancer Institute (NCI)\" in x else False)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection_identificationModule_nctId</th>\n",
       "      <th>protocolSection_identificationModule_orgStudyIdInfo_id</th>\n",
       "      <th>protocolSection_identificationModule_organization_fullName</th>\n",
       "      <th>protocolSection_identificationModule_organization_class</th>\n",
       "      <th>protocolSection_identificationModule_briefTitle</th>\n",
       "      <th>protocolSection_identificationModule_officialTitle</th>\n",
       "      <th>protocolSection_statusModule_statusVerifiedDate</th>\n",
       "      <th>protocolSection_statusModule_overallStatus</th>\n",
       "      <th>protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess</th>\n",
       "      <th>protocolSection_statusModule_startDateStruct_date</th>\n",
       "      <th>...</th>\n",
       "      <th>study_eq_labels</th>\n",
       "      <th>num_protocolSection_outcomesModule_primaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_secondaryOutcomes</th>\n",
       "      <th>num_protocolSection_outcomesModule_otherOutcomes</th>\n",
       "      <th>num_oms</th>\n",
       "      <th>us_included</th>\n",
       "      <th>location0</th>\n",
       "      <th>us_led</th>\n",
       "      <th>nci_sponsor</th>\n",
       "      <th>crossover</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03316144</td>\n",
       "      <td>Junshi-JS001-011</td>\n",
       "      <td>Shanghai Junshi Bioscience Co., Ltd.</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Safety, Tolerability, Pharmacokinetics &amp; Pharm...</td>\n",
       "      <td>A Phase I Study of Safety, Tolerability, Pharm...</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2017-07-12</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01212341</td>\n",
       "      <td>MG4101_P1</td>\n",
       "      <td>Seoul National University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Allogeneic Natural Killer (NK) Cell Therapy in...</td>\n",
       "      <td>A Phase I Study of Allogeneic NK Cell Therapy ...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-09</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01800630</td>\n",
       "      <td>HR-12-001</td>\n",
       "      <td>InnoPharmax Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Phase1 Study of Gemcitabine HCl Oral Formulati...</td>\n",
       "      <td>An Open Label, Phase 1, Dose Escalation Study ...</td>\n",
       "      <td>2019-07</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2013-04</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01065025</td>\n",
       "      <td>4SC-205-1-2009</td>\n",
       "      <td>4SC AG</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral Eg5 ...</td>\n",
       "      <td>Open Label, Dose Escalation Trial of Oral 4SC-...</td>\n",
       "      <td>2015-04</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2010-01</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01588548</td>\n",
       "      <td>D4510C00005</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>Global Phase1 Study to Assess the Safety and T...</td>\n",
       "      <td>A Phase I, Open-Label, Multicentre Study to As...</td>\n",
       "      <td>2015-10</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>non-USA</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1095</th>\n",
       "      <td>NCT00004910</td>\n",
       "      <td>NU 98CC2</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Endoscopic Placement of Metal Stents in Treati...</td>\n",
       "      <td>A Pilot Phase I/II Trial of Enteral Wallstents...</td>\n",
       "      <td>2012-05</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2000-01</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1096</th>\n",
       "      <td>NCT00654160</td>\n",
       "      <td>CDR0000592931</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan, Fluorouracil, and Leucovorin in Tr...</td>\n",
       "      <td>A Pharmacogenetic-Based Phase I Trial of Irino...</td>\n",
       "      <td>2016-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2008-06</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1097</th>\n",
       "      <td>NCT00003867</td>\n",
       "      <td>CDR0000067031</td>\n",
       "      <td>Montefiore Medical Center</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Irinotecan and Capecitabine in Treating Patien...</td>\n",
       "      <td>Phase I Clinical Study of Every Three Week Iri...</td>\n",
       "      <td>2018-09</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>1999-03</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1098</th>\n",
       "      <td>NCT00397384</td>\n",
       "      <td>NCI-2009-00107</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>NIH</td>\n",
       "      <td>Erlotinib Hydrochloride and Cetuximab in Treat...</td>\n",
       "      <td>A Phase I Clinical and Biological Evaluation o...</td>\n",
       "      <td>2014-02</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "      <td>5</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1099</th>\n",
       "      <td>NCT04723602</td>\n",
       "      <td>Sabin 001</td>\n",
       "      <td>Albert B. Sabin Vaccine Institute</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>Evaluation of Safety, Tolerability and Immune ...</td>\n",
       "      <td>Phase 1b Trial to Evaluate Safety, Tolerabilit...</td>\n",
       "      <td>2022-08</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>False</td>\n",
       "      <td>2021-01-06</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>True</td>\n",
       "      <td>USA</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1100 rows Ã— 102 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     protocolSection_identificationModule_nctId  \\\n",
       "0                                   NCT03316144   \n",
       "1                                   NCT01212341   \n",
       "2                                   NCT01800630   \n",
       "3                                   NCT01065025   \n",
       "4                                   NCT01588548   \n",
       "...                                         ...   \n",
       "1095                                NCT00004910   \n",
       "1096                                NCT00654160   \n",
       "1097                                NCT00003867   \n",
       "1098                                NCT00397384   \n",
       "1099                                NCT04723602   \n",
       "\n",
       "     protocolSection_identificationModule_orgStudyIdInfo_id  \\\n",
       "0                                      Junshi-JS001-011       \n",
       "1                                             MG4101_P1       \n",
       "2                                             HR-12-001       \n",
       "3                                        4SC-205-1-2009       \n",
       "4                                           D4510C00005       \n",
       "...                                                 ...       \n",
       "1095                                           NU 98CC2       \n",
       "1096                                      CDR0000592931       \n",
       "1097                                      CDR0000067031       \n",
       "1098                                     NCI-2009-00107       \n",
       "1099                                          Sabin 001       \n",
       "\n",
       "     protocolSection_identificationModule_organization_fullName  \\\n",
       "0                  Shanghai Junshi Bioscience Co., Ltd.           \n",
       "1                    Seoul National University Hospital           \n",
       "2                                      InnoPharmax Inc.           \n",
       "3                                                4SC AG           \n",
       "4                                           AstraZeneca           \n",
       "...                                                 ...           \n",
       "1095                            Northwestern University           \n",
       "1096                                        Mayo Clinic           \n",
       "1097                          Montefiore Medical Center           \n",
       "1098                    National Cancer Institute (NCI)           \n",
       "1099                  Albert B. Sabin Vaccine Institute           \n",
       "\n",
       "     protocolSection_identificationModule_organization_class  \\\n",
       "0                                                 OTHER        \n",
       "1                                                 OTHER        \n",
       "2                                              INDUSTRY        \n",
       "3                                              INDUSTRY        \n",
       "4                                              INDUSTRY        \n",
       "...                                                 ...        \n",
       "1095                                              OTHER        \n",
       "1096                                              OTHER        \n",
       "1097                                              OTHER        \n",
       "1098                                                NIH        \n",
       "1099                                              OTHER        \n",
       "\n",
       "        protocolSection_identificationModule_briefTitle  \\\n",
       "0     Safety, Tolerability, Pharmacokinetics & Pharm...   \n",
       "1     Allogeneic Natural Killer (NK) Cell Therapy in...   \n",
       "2     Phase1 Study of Gemcitabine HCl Oral Formulati...   \n",
       "3     Open Label, Dose Escalation Trial of Oral Eg5 ...   \n",
       "4     Global Phase1 Study to Assess the Safety and T...   \n",
       "...                                                 ...   \n",
       "1095  Endoscopic Placement of Metal Stents in Treati...   \n",
       "1096  Irinotecan, Fluorouracil, and Leucovorin in Tr...   \n",
       "1097  Irinotecan and Capecitabine in Treating Patien...   \n",
       "1098  Erlotinib Hydrochloride and Cetuximab in Treat...   \n",
       "1099  Evaluation of Safety, Tolerability and Immune ...   \n",
       "\n",
       "     protocolSection_identificationModule_officialTitle  \\\n",
       "0     A Phase I Study of Safety, Tolerability, Pharm...   \n",
       "1     A Phase I Study of Allogeneic NK Cell Therapy ...   \n",
       "2     An Open Label, Phase 1, Dose Escalation Study ...   \n",
       "3     Open Label, Dose Escalation Trial of Oral 4SC-...   \n",
       "4     A Phase I, Open-Label, Multicentre Study to As...   \n",
       "...                                                 ...   \n",
       "1095  A Pilot Phase I/II Trial of Enteral Wallstents...   \n",
       "1096  A Pharmacogenetic-Based Phase I Trial of Irino...   \n",
       "1097  Phase I Clinical Study of Every Three Week Iri...   \n",
       "1098  A Phase I Clinical and Biological Evaluation o...   \n",
       "1099  Phase 1b Trial to Evaluate Safety, Tolerabilit...   \n",
       "\n",
       "     protocolSection_statusModule_statusVerifiedDate  \\\n",
       "0                                            2020-09   \n",
       "1                                            2013-08   \n",
       "2                                            2019-07   \n",
       "3                                            2015-04   \n",
       "4                                            2015-10   \n",
       "...                                              ...   \n",
       "1095                                         2012-05   \n",
       "1096                                         2016-09   \n",
       "1097                                         2018-09   \n",
       "1098                                         2014-02   \n",
       "1099                                         2022-08   \n",
       "\n",
       "     protocolSection_statusModule_overallStatus  \\\n",
       "0                                     COMPLETED   \n",
       "1                                     COMPLETED   \n",
       "2                                     COMPLETED   \n",
       "3                                     COMPLETED   \n",
       "4                                     COMPLETED   \n",
       "...                                         ...   \n",
       "1095                                  COMPLETED   \n",
       "1096                                  COMPLETED   \n",
       "1097                                  COMPLETED   \n",
       "1098                                  COMPLETED   \n",
       "1099                                  COMPLETED   \n",
       "\n",
       "     protocolSection_statusModule_expandedAccessInfo_hasExpandedAccess  \\\n",
       "0                                                 False                  \n",
       "1                                                 False                  \n",
       "2                                                 False                  \n",
       "3                                                 False                  \n",
       "4                                                 False                  \n",
       "...                                                 ...                  \n",
       "1095                                              False                  \n",
       "1096                                              False                  \n",
       "1097                                              False                  \n",
       "1098                                              False                  \n",
       "1099                                              False                  \n",
       "\n",
       "     protocolSection_statusModule_startDateStruct_date  ... study_eq_labels  \\\n",
       "0                                           2017-07-12  ...               0   \n",
       "1                                              2010-09  ...               0   \n",
       "2                                              2013-04  ...               0   \n",
       "3                                              2010-01  ...               1   \n",
       "4                                              2012-07  ...               0   \n",
       "...                                                ...  ...             ...   \n",
       "1095                                           2000-01  ...               0   \n",
       "1096                                           2008-06  ...               0   \n",
       "1097                                           1999-03  ...               0   \n",
       "1098                                           2007-01  ...               1   \n",
       "1099                                        2021-01-06  ...               0   \n",
       "\n",
       "     num_protocolSection_outcomesModule_primaryOutcomes  \\\n",
       "0                                                     1   \n",
       "1                                                     1   \n",
       "2                                                     1   \n",
       "3                                                     1   \n",
       "4                                                     1   \n",
       "...                                                 ...   \n",
       "1095                                                  0   \n",
       "1096                                                  1   \n",
       "1097                                                  0   \n",
       "1098                                                  2   \n",
       "1099                                                  7   \n",
       "\n",
       "     num_protocolSection_outcomesModule_secondaryOutcomes  \\\n",
       "0                                                     2     \n",
       "1                                                     3     \n",
       "2                                                     4     \n",
       "3                                                     3     \n",
       "4                                                     0     \n",
       "...                                                 ...     \n",
       "1095                                                  0     \n",
       "1096                                                  1     \n",
       "1097                                                  0     \n",
       "1098                                                  3     \n",
       "1099                                                  2     \n",
       "\n",
       "     num_protocolSection_outcomesModule_otherOutcomes num_oms us_included  \\\n",
       "0                                                   0       3       False   \n",
       "1                                                   0       4       False   \n",
       "2                                                   0       5       False   \n",
       "3                                                   0       4       False   \n",
       "4                                                   0       1       False   \n",
       "...                                               ...     ...         ...   \n",
       "1095                                                0       0        True   \n",
       "1096                                                0       2        True   \n",
       "1097                                                0       0        True   \n",
       "1098                                                0       5        True   \n",
       "1099                                                0       9        True   \n",
       "\n",
       "     location0 us_led nci_sponsor crossover  \n",
       "0      non-USA  False       False     False  \n",
       "1      non-USA  False       False     False  \n",
       "2      non-USA  False       False     False  \n",
       "3      non-USA  False       False     False  \n",
       "4      non-USA  False       False     False  \n",
       "...        ...    ...         ...       ...  \n",
       "1095       USA   True       False     False  \n",
       "1096       USA   True       False     False  \n",
       "1097       USA   True       False     False  \n",
       "1098       USA   True        True     False  \n",
       "1099       USA   True       False     False  \n",
       "\n",
       "[1100 rows x 102 columns]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def check_crossover(item):\n",
    "    if isinstance(item, str):  # Ensure item is a string\n",
    "        # Check if \"CROSSOVER\" is in the string\n",
    "        return \"CROSSOVER\" in item.upper()  # Convert to uppercase for case-insensitive check\n",
    "    return False  # Return False if item is not a string\n",
    "\n",
    "# Apply the check_crossover function to the desired column\n",
    "df['crossover'] = df['protocolSection_designModule_designInfo_interventionModel'].apply(check_crossover)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'PARALLEL' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[79], line 6\u001b[0m\n\u001b[1;32m      3\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28meval\u001b[39m(item)\n\u001b[1;32m      4\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m item  \u001b[38;5;66;03m# Return the item unchanged if it's not a string\u001b[39;00m\n\u001b[0;32m----> 6\u001b[0m df[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mcrossover\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m df[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mprotocolSection_designModule_designInfo_interventionModel\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39mapply(safe_eval)\u001b[38;5;241m.\u001b[39mapply(\u001b[38;5;28;01mlambda\u001b[39;00m x: \u001b[38;5;28;01mTrue\u001b[39;00m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCROSSOVER\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m x \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mFalse\u001b[39;00m)\n\u001b[1;32m      7\u001b[0m df\n",
      "File \u001b[0;32m~/miniconda3/envs/clinical/lib/python3.12/site-packages/pandas/core/series.py:4924\u001b[0m, in \u001b[0;36mSeries.apply\u001b[0;34m(self, func, convert_dtype, args, by_row, **kwargs)\u001b[0m\n\u001b[1;32m   4789\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mapply\u001b[39m(\n\u001b[1;32m   4790\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   4791\u001b[0m     func: AggFuncType,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   4796\u001b[0m     \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs,\n\u001b[1;32m   4797\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m DataFrame \u001b[38;5;241m|\u001b[39m Series:\n\u001b[1;32m   4798\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m   4799\u001b[0m \u001b[38;5;124;03m    Invoke function on values of Series.\u001b[39;00m\n\u001b[1;32m   4800\u001b[0m \n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   4915\u001b[0m \u001b[38;5;124;03m    dtype: float64\u001b[39;00m\n\u001b[1;32m   4916\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[1;32m   4917\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m SeriesApply(\n\u001b[1;32m   4918\u001b[0m         \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   4919\u001b[0m         func,\n\u001b[1;32m   4920\u001b[0m         convert_dtype\u001b[38;5;241m=\u001b[39mconvert_dtype,\n\u001b[1;32m   4921\u001b[0m         by_row\u001b[38;5;241m=\u001b[39mby_row,\n\u001b[1;32m   4922\u001b[0m         args\u001b[38;5;241m=\u001b[39margs,\n\u001b[1;32m   4923\u001b[0m         kwargs\u001b[38;5;241m=\u001b[39mkwargs,\n\u001b[0;32m-> 4924\u001b[0m     )\u001b[38;5;241m.\u001b[39mapply()\n",
      "File \u001b[0;32m~/miniconda3/envs/clinical/lib/python3.12/site-packages/pandas/core/apply.py:1427\u001b[0m, in \u001b[0;36mSeriesApply.apply\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1424\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mapply_compat()\n\u001b[1;32m   1426\u001b[0m \u001b[38;5;66;03m# self.func is Callable\u001b[39;00m\n\u001b[0;32m-> 1427\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mapply_standard()\n",
      "File \u001b[0;32m~/miniconda3/envs/clinical/lib/python3.12/site-packages/pandas/core/apply.py:1507\u001b[0m, in \u001b[0;36mSeriesApply.apply_standard\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1501\u001b[0m \u001b[38;5;66;03m# row-wise access\u001b[39;00m\n\u001b[1;32m   1502\u001b[0m \u001b[38;5;66;03m# apply doesn't have a `na_action` keyword and for backward compat reasons\u001b[39;00m\n\u001b[1;32m   1503\u001b[0m \u001b[38;5;66;03m# we need to give `na_action=\"ignore\"` for categorical data.\u001b[39;00m\n\u001b[1;32m   1504\u001b[0m \u001b[38;5;66;03m# TODO: remove the `na_action=\"ignore\"` when that default has been changed in\u001b[39;00m\n\u001b[1;32m   1505\u001b[0m \u001b[38;5;66;03m#  Categorical (GH51645).\u001b[39;00m\n\u001b[1;32m   1506\u001b[0m action \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mignore\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(obj\u001b[38;5;241m.\u001b[39mdtype, CategoricalDtype) \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m-> 1507\u001b[0m mapped \u001b[38;5;241m=\u001b[39m obj\u001b[38;5;241m.\u001b[39m_map_values(\n\u001b[1;32m   1508\u001b[0m     mapper\u001b[38;5;241m=\u001b[39mcurried, na_action\u001b[38;5;241m=\u001b[39maction, convert\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mconvert_dtype\n\u001b[1;32m   1509\u001b[0m )\n\u001b[1;32m   1511\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(mapped) \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(mapped[\u001b[38;5;241m0\u001b[39m], ABCSeries):\n\u001b[1;32m   1512\u001b[0m     \u001b[38;5;66;03m# GH#43986 Need to do list(mapped) in order to get treated as nested\u001b[39;00m\n\u001b[1;32m   1513\u001b[0m     \u001b[38;5;66;03m#  See also GH#25959 regarding EA support\u001b[39;00m\n\u001b[1;32m   1514\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m obj\u001b[38;5;241m.\u001b[39m_constructor_expanddim(\u001b[38;5;28mlist\u001b[39m(mapped), index\u001b[38;5;241m=\u001b[39mobj\u001b[38;5;241m.\u001b[39mindex)\n",
      "File \u001b[0;32m~/miniconda3/envs/clinical/lib/python3.12/site-packages/pandas/core/base.py:921\u001b[0m, in \u001b[0;36mIndexOpsMixin._map_values\u001b[0;34m(self, mapper, na_action, convert)\u001b[0m\n\u001b[1;32m    918\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(arr, ExtensionArray):\n\u001b[1;32m    919\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m arr\u001b[38;5;241m.\u001b[39mmap(mapper, na_action\u001b[38;5;241m=\u001b[39mna_action)\n\u001b[0;32m--> 921\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m algorithms\u001b[38;5;241m.\u001b[39mmap_array(arr, mapper, na_action\u001b[38;5;241m=\u001b[39mna_action, convert\u001b[38;5;241m=\u001b[39mconvert)\n",
      "File \u001b[0;32m~/miniconda3/envs/clinical/lib/python3.12/site-packages/pandas/core/algorithms.py:1743\u001b[0m, in \u001b[0;36mmap_array\u001b[0;34m(arr, mapper, na_action, convert)\u001b[0m\n\u001b[1;32m   1741\u001b[0m values \u001b[38;5;241m=\u001b[39m arr\u001b[38;5;241m.\u001b[39mastype(\u001b[38;5;28mobject\u001b[39m, copy\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mFalse\u001b[39;00m)\n\u001b[1;32m   1742\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m na_action \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m-> 1743\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m lib\u001b[38;5;241m.\u001b[39mmap_infer(values, mapper, convert\u001b[38;5;241m=\u001b[39mconvert)\n\u001b[1;32m   1744\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1745\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m lib\u001b[38;5;241m.\u001b[39mmap_infer_mask(\n\u001b[1;32m   1746\u001b[0m         values, mapper, mask\u001b[38;5;241m=\u001b[39misna(values)\u001b[38;5;241m.\u001b[39mview(np\u001b[38;5;241m.\u001b[39muint8), convert\u001b[38;5;241m=\u001b[39mconvert\n\u001b[1;32m   1747\u001b[0m     )\n",
      "File \u001b[0;32mlib.pyx:2972\u001b[0m, in \u001b[0;36mpandas._libs.lib.map_infer\u001b[0;34m()\u001b[0m\n",
      "Cell \u001b[0;32mIn[79], line 3\u001b[0m, in \u001b[0;36msafe_eval\u001b[0;34m(item)\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21msafe_eval\u001b[39m(item):\n\u001b[1;32m      2\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(item, \u001b[38;5;28mstr\u001b[39m):  \u001b[38;5;66;03m# Check if the item is a string\u001b[39;00m\n\u001b[0;32m----> 3\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28meval\u001b[39m(item)\n\u001b[1;32m      4\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m item\n",
      "File \u001b[0;32m<string>:1\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'PARALLEL' is not defined"
     ]
    }
   ],
   "source": [
    "def safe_eval(item):\n",
    "    if isinstance(item, str):  # Check if the item is a string\n",
    "        return eval(item)\n",
    "    return item  # Return the item unchanged if it's not a string\n",
    "\n",
    "df['crossover'] = df['protocolSection_designModule_designInfo_interventionModel'].apply(safe_eval).apply(lambda x: True if \"CROSSOVER\" in x else False)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "clinical",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
